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ABSTRACT
Patrick Y. Lang: ATR is a novel therapeutic target for medulloblastoma identified by
its role in cerebellar development
(Under the direction of Timothy R. Gershon)
Microcephaly and brain tumors can both arise as a consequence of dysregulated
expansion of neural progenitor cells. Inadequate progenitor proliferation, premature
cell cycle exit, and inappropriate cell death can all result in neurodevelopmental
disorders characterized by microcephaly. In contrast, brain tumors may form in
response to overactive progenitor proliferation, failed cell cycle exit, and/or escape
from cell death. This dissertation focuses on the role of the DNA damage response
protein ATR (Ataxia-telangiectasia and Rad3-related) in the survival of cerebellar
granule neuron progenitors (CGNPs) and CGNP-derived medulloblastoma, a
cerebellar tumor that is the most common brain cancer of childhood. Chapter 1
provides background information on medulloblastoma, cerebellar development,
CGNP biology, the ATR-mutated microcephalic disorder Seckel syndrome, ATR’s
mechanism of action, and the apoptotic pathway. Chapter 2 is written in the form of
a review article on how insights from primary microcephalic disorders in general can
inform the development of novel brain cancer therapeutics. Chapter 3 is a
published article that explores the function of ATR in CGNPs during neonatal
cerebellar development. Specifically, we show that Atr deletion in CGNPs leads to
widespread, p53-mediated, BAX/BAK-dependent apoptosis in the early postnatal
period due to the accumulation of severe chromosomal abnormalities. This chapter
also provides initial data suggesting the therapeutic value of targeting ATR using a
novel nanoparticle formulation of the small molecule ATR inhibitor VE-822,
pVE-822, for treating medulloblastoma. Chapter 4 presents ongoing work in the
iii
form of two research-in-brief articles in progress. The first section further
investigates the possibility of treating CGNP-derived medulloblastoma with
pVE-822, showing that pVE-822 has an anti-tumor eﬀect in mice with established,
spontaneous medulloblastoma. In the second section, data are presented
demonstrating that in vivo inhibition of the mitotically-limited, microtubule-
associated motor protein KIF11/EG5 potently arrests CGNPs in mitosis without
producing DNA damage or apoptosis. Finally, Chapter 5 provides a discussion on
how, if at all, ATR performs a special and unique function in CGNPs compared to
other brain cells and whether ATR inhibition for the treatment of medulloblastoma
should be further pursued.
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PREFACE
I began my research career as a junior in high school, where I studied the etiology
of Parkinson’s disease with Dr. Paul Carvey at Rush Medical University in Chicago,
IL. My high school, the IL Mathematics and Science Academy, encouraged lab-based
research and it was the influence of my grandfather, a neurosurgeon in Harbin,
China, that caused me to seek out Dr. Carvey. After high school, I continued
researching Parkinson’s for four years with Dr. Mark Stacy at Duke University.
Incredibly, it took me six years to realize that I was neither interested in Parkinson’s
disease nor in neuroscience. Just goes to show how much of what one does depends
on to what one has been exposed. This thought prevailed in my mind throughout my
undergraduate years, compelling me to gain exposure in several areas, including
medical specialties like Radiology, Neurosurgery, Psychiatry, and Geriatrics, as well
as basic science fields like Genetics, Developmental Biology, and Cancer Biology. I
had passing interest in most of these topics, electing to try something else after one
semester in each case, but the study of Developmental and Cancer Biology with Dr.
Robert Wechsler-Reya held my captivation. It was ultimately my research with Dr.
Wechsler-Reya that led me to join the lab of Dr. Timothy Gershon at UNC, where I
continued my research on the interrelated processes of normal development and
tumor formation. Before joining Dr. Gershon’s lab, I rotated with Dr. Mark Zylka,
whose work is primarily on brain development, and with Dr. Channing Der, whose
work is primarily on cancer pathogenesis and treatment. These rotations helped me
realize that I was interested in the intersection of the development and cancer fields.
As such, my graduate training with Dr. Gershon has been profoundly rewarding and
has set me up for a career researching development and cancer.
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CHAPTER 1: INTRODUCTION
Overview
Cerebellar hypoplasia and medulloblastoma are severe childhood neurological
disorders that both result from failed regulation of progenitor proliferation
(Wechsler-Reya and Scott, 1999; Garel et al., 2011; Chizhikov et al., 2007).
Hypoplasia of the cerebellum is seen in Seckel syndrome, which is caused by
mutation of the gene coding for the DNA damage response protein ATR
(Ataxia-telangiectasia and Rad3-related) (O’Driscoll et al., 2003). Deficiency of ATR
throughout the brain specifically disrupts the growth of cerebellar progenitors,
leading to cerebellar hypoplasia (Lee et al., 2012; Lang et al., 2016), although the
mechanism for this pathogenesis was not well understood until recently (Lang et al.,
2016). Cerebellar progenitors are also uniquely vulnerable to transformation (Yang
et al., 2008; Dey et al., 2012; Mao et al., 2006), giving rise to medulloblastoma, a
tumor of cerebellar origin that is the most common pediatric brain cancer (CBTRUS,
2010; Rutka, 1997; McNeil et al., 2002; Smoll and Drummond, 2012). Seckel
syndrome and medulloblastoma both involve genomic instability from accumulated
DNA damage (Fernandez et al., 2012; Kalay et al., 2011; Kool et al., 2014),
highlighting the potential for DNA damage to disrupt cerebellar growth.
Importantly, medulloblastoma remains profoundly sensitive to DNA damage, as
radiation and chemotherapy are highly eﬀective against this tumor (Bartlett et al.,
2013; Packer et al., 1991). These non-specific therapies, however, are associated with
significant morbidity in young patients, and not all patients are responsive
(Schroeder and Gururangan, 2014; Miralbell et al., 1997; Ris et al., 2001). One of the
goals of my dissertation was to determine the precise function of ATR in cerebellar
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granule neuron progenitors (CGNPs) and elucidate how ATR disruption leads to
cerebellar hypoplasia, providing knowledge of Seckel syndrome pathogenesis. I
further predicted that medulloblastoma cells, like cerebellar progenitors, depend on
ATR for growth and that ATR would therefore be an eﬀective therapeutic target in
medulloblastoma that could produce improved eﬃcacy with reduced toxicity. To
appreciate the scope of these aims and the results that have followed requires a
foundational understanding of medulloblastoma, normal cerebellar development,
Seckel syndrome, and ATR function.
Medulloblastoma and normal cerebellar development
Medulloblastoma background
Medulloblastoma (MB) is a malignant pediatric brain tumor of the cerebellum
(Rorke, 1983; Parsons et al., 2011). It was initially described as a glioma – a tumor
derived from cells of the glial lineages – until Bailey and Cushing provided evidence
in 1925 for its non-glial cell origins (Bailey and Cushing, 1925). They observed that
MB predominantly presented in the cerebellum and frequently extended into the
fourth ventricle, causing blockage of cerebrospinal fluid (CSF) flow, resulting in
hydrocephalus. In addition, most cases of MB were found to occur in pediatric
patients – that is, in individuals younger than 20.
Since Bailey and Cushings seminal study, MB has been alternately designated as
an infratentorial primitive neuroectodermal tumor (PNET) (Hart and Earle, 1973;
Rorke, 1983) and as a tumor distinct from PNETs (Kleihues et al., 1993; McManamy
et al., 2007; Rubinstein, 1985). The controversy as to this cancer’s classification was
a result of limited knowledge regarding its cell of origin. Whereas PNETs derive
from pluripotent neural crest cells, MBs can arise from mutation in more committed
progenitor cells (Wechsler-Reya and Scott, 1999; Yang et al., 2008; Molenaar and
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Trojanowski, 1994; Oliver et al., 2003). Regardless of its designation, MB is an
invasive tumor that represents a serious disease burden.
In 2010, the cost of care for MB in the United States (US) was estimated at $40
million (NCI, 2010). Between 2004 and 2007, MB comprised 1% of primary brain and
central nervous system (CNS) tumors among all age groups and nearly 20% of newly
diagnosed cases of CNS tumors in the pediatric population (CBTRUS, 2010;
Crawford et al., 2007). Approximately 13% of children between 0 - 14-years-old and
3.9% of teens between 15 - 19 were living with MB during those years. Generally,
this cancer is seen more in boys than in girls (2:1), although girls tend to have a
better prognosis (Bloom et al., 1969). As a rare disease, MB has a prevalence of less
than 200,000 aﬀected individuals and an incidence of approximately 2 per 100,000
people, or 350 new cases each year in the US (CBTRUS, 2010). Despite this low
prevalence, diagnosis of MB has been facilitated by decades of research.
Clinically, MB presents as a cerebellar mass – frequently localized initially to the
surface of the cerebellum – that impinges upon the fourth ventricle (Bailey and
Cushing, 1925). Hydrocephalus causes the majority of outwardly manifest symptoms
in patients, including headache, lethargy, vomiting, and gait imbalance (MacDonald
et al., 2003). Diagnosis is confirmed by magnetic resonance imaging (MRI),
computerized tomography (CT) scan, and histology on tumor biopsy (Chang et al.,
1969; Tomlinson et al., 1992a,b). Histological examination of human tumor samples
have revealed at least three subtypes of MB: classic, desmoplastic/nodular, and
large-cell anaplastic (Gilbertson and Ellison, 2008). Classic MB cells tend to be
small, round-to-oval, and contain little cytoplasm (Kleihues et al., 1993; Katsetos
et al., 1988). Most cells appear undiﬀerentiated on the basis of lineage marker
analysis, although some may express markers of neurons and glia. In addition,
approximately 40% of classic MB samples are characterized by Homer-Wright
rosettes – circular or spherical groupings of tumor cells organized around a central
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cavity of neurofibrils. Classic MB comprises the majority (approximately 50%) of
diagnosed MB cases and is associated with a medium outcome and prognosis.
Desmoplastic, or nodular, MB is distinguished by regions of densely packed,
undiﬀerentiated cells with extensive reticulin fibers surrounding islands of more
diﬀerentiated cells (Katsetos et al., 1988; Leary et al., 2011). This subtype
represents approximately 25% of all MB cases and is associated with a better
prognosis than the classic subtype. In contrast, the large-cell anaplastic variant is
thought to correlate with low survival and the worst overall prognosis of all three
MB subtypes (Eberhart et al., 2002a; Leonard et al., 2001; von Hoﬀ et al., 2010).
These tumors are noted for their invasiveness, which is a consequence of highly
proliferative cells. Compared to classic MB cells, those in the large-cell anaplastic
subtype tend to be 2-3 times larger, dediﬀerentiated (reversion of cells to less
specialized form), and in densely packed clusters. While histology has allowed for the
categorization of MB into distinct variants, correlating these subtypes with genetic
and molecular mechanisms is not always straightforward.
Risk for MB is associated with a number of genetic factors. Losses in
chromosomes 6q, 16q, 10q, and, most frequently, 17p have been seen in many tumor
samples (Rasheed and Bigner, 1991). Notably, the human p53 (TP53, tumor protein
p53) tumor suppressor gene lies within chromosome 17p (chromosome 11 in mouse)
and the PTEN (Phosphate and tensin homolog) tumor suppressor gene lies within
10q; however, complete loss of these genes have been absent in nearly all cases of
MB. On the other hand, mutations in known genes, such asMYC (V-Myc avian
myelocyomatosis viral oncogene homolog),MYCN (MYC neuroblastoma-derived),
TP53, Sonic hedgehog (SHH) pathway members (PTCH1/2 (Patched 1/2), SMO
(Smoothened), and SUFU (Suppressor of fused)), and WNT (Wingless-related
integration site) pathway members (CTNNB1 (Catenin-beta 1), GSK3B (Glycogen
synthase kinase 3 beta), AXIN2 (Axis inhibition protein 2), and APC(Adenomatous
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polyposis coli)), are found in many MBs (Kool et al., 2012; Northcott et al., 2012;
Taylor et al., 2012). Indeed, the expression pattern of certain genes is perhaps linked
to histological MB subtypes and therefore associated with disease prognosis. For
instance, loss of wild-type Ptc in conjunction withMycN overexpression in CGNPs is
able to induce the formation of tumors in mice that resemble the desmoplastic
subtype of MB (Kessler et al., 2009). Constitutive Smo activation (SmoM2) in
CGNPs in mice results in classic-like medulloblastoma (Mao et al., 2006). As another
example, disruption of p53 acting together withMyc overexpression in cerebellar
stem cells may be causative in large-cell anaplastic MB (Pei et al., 2012).
Despite this wide array of chromosomal aberrations and genetic mutations, few
risk factors are actually inherited. However, certain heritable conditions have been
implicated as increasing the risk for acquiring MB (Taylor et al., 2000).
Predisposition for MB as a consequence of these other diseases is thought to be a
result of mutations in similar pathways. For instance, patients with inherited Gorlin
syndrome (also known as basal cell nevus syndrome or nevoid basal cell carcinoma
syndrome) have on average a 3 - 5% higher chance for acquiring MB than people in
the general population (Evans et al., 1991b,a). Gorlin usually develops as a result of
mutations in PTCH1, which encodes a SHH pathway antagonist (Bale et al., 1998).
Furthermore, patients with heritable Turcot, Li-Fraumeni, and Rubinstein-Taybi
syndromes have also shown increased incidence of MB (Taylor et al., 2000;
Bourdeaut et al., 2014; Skousen et al., 1996). In both Turcot (a type of adenoma) and
some cases of MB, the gene for APC, which is a part of the WNT signaling pathway
and has been implicated in MB tumorigenesis, is mutated (Eberhart et al., 2000;
Gibson et al., 2010; Huang et al., 2000; Zurawel et al., 1998). Studies on conditions
such as Gorlin and Turcot have contributed to a greater understanding of the genetic
background and molecular pathways underlying MB.
At present, 5-year mortality can be as high as 30% among MB patients receiving
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treatment (Ray et al., 2004). While a combination of surgery, radiation, and
chemotherapy is commonly used in MB, side eﬀects frequently include severe
developmental defects, cognitive impairment, and early strokes (Packer and Vezina,
2008). Prognosis tends to be worse in very young patients, who also stand a greater
chance of suﬀering adverse side eﬀects as a result of treatment (Raﬀel, 2004).
Children under 3-years-old are generally not given radiation so as to minimize the
chances of developing intellectual deficits (Bouﬀet, 2010; Copeland et al., 1999;
Jakacki et al., 2004; Kellie, 1999; Walter et al., 1999). However, among older
patients, radiation is the tool of choice for preventing the metastasis of MB cells
through the CSF (Packer et al., 1999; Sirachainan et al., 2011). Current
chemotherapeutic agents tend to be general, non-specific compounds like Cisplatin,
Vincristine, Etoposide, and Cyclophosphamide (Packer and Vezina, 2008). Popular
treatment regimens for children include eight-in-one: Carmustine, Cisplatin,
Cyclophosphamide, Cytarabine, Hydroxyurea, Procarbazine, Prednisone, and
Vincristine (Gentet et al., 1995). VCP, developed by the Children’s Cancer Group
(CCG), involves Vincristine, Lomustine (CCNU), and Prednisone (Mulhern et al.,
1998). A Pediatric Oncology Group (POG) therapy plan entails Vincristine,
Cisplatin, Cyclophosphamide, and Etoposide (Packer et al., 2006). Targeted
molecular approaches, such as the SHH pathway inhibitors Cyclopamine and
Vismodegib, have only recently come under consideration (Bar and Stearns, 2008;
Robinson et al., 2015). The diﬃculty in developing MB-specific drugs comes in part
from an incomplete understanding of the disease subtypes, but it is also a result of
the lack of strong in vitromodels for rapid testing of therapeutics. Therefore, a better
understanding of MB onset and progression will lead to advances in treating this
cancer.
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Normal cerebellar development
Classically, the study of cancer has equated with the study of normal
developmental processes and the mechanisms underlying their aberration
(Weinberg, 2013; Hanahan and Weinberg, 2011, 2000). For medulloblastoma, this
has meant first and foremost a firm understanding of normal cerebellar development
(Bihannic and Ayrault, 2016; Marshall et al., 2014; Roussel and Hatten, 2011;
Wechsler-Reya and Scott, 2001). The cerebellum is a prominent hindbrain structure
tucked beneath the occipital lobe of the cerebellar cortex and posterior to both the
fourth ventricle and, by extension, the pons of the brainstem (Glickstein et al., 2009).
Anatomically, the cerebellum appears highly folded due to a crumpled outer layer of
cortex overlaying an inner region of white matter. Top-to-bottom subdivisions
(anterior, posterior, and flocculonodular lobes) emphasize anatomical distinctions
whereas medial-to-lateral subdivisions (vermis, spinocerebellum, cerebrocerebellum)
relate to functional diﬀerences (Manto, 2008) (Fig. 1.1A).
The vermis is the medial-most region of the cerebellum and is thought to
influence speech, language, social behavior, and fear (Riva and Giorgi, 2000b,a). Most
MBs in the pediatric population arise within this specific area of the cerebellum, and
as such, MB patients often experience speech deficits and altered behavior early in
disease progression (Koeller and Rushing, 2003). Lateral to the vermis is the
spinocerebellum, or paleocerebellum, which plays a role in fine-tuning motor control
by responding to input from the spinal cord (Perciavalle et al., 1995). Lesions to this
region result in the onset of ataxias, or neurodegenerative disorders characterized by
balance diﬃculty and uncoordinated movements (Duenas et al., 2006). The
cerebrocerebellum, or neocerebellum, is the lateral-most division of the cerebellum.
Function of this area is not well understood, but is perhaps related to motor planning
and information processing (Ishikawa et al., 2016; Timmann and Daum, 2007).
Finally, the flocculonodular lobe at the base of the cerebellum participates in balance
7
and spatial orientation (Schmahmann, 1991). Disturbance to this region is found in
patients with gait imbalance. As MB progresses, tumor expansion can damage all of
these cerebellar areas, leading to the problems described.
At the cellular level, the adult cerebellum can be further subdivided into three
distinct layers: the molecular cell layer (MCL), the Purkinje cell layer (PCL), and the
granular cell layer (GCL) (Carletti and Rossi, 2008). The MCL is the outermost sheet
of the cerebellar cortex and is dense with dendritic projections extending from the
PCL and with axons from neurons in the granular layer (Chu et al., 2012; Sotelo,
2015). Scattered throughout these projections are inhibitory neurons in the form of
star-shaped stellate cells and basket cells with axons that form cone-like structures.
Beneath the MCL is a region enriched for the cell bodies of Purkinje neurons
(Kapfhammer, 2004; Zhang et al., 2010). These easily-recognizable cells have an
intricate dendritic meshwork and some of the longest axons of any neuron in the
brain. Their dendrites receive excitatory signals (glutamate) from the underlying
GCL, which is populated by small granule neurons that constitute nearly half of all
neurons in the CNS. In contrast, inhibitory messages like GABA (-aminobutyric
acid) for Purkinje cells originate from the MCL. Glutamate and GABA signals
combine to modulate the strength of the inhibitory message outputted by Purkinje
axons to neurons within the cerebellar white matter. Those white matter neurons
reside in the deep cerebellar nuclei, which also receive excitatory signals from the
cerebral cortex and the brainstem. The deep cerebellar nuclei integrate inhibitory
and excitatory signals to regulate motor control.
Establishment of the cerebellar landscape begins with closing of the neural tube
during early development (Goldowitz and Hamre, 1998). Specifically, the flat, oval
fetal cerebellum arises as a protrusion of the neural tube’s alar plate within the
metencephalon region (Hatten and Heintz, 1995). Unlike other brain structures, the
developing cerebellum initially contains two germinal zones: the ventricular zone
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(CVZ) and the rhombic lip, which gives rise to the external granular layer (EGL)
(Voogd and Glickstein, 1998) (Fig. 1.1B, top). In mice, neurons of the deep nuclei
and Purkinje cells begin migrating away from the VZ between embryonic day (E) 10
and E12.5 (Butts et al., 2014). Purkinje cells form a temporary plate-like structure
just caudal and rostral to the rhombic lip. Around the same time, the precursors to
granule neurons (CGNs), CGNPs, begin migrating tangentially, in a caudorostral
stream, away from the rhombic lip (E13 in mice) and over the dorsal surface of the
cerebellar anlage to populate the EGL (Martinez et al., 2013). CGNP migration
concludes around E18.5 in mice, after which these cells enter a period of rapid
proliferation in response to SHH signaling from underlying Purkinje cells. Starting
around postnatal day (P) 3, CGNPs form a T-shaped process as they begin migrating
radially inward past the PCL to populate the internal granular layer (IGL), which
becomes the GCL in adults (Fig. 1.1B, bottom).
CGNP migration is mediated by the radial fibers of Bergmann glia (astrocytes
that are also known as Golgi epithelial cells) and signaling molecules like NMDA
(N-methyl-D-aspartic acid) and neuregulin (Meissirel et al., 2011; Rieﬀ et al., 1999;
Xu et al., 2013). En route to the IGL, CGNPs cease proliferation and commence
terminal diﬀerentiation into mature CGNs (Behesti and Marino, 2009; Gazit et al.,
2004; Mellor et al., 1998). By P21, CGNPs have completed migration to the IGL, the
EGL has disappeared, and the cerebellum has assumed its mature, complex
structure with deep fissures and large folia. However, mutations in the SHH
pathway can cause CGNPs to remain in a proliferative state in the EGL, potentially
leading to the formation of MB (Fernandez et al., 2009; Kim et al., 2003; Schuller
et al., 2008; Wechsler-Reya and Scott, 1999; Dey et al., 2012; Mao et al., 2006).
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Cerebellar granule neuron progenitors
CGNPs are the precursors of CGNs – the most abundant type of neuron in the
adult mammalian brain (Altman and Bayer, 1997). Microscopically, CGNPs appear
small and round, resembling the neoplastic cells seen in tumors of some patients
with MB (Gilbertson and Ellison, 2008; Wechsler-Reya and Scott, 2001). The striking
similarity between CGNPs and cells in MB has led to eﬀorts to better characterize
CGNPs at the molecular level. As a part of this interest in these cells, the
transcription factor Math1 (Mammalian atonal homolog 1; Atoh1, Atonal homolog 1)
was identified as being expressed exclusively by CGNPs within the cerebellum
(Helms and Johnson, 1998). In mice,Math1 expression is weak in mid-postnatal
development (P7) and mostly absent beyond P20. This suggests thatMath1 is only
expressed in CGNPs and not in their diﬀerentiated daughter CGNs.
Math1 is the mammalian homolog to the atonal gene in Drosophila, which codes
for a basic helix-loop-helix (bHLH) transcription factor (Akazawa et al., 1995). In
Drosophila, atonal is critical for proper development of photoreceptors and
proprioception – loss or mutation results in uncoordinated flies lacking
photoreceptors (Jarman et al., 1993, 1995). Similarly, other eukaryotic organisms
like mice and yeast also possess bHLHs, which control a diverse array of
developmental processes, including cell diﬀerentiation and proliferation (Massari
and Murre, 2000). Math1 and its homologs are activated through dimerization with
other bHLHs like TCF3 (Transcription factor 3) (Bertrand et al., 2002; Johnson
et al., 1992; Hu et al., 1992; Murre et al., 1989). Once dimerized, Math1 regulates
transcription of its target genes by docking at enhancers with the E-box motif
(CANNTG hexonucleotide sequence) (Chien et al., 1996; Klisch et al., 2011). In
CGNPs, Math1 is implicated in both cellular proliferation and, paradoxically,
diﬀerentiation, and its expression is necessary for normal CGNP development
(Ben-Arie et al., 1997; Helms et al., 2001; Gazit et al., 2004).
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Math1 expression can first be detected by E13 in mice (Akazawa et al., 1995).
Although the mechanism leading to this early activation is not well understood,
research has suggested that once activated, Math1 promotes its own expression
through positive auto-regulation (Helms et al., 2000). Increased Math1 activity
correlates with upregulation of proteins in the Notch signaling pathway (Gazit et al.,
2004) (Fig. 1.1C). This includes the Notch receptor (Notch2 in CGNPs) and its
corresponding ligands, DLL1 (Delta-like 1) and JAG1 (Jagged 1). The binding of
ligand to receptor causes cleavage of the cytosolic portion of Notch, which then
translocates to the nucleus to act as a transcription factor (Artavanis-Tsakonas et al.,
1999). Within the nucleus, Notch2 activates transcription of Hes1 (Hairy and
enhancer of split 1) and Hes5, which code for negative regulators of Math1 (Gazit
et al., 2004; Zine and de Ribaupierre, 2002; Lanford et al., 2000; Solecki et al., 2001).
Thus, Math1 seems to participate in both positive and negative auto-regulation.
This careful balance betweenMath1 activation and repression is likely responsible
for delineating the brief developmental interval when Math1 is active in CGNPs.
The importance of balancingMath1 expression is due to its implicated role in
both CGNP diﬀerentiation and proliferation. One study found that normalMath1
expression was required for the proper diﬀerentiation of CGNPs into CGNs (Gazit
et al., 2004). However, constitutive or overexpression ofMath1 has also been shown
to prevent CGNP diﬀerentiation (Helms et al., 2001). Math1 hyperactivity led to the
expression of some genes involved in CGNP diﬀerentiation, but ultimately prevented
actual morphological diﬀerentiation. These results suggest that the normally brief
window of Math1 activity is required for the expression of CGNP diﬀerentiation
genes; however,Math1 must then be silenced to permit diﬀerentiation to occur.
Silencing is likely maintained by Notch signaling as these cells diﬀerentiate and
migrate to the IGL – indeed, Notch pathway activity is detected within the EGL and
IGL in early postnatal development (Solecki et al., 2001; Irvin et al., 2004; Kusumi
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et al., 2001; Fan et al., 2004).
In terms of the proliferative role of Math1, murine Math1 appears to bind to an
E-box-rich enhancer on Gli2 (Glioma-associated oncogene family zinc finger 2), which
encodes a SHH pathway transcription factor that activates genes involved in cell
proliferation (Flora et al., 2009; Stanton and Peng, 2010). Furthermore, deletion of
Math1 was found to prevent tumor development in the SmoM2 mouse model of MB.
On its own,Math1 deletion in otherwise normal mice leads to the establishment of a
diminished rhombic lip and a subsequently reduced EGL (Ben-Arie et al., 1997,
2000). Within this shrunken rhombic lip resides migratory Math1-independent cells
that will populate various areas of the cerebellum (Jensen et al., 2004). However,
their fate and function are not fully understood. In the context of cancer,MATH1 is
found to be highly expressed in MB tumor samples, especially in those correlated
with poor patient prognosis (Salsano et al., 2004). Taken together, these results
strongly suggest that MB tumorigenesis likely involves some interaction between
MATH1 and the SHH pathway in CGNPs.
Apart fromMath1, expression of the genes Pax6 (Paired box 6) (Engelkamp et al.,
1999; Yamasaki et al., 2001), Zscan21 (Zipro1; Zinc finger and SCAN domain-
containing 21) (Yang et al., 1996), Zic1/2/3 (Zinc finger protein 1/2/3) (Yokota et al.,
1996), En2 (Engrailed 2) (Liu and Joyner, 2001), and NeuroD1/2 (Neuronal
diﬀerentiation 1/2) (Miyata et al., 1999; Olson et al., 2001) is also characteristic of
cells of the granule lineage. Some of these markers can be helpful as Math1-
adjunctive identifiers of CGNPs, while others are used to delineate the diﬀerence
between CGNPs and mature CGNs. PAX6 is most recognized for its role in eye
development – a role that demonstrates remarkable interspecies conservation
(Callaerts et al., 1997). In the developing cerebellum, the Pax6 gene product is
thought to mediate CGNP cytoskeletal organization and migration (Yamasaki et al.,
2001). Zscan21, according to one study, encodes a zinc-finger transcription factor
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that can induce increased postnatal CGNP proliferation in mice (Yang et al., 1999).
Yet, in that same study, it was determined that mitotic activity and cerebellar
development were not apparently altered in mice with loss of Zscan21.
Like Zscan21, Zic encodes several zinc-finger transcription factors (Aruga et al.,
1996). In one study, expression of Zic members was detected not only in CGNPs, but
in mature CGNs as well (Yokota et al., 1996). Furthermore, ZIC proteins were found
in 26 of 29 MB samples, but not in any cases among 70 other tumors, suggesting a
role for ZIC in genesis of MB through cells of the granule lineage. However, other
studies have also shown that ZIC proteins are only detected in mature CGNs, thereby
putting into question its usefulness as a marker of CGNPs (Aruga et al., 1998, 2002).
The homeobox protein EN2 is thought to control a diverse set of developmental
functions, including CGNP migration and proliferation and cerebellar pattern
formation (Cheng et al., 2010). NEUROD proteins, on the other hand, are bHLHs
that are important for CGNP survival and diﬀerentiation (Miyata et al., 1999; Olson
et al., 2001). In the end though, while markers like PAX6, ZSCAN21, ZIC, EN2, and
NEUROD are useful for distinguishing granule neurons from other cerebellar cells,
their roles in MB tumorigenesis have not been extensively studied. Furthermore,
most of these genes (Pax6, Zic1/2/3, Zscan21, and En2) are active both in CGNPs
and terminally diﬀerentiated CGNs. In contrast, NeuroD and, by many indications,
Zic, are only expressed in granule neurons, and not at all in CGNPs. Thus, Math1
remains an important protein for distinguishing granule neurons from other
cerebellar cells, but also for separating CGNPs from their mature daughters.
The Sonic hedgehog pathway
The importance of Math1 is emphasized by its role in medulloblastomas with
SHH pathway mutation (Flora et al., 2009; Salsano et al., 2004). SHH was originally
identified as a morphogen in the classic Heidelberg screens of Nusslein-Volhard and
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Wieschaus (Nusslein-Volhard and Wieschaus, 1980). Since then, SHH has also been
recognized as a potent mitogen (Fuccillo et al., 2006). A morphogen is a signaling
molecule that controls the pattern of tissue formation and organogenesis during
organismal development. Mitogens are secreted proteins that trigger activation of
mitotic pathways upon binding cognate receptors on their target cells. This dual role
of SHH underscores its pivotal role in development and its continued,
post-developmental relevance as a tumorigenic factor.
At the molecular level, SHH acts by binding a transmembrane receptor called
PTC (PTCH1/2) (Fuccillo et al., 2006). SHH binding to PTC is thought to release
inhibition of the G protein-coupled receptor SMO (Vaillant and Monard, 2009) (Fig.
1.1D). Once freed, SMO liberates GLI2/3 in a still poorly understood mechanism in
mammals. Unstimulated cells are thought to have GLI2/3 bound to a destruction
complex, which subsequently marks GLI for degradation by the proteasome (Wang
and Zoghbi, 2001). Proteasomal cleavage of GLI3 results in the formation of a small
peptide fragment, which enters the nucleus to act as a transcriptional co-repressor of
GLI2/3 target genes. The gli destruction complex has most extensively been studied
in Drosophila and consists of at least three proteins: fu (fused) (Therond et al., 1996),
sufu (suppressor of fused) (Methot and Basler, 2000), and the kinesin-related protein
cos2 (costal-2) (Zadorozny et al., 2015). The mammalian homologs – ULK3
(Unc51-like kinase 3), SUFU, and KIF7 (Kinesin family member 7), respectively –
have been shown to perform similar functions. Fu/ULK3 is a serine/threonine kinase
that potentially modifies GLI2/3 for nuclear entry in the absence of SUFU
(Maloverjan and Piirsoo, 2012). Kinesins like Cos2/KIF7 regulate intracellular
mobility through interaction with microtubules. Thus, KIF7 has been thought to
play a role in coordinating translocation of the GLI destruction complex and to allow
its interaction with SMO (Cheung et al., 2009; Endoh-Yamagami et al., 2009; Liem
et al., 2009). Untethered SMO could act to dissociate SUFU from the destruction
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complex, thereby permitting Fu/ULK3 to activate GLI2/3 for nuclear localization
(Kim et al., 2011). Within the nucleus, GLI2/3 initiates transcription of genes such
as the SHH pathway antagonist Ptch1/2 and the transcription factor Gli1. In turn,
GLI1 activates expression of the cell cycle proteins Cyclin D and Cyclin E and of the
proto-oncogeneMycN (Katoh and Katoh, 2009).
Cyclins are the actual eﬀectors of cell proliferation in the SHH signal cascade. On
the other hand, promotion of Ptch1/2 transcription is thought to provide a negative
feedback signal for this pathway. Mouse models show that complete loss of Ptc is
embryonically lethal (death by 10 days into gestation), while loss of one wild-type Ptc
allele can sometimes cause MB formation by 4-6 months of age (Goodrich et al., 1997;
Wetmore et al., 2000). These Ptc-mutant-heterozygous mice also display an
increased incidence of polydactyly, acromegaly, and rhabdomyosarcoma (Hahn et al.,
1999; Goodrich et al., 1997). With the proto-oncogeneMycN, one study found that
cultured CGNPs treated with SHH showed increasedMycN expression (Kenney
et al., 2003). When its protein product NMYC was inhibited, the SHH-induced
CGNP proliferative response was attenuated. In mouse models of MB, animals
heterozygous for Ptc mutation only develop tumors 15 - 25% of the time (Pietsch
et al., 1997; Vorechovsky et al., 1997). However, these Ptc heterozygotes developed
tumors resembling desmoplastic MB 100% of the time whenMycN was forcibly
overexpressed (Kessler et al., 2009). Indeed,MYCN is amplified in a subset of MB
tumors in human patients (Eberhart et al., 2002b; Aldosari et al., 2002; Pomeroy
et al., 2002). While alteredMYCN expression in human MBs has been described in
all four molecular subgroups, it is most perturbed in the MBs with SHH pathway
hyperactivation (Roussel and Robinson, 2013). Mutations in SMO represent the
second-most common genetic alteration, after PTCH1 mutation, in patients with
SHH subgroup MB and these mutations tend to occur more frequently in adult MB
(Kool et al., 2014). When CGNPs in mice are engineered to express a mutant,
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constitutively active form of Smo, SmoM2, MB-like tumors develop 100% of the time
in early postnatal life (Schuller et al., 2008). Expression of an alternate mutant form
of Smo, SmoA1, causes mice to develop tumors later in life but only about 50% of
mice get tumors and the age of phenotypic tumor onset can be highly variable
(Hallahan et al., 2004).
Apart from the main components of the SHH pathway, other molecules have also
demonstrated roles in mediating SHH signaling (Table 1.1). The complexity of
cerebellar development begets an understanding of how these additional factors may
also influence SHH-mediated CGNP proliferation. PKA (Protein kinase A) is thought
to phosphorylate GLI3 and thus cause its degradation by the proteasome (Tempe
et al., 2006). SHH signaling was found to inhibit PKA activity in CGNPs, and, in
turn, sustained PKA activation blocked CGNP proliferation in vitro despite
stimulation by SHH (Barzi et al., 2010; Nicot et al., 2002). In the cerebellum, PKA
may be activated through signaling by PACAP (pituitary adenylate cyclase activating
polypeptide) – a molecule released by Purkinje cells (Vaudry et al., 1998). Secreted
PACAP is received in the outer and inner EGL by CGNPs, which express PACAP
receptors during early development (Basille et al., 1993, 1995; Favit et al., 1995).
Another negative regulator of CGNP proliferation, and an inducer of their
diﬀerentiation, is the extracellular matrix (ECM) glycoprotein VTN (Vitronectin),
which can be found from the inner EGL through the IGL (Wechsler-Reya, 2001;
Hashimoto et al., 2016). Although the method by which VTN acts on CGNPs is not
well understood, one possibility is that it binds to receptors on CGNPs to activate
PKA. Research along this line has also shown that PKA achieves transcriptional
control by stimulating CREB (cAMP (cyclic adenosine monophosphate) response
element-binding protein), which is a transcription factor found in CGNPs (Delghandi
et al., 2005; Pons et al., 2001). Thus, the emerging picture is that as CGNPs migrate
inward from the outer EGL, VTN and PACAP activate PKA, which phosphorylates
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GLI3 and CREB. This marks GLI3 and CREB for degradation and heralds cellular
exit from proliferation and the commencement of diﬀerentiation.
Several potential positive regulators of CGNP proliferation also exist along the
outer EGL. The ECM protein laminin has been shown to increase the proliferative
ability of CGNP cultured with SHH (Pons et al., 2001). Additionally, HSPGs
(heparan sulfate proteoglycans) and the chemokine SDF-1 (stromal cell-derived
factor-1; CXCL12, Chemokine C-X-C motif ligand 12) have also demonstrated the
ability to act synergistically with SHH signaling (Rubin et al., 2002; Klein et al.,
2001). On their own (without SHH signal), these molecules can only stimulate
modest CGNP proliferation. In contrast, growth factors such as EGF (epidermal
growth factor), IGF1 (insulin-like growth factor 1), and bFGF (basic fibroblast
growth factor) can induce CGNP proliferation without SHH (Gao et al., 1991).
Interestingly, when these factors are provided in addition to SHH, EGF and IGF1
cause a mild suppression of CGNP proliferation, and bFGF, likely acting through
CREB, significantly reduces the SHH-mediated proliferative response
(Wechsler-Reya and Scott, 1999). Yet, another study found that IGF1 and IGF2
signaling increased CGNP proliferation both synergistically with SHH and
independent of SHH (Fernandez et al., 2010).
The significance of these pro- and anti-proliferative factors is realized when
viewed in light of the complexity of cerebellar development. In the cerebellum,
Purkinje cells secrete SHH (Wallace, 1999). CGNPs initially proliferate in response
to this signal while in the EGL during early development. Maturation of CGNPs into
CGNs requires cessation of proliferation, migration to the IGL, and terminal
diﬀerentiation. Paradoxically, CGNPs achieve this maturation as they travel from
the EGL past the PCL – the very source of SHH signaling. While CGNPs could
somehow convert a proliferative SHH signal into a diﬀerentiative one, it appears
that SHH is actually unnecessary for CGNP maturation (Lewis et al., 2004). A
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possibility is that extracellular SHH is maximal in the EGL through secretion from
the tips of Purkinje axons, rather than being maximal in the ECM of the PCL.
Switching from proliferation to diﬀerentiation could also involve reduced contact
with proliferative signals in the outer EGL such as laminin as increased contact with
diﬀerentiative signals in the inner EGL such as VTN, as CGNPs migrate inwards.
Thus, normal CGNP development conceivably requires a delicate interplay between
the factors promoting SHH-mediated proliferation and those signaling for
diﬀerentiation through blocking SHH activity. The timing of these interactions is
also likely to be of the utmost importance, with dysregulation of signaling events
potentially leading to the formation of cancer.
Seckel syndrome and ATR
The history of Seckel syndrome
In 1960, the German-American pediatrician Helmut Paul George Seckel
described thirteen cases of what he called bird-headed dwarfism from researching
the literature, with two cases being from personal interaction (Seckel, 1960). Seckel
borrowed the term bird-headed dwarf from the German physician Rudolf Ludwig
Carl Virchow, who first observed isolated instances of the condition in the late-19th
century (Virchow, 1892). Aﬀected patients displayed intrauterine growth restriction,
microcephaly, mental disability, and characteristic facies including a sloping/
receding forehead and chin with a protruding nose. Among the documented cases,
several occurred in siblings with normal, consanguineous parents at equal frequency
between both sexes, suggesting autosomal recessive inheritance. This condition was
thereafter called Seckel syndrome (SS), and since its initial report, only
approximately one hundred other cases have been chronicled.
Before the age of genetic testing, SS was diagnosed solely based on clinical
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findings. Seckel himself delineated what he considered the most important features
in diagnosing SS as opposed to other types of primordial dwarfism, intrauterine
growth restriction, or microcephaly. That is, characteristic craniofacial deformities
must be present in addition to microcephaly and mental disability. Indeed,
throughout the years, various authors have questioned earlier historical accounts of
SS, putting into doubt the true number of cases of Seckel that have ever been
diagnosed (Thompson and Pembrey, 1985; Majewski and Goecke, 1982). As it stands,
SS is an extremely rare condition with unknown incidence and prevalence.
Soon after Seckel’s initial report on his eponymous syndrome, John Black
described two sisters with bird-headed dwarfism and microcephaly consistent with
SS (Black, 1961). Over the next five years, four more patients were purported to have
SS (Aarons, 1964; De La Cruz, 1963; Szalay, 1964). Then in 1967, pairs of siblings in
three separate families were reported as having SS by two groups (McKusick et al.,
1967; Harper et al., 1967). Only five more descriptions of SS surfaced globally
through the course of the next ten years, emphasizing the rarity of this condition
(Nunez et al., 1971; Sauk et al., 1973; Anoussakis et al., 1974; Cervenka et al., 1979;
Lambotte et al., 1976). Interestingly, a meta-analysis in 1982 reputed some of the SS
diagnoses made by several authors, including Seckel himself, stating that only
seventeen cases had been reported to date that fit the physiological criteria of SS
(Majewski and Goecke, 1982). A decade later, a separate group expressed support for
these conclusions (Sugio et al., 1993), and also included one additional case that they
had recently identified as well as two cases identified by Butler and colleagues in
1987, who proposed to expand the SS criteria since they observed chromosome
breakage in the cells of two patients, one of whom also had pancytopenia (Butler
et al., 1987). Similarly, a patient with SS who later in life developed acute myeloid
leukemia (AML) and was treated with chemotherapy that produced severe
hematological toxicity further raised the question of whether SS patients
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reproducibly harbor some hematological abnormality (Hayani et al., 1994).
The first neuroimaging on SS patients was performed in 1997 on three siblings
from a consanguineous family (Shanske et al., 1997). On CT scan, the authors noted
agenesis of the corpus callosum, pachygyria, and cortical cysts. More than fifty
additional cases of SS were reported over the next two decades, including one
instance accompanied by extensive congenital heart anomalies and one patient with
a hypoplastic corpus callosum (Abou-Zahr et al., 1999; Can et al., 2010;
Mokrani-Benhelli et al., 2013; Borglum et al., 2001; Goodship et al., 2000). Genetic
testing that was performed in one of those studies on five aﬀected patients in two
unrelated, consanguineous families suggested chromosome 3q22.1-q24 as the SS
locus (Goodship et al., 2000). Another study on four SS patients from a
consanguineous family identified instead chromosome 18p11.31-q11.2 as the
putative SS locus (Borglum et al., 2001). With this greater ease of genetic mapping
and growing interest in SS, it increasingly appeared to be a genetically
heterogeneous condition, which was supported by findings in eleven SS patients
spanning six consanguineous families who all lacked mutations in these two loci
(Faivre et al., 2002).
The genetics of Seckel syndrome
Two candidates were proposed in 2003 as the gene mutated in SS (Table 1.2). In
one study, among eighteen SS patients across thirteen families, individuals in five
families demonstrated mutation in chromosome 14q23, which contains theMNAT1
(Ménage à trois homolog 1) gene that is involved in cell cycle and transcriptional
regulation (Kilinc et al., 2003; Tassan et al., 1995). Later, the authors amended their
findings in light of faulty data, andMNAT1 is no longer considered a SS gene nor
14q23 a SS locus – formerly referred to as causative of SS type 3. In another study
that same year, Goodship and colleagues, who identified the 3q22.1-q24 SS locus,
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performed further studies on their five patients and found that the ATR gene, which
codes for a DNA damage response protein, specifically was mutated in that locus, so
that SS type 1 is now considered to be defined by ATR mutation (O’Driscoll et al.,
2003). Over the next decade, seven more genes would be identified as mutated in
diﬀerent subtypes of SS.
SS type 4 was described in 2007 in three individuals who harbored mutations in
PCTN (Pericentrin; chromosome 21q22.3), which codes for a protein that ensures
proper mitotic spindle formation (Griﬃth et al., 2008; Doxsey et al., 1994).
Alternately, SS type 4 has been proposed to be due to mutations in CENPJ
(Centromere protein J; chromosome 13q12.12-q12.13) – responsible for centriole
duplication and centrosome maintenance – which were found in five aﬀected
individuals from a consanguineous family (Al-Dosari et al., 2010; McIntyre et al.,
2012). The authors of the latter study suggested that the purported SS patients with
PCTN mutation would more accurately be described as having microcephalic
osteodysplastic primordial dwarfism type II (MOPDII) rather than SS since their
presentation was more MOPDII-like than SS-like. Shortly thereafter, in rapid
succession, SS types 2, 5, and 6 were defined in 2011. Using the SS patients in which
chromosome 18p11.31-q11.2 anomalies had been discovered, Qvist and colleagues
determined the RBBP8 (Retinoblastoma-binding protein 8) gene, which codes for an
endonuclease associated with ATM- (Ataxia-telangiectasia mutated) and ATR-
mediated DNA repair, to be mutated in all aﬀected individuals (Qvist et al., 2011;
Huertas and Jackson, 2009; Sartori et al., 2007). Three years later, this same
mutation was found in an unrelated SS patient, and SS associated with this
mutation is now categorized as SS type 2 (Shaheen et al., 2014). SS types 5 and 6 are
defined by mutations in genes that code for the interacting/cooperative centrosomal
proteins CEP152 (Centrosomal protein 152) and CEP63, respectively (Blachon et al.,
2008; Smith et al., 2009; Brown et al., 2013). Four subjects from three
21
consanguineous families and one unrelated subject were diagnosed with SS and
found to have mutations in CEP152 (chromosome 15q21.1-q21.2) (Kalay et al., 2011).
Independently that same year, CEP63 (chromosome 3q22.2) was seen to be mutated
in three female cousins from consanguineous families (Sir et al., 2011).
Although SS type 3 has been dropped from the SS spectrum, a gene nearMNAT1,
NIN (Ninein; chromosome 14q22.1), is considered to be mutated in SS type 7. Two
sisters born from distantly-related parents were diagnosed with a SS-like condition
based on pre- and postnatal growth impairment, microcephaly, mental disability, and
facies such as prominent nose, and found to have mutations in NIN, which codes for a
centrosomal protein (Dauber et al., 2012; Ou et al., 2002). SS type 8 was categorized
based on observed mutations in DNA2 (DNA replication helicase/nuclease 2;
chromosome 10q21.3), which codes for a nuclear and mitochondrial DNA replication
and repair enzyme, seen in two members of a consanguineous family with distinct
features of SS (Shaheen et al., 2014; Zheng et al., 2008). Most recently, whole-exome
sequencing has determined a mutation in three unrelated SS patients of the TRAIP
(Tumor necrosis factor receptor-associated factor interacting protein; chromosome
3p21.31) gene whose protein product negatively regulates innate immune signaling
and has a putative role in resolving DNA replication forks (Harley et al., 2016).
Apart from the nine categorized subtypes of SS, mutations in other genes have
also been described in SS patients. In 2012, three patients were found to have
mutations in the ATRIP (ATR-interacting protein) gene (Ogi et al., 2012). ATRIP
forms a complex with ATR and is required for its recruitment and activation (Cortez
et al., 2001), so given that ATR mutation causes SS type 1, it was reasonable that
ATRIP mutation should also produce a form of SS. A final gene thought to be
mutated in a type of SS is CDK5RAP2 (CDK (Cyclin-dependent kinase) 5 regulatory
subunit-associated protein 2; chromosome 9q33.2), whose protein regulates mitotic
spindle orientation and spindle checkpoint activation (Yigit et al., 2015; Lizarraga
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et al., 2010). Two sibling pairs from two consanguineous families with characteristics
of SS were sequenced as having splice-site mutations in CDK5RAP2 that produced a
truncated, unstable protein associated with spindle disorganization and mitotic
defects. Altogether, this wide array of genetic alterations reported in patients with
SS underscores the genotypic heterogeneity and helps explain some of the phenotypic
diversity of this condition. That is, beyond the intrauterine growth restriction,
microcephaly, mental disability, and characteristic facies that typify SS, patients can
suﬀer from a multitude of comorbidities, as described in the case reports above.
Animal models of Seckel syndrome
In 2009, the first animal model of SS, specifically SS type 1, was introduced
(Murga et al., 2009). To create this model, the authors replaced exons 8, 9, and 10 of
the mouse Atr coding sequence with the human counterparts and altered exon 9 with
the splicing mutation previously observed in Seckel patients that causes skipping of
that exon (O’Driscoll et al., 2003). Exons 8 and 10 were also introduced into mice
because the authors reasoned that although ATR exons are conserved between man
and mouse, the introns are divergent and represent important regions for splicing
reactions. Mice with mutant, humanized Atr expressed very low, but life-sustaining,
levels of the protein, as in human patients. This last consideration was important
since prior research had shown that complete loss of ATR is embryonic lethal in mice
by E8.5, although maintenance of one allele results in decreased ATR levels, but
enough to sustain life (de Klein et al., 2000). Atr mutation in mice modeled human
SS by recapitulating several important phenotypic findings: intrauterine growth
restriction, postnatal dwarfism, microcephaly, craniofacial dysmorphia including a
receding forehead and prominent nose, and MRI findings of agenesis of the corpus
callosum and cortical cysts. While ATR protein levels were globally very low in
mutant neonatal mice, tissues such as the testes and lungs partially regained
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normal ATR levels later in postnatal life, suggesting clonal selection for isolated cells
with normally-spliced rather than mutant Atr and highlighting the critical
importance of ATR. Although the lifespan and long-term medical consequences of SS
patients has not been well-documented, SS type 1-like Atr-mutant mice typically
died by 20 weeks of life, with none surviving past 35 weeks, due to multiple organ
failure. That is, in later postnatal development, these mice appeared progeric, with
canities, kyphosis, osteoporosis, bone marrow fat accumulation, and pancytopenia.
Molecular analysis revealed that the SS-like phenotype from Atr mutation was due
to widespread DNA damage, despite attempted repair by ATM and DNA-PKc
(DNA-dependent protein kinase, catalytic subunit), that led to decreased
proliferation through G2/M arrest and p53-mediated, caspase-dependent apoptosis
during embryonic development and focally to the brain compared to other organs in
neonatal development. Molecular and phenotypic events were exacerbated in
Atr/p53-double-mutants, who interestingly never developed tumors though despite
very high levels of widespread DNA damage.
Animal models for SS types 4 and 7 were then simultaneously revealed in
November 2012. A hypomorphic mutation in Cenpj, as found in human SS type 4
patients, was developed in mice that led to greatly reduced levels of the normal
protein product due to alternative splicing of a critical exon (McIntyre et al., 2012).
Mutant animals experienced intrauterine growth restriction and showed signs of
postnatal growth impairment, microcephaly, abnormal bone ossification, and
characteristic facies such as a prominent nose, receding chin, and high forehead.
Cellular studies found that neuropathology was due to increased DNA damage that
led to caspase-dependent apoptosis, but not attenuated proliferation, in neural stem
and progenitor cells of the embryonic brain. DNA damage, in turn, was shown to be
a result of dysregulated mitotic processes, normally controlled by CENPJ, that led to
supernumerary centrosomes, chromosome damage, and aneuploidy.
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Although NIN mutation is considered the putative defining characteristic of SS
type 7 (Zheng et al., 2016), the original authors who identified the only known NIN
mutations believed they had discovered a novel locus for an unreported type of
primordial dwarfism rather than SS specifically (Dauber et al., 2012). The aﬀected
siblings with NIN mutations had many hallmarks of SS, but the authors felt that
some physical deformities did not match up well. Nevertheless, the authors
acknowledged the recognized phenotypic heterogeneity of SS and conceded that the
patients could have a new form of SS. Primary fibroblasts isolated from the patients
showed normal levels of NIN that localized to interphase, but not mitotic,
centrosomes. Cell proliferation and mitotic progression were curiously normal in
these cells. Morpholino knockdown of ninein in zebrafish led to embryonic
neurodevelopmental disturbances, including prominently at the rhombic lip, and the
postnatal microcephaly and craniofacial deformities reminiscent of SS. Recently, a
diﬀerent group mutated nin in Drosophila, but found that decreased nin expression
had no impact on embryonic or neural development, suggesting diﬀerent
dependencies on NIN between vertebrates and flies (Zheng et al., 2016).
A final animal model for SS involves mutation of CEP63, as seen in SS type 6.
Mice were engineered to express gene-trapped alleles of Cep63, significantly
reducing Cep63 expression and producing mice with postnatal growth impairment
and microcephaly, albeit with normal lifespans (Marjanovic et al., 2015). Looking
specifically at neural stem and progenitor cells in Cep63-mutant E14.5 mice, the
authors found normal or increased levels of mitosis and weak levels of DNA damage
but strong induction of p53-mediated, caspase-dependent apoptosis. Co-deletion of
p53 rescued microcephaly but co-deletion of Atm or Chk2 failed to rescue pathology,
indicating that the cellular response to CEP63 deficiency is independent of the
double strand break repair pathway. Increased cell death from CEP63 disruption
was seen to be a result of failed centriole duplication, abnormal centrosome
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formation and numbers, and mitotic spindle defects that led to spindle assembly
checkpoint activation, which can induce apoptosis. Cep63-mutant neural stem and
progenitor cells were also seen with aneuploidy in G1-phase, suggesting escape of
mitotic arrest, which could precipitate apoptosis later in the cell cycle. These four
animal models of SS thus suggest that microcephaly in this condition occurs due to
apoptosis of neural stem and progenitor cells.
ATR kinase and the DNA damage response
ATR was one of the first genes linked to SS and its protein function has been
extensively studied. The importance of ATR in SS is emphasized by observations of
disrupted ATR pathway signaling not just in SS type 1 but in more than half of all of
the recognized subtypes of SS, including type 2 (RBBP8 mutation), type 5 (CEP152
mutation), type 6 (CEP63 mutation), type 8 (DNA2 mutation), and an unclassified
subtype defined by ATRIP mutation. In a way, disruption of ATR pathway signaling
has come to define SS. Therefore, understanding of SS pathogenesis has been heavily
informed by studies of ATR function in diﬀerent cells and the consequences of its
absence.
ATR was first described in yeast, as Esr1 (Essential gene required for DNA repair
and meiotic recombination 1) or Mec1p (Mitosis entry checkpoint protein 1) (Kato
and Ogawa, 1994). Complete absence of the Atr homolog was lethal and mutant yeast
with hypomorphic Atr experienced increased sensitivity to ultraviolet (UV) light and
the DNA replication fork stalling agent methyl methanesulfonate (MMS). Esr1 was
seen to be induced during mitosis and analysis of its structure revealed similarities
to the DNA repair enzyme Rad3 (XPD, Xeroderma pigmentosum group D, in
mammals), the regulator of chromosome segregation Cut1 (ESPL1, Extra spindle
pole bodies-like 1 in mammals), and the PI3K (phosphoinositide 3-kinase) family.
Shortly after the characterization of Esr1/Mec1p in yeast, the mammalian homolog
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ATR (originally named FRP1, Fluorescence recovery after photobleaching-related
protein 1) was discovered by cDNA cloning and gene mapping in human Jurkat
T-cells (Cimprich et al., 1996). The ATR gene was mapped to chromosome 3q22-q24
and structural analysis showed its similarity to yeast Mec1p and Rad3. Since these
initial reports, an enormous body of literature has minutely dissected the ATR
pathway, revealing that ATR is broadly possibly involved in numerous processes
through interactions with hundreds of putative targets (Matsuoka et al., 2007). The
exact function of ATR may diﬀer by cell type and depend on the cellular situation,
but suggested or confirmed processes include cell cycle control, signal transduction,
cell proliferation and diﬀerentiation, immune function, protein metabolism and
modification, mRNA transcription, and DNA replication, recombination, and repair.
Perhaps the most well-studied function of ATR is in responding to DNA damage
and inducing cell cycle arrest to allow for repair (Nam and Cortez, 2011). In dividing
cells, DNA damage can occur as a result of endogenous processes such as oxidation
(Willis et al., 2013), transcription-replication collision (Deshpande and Newlon, 1996;
Takeuchi et al., 2003; Ivessa et al., 2003), transcription-associated recombination
and mutation (Paques and Haber, 1999; Prado and Aguilera, 2005), and R-loop
formation (Santamaria et al., 1998, 2000; Viguera et al., 1996). Exogenous sources
like UV light, X-ray irradiation, and chemical mutagens can also produce DNA
damage (Ciccia and Elledge, 2010). The presence of DNA damage induced by such
sources promotes stalling of the replication fork in S-phase (Mirkin and Mirkin,
2007). Similarly, fork stalling can occur as a result of depletion of materials requisite
for replication such as nucleotides and RPA (replication protein A), which must coat
single-stranded DNA (ssDNA) at open replication forks (Poli et al., 2012; Toledo
et al., 2013).
DNA replication is a highly regulated event requisite for distribution of genetic
material and cell division. During the first interphase, areas of the genome are
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marked as replication origins by the origin recognition complex (ORC), a hetero-
hexameric scaﬀold composed of ORC1 - ORC6 (Dutta and Bell, 1997). The ORC
binds to specific DNA sequences, including AT-rich sequences or dinucleotide repeats
in general (Paixao et al., 2004; Altman and Fanning, 2004; Wang et al., 2004),
asymmetrical purine-pyrimidine regions (Wang et al., 2004), and parts of the DNA
that attach to the nuclear matrix (Schaarschmidt et al., 2004). The minichromosome
maintenance (MCM) complex, a hexameric structure composed of MCM2 - MCM7, is
then loaded onto the ORC along with CDC6 (Cell division cycle 6) and CDT1
(Chromatin licensing and DNA replication factor 1), generating the pre-replication
complex (pre-RC) (Wyrick et al., 2001). Activation of the pre-RC, which is required
for binding of further components needed to initiate replication, is achieved by
phosphorylation by CDC7 and CDK2-Cyclin A/CDK2-Cyclin E (Woo and Poon, 2003).
In mammalian cells, not all pre-RCs will initiate replication and it is an active area
of research as to what dictates which pre-RCs will fire (Edwards et al., 2002; Hyrien
et al., 2003), but may be related to the influence of certain DNA elements outside the
pre-RC (Aladjem et al., 1995), chromatin accessibility (Pasero et al., 2002; Pappas
et al., 2004), and transcriptional activity (Nieduszynski et al., 2005; Haase et al.,
1994). However, the function of the excess, non-firing pre-RCs seems to be in
maintaining genomic integrity and that they will activate to ensure complete DNA
replication when the replication fork stalls at other regions initiated by primary
pre-RCs (Woodward et al., 2006; Ge et al., 2007; Ibarra et al., 2008).
In S-phase, binding of additional factors to the pre-RC, namely CDC45 and the
GINS complex (Go-ichi-ni-san; composed of GINS1, GINS2, GINS3, and GINS4),
establishes the nascent replisome, or active area of DNA replication (Takayama
et al., 2003; Kamada et al., 2007). A fully function replication fork requires further
recruitment of proteins like helicase (MCM), topoisomerase, DNA primase, DNA
polymerase, DNA ligase, fork stability/protection factors, and RPA (Masai et al.,
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2010). Establishment of a functional replication fork allows DNA replication to
proceed, which can be hindered by factors that stall the replication fork, as detailed
above. Replication fork stalling promotes the uncoupling of the MCM helicase and
DNA polymerase, which provides a signal for the binding of ATRIP to the RPA that
coats strands of unwound DNA in active forks (Byun et al., 2005; Zou and Elledge,
2003). ATRIP recognition of RPA is enhanced by, but does not require, interaction
with CINP (CDK2-interacting protein), which forms a complex with CEP152 (Kalay
et al., 2011; Lovejoy et al., 2009). ATR exists in a functional dimer with ATRIP, so
recruitment of ATRIP to RPA recruits ATR as well (Cortez et al., 2001).
Independently, RPA also attracts the RAD17 protein, which localizes the 9-1-1
(RAD9-RAD1-HUS1) complex (Zou et al., 2002). The 9-1-1 complex has been found to
recruit TOPBP1 (DNA topoisomerase 2-binding protein 1) and RHNO1 (9-1-1-
interacting nuclear orphan 1), which are essential activators of ATR (Delacroix et al.,
2007; Cotta-Ramusino et al., 2011). Claspin is another component of the stalled
replication fork recognition complex that is recruited independently of ATR/ATRIP
and RAD17/9-1-1 and is suggested to act as a scaﬀold for localization of CHK1
(Chekpoint kinase 1) and mediate the interaction between ATR and CHK1 through
TOPBP1 (Kumagai and Dunphy, 2000; Liu et al., 2006b). Claspin may be tethered to
RPA through the action of TIPIN (Timeless-ineracting protein), which also facilitates
TIM (Timeless circadian clock)-mediated modification of ATR to allow for CHK1
activation (Kondratov and Antoch, 2007; Kemp et al., 2010). Ultimately, a major
eﬀect of this complicated network is CHK1 activation by ATR through
phosphorylation on Ser-317 and Ser-345 (Liu et al., 2000).
CHK1 activity is mostly limited to S- and G2-phases to reflect the maximal
periods of possible ATR activity (Lukas et al., 2001). In support of the hypothesis
that replication forks regularly stall from endogenous sources in proliferative cells,
activated CHK1 has been found in cells not exposed to exogenous insults (Kaneko
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et al., 1999; Zhao et al., 2002; Sorensen et al., 2003). CHK1 is a serine/threonine
kinase that was originally described in S. pombe as a controller of progression
through the G2/M checkpoint (Walworth et al., 1993). Since its original discovery,
several roles have been elucidated for CHK1, and other controllers of its activation
have also been found. In S-phase, CHK1 phosphorylates CDC25A, targeting it for
proteasomal degradation (Sorensen et al., 2003; Mailand et al., 2000; Shimuta et al.,
2002). CDC25A removes inhibitory phosphate groups from CDK2, which promotes
the activity of the CDK2-Cyclin E and CDK2-Cyclin A complexes that are important
for G1-S transition, S-phase progression, and S-G2 transition (Shen and Huang,
2012). Thus, CHK1 activation in S-phase acts to slow S-phase progression and delay
transition into G2-phase. Delay is also induced by CHK1 phosphorylation and
inhibition of CDC7, preventing activation of the pre-RC (Heﬀernan et al., 2007).
Evidence suggests that CHK1 can additionally remove CDC45 from replisomes,
further halting S-phase progression (Liu et al., 2006a). In essence, these delays in
S-phase progression are a consequence of reduced replication origin firing as a
means of reducing the amount of possible stalled forks. The role of CHK1 in
regulating G2/M transition is mediated by phosphorylation and inactivation of
CDC25C, which, when active, removes inhibitory phosphates from CDK1 (CDC2), an
important controller of mitotic entry (Furnari et al., 1999; Blasina et al., 1999; Peng
et al., 1997). CHK1 also phosphorylates and activates WEE1, which further
inactivates CDK1 and prevents G2/M transition (Lee et al., 2001). Similar to
CDC25C, another member of that phosphatase family, CDC25B, can also activate
CDK1. CHK1 apparently associates with interphase centrosomes to inactivate
CDC25B and thereby prevent inappropriate mitotic entry (Kramer et al., 2004).
Finally, arrest at G2/M can be achieved by ATR targeting of CEP63 to block assembly
of the mitotic spindle (Smith et al., 2009; Marjanovic et al., 2015). Just as continued
DNA replication and cell cycle progression in the presence of stalled replication forks
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can be toxic, so too can continued transcription potentially exacerbate fork stalling.
In response, CHK1 phosphorylates histone H3 to repress transcription (Shimada
et al., 2008).
The primary goal of halting the cell cycle through ATR activation of CHK1 is to
allow for the resolution of stalled replication forks, which often requires DNA repair.
ATR is capable of phosphorylating and activating several substrates involved in
homologous recombination (HR), including BRCA1 (Breast cancer 1) (Tibbetts et al.,
2000), WRN (Werner syndrome RecQ-like helicase) (Pichierri et al., 2003), and BLM
(Bloom syndrome RecQ-like helicase) (Davies et al., 2004; Li et al., 2004). WRN is
believed to interact with the nuclease DNA2 in processing DNA damage and
promoting replication fork restart (Thangavel et al., 2015). Similarly, CHK1 can
activate the HR proteins RAD51 (Syljuasen et al., 2005; Sorensen et al., 2005) and
BRCA2 (Bahassi et al., 2008). Besides HR, ATR can also promote DNA repair
through FANCD2 (Fanconi anemia complementation group D2)-mediated crosslink
repair (Andreassen et al., 2004) and XPA (Xeroderma pigmentosum group
A)-mediated nucleotide excision repair (Wu et al., 2007). However, it still unclear
how ATR dictates whether DNA repair is requisite at a stalled fork and how it then
decides which type of repair to utilize, but this choice could relate to cell cycle phase
and the availability of homologous chromosomes. Should DNA damage be extensive,
ATR and CHK1 are both capable of directly activating p53, or indirectly through
inactivation of the p53 ubiquitin ligase MDM2 (Mouse double minute 2 homolog),
which can either further halt the cell cycle, especially at the G1/S checkpoint, or
initiate the apoptotic program (Tibbetts et al., 1999; Nghiem et al., 2002). Once DNA
damage has been repaired or the source of fork stalling otherwise resolved, ATR
phosphorylates MCM2, a component of the replication helicase, which allows for the
docking of PLK1 (Polo-like kinase 1) (Trenz et al., 2008; Cortez et al., 2004; Yoo et al.,
2004). The addition of PLK1 to the replication fork promotes fork restart, at least in
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part through inhibition of CHK1 and the re-recruitment of CDC45. In this way, ATR
self-regulates its signaling to allow for cell cycle arrest and DNA repair in the
presence of stalled replication forks and then fork restart upon resolution of stalling.
ATM kinase and the consequences of replication fork collapse
As the name ATR suggests, it is morphologically and functionally related to
another PI3K-like protein, ATM. Although originally thought to be involved in
relatively separate and independent DNA damage response processes, namely
ssDNA DNA break (SSB) repair at stalled replication forks for ATR and dsDNA
break (DSB) repair for ATM, the prevailing belief now is that ATR and ATM have
many of the same substrates and can also promote the activation of each other
(Cimprich and Cortez, 2008; Smith et al., 2010). At sites of DNA damage at stalled
replication forks, ATR is able to phosphorylate H2A.X (Histone H2A, member X) on
Ser-139, generating H2A.X, which is thought to recruit ATM (Ward and Chen,
2001). Once recruited, ATM can be activated by ATR through phosphorylation of
Ser-1981 (Stiﬀ et al., 2006). Activated ATM can mediate repair of DSBs, but has also
been shown to localize and promote the activity of TOPBP1, thereby activating ATR
in kind (Yoo et al., 2007, 2009; Wang et al., 2011). ATM may further enhance ATR
pathway signaling by stabilizing the 9-1-1 complex through RAD9 phosphorylation
(Shin et al., 2012). Downstream of ATR/ATM activation, among the hundreds of
putative ATR targets, many are shared by ATM, although the functional significance
of most of these interactions is still not well understood (Matsuoka et al., 2007).
An understanding of ATM function is important in light of the consequences of
replication fork collapse. As discussed, stalled replication forks trigger ATR/CHK1-
mediated cell cycle arrest and attempted DNA repair. However, extensive DNA
damage can overwhelm the repair machinery, prolonging replication fork stalling,
which can also be caused by absence of ATR. Prolonged fork stalling leads to
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replication fork collapse, or the formation of DSBs, through an as yet poorly
understood mechanism (Sirbu et al., 2011; Hanada et al., 2007). One possible
method of fork collapse is the digestion of ssDNA by endonucleases into DSBs
(Hanada et al., 2007; Lopes et al., 2006, 2001; Sogo et al., 2002). Regardless of how
exactly stalled forks collapse, the consequence is the generation of DSBs, considered
the most toxic form of DNA damage, which can also form in response to ionizing
radiation (IR), radiomimetic chemicals, and oxygen free radicals (Brown and
Baltimore, 2000; Ragland et al., 2013; Saleh-Gohari et al., 2005). DSBs rapidly
recruit the MRN complex consisting of the endo- and exonuclease MRE11 (Meiotic
recombination 11 homology), the DNA binding element RAD50, and the recruiter of
ATM NBS1 (Nijmegen breakage syndrome 1) (Shiloh, 2003; Shiloh and Ziv, 2013;
Shiloh, 2006). MDC1 (Mediator of DNA damage checkpoint 1) is recruited next to a
DSB site if the site contains H2A.X, which is phosphorylated by ATR, ATM, and
DNA-PKc (Lukas et al., 2004; Mukherjee et al., 2006; Reitsema et al., 2005). The last
member recruited to DSBs is 53BP1 (p53-binding protein 1), an activator of p53
(Wang et al., 2004). The presence of MDC1 is thought to stabilize the long-term DNA
association of the MRN and 53BP1. ATM is recruited by the MRN and enhances the
activity of NBS1, MDC1, and 53BP1, which in turn promote its recruitment and
activation through a cyclical process. While ATM can be activated from replication
fork collapse, or the conversion of SSBs to DSBs, so too has it been shown that DSBs,
such as formed directly from IR, can be converted to SSBs via nuclease digestion of a
single strand of DNA in order to recruit ATR (Jazayeri et al., 2006; Myers and
Cortez, 2006; Adams et al., 2006; Cuadrado et al., 2006).
The canonical target of activated ATM is the serine/threonine kinase CHK2,
which is closely related to CHK1 and acts on many of the same downstream eﬀectors
(Smith et al., 2010; Shiloh, 2006, 2003). Together, ATM and CHK2, like ATR and
CHK1, increase the activity of the important tumor suppressor p53 both directly and
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through inactivation of MDM2, which allows p53 to halt the cell cycle and/or induce
apoptosis (Meek, 2004; Stommel and Wahl, 2004; Kurz and Lees-Miller, 2004).
CHEK2 can also promote cell cycle arrest via similar mechanisms used by
ATR/CHK1 such as activation of G1/S and intra-S checkpoints through
phosphorylation of CDC25A and activation of the G2/M checkpoint through
phosphorylation of CDC25C (Falck et al., 2001; Thanasoula et al., 2012). Arrest of
the cell cycle facilitates repair of the causative DNA damage, which can be
accomplished by several molecules. CHK2 directly activates the HR protein BRCA1
and indirectly activates the related HR protein BRCA2 and the base excision repair
factor XRCC1 (X-ray cross-complementing group 1) through stabilization of the
FOXM1 (Forkhead box M1) transcription factor (Lee et al., 2000; Tan et al., 2007).
DNA repair by HR requires exposure of template DNA, which is facilitated by
MRE11, BRCA1, and the nuclease CtIP (C-terminal-binding protein-interacting
protein; RBBP8), which is activated indirectly by CHK2 through CDK2 (Sartori
et al., 2007).
Apoptosis
When genotoxicity overwhelms the capabilities of the DNA repair machinery, or
should any component of that machinery be faulty due to mutation, then
programmed apoptotic cell death can be initiated. As discussed, the DNA damage
response proteins ATR and ATM can both directly and indirectly activate the master
regulator of apoptosis, p53. How precisely p53 decides whether DNA repair,
temporary cell cycle arrest, cell cycle exit/senescence, or apoptosis should occur is an
area of active investigation. Presumably, widespread and prolonged presence of DNA
damage allows for diﬀerential activation of p53 to promote the apoptotic program
(Elmore, 2007; Fridman and Lowe, 2003). Once convinced to induce apoptosis, an
important function of p53 is to transcriptionally and mechanically activate
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pro-apoptotic members of the BCL2 (B-cell lymphoma 2) family such as BAX
(BCL2-associated X) (Miyashita et al., 1994), BAK/BAK1 (BCL2 antagonist/killer 1)
(Perfettini et al., 2004; Leu et al., 2004), BAD (BCL2-associated death promoter)
(Yang et al., 1995), BID (BH3-interacting domain death agonist) (Sax et al., 2002),
BIM/BCL2L11 (BCL2-interacting mediator of cell death/BCL2-like 11) (O’Connor
et al., 1998), PUMA/BBC3 (p53-upregulated modulator of apoptosis/BCL2-binding
component 3) (Nakano and Vousden, 2001), and NOXA/PMAIP1 (Phorbol-12-
myristate-13-acetate-induced protein 1) (Oda et al., 2000). High levels of pro-
apoptotic mediators overcomes the anti-apoptotic eﬀects of other BCL2 members like
BCL2 (Vaux et al., 1988; Tsujimoto, 1989), BCL-xL/BCL2L1 (BCL2-like protein 1)
(Minn et al., 1997), and MCL1 (Myeloid cell leukemia 1) (Perciavalle et al., 2012). In
the absence of a cell death signal, anti-apoptotic BCL2 proteins reside in the
mitochondria and prevent the association of the pro-apoptotic factors BAX and BAK
as well as directly alter the mitochondrial membrane to stop release of molecules
such as Cytochrome C and AIF (Apoptosis-inducing factor) (Liu et al., 1996; Kluck
et al., 1997; Yang et al., 1997). Pro-apoptotic BCL2 proteins can promote cell death
either through direct activation of BAX and BAK, the key mediators of mitochondrial
outer membrane permiabilization, or bind and inactivate anti-apoptotic BCL2
proteins. For instance, BIM and BID are capable of inducing activating
oligomerization of BAX and BAK (Letai et al., 2002), whereas BIM, BID, BAD,
PUMA, and NOXA suppress either certain or all members of the pro-apoptotic BCL2
family (Chen et al., 2005; Willis et al., 2007, 2005).
Regulation of pro-apoptotic proteins like PUMA and NOXA is predominantly
controlled at the transcriptional level by p53 (Michalak et al., 2008). BIM activity
may be controlled both at the transcriptional level, though not necessarily directly by
p53, or through post-translational modification and altered protein localization
(Herold et al., 2013; Clybouw et al., 2012; Gogada et al., 2013; Gillings et al., 2009).
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Finally, BAX (Gross et al., 1998; Wolter et al., 1997), BAK (Cartron et al., 2014), BAD
(Kitada et al., 1998), and BID (Billen et al., 2008) are regulated through changes to
their structure that adjust their function or location to enhance apoptotic signaling
(Kutuk and Letai, 2008; Elkholi et al., 2011). Through activation of BAX and BAK
and inhibition of anti-apoptotic factors, BAX and BAK are able to localize in
activated forms to the mitochondrial outer membrane where their pore-forming
ability releases Cytochrome C from the mitochondria (Jurgensmeier et al., 1998;
Eskes et al., 1998). Cytosolic Cytochrome C can then associate with APAF1
(Apoptosis peptidase-activating factor 1) to form the apoptosome (Tsujimoto, 1998;
Adrain and Martin, 2001; Chinnaiyan, 1999). p53 acts as a transcriptional activator
of APAF1 (Robles et al., 2001; Fortin et al., 2001), although BCL2 and BCL-xL,
potentially through intermediaries, may prevent APAF1 association with
Cytochrome C until their activity is attenuated by the pro-apoptotic factors (Hu et al.,
1998; Pan et al., 1998; Inohara et al., 1998; Chau et al., 2000). A fully functional
apoptosome also includes binding of pro-Caspase-9 to APAF1, an interaction that is
again denied by BCL2 and BCL-xL in the absence of pro-apoptotic factors (Hill et al.,
2004; Bratton and Salvesen, 2010). Pro-Caspase-9 clustering on the apoptosome
leads to its activation into the initiator Caspase-9, which is capable of cleaving and
activating executioner Caspases-3, -6, and -7 responsible for continuing apoptosis
(Wurstle et al., 2012). However, as another layer of protection against inappropriate
apoptosis, which would be highly detrimental to a tissue, executioner caspases are
inactivated by inhibitor of apoptosis proteins (IAPs) like XIAP (X-linked IAP)
(Deveraux et al., 1997; Suzuki et al., 2001; Shiozaki et al., 2003). In addition to
Cytochrome C and AIF, permeabilization of the mitochondrial outer membrane also
releases the IAP inhibitor SMAC/DIABLO (Second mitochondria-derived activator of
caspase, Direct inhibitor of apoptosis-binding protein with low PI) (Wu et al., 2000;
Chai et al., 2000; Du et al., 2000). Thus, through BAX/BAK activity, the apoptosome
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forms to activate executioner caspases that are freed from inhibition.
Caspase-9 is able to directly cleave and activate Caspases-3 and -7, and Caspase-3
in turn is able to activate Caspases-6 and -7 (Logue and Martin, 2008). Caspase-3 is
considered the primary executioner caspase as Caspases-6 and -7 perform many
redundant functions albeit with diﬀering specificities (Slee et al., 2001; Walsh et al.,
2008). These executioner caspases cleave many substrates that are either directly
vital to cell survival or activate molecules that then directly destroy key cellular
components. For instance, -fodrin maintains cytoskeletal integrity and is cleaved by
the executioner caspases (Janicke et al., 1998). Another group targeted for
degradation is the cytokeratins, which are also important for providing mechanical
support to cells (Caulin et al., 1997; MacFarlane et al., 2000). Gelsolin is a center for
actin polymerization, creating a permissive environment for intracellular signal
transduction (Sun et al., 1999). When this molecule is cleaved by Caspase-3, its
fragments degrade integral actin filaments in the cell, thereby preventing
intracellular transport and signal transduction and compromising the cytoskeletal
architecture (Kothakota et al., 1997). Nuclear destruction proceeds in part through
cleavage, especially by Caspases-3 and -6, of NUMA (Nuclear mitotic apparatus
protein), a molecule that both organizes the mitotic spindle and enforces the
organized structure of the nuclear matrix (Hirata et al., 1998). In addition, CAD
(Caspase-activated DNase) is released from its inhibitor partner ICAD (Inhibitor of
CAD), allowing it to migrate to the nucleus and actively degrade genomic DNA
(Sakahira et al., 1998). Possibly as a mechanism to prevent attempted cellular repair
of degraded DNA during apoptosis, Caspases-3 and -7 also inactivate the nuclear
repair enzyme and transcriptional activator of DNA repair genes PARP (Poly[ADP-
ribose]polymerase) (Kaufmann et al., 1993; Boulares et al., 1999).
One consequence of complete intracellular breakdown is that the phospholipid
membrane component phosphatidylserine will flip from the inside to the outside of
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the cell (Bratton et al., 1997). This conformational change facilitates recognition by
phagocytes through a non-inflammatory mechanism, enabling the uptake of dying
cells (Fadok et al., 2001). Grossly, the changes that occur to a cell as a result of
apoptosis can be appreciated as a sequence of defined events (Hacker, 2000). Early
on, an apoptotic cell shrinks in size, making the organelles more compact, and its
chromatin becomes highly condensed in what is known as pyknosis. Shrinking of the
cell is likely a result of caspase-mediated interference with the normal cytoskeleton
architecture, however the exact mechanism of pyknosis is still being explored, but
thought to involve the action of caspase-activated DNases like CAD (Tone et al.,
2007; Topiwala et al., 2013). As apoptosis proceeds, membrane blebbing occurs in
response to novel actin-myosin attachments between the membrane and cytoskeleton
that are promoted by the caspase-activated kinase ROCK1 (Rho-associated,
coiled-coil-containing protein kinase 1), which also contributes to the contractile
activity of these newly formed filaments (Coleman et al., 2001). This event is closely
followed by further nuclear destruction in what is termed karyorrhexis, or
widespread DNA fragmentation likely resulting from activation of DNases and
nucleases. Just as the DNA fragments during apoptosis, so too does the entire cell
into small phospholipid-enclosed entities known as apoptotic bodies. Cellular
fragmentation, along with phosphatidylserine exposure, allows rapid uptake of
destroyed cells by macrophages and parenchymal cells without the release of
intracellular materials, circumventing the necessity for an inflammatory response
(Savill and Fadok, 2000; Kurosaka et al., 2003). Apoptosis is complete upon the
engulfment of all cellular components.
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Table 1.2: Seckel syndrome is a genetically heterogeneous disease defined by possible 
mutations in several genes. 
*Locations are cytogenetic bands on human chromosomes. 
†Subtypes as listed by Online Mendelian Inheritance in Man. Blanks indicate genetic mutations 
not currently associated with a recognized subtype. 
‡Mutations in the region containing MNAT1 were originally described as causative of SS type 3, 
but the authors later amended their findings and retracted the claim. 
§PCTN mutation was originally described as causative of SS type 4 but later retracted, as 
reported subjects more likely had MOPDII. 
Gene Location* Function Subtype† Animal model? References 
ATR Chr. 3q23 
DNA damage response, 
replication fork repair, 
mitotic entry 
1 Yes 
O’Driscoll 2003, 
Murga 2009, 
Lang 2016 
RBBP8 Chr. 18q11.2 
ATM/ATR-mediated 
DNA repair 2 No 
Sartori 2007, 
Huertas 2009, 
Qvist 2011 
MNAT1 Chr. 14q23 
Cell cycle/transcription 
regulation 3
‡ No Tassan 1995, Kilinc 2003 
PCTN Chr. 21q22.3 Mitotic spindle assembly 4
§ No Doxsey 1994, Griffith 2008 
CENPJ 
Chr. 
13q12.12-
q12.13 
Centrosome 
maintenance 4 Yes 
Al-Dosari 2010, 
McIntyre 2012 
CEP152 Chr. 15q21.1 Centrosome duplication; 
ATR/ATM-mediated 
spindle assembly 
checkpoint 
5 No Blachon 2008, 
Smith 2009, 
Kalay 2011, Sir 
2011, Brown 
2013, Marjanovic 
2015 
CEP63 Chr. 3q22.2 6 Yes 
NIN Chr. 14q22.1 
Anchor interphase 
microtubules to 
centrosome 
7 Yes 
Ou 2002, Dauber 
2012, Zheng 
2016 
DNA2 Chr. 10q21.3 
DNA replication and 
repair 8 No 
Zheng 2008, 
Shaheen 2014 
TRAIP Chr. 3p21.31 Immune signaling 9 No Harley 2016 
ATRIP Chr. 3p21.31 DNA damage response - No 
Cortez 2001, Ogi 
2012 
CDK5RAP2 Chr. 9q33.2 
Mitotic spindle 
orientation - No 
Lizarraga 2010, 
Yigit 2015 
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FIGURES
Figure 1.1: The cerebellum and how it develops. (A) The developed, adult
cerebellum shown in mid-sagittal (left) and inferior axial (right) views. Adapted from
(Netter, 2011).
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(B) CGNPs and their precursors migrate tangentially away from the rhombic lip, a
transitory dorsal hindbrain germinal zone, in mid-embryonic development to
populate the EGL (top). CGNPs then proliferate in the EGL in early postnatal
development, gradually migrating radially inwards past the MCL and PCL to
populate the IGL (bottom). Ages refer to mouse development. (C) The Math1
transcription factor is activated in mid-embryonic development, as CGNPs and their
precursors begin migrating away from the rhombic lip. Math1 both directly increases
its own expression and increases expression of its repressors in the Notch pathway,
which eventually silence Math1 and allow for CGNP diﬀerentiation. (D) In the
absence of SHH, the PTC transmembrane receptor inhibits SMO, and GLI2/3 is
marked for destruction by a complex consisting of Fu/ULK3, SUFU, and Cos2/KIF7
(top). The degraded GLI3 fragment is a transcriptional repressor. SHH binding
releases SMO from PTC, liberating GLI2/3, which activates transcription of targets
like Ptch1/2, Gli1, andMycN (bottom). D: dorsal, V: ventral, A: anterior, P:
posterior, R: rostral, C: caudal, EGL: external granular layer, MCL: molecular cell
layer, PCL: Purkinje cell layer, IGL: internal granular layer.
42
REFERENCES
Aarons, P. (1964). Vogelkpdwergen. Maandschr Kindergeneesk, 32:9.
Abou-Zahr, F., Bejjani, B., Kruyt, F. A., Kurg, R., Bacino, C., Shapira, S. K., and
Youssoufian, H. (1999). Normal expression of the fanconi anemia proteins faa and
fac and sensitivity to mitomycin c in two patients with seckel syndrome. Am J Med
Genet, 83(5):388–91.
Adams, K. E., Medhurst, A. L., Dart, D. A., and Lakin, N. D. (2006). Recruitment of
atr to sites of ionising radiation-induced dna damage requires atm and
components of the mrn protein complex. Oncogene, 25(28):3894–904.
Adrain, C. and Martin, S. J. (2001). The mitochondrial apoptosome: a killer
unleashed by the cytochrome seas. Trends Biochem Sci, 26(6):390–7.
Akazawa, C., Ishibashi, M., Shimizu, C., Nakanishi, S., and Kageyama, R. (1995). A
mammalian helix-loop-helix factor structurally related to the product of drosophila
proneural gene atonal is a positive transcriptional regulator expressed in the
developing nervous system. J Biol Chem, 270(15):8730–8.
Al-Dosari, M. S., Shaheen, R., Colak, D., and Alkuraya, F. S. (2010). Novel cenpj
mutation causes seckel syndrome. J Med Genet, 47(6):411–4.
Aladjem, M. I., Groudine, M., Brody, L. L., Dieken, E. S., Fournier, R. E., Wahl,
G. M., and Epner, E. M. (1995). Participation of the human beta-globin locus
control region in initiation of dna replication. Science, 270(5237):815–9.
Aldosari, N., Bigner, S. H., Burger, P. C., Becker, L., Kepner, J. L., Friedman, H. S.,
and McLendon, R. E. (2002). Mycc and mycn oncogene amplification in
medulloblastoma. a fluorescence in situ hybridization study on paraﬃn sections
from the children’s oncology group. Arch Pathol Lab Med, 126(5):540–4.
Altman, A. L. and Fanning, E. (2004). Defined sequence modules and an
architectural element cooperate to promote initiation at an ectopic mammalian
chromosomal replication origin. Mol Cell Biol, 24(10):4138–50.
Altman, J. and Bayer, S. A. (1997). Development of the cerebellar system: in relation
to its evolution, structure, and functions. CRC Press, The University of Michigan.
Andreassen, P. R., D’Andrea, A. D., and Taniguchi, T. (2004). Atr couples fancd2
monoubiquitination to the dna-damage response. Genes Dev, 18(16):1958–63.
Anoussakis, C., Liakakos, D., Zervos, N., and Karpathios, T. (1974). [congenital
dwarfisms with dysmorphism. 2. bird-head congenital dwarfism (virchow-seckel
type)]. Pediatrie, 29(3):261–7.
Artavanis-Tsakonas, S., Rand, M. D., and Lake, R. J. (1999). Notch signaling: cell
fate control and signal integration in development. Science, 284(5415):770–6.
43
Aruga, J., Inoue, T., Hoshino, J., and Mikoshiba, K. (2002). Zic2 controls cerebellar
development in cooperation with zic1. J Neurosci, 22(1):218–25.
Aruga, J., Minowa, O., Yaginuma, H., Kuno, J., Nagai, T., Noda, T., and Mikoshiba,
K. (1998). Mouse zic1 is involved in cerebellar development. J Neurosci,
18(1):284–93.
Aruga, J., Nagai, T., Tokuyama, T., Hayashizaki, Y., Okazaki, Y., Chapman, V. M.,
and Mikoshiba, K. (1996). The mouse zic gene family. homologues of the drosophila
pair-rule gene odd-paired. J Biol Chem, 271(2):1043–7.
Bahassi, E. M., Ovesen, J. L., Riesenberg, A. L., Bernstein, W. Z., Hasty, P. E., and
Stambrook, P. J. (2008). The checkpoint kinases chk1 and chk2 regulate the
functional associations between hbrca2 and rad51 in response to dna damage.
Oncogene, 27(28):3977–85.
Bailey, P. and Cushing, H. (1925). Medulloblastoma cerebelli: a common type of
midcerebellar glioma of childhood. Archives of Neurology and Psychiatry, 14(2):33.
Bale, S. J., Falk, R. T., and Rogers, G. R. (1998). Patching together the genetics of
gorlin syndrome. J Cutan Med Surg, 3(1):31–4.
Bar, E. E. and Stearns, D. (2008). New developments in medulloblastoma treatment:
the potential of a cyclopamine-lovastatin combination. Expert Opin Investig Drugs,
17(2):185–95.
Bartlett, F., Kortmann, R., and Saran, F. (2013). Medulloblastoma. Clin Oncol (R
Coll Radiol), 25(1):36–45.
Barzi, M., Berenguer, J., Menendez, A., Alvarez-Rodriguez, R., and Pons, S. (2010).
Sonic-hedgehog-mediated proliferation requires the localization of pka to the
cilium base. J Cell Sci, 123(Pt 1):62–9.
Basille, M., Gonzalez, B. J., Desrues, L., Demas, M., Fournier, A., and Vaudry, H.
(1995). Pituitary adenylate cyclase-activating polypeptide (pacap) stimulates
adenylyl cyclase and phospholipase c activity in rat cerebellar neuroblasts. J
Neurochem, 65(3):1318–24.
Basille, M., Gonzalez, B. J., Leroux, P., Jeandel, L., Fournier, A., and Vaudry, H.
(1993). Localization and characterization of pacap receptors in the rat cerebellum
during development: evidence for a stimulatory eﬀect of pacap on immature
cerebellar granule cells. Neuroscience, 57(2):329–38.
Behesti, H. and Marino, S. (2009). Cerebellar granule cells: insights into
proliferation, diﬀerentiation, and role in medulloblastoma pathogenesis. Int J
Biochem Cell Biol, 41(3):435–45.
44
Ben-Arie, N., Bellen, H. J., Armstrong, D. L., McCall, A. E., Gordadze, P. R., Guo, Q.,
Matzuk, M. M., and Zoghbi, H. Y. (1997). Math1 is essential for genesis of
cerebellar granule neurons. Nature, 390(6656):169–72.
Ben-Arie, N., Hassan, B. A., Bermingham, N. A., Malicki, D. M., Armstrong, D.,
Matzuk, M., Bellen, H. J., and Zoghbi, H. Y. (2000). Functional conservation of
atonal and math1 in the cns and pns. Development, 127(5):1039–48.
Bertrand, N., Castro, D. S., and Guillemot, F. (2002). Proneural genes and the
specification of neural cell types. Nat Rev Neurosci, 3(7):517–30.
Bihannic, L. and Ayrault, O. (2016). Insights into cerebellar development and
medulloblastoma. Bull Cancer, 103(1):30–40.
Billen, L. P., Shamas-Din, A., and Andrews, D. W. (2008). Bid: a bax-like bh3
protein. Oncogene, 27 Suppl 1:S93–104.
Blachon, S., Gopalakrishnan, J., Omori, Y., Polyanovsky, A., Church, A., Nicastro, D.,
Malicki, J., and Avidor-Reiss, T. (2008). Drosophila asterless and vertebrate
cep152 are orthologs essential for centriole duplication. Genetics, 180(4):2081–94.
Black, J. (1961). Low birth weight dwarfism. Arch Dis Child, 36:633–44.
Blasina, A., de Weyer, I. V., Laus, M. C., Luyten, W. H., Parker, A. E., and McGowan,
C. H. (1999). A human homologue of the checkpoint kinase cds1 directly inhibits
cdc25 phosphatase. Curr Biol, 9(1):1–10.
Bloom, H. J., Wallace, E. N., and Henk, J. M. (1969). The treatment and prognosis of
medulloblastoma in children. a study of 82 verified cases. Am J Roentgenol
Radium Ther Nucl Med, 105(1):43–62.
Borglum, A. D., Balslev, T., Haagerup, A., Birkebaek, N., Binderup, H., Kruse, T. A.,
and Hertz, J. M. (2001). A new locus for seckel syndrome on chromosome
18p11.31-q11.2. Eur J Hum Genet, 9(10):753–7.
Bouﬀet, E. (2010). Medulloblastoma in infants: the critical issues of the dilemma.
Curr Oncol, 17(3):2–3.
Boulares, A. H., Yakovlev, A. G., Ivanova, V., Stoica, B. A., Wang, G., Iyer, S., and
Smulson, M. (1999). Role of poly(adp-ribose) polymerase (parp) cleavage in
apoptosis. caspase 3-resistant parp mutant increases rates of apoptosis in
transfected cells. J Biol Chem, 274(33):22932–40.
Bourdeaut, F., Miquel, C., Richer, W., Grill, J., Zerah, M., Grison, C., Pierron, G.,
Amiel, J., Krucker, C., Radvanyi, F., Brugieres, L., and Delattre, O. (2014).
Rubinstein-taybi syndrome predisposing to non-wnt, non-shh, group 3
medulloblastoma. Pediatr Blood Cancer, 61(2):383–6.
45
Bratton, D. L., Fadok, V. A., Richter, D. A., Kailey, J. M., Guthrie, L. A., and Henson,
P. M. (1997). Appearance of phosphatidylserine on apoptotic cells requires
calcium-mediated nonspecific flip-flop and is enhanced by loss of the
aminophospholipid translocase. J Biol Chem, 272(42):26159–65.
Bratton, S. B. and Salvesen, G. S. (2010). Regulation of the apaf-1-caspase-9
apoptosome. J Cell Sci, 123(Pt 19):3209–14.
Brown, E. J. and Baltimore, D. (2000). Atr disruption leads to chromosomal
fragmentation and early embryonic lethality. Genes Dev, 14(4):397–402.
Brown, N. J., Marjanovic, M., Luders, J., Stracker, T. H., and Costanzo, V. (2013).
Cep63 and cep152 cooperate to ensure centriole duplication. PLoS One,
8(7):e69986.
Butler, M. G., Hall, B. D., Maclean, R. N., and Lozzio, C. B. (1987). Do some patients
with seckel syndrome have hematological problems and/or chromosome breakage?
Am J Med Genet, 27(3):645–9.
Butts, T., Green, M. J., and Wingate, R. J. (2014). Development of the cerebellum:
simple steps to make a ’little brain’. Development, 141(21):4031–41.
Byun, T. S., Pacek, M., Yee, M. C., Walter, J. C., and Cimprich, K. A. (2005).
Functional uncoupling of mcm helicase and dna polymerase activities activates the
atr-dependent checkpoint. Genes Dev, 19(9):1040–52.
Callaerts, P., Halder, G., and Gehring, W. J. (1997). Pax-6 in development and
evolution. Annu Rev Neurosci, 20:483–532.
Can, E., Bulbul, A., Uslu, S., Demirin, H., Comert, S., Bolat, F., and Nuhoglu, A.
(2010). A case of seckel syndrome with tetralogy of fallot. Genet Couns,
21(1):49–51.
Carletti, B. and Rossi, F. (2008). Neurogenesis in the cerebellum. Neuroscientist,
14(1):91–100.
Cartron, P. F., Petit, E., Bellot, G., Oliver, L., and Vallette, F. M. (2014). Metaxins 1
and 2, two proteins of the mitochondrial protein sorting and assembly machinery,
are essential for bak activation during tnf alpha triggered apoptosis. Cell Signal,
26(9):1928–34.
Caulin, C., Salvesen, G. S., and Oshima, R. G. (1997). Caspase cleavage of keratin 18
and reorganization of intermediate filaments during epithelial cell apoptosis. J
Cell Biol, 138(6):1379–94.
CBTRUS (2010). Cbtrus statistical report: Primary brain and central nervous
system tumors diagnosed in the united states in 2004-2006. Report, Central Brain
Tumor Registry of the United States.
46
Cervenka, J., Tsuchiya, H., Ishiki, T., Suzuki, M., and Mori, H. (1979). Seckel’s
dwarfism: analysis of chromosome breakage and sister chromatid exchanges. Am
J Dis Child, 133(5):555–6.
Chai, J., Du, C., Wu, J. W., Kyin, S., Wang, X., and Shi, Y. (2000). Structural and
biochemical basis of apoptotic activation by smac/diablo. Nature,
406(6798):855–62.
Chang, C. H., Housepian, E. M., and Herbert, C., J. (1969). An operative staging
system and a megavoltage radiotherapeutic technic for cerebellar
medulloblastomas. Radiology, 93(6):1351–9.
Chau, B. N., Cheng, E. H., Kerr, D. A., and Hardwick, J. M. (2000). Aven, a novel
inhibitor of caspase activation, binds bcl-xl and apaf-1. Mol Cell, 6(1):31–40.
Chen, L., Willis, S. N., Wei, A., Smith, B. J., Fletcher, J. I., Hinds, M. G., Colman,
P. M., Day, C. L., Adams, J. M., and Huang, D. C. (2005). Diﬀerential targeting of
prosurvival bcl-2 proteins by their bh3-only ligands allows complementary
apoptotic function. Mol Cell, 17(3):393–403.
Cheng, Y., Sudarov, A., Szulc, K. U., Sgaier, S. K., Stephen, D., Turnbull, D. H., and
Joyner, A. L. (2010). The engrailed homeobox genes determine the diﬀerent
foliation patterns in the vermis and hemispheres of the mammalian cerebellum.
Development, 137(3):519–29.
Cheung, H. O., Zhang, X., Ribeiro, A., Mo, R., Makino, S., Puviindran, V., Law, K. K.,
Briscoe, J., and Hui, C. C. (2009). The kinesin protein kif7 is a critical regulator of
gli transcription factors in mammalian hedgehog signaling. Sci Signal, 2(76):ra29.
Chien, C. T., Hsiao, C. D., Jan, L. Y., and Jan, Y. N. (1996). Neuronal type
information encoded in the basic-helix-loop-helix domain of proneural genes. Proc
Natl Acad Sci U S A, 93(23):13239–44.
Chinnaiyan, A. M. (1999). The apoptosome: heart and soul of the cell death machine.
Neoplasia, 1(1):5–15.
Chizhikov, V. V., Davenport, J., Zhang, Q., Shih, E. K., Cabello, O. A., Fuchs, J. L.,
Yoder, B. K., and Millen, K. J. (2007). Cilia proteins control cerebellar
morphogenesis by promoting expansion of the granule progenitor pool. J Neurosci,
27(36):9780–9.
Chu, C. P., Bing, Y. H., Liu, H., and Qiu, D. L. (2012). Roles of molecular layer
interneurons in sensory information processing in mouse cerebellar cortex crus ii
in vivo. PLoS One, 7(5):e37031.
Ciccia, A. and Elledge, S. J. (2010). The dna damage response: making it safe to play
with knives. Mol Cell, 40(2):179–204.
47
Cimprich, K. A. and Cortez, D. (2008). Atr: an essential regulator of genome
integrity. Nat Rev Mol Cell Biol, 9(8):616–27.
Cimprich, K. A., Shin, T. B., Keith, C. T., and Schreiber, S. L. (1996). cdna cloning
and gene mapping of a candidate human cell cycle checkpoint protein. Proc Natl
Acad Sci U S A, 93(7):2850–5.
Clybouw, C., Merino, D., Nebl, T., Masson, F., Robati, M., O’Reilly, L., Hubner, A.,
Davis, R. J., Strasser, A., and Bouillet, P. (2012). Alternative splicing of bim and
erk-mediated bim(el) phosphorylation are dispensable for hematopoietic
homeostasis in vivo. Cell Death Diﬀer, 19(6):1060–8.
Coleman, M. L., Sahai, E. A., Yeo, M., Bosch, M., Dewar, A., and Olson, M. F. (2001).
Membrane blebbing during apoptosis results from caspase-mediated activation of
rock i. Nat Cell Biol, 3(4):339–45.
Copeland, D. R., deMoor, C., Moore, B. D., r., and Ater, J. L. (1999). Neurocognitive
development of children after a cerebellar tumor in infancy: A longitudinal study.
J Clin Oncol, 17(11):3476–86.
Cortez, D., Glick, G., and Elledge, S. J. (2004). Minichromosome maintenance
proteins are direct targets of the atm and atr checkpoint kinases. Proc Natl Acad
Sci U S A, 101(27):10078–83.
Cortez, D., Guntuku, S., Qin, J., and Elledge, S. J. (2001). Atr and atrip: partners in
checkpoint signaling. Science, 294(5547):1713–6.
Cotta-Ramusino, C., McDonald, E. R., r., Hurov, K., Sowa, M. E., Harper, J. W., and
Elledge, S. J. (2011). A dna damage response screen identifies rhino, a 9-1-1 and
topbp1 interacting protein required for atr signaling. Science, 332(6035):1313–7.
Crawford, J. R., MacDonald, T. J., and Packer, R. J. (2007). Medulloblastoma in
childhood: new biological advances. Lancet Neurol, 6(12):1073–85.
Cuadrado, M., Martinez-Pastor, B., Murga, M., Toledo, L. I., Gutierrez-Martinez, P.,
Lopez, E., and Fernandez-Capetillo, O. (2006). Atm regulates atr chromatin
loading in response to dna double-strand breaks. J Exp Med, 203(2):297–303.
Dauber, A., Lafranchi, S. H., Maliga, Z., Lui, J. C., Moon, J. E., McDeed, C., Henke,
K., Zonana, J., Kingman, G. A., Pers, T. H., Baron, J., Rosenfeld, R. G.,
Hirschhorn, J. N., Harris, M. P., and Hwa, V. (2012). Novel microcephalic
primordial dwarfism disorder associated with variants in the centrosomal protein
ninein. J Clin Endocrinol Metab, 97(11):E2140–51.
Davies, S. L., North, P. S., Dart, A., Lakin, N. D., and Hickson, I. D. (2004).
Phosphorylation of the bloom’s syndrome helicase and its role in recovery from
s-phase arrest. Mol Cell Biol, 24(3):1279–91.
48
de Klein, A., Muijtjens, M., van Os, R., Verhoeven, Y., Smit, B., Carr, A. M.,
Lehmann, A. R., and Hoeijmakers, J. H. (2000). Targeted disruption of the
cell-cycle checkpoint gene atr leads to early embryonic lethality in mice. Curr Biol,
10(8):479–82.
De La Cruz, F. F. (1963). Bird-headed dwarf: a case report. Am J Ment Defic,
68:54–62.
Delacroix, S., Wagner, J. M., Kobayashi, M., Yamamoto, K., and Karnitz, L. M.
(2007). The rad9-hus1-rad1 (9-1-1) clamp activates checkpoint signaling via
topbp1. Genes Dev, 21(12):1472–7.
Delghandi, M. P., Johannessen, M., and Moens, U. (2005). The camp signalling
pathway activates creb through pka, p38 and msk1 in nih 3t3 cells. Cell Signal,
17(11):1343–51.
Deshpande, A. M. and Newlon, C. S. (1996). Dna replication fork pause sites
dependent on transcription. Science, 272(5264):1030–3.
Deveraux, Q. L., Takahashi, R., Salvesen, G. S., and Reed, J. C. (1997). X-linked iap
is a direct inhibitor of cell-death proteases. Nature, 388(6639):300–4.
Dey, J., Ditzler, S., Knoblaugh, S. E., Hatton, B. A., Schelter, J. M., Cleary, M. A.,
Mecham, B., Rorke-Adams, L. B., and Olson, J. M. (2012). A distinct smoothened
mutation causes severe cerebellar developmental defects and medulloblastoma in
a novel transgenic mouse model. Mol Cell Biol, 32(20):4104–15.
Doxsey, S. J., Stein, P., Evans, L., Calarco, P. D., and Kirschner, M. (1994).
Pericentrin, a highly conserved centrosome protein involved in microtubule
organization. Cell, 76(4):639–50.
Du, C., Fang, M., Li, Y., Li, L., and Wang, X. (2000). Smac, a mitochondrial protein
that promotes cytochrome c-dependent caspase activation by eliminating iap
inhibition. Cell, 102(1):33–42.
Duenas, A. M., Goold, R., and Giunti, P. (2006). Molecular pathogenesis of
spinocerebellar ataxias. Brain, 129(Pt 6):1357–70.
Dutta, A. and Bell, S. P. (1997). Initiation of dna replication in eukaryotic cells.
Annu Rev Cell Dev Biol, 13:293–332.
Eberhart, C. G., Kepner, J. L., Goldthwaite, P. T., Kun, L. E., Duﬀner, P. K.,
Friedman, H. S., Strother, D. R., and Burger, P. C. (2002a). Histopathologic
grading of medulloblastomas: a pediatric oncology group study. Cancer,
94(2):552–60.
Eberhart, C. G., Kratz, J. E., Schuster, A., Goldthwaite, P., Cohen, K. J., Perlman,
E. J., and Burger, P. C. (2002b). Comparative genomic hybridization detects an
increased number of chromosomal alterations in large cell/anaplastic
medulloblastomas. Brain Pathol, 12(1):36–44.
49
Eberhart, C. G., Tihan, T., and Burger, P. C. (2000). Nuclear localization and
mutation of beta-catenin in medulloblastomas. J Neuropathol Exp Neurol,
59(4):333–7.
Edwards, M. C., Tutter, A. V., Cvetic, C., Gilbert, C. H., Prokhorova, T. A., and
Walter, J. C. (2002). Mcm2-7 complexes bind chromatin in a distributed pattern
surrounding the origin recognition complex in xenopus egg extracts. J Biol Chem,
277(36):33049–57.
Elkholi, R., Floros, K. V., and Chipuk, J. E. (2011). The role of bh3-only proteins in
tumor cell development, signaling, and treatment. Genes Cancer, 2(5):523–37.
Elmore, S. (2007). Apoptosis: a review of programmed cell death. Toxicol Pathol,
35(4):495–516.
Endoh-Yamagami, S., Evangelista, M., Wilson, D., Wen, X., Theunissen, J. W.,
Phamluong, K., Davis, M., Scales, S. J., Solloway, M. J., de Sauvage, F. J., and
Peterson, A. S. (2009). The mammalian cos2 homolog kif7 plays an essential role in
modulating hh signal transduction during development. Curr Biol, 19(15):1320–6.
Engelkamp, D., Rashbass, P., Seawright, A., and van Heyningen, V. (1999). Role of
pax6 in development of the cerebellar system. Development, 126(16):3585–96.
Eskes, R., Antonsson, B., Osen-Sand, A., Montessuit, S., Richter, C., Sadoul, R.,
Mazzei, G., Nichols, A., and Martinou, J. C. (1998). Bax-induced cytochrome c
release from mitochondria is independent of the permeability transition pore but
highly dependent on mg2+ ions. J Cell Biol, 143(1):217–24.
Evans, D. G., Birch, J. M., and Orton, C. I. (1991a). Brain tumours and the
occurrence of severe invasive basal cell carcinoma in first degree relatives with
gorlin syndrome. Br J Neurosurg, 5(6):643–6.
Evans, D. G., Farndon, P. A., Burnell, L. D., Gattamaneni, H. R., and Birch, J. M.
(1991b). The incidence of gorlin syndrome in 173 consecutive cases of
medulloblastoma. Br J Cancer, 64(5):959–61.
Fadok, V. A., de Cathelineau, A., Daleke, D. L., Henson, P. M., and Bratton, D. L.
(2001). Loss of phospholipid asymmetry and surface exposure of
phosphatidylserine is required for phagocytosis of apoptotic cells by macrophages
and fibroblasts. J Biol Chem, 276(2):1071–7.
Faivre, L., Le Merrer, M., Lyonnet, S., Plauchu, H., Dagoneau, N., Campos-Xavier,
A. B., Attia-Sobol, J., Verloes, A., Munnich, A., and Cormier-Daire, V. (2002).
Clinical and genetic heterogeneity of seckel syndrome. Am J Med Genet,
112(4):379–83.
Falck, J., Mailand, N., Syljuasen, R. G., Bartek, J., and Lukas, J. (2001). The
atm-chk2-cdc25a checkpoint pathway guards against radioresistant dna synthesis.
Nature, 410(6830):842–7.
50
Fan, X., Mikolaenko, I., Elhassan, I., Ni, X., Wang, Y., Ball, D., Brat, D. J., Perry, A.,
and Eberhart, C. G. (2004). Notch1 and notch2 have opposite eﬀects on embryonal
brain tumor growth. Cancer Res, 64(21):7787–93.
Favit, A., Scapagnini, U., and Canonico, P. L. (1995). Pituitary adenylate
cyclase-activating polypeptide activates diﬀerent signal transducing mechanisms
in cultured cerebellar granule cells. Neuroendocrinology, 61(4):377–82.
Fernandez, C., Tatard, V. M., Bertrand, N., and Dahmane, N. (2010). Diﬀerential
modulation of sonic-hedgehog-induced cerebellar granule cell precursor
proliferation by the igf signaling network. Dev Neurosci, 32(1):59–70.
Fernandez, L. A., Northcott, P. A., Dalton, J., Fraga, C., Ellison, D., Angers, S.,
Taylor, M. D., and Kenney, A. M. (2009). Yap1 is amplified and up-regulated in
hedgehog-associated medulloblastomas and mediates sonic hedgehog-driven
neural precursor proliferation. Genes Dev, 23(23):2729–41.
Fernandez, L. A., Squatrito, M., Northcott, P., Awan, A., Holland, E. C., Taylor,
M. D., Nahle, Z., and Kenney, A. M. (2012). Oncogenic yap promotes
radioresistance and genomic instability in medulloblastoma through igf2-mediated
akt activation. Oncogene, 31(15):1923–37.
Flora, A., Klisch, T. J., Schuster, G., and Zoghbi, H. Y. (2009). Deletion of atoh1
disrupts sonic hedgehog signaling in the developing cerebellum and prevents
medulloblastoma. Science, 326(5958):1424–7.
Fortin, A., Cregan, S. P., MacLaurin, J. G., Kushwaha, N., Hickman, E. S.,
Thompson, C. S., Hakim, A., Albert, P. R., Cecconi, F., Helin, K., Park, D. S., and
Slack, R. S. (2001). Apaf1 is a key transcriptional target for p53 in the regulation
of neuronal cell death. J Cell Biol, 155(2):207–16.
Fridman, J. S. and Lowe, S. W. (2003). Control of apoptosis by p53. Oncogene,
22(56):9030–40.
Fuccillo, M., Joyner, A. L., and Fishell, G. (2006). Morphogen to mitogen: the
multiple roles of hedgehog signalling in vertebrate neural development. Nat Rev
Neurosci, 7(10):772–83.
Furnari, B., Blasina, A., Boddy, M. N., McGowan, C. H., and Russell, P. (1999).
Cdc25 inhibited in vivo and in vitro by checkpoint kinases cds1 and chk1. Mol Biol
Cell, 10(4):833–45.
Gao, W. O., Heintz, N., and Hatten, M. E. (1991). Cerebellar granule cell
neurogenesis is regulated by cell-cell interactions in vitro. Neuron, 6(5):705–15.
Garel, C., Fallet-Bianco, C., and Guibaud, L. (2011). The fetal cerebellum:
development and common malformations. J Child Neurol, 26(12):1483–92.
51
Gazit, R., Krizhanovsky, V., and Ben-Arie, N. (2004). Math1 controls cerebellar
granule cell diﬀerentiation by regulating multiple components of the notch
signaling pathway. Development, 131(4):903–13.
Ge, X. Q., Jackson, D. A., and Blow, J. J. (2007). Dormant origins licensed by excess
mcm2-7 are required for human cells to survive replicative stress. Genes Dev,
21(24):3331–41.
Gentet, J. C., Bouﬀet, E., Doz, F., Tron, P., Roche, H., Thyss, A., Plantaz, D.,
Stephan, J. L., Mottolese, C., Ponvert, D., and et al. (1995). Preirradiation
chemotherapy including "eight drugs in 1 day" regimen and high-dose
methotrexate in childhood medulloblastoma: results of the m7 french cooperative
study. J Neurosurg, 82(4):608–14.
Gibson, P., Tong, Y., Robinson, G., Thompson, M. C., Currle, D. S., Eden, C.,
Kranenburg, T. A., Hogg, T., Poppleton, H., Martin, J., Finkelstein, D., Pounds, S.,
Weiss, A., Patay, Z., Scoggins, M., Ogg, R., Pei, Y., Yang, Z. J., Brun, S., Lee, Y.,
Zindy, F., Lindsey, J. C., Taketo, M. M., Boop, F. A., Sanford, R. A., Gajjar, A.,
Cliﬀord, S. C., Roussel, M. F., McKinnon, P. J., Gutmann, D. H., Ellison, D. W.,
Wechsler-Reya, R., and Gilbertson, R. J. (2010). Subtypes of medulloblastoma have
distinct developmental origins. Nature, 468(7327):1095–9.
Gilbertson, R. J. and Ellison, D. W. (2008). The origins of medulloblastoma subtypes.
Annu Rev Pathol, 3:341–65.
Gillings, A. S., Balmanno, K., Wiggins, C. M., Johnson, M., and Cook, S. J. (2009).
Apoptosis and autophagy: Bim as a mediator of tumour cell death in response to
oncogene-targeted therapeutics. FEBS J, 276(21):6050–62.
Glickstein, M., Strata, P., and Voogd, J. (2009). Cerebellum: history. Neuroscience,
162(3):549–59.
Gogada, R., Yadav, N., Liu, J., Tang, S., Zhang, D., Schneider, A., Seshadri, A., Sun,
L., Aldaz, C. M., Tang, D. G., and Chandra, D. (2013). Bim, a proapoptotic protein,
up-regulated via transcription factor e2f1-dependent mechanism, functions as a
prosurvival molecule in cancer. J Biol Chem, 288(1):368–81.
Goldowitz, D. and Hamre, K. (1998). The cells and molecules that make a
cerebellum. Trends Neurosci, 21(9):375–82.
Goodrich, L. V., Milenkovic, L., Higgins, K. M., and Scott, M. P. (1997). Altered
neural cell fates and medulloblastoma in mouse patched mutants. Science,
277(5329):1109–13.
Goodship, J., Gill, H., Carter, J., Jackson, A., Splitt, M., and Wright, M. (2000).
Autozygosity mapping of a seckel syndrome locus to chromosome 3q22. 1-q24. Am
J Hum Genet, 67(2):498–503.
52
Griﬃth, E., Walker, S., Martin, C. A., Vagnarelli, P., Stiﬀ, T., Vernay, B., Al Sanna,
N., Saggar, A., Hamel, B., Earnshaw, W. C., Jeggo, P. A., Jackson, A. P., and
O’Driscoll, M. (2008). Mutations in pericentrin cause seckel syndrome with
defective atr-dependent dna damage signaling. Nat Genet, 40(2):232–6.
Gross, A., Jockel, J., Wei, M. C., and Korsmeyer, S. J. (1998). Enforced dimerization
of bax results in its translocation, mitochondrial dysfunction and apoptosis.
EMBO J, 17(14):3878–85.
Haase, S. B., Heinzel, S. S., and Calos, M. P. (1994). Transcription inhibits the
replication of autonomously replicating plasmids in human cells. Mol Cell Biol,
14(4):2516–24.
Hacker, G. (2000). The morphology of apoptosis. Cell Tissue Res, 301(1):5–17.
Hahn, H., Wojnowski, L., Miller, G., and Zimmer, A. (1999). The patched signaling
pathway in tumorigenesis and development: lessons from animal models. J Mol
Med (Berl), 77(6):459–68.
Hallahan, A. R., Pritchard, J. I., Hansen, S., Benson, M., Stoeck, J., Hatton, B. A.,
Russell, T. L., Ellenbogen, R. G., Bernstein, I. D., Beachy, P. A., and Olson, J. M.
(2004). The smoa1 mouse model reveals that notch signaling is critical for the
growth and survival of sonic hedgehog-induced medulloblastomas. Cancer Res,
64(21):7794–800.
Hanada, K., Budzowska, M., Davies, S. L., van Drunen, E., Onizawa, H., Beverloo,
H. B., Maas, A., Essers, J., Hickson, I. D., and Kanaar, R. (2007). The
structure-specific endonuclease mus81 contributes to replication restart by
generating double-strand dna breaks. Nat Struct Mol Biol, 14(11):1096–104.
Hanahan, D. and Weinberg, R. A. (2000). The hallmarks of cancer. Cell,
100(1):57–70.
Hanahan, D. and Weinberg, R. A. (2011). Hallmarks of cancer: the next generation.
Cell, 144(5):646–74.
Harley, M. E., Murina, O., Leitch, A., Higgs, M. R., Bicknell, L. S., Yigit, G.,
Blackford, A. N., Zlatanou, A., Mackenzie, K. J., Reddy, K., Halachev, M.,
McGlasson, S., Reijns, M. A., Fluteau, A., Martin, C. A., Sabbioneda, S., Elcioglu,
N. H., Altmuller, J., Thiele, H., Greenhalgh, L., Chessa, L., Maghnie, M., Salim,
M., Bober, M. B., Nurnberg, P., Jackson, S. P., Hurles, M. E., Wollnik, B., Stewart,
G. S., and Jackson, A. P. (2016). Traip promotes dna damage response during
genome replication and is mutated in primordial dwarfism. Nat Genet,
48(1):36–43.
Harper, R. G., Orti, E., and Baker, R. K. (1967). Bird-beaded dwarfs (seckel’s
syndrome). a familial pattern of developmental, dental, skeletal, genital, and
central nervous system anomalies. J Pediatr, 70(5):799–804.
53
Hart, M. N. and Earle, K. M. (1973). Primitive neuroectodermal tumors of the brain
in children. Cancer, 32(4):890–7.
Hashimoto, K., Sakane, F., Ikeda, N., Akiyama, A., Sugahara, M., and Miyamoto, Y.
(2016). Vitronectin promotes the progress of the initial diﬀerentiation stage in
cerebellar granule cells. Mol Cell Neurosci, 70:76–85.
Hatten, M. E. and Heintz, N. (1995). Mechanisms of neural patterning and
specification in the developing cerebellum. Annu Rev Neurosci, 18:385–408.
Hayani, A., Suarez, C. R., Molnar, Z., LeBeau, M., and Godwin, J. (1994). Acute
myeloid leukaemia in a patient with seckel syndrome. J Med Genet, 31(2):148–9.
Heﬀernan, T. P., Unsal-Kacmaz, K., Heinloth, A. N., Simpson, D. A., Paules, R. S.,
Sancar, A., Cordeiro-Stone, M., and Kaufmann, W. K. (2007). Cdc7-dbf4 and the
human s checkpoint response to uvc. J Biol Chem, 282(13):9458–68.
Helms, A. W., Abney, A. L., Ben-Arie, N., Zoghbi, H. Y., and Johnson, J. E. (2000).
Autoregulation and multiple enhancers control math1 expression in the
developing nervous system. Development, 127(6):1185–96.
Helms, A. W., Gowan, K., Abney, A., Savage, T., and Johnson, J. E. (2001).
Overexpression of math1 disrupts the coordination of neural diﬀerentiation in
cerebellum development. Mol Cell Neurosci, 17(4):671–82.
Helms, A. W. and Johnson, J. E. (1998). Progenitors of dorsal commissural
interneurons are defined by math1 expression. Development, 125(5):919–28.
Herold, M. J., Rohrbeck, L., Lang, M. J., Grumont, R., Gerondakis, S., Tai, L.,
Bouillet, P., Kaufmann, T., and Strasser, A. (2013). Foxo-mediated bim
transcription is dispensable for the apoptosis of hematopoietic cells that is
mediated by this bh3-only protein. EMBO Rep, 14(11):992–8.
Hill, M. M., Adrain, C., Duriez, P. J., Creagh, E. M., and Martin, S. J. (2004).
Analysis of the composition, assembly kinetics and activity of native apaf-1
apoptosomes. EMBO J, 23(10):2134–45.
Hirata, H., Takahashi, A., Kobayashi, S., Yonehara, S., Sawai, H., Okazaki, T.,
Yamamoto, K., and Sasada, M. (1998). Caspases are activated in a branched
protease cascade and control distinct downstream processes in fas-induced
apoptosis. J Exp Med, 187(4):587–600.
Hu, J. S., Olson, E. N., and Kingston, R. E. (1992). Heb, a helix-loop-helix protein
related to e2a and itf2 that can modulate the dna-binding ability of myogenic
regulatory factors. Mol Cell Biol, 12(3):1031–42.
Hu, Y., Benedict, M. A., Wu, D., Inohara, N., and Nunez, G. (1998). Bcl-xl interacts
with apaf-1 and inhibits apaf-1-dependent caspase-9 activation. Proc Natl Acad
Sci U S A, 95(8):4386–91.
54
Huang, H., Mahler-Araujo, B. M., Sankila, A., Chimelli, L., Yonekawa, Y., Kleihues,
P., and Ohgaki, H. (2000). Apc mutations in sporadic medulloblastomas. Am J
Pathol, 156(2):433–7.
Huertas, P. and Jackson, S. P. (2009). Human ctip mediates cell cycle control of dna
end resection and double strand break repair. J Biol Chem, 284(14):9558–65.
Hyrien, O., Marheineke, K., and Goldar, A. (2003). Paradoxes of eukaryotic dna
replication: Mcm proteins and the random completion problem. Bioessays,
25(2):116–25.
Ibarra, A., Schwob, E., and Mendez, J. (2008). Excess mcm proteins protect human
cells from replicative stress by licensing backup origins of replication. Proc Natl
Acad Sci U S A, 105(26):8956–61.
Inohara, N., Gourley, T. S., Carrio, R., Muniz, M., Merino, J., Garcia, I., Koseki, T.,
Hu, Y., Chen, S., and Nunez, G. (1998). Diva, a bcl-2 homologue that binds directly
to apaf-1 and induces bh3-independent cell death. J Biol Chem, 273(49):32479–86.
Irvin, D. K., Nakano, I., Paucar, A., and Kornblum, H. I. (2004). Patterns of jagged1,
jagged2, delta-like 1 and delta-like 3 expression during late embryonic and
postnatal brain development suggest multiple functional roles in progenitors and
diﬀerentiated cells. J Neurosci Res, 75(3):330–43.
Ishikawa, T., Tomatsu, S., Izawa, J., and Kakei, S. (2016). The cerebro-cerebellum:
Could it be loci of forward models? Neurosci Res, 104:72–9.
Ivessa, A. S., Lenzmeier, B. A., Bessler, J. B., Goudsouzian, L. K., Schnakenberg,
S. L., and Zakian, V. A. (2003). The saccharomyces cerevisiae helicase rrm3p
facilitates replication past nonhistone protein-dna complexes. Mol Cell,
12(6):1525–36.
Jakacki, R. I., Feldman, H., Jamison, C., Boaz, J. C., Luerssen, T. G., and
Timmerman, R. (2004). A pilot study of preirradiation chemotherapy and 1800 cgy
craniospinal irradiation in young children with medulloblastoma. Int J Radiat
Oncol Biol Phys, 60(2):531–6.
Janicke, R. U., Ng, P., Sprengart, M. L., and Porter, A. G. (1998). Caspase-3 is
required for alpha-fodrin cleavage but dispensable for cleavage of other death
substrates in apoptosis. J Biol Chem, 273(25):15540–5.
Jarman, A. P., Grau, Y., Jan, L. Y., and Jan, Y. N. (1993). atonal is a proneural gene
that directs chordotonal organ formation in the drosophila peripheral nervous
system. Cell, 73(7):1307–21.
Jarman, A. P., Sun, Y., Jan, L. Y., and Jan, Y. N. (1995). Role of the proneural gene,
atonal, in formation of drosophila chordotonal organs and photoreceptors.
Development, 121(7):2019–30.
55
Jazayeri, A., Falck, J., Lukas, C., Bartek, J., Smith, G. C., Lukas, J., and Jackson,
S. P. (2006). Atm- and cell cycle-dependent regulation of atr in response to dna
double-strand breaks. Nat Cell Biol, 8(1):37–45.
Jensen, P., Smeyne, R., and Goldowitz, D. (2004). Analysis of cerebellar development
in math1 null embryos and chimeras. J Neurosci, 24(9):2202–11.
Johnson, J. E., Birren, S. J., Saito, T., and Anderson, D. J. (1992). Dna binding and
transcriptional regulatory activity of mammalian achaete-scute homologous
(mash) proteins revealed by interaction with a muscle-specific enhancer. Proc Natl
Acad Sci U S A, 89(8):3596–600.
Jurgensmeier, J. M., Xie, Z., Deveraux, Q., Ellerby, L., Bredesen, D., and Reed, J. C.
(1998). Bax directly induces release of cytochrome c from isolated mitochondria.
Proc Natl Acad Sci U S A, 95(9):4997–5002.
Kalay, E., Yigit, G., Aslan, Y., Brown, K. E., Pohl, E., Bicknell, L. S., Kayserili, H., Li,
Y., Tuysuz, B., Nurnberg, G., Kiess, W., Koegl, M., Baessmann, I., Buruk, K.,
Toraman, B., Kayipmaz, S., Kul, S., Ikbal, M., Turner, D. J., Taylor, M. S., Aerts,
J., Scott, C., Milstein, K., Dollfus, H., Wieczorek, D., Brunner, H. G., Hurles, M.,
Jackson, A. P., Rauch, A., Nurnberg, P., Karaguzel, A., and Wollnik, B. (2011).
Cep152 is a genome maintenance protein disrupted in seckel syndrome. Nat
Genet, 43(1):23–6.
Kamada, K., Kubota, Y., Arata, T., Shindo, Y., and Hanaoka, F. (2007). Structure of
the human gins complex and its assembly and functional interface in replication
initiation. Nat Struct Mol Biol, 14(5):388–96.
Kaneko, Y. S., Watanabe, N., Morisaki, H., Akita, H., Fujimoto, A., Tominaga, K.,
Terasawa, M., Tachibana, A., Ikeda, K., and Nakanishi, M. (1999).
Cell-cycle-dependent and atm-independent expression of human chk1 kinase.
Oncogene, 18(25):3673–81.
Kapfhammer, J. P. (2004). Cellular and molecular control of dendritic growth and
development of cerebellar purkinje cells. Prog Histochem Cytochem, 39(3):131–82.
Kato, R. and Ogawa, H. (1994). An essential gene, esr1, is required for mitotic cell
growth, dna repair and meiotic recombination in saccharomyces cerevisiae.
Nucleic Acids Res, 22(15):3104–12.
Katoh, Y. and Katoh, M. (2009). Hedgehog target genes: mechanisms of
carcinogenesis induced by aberrant hedgehog signaling activation. Curr Mol Med,
9(7):873–86.
Katsetos, C. D., Liu, H. M., and Zacks, S. I. (1988). Immunohistochemical and
ultrastructural observations on homer wright (neuroblastic) rosettes and the "pale
islands" of human cerebellar medulloblastomas. Hum Pathol, 19(10):1219–27.
56
Kaufmann, S. H., Desnoyers, S., Ottaviano, Y., Davidson, N. E., and Poirier, G. G.
(1993). Specific proteolytic cleavage of poly(adp-ribose) polymerase: an early
marker of chemotherapy-induced apoptosis. Cancer Res, 53(17):3976–85.
Kellie, S. J. (1999). Chemotherapy of central nervous system tumours in infants.
Childs Nerv Syst, 15(10):592–612.
Kemp, M. G., Akan, Z., Yilmaz, S., Grillo, M., Smith-Roe, S. L., Kang, T. H.,
Cordeiro-Stone, M., Kaufmann, W. K., Abraham, R. T., Sancar, A., and
Unsal-Kacmaz, K. (2010). Tipin-replication protein a interaction mediates chk1
phosphorylation by atr in response to genotoxic stress. J Biol Chem,
285(22):16562–71.
Kenney, A. M., Cole, M. D., and Rowitch, D. H. (2003). Nmyc upregulation by sonic
hedgehog signaling promotes proliferation in developing cerebellar granule neuron
precursors. Development, 130(1):15–28.
Kessler, J. D., Hasegawa, H., Brun, S. N., Emmenegger, B. A., Yang, Z. J., Dutton,
J. W., Wang, F., and Wechsler-Reya, R. J. (2009). N-myc alters the fate of
preneoplastic cells in a mouse model of medulloblastoma. Genes Dev, 23(2):157–70.
Kilinc, M. O., Ninis, V. N., Ugur, S. A., Tuysuz, B., Seven, M., Balci, S., Goodship, J.,
and Tolun, A. (2003). Is the novel sckl3 at 14q23 the predominant seckel locus?
Eur J Hum Genet, 11(11):851–7.
Kim, J. J., Gill, P. S., Rotin, L., van Eede, M., Henkelman, R. M., Hui, C. C., and
Rosenblum, N. D. (2011). Suppressor of fused controls mid-hindbrain patterning
and cerebellar morphogenesis via gli3 repressor. J Neurosci, 31(5):1825–36.
Kim, J. Y., Nelson, A. L., Algon, S. A., Graves, O., Sturla, L. M., Goumnerova, L. C.,
Rowitch, D. H., Segal, R. A., and Pomeroy, S. L. (2003). Medulloblastoma
tumorigenesis diverges from cerebellar granule cell diﬀerentiation in patched
heterozygous mice. Dev Biol, 263(1):50–66.
Kitada, S., Krajewska, M., Zhang, X., Scudiero, D., Zapata, J. M., Wang, H. G.,
Shabaik, A., Tudor, G., Krajewski, S., Myers, T. G., Johnson, G. S., Sausville, E. A.,
and Reed, J. C. (1998). Expression and location of pro-apoptotic bcl-2 family
protein bad in normal human tissues and tumor cell lines. Am J Pathol,
152(1):51–61.
Kleihues, P., Burger, P. C., and Scheithauer, B. W. (1993). The new who classification
of brain tumours. Brain Pathol, 3(3):255–68.
Klein, R. S., Rubin, J. B., Gibson, H. D., DeHaan, E. N., Alvarez-Hernandez, X.,
Segal, R. A., and Luster, A. D. (2001). Sdf-1 alpha induces chemotaxis and
enhances sonic hedgehog-induced proliferation of cerebellar granule cells.
Development, 128(11):1971–81.
57
Klisch, T. J., Xi, Y., Flora, A., Wang, L., Li, W., and Zoghbi, H. Y. (2011). In vivo
atoh1 targetome reveals how a proneural transcription factor regulates cerebellar
development. Proc Natl Acad Sci U S A, 108(8):3288–93.
Kluck, R. M., Bossy-Wetzel, E., Green, D. R., and Newmeyer, D. D. (1997). The
release of cytochrome c from mitochondria: a primary site for bcl-2 regulation of
apoptosis. Science, 275(5303):1132–6.
Koeller, K. K. and Rushing, E. J. (2003). From the archives of the afip:
medulloblastoma: a comprehensive review with radiologic-pathologic correlation.
Radiographics, 23(6):1613–37.
Kondratov, R. V. and Antoch, M. P. (2007). Circadian proteins in the regulation of
cell cycle and genotoxic stress responses. Trends Cell Biol, 17(7):311–7.
Kool, M., Jones, D. T., Jager, N., Northcott, P. A., Pugh, T. J., Hovestadt, V., Piro,
R. M., Esparza, L. A., Markant, S. L., Remke, M., Milde, T., Bourdeaut, F.,
Ryzhova, M., Sturm, D., Pfaﬀ, E., Stark, S., Hutter, S., Seker-Cin, H., Johann, P.,
Bender, S., Schmidt, C., Rausch, T., Shih, D., Reimand, J., Sieber, L., Wittmann,
A., Linke, L., Witt, H., Weber, U. D., Zapatka, M., Konig, R., Beroukhim, R.,
Bergthold, G., van Sluis, P., Volckmann, R., Koster, J., Versteeg, R., Schmidt, S.,
Wolf, S., Lawerenz, C., Bartholomae, C. C., von Kalle, C., Unterberg, A.,
Herold-Mende, C., Hofer, S., Kulozik, A. E., von Deimling, A., Scheurlen, W.,
Felsberg, J., Reifenberger, G., Hasselblatt, M., Crawford, J. R., Grant, G. A.,
Jabado, N., Perry, A., Cowdrey, C., Croul, S., Zadeh, G., Korbel, J. O., Doz, F.,
Delattre, O., Bader, G. D., McCabe, M. G., Collins, V. P., Kieran, M. W., Cho, Y. J.,
Pomeroy, S. L., Witt, O., Brors, B., Taylor, M. D., Schuller, U., Korshunov, A., Eils,
R., Wechsler-Reya, R. J., Lichter, P., and Pfister, S. M. (2014). Genome sequencing
of shh medulloblastoma predicts genotype-related response to smoothened
inhibition. Cancer Cell, 25(3):393–405.
Kool, M., Korshunov, A., Remke, M., Jones, D. T., Schlanstein, M., Northcott, P. A.,
Cho, Y. J., Koster, J., Schouten-van Meeteren, A., van Vuurden, D., Cliﬀord, S. C.,
Pietsch, T., von Bueren, A. O., Rutkowski, S., McCabe, M., Collins, V. P., Backlund,
M. L., Haberler, C., Bourdeaut, F., Delattre, O., Doz, F., Ellison, D. W., Gilbertson,
R. J., Pomeroy, S. L., Taylor, M. D., Lichter, P., and Pfister, S. M. (2012). Molecular
subgroups of medulloblastoma: an international meta-analysis of transcriptome,
genetic aberrations, and clinical data of wnt, shh, group 3, and group 4
medulloblastomas. Acta Neuropathol, 123(4):473–84.
Kothakota, S., Azuma, T., Reinhard, C., Klippel, A., Tang, J., Chu, K., McGarry,
T. J., Kirschner, M. W., Koths, K., Kwiatkowski, D. J., and Williams, L. T. (1997).
Caspase-3-generated fragment of gelsolin: eﬀector of morphological change in
apoptosis. Science, 278(5336):294–8.
Kramer, A., Mailand, N., Lukas, C., Syljuasen, R. G., Wilkinson, C. J., Nigg, E. A.,
Bartek, J., and Lukas, J. (2004). Centrosome-associated chk1 prevents premature
activation of cyclin-b-cdk1 kinase. Nat Cell Biol, 6(9):884–91.
58
Kumagai, A. and Dunphy, W. G. (2000). Claspin, a novel protein required for the
activation of chk1 during a dna replication checkpoint response in xenopus egg
extracts. Mol Cell, 6(4):839–49.
Kurosaka, K., Takahashi, M., Watanabe, N., and Kobayashi, Y. (2003). Silent
cleanup of very early apoptotic cells by macrophages. J Immunol, 171(9):4672–9.
Kurz, E. U. and Lees-Miller, S. P. (2004). Dna damage-induced activation of atm and
atm-dependent signaling pathways. DNA Repair (Amst), 3(8-9):889–900.
Kusumi, K., Dunwoodie, S. L., and Krumlauf, R. (2001). Dynamic expression
patterns of the pudgy/spondylocostal dysostosis gene dll3 in the developing
nervous system. Mech Dev, 100(1):141–4.
Kutuk, O. and Letai, A. (2008). Regulation of bcl-2 family proteins by
posttranslational modifications. Curr Mol Med, 8(2):102–18.
Lambotte, C., Dony, G., and Bonnet, F. (1976). Seckel syndrome: bird-headed
dwarfism. Acta Paediatr Belg, 29(2):79–82.
Lanford, P. J., Shailam, R., Norton, C. R., Gridley, T., and Kelley, M. W. (2000).
Expression of math1 and hes5 in the cochleae of wildtype and jag2 mutant mice. J
Assoc Res Otolaryngol, 1(2):161–71.
Lang, P. Y., Nanjangud, G. J., Sokolsky-Papkov, M., Shaw, C., Hwang, D., Parker,
J. S., Kabanov, A. V., and Gershon, T. R. (2016). Atr maintains chromosomal
integrity during postnatal cerebellar neurogenesis and is required for
medulloblastoma formation. Development, 143(21):4038–52.
Leary, S. E., Zhou, T., Holmes, E., Geyer, J. R., and Miller, D. C. (2011). Histology
predicts a favorable outcome in young children with desmoplastic
medulloblastoma: a report from the children’s oncology group. Cancer,
117(14):3262–7.
Lee, J., Kumagai, A., and Dunphy, W. G. (2001). Positive regulation of wee1 by chk1
and 14-3-3 proteins. Mol Biol Cell, 12(3):551–63.
Lee, J. S., Collins, K. M., Brown, A. L., Lee, C. H., and Chung, J. H. (2000).
hcds1-mediated phosphorylation of brca1 regulates the dna damage response.
Nature, 404(6774):201–4.
Lee, Y., Shull, E. R. P., Frappart, P.-O., Katyal, S., Enriquez-Rios, V., Zhao, J.,
Russell, H. R., Brown, E. J., and McKinnon, P. J. (2012). Atr maintains select
progenitors during nervous system development. EMBO J, 31(5):1177–1189.
Leonard, J. R., Cai, D. X., Rivet, D. J., Kaufman, B. A., Park, T. S., Levy, B. K., and
Perry, A. (2001). Large cell/anaplastic medulloblastomas and
medullomyoblastomas: clinicopathological and genetic features. J Neurosurg,
95(1):82–8.
59
Letai, A., Bassik, M. C., Walensky, L. D., Sorcinelli, M. D., Weiler, S., and Korsmeyer,
S. J. (2002). Distinct bh3 domains either sensitize or activate mitochondrial
apoptosis, serving as prototype cancer therapeutics. Cancer Cell, 2(3):183–92.
Leu, J. I., Dumont, P., Hafey, M., Murphy, M. E., and George, D. L. (2004).
Mitochondrial p53 activates bak and causes disruption of a bak-mcl1 complex. Nat
Cell Biol, 6(5):443–50.
Lewis, P. M., Gritli-Linde, A., Smeyne, R., Kottmann, A., and McMahon, A. P. (2004).
Sonic hedgehog signaling is required for expansion of granule neuron precursors
and patterning of the mouse cerebellum. Dev Biol, 270(2):393–410.
Li, W., Kim, S. M., Lee, J., and Dunphy, W. G. (2004). Absence of blm leads to
accumulation of chromosomal dna breaks during both unperturbed and disrupted
s phases. J Cell Biol, 165(6):801–12.
Liem, K. F., J., He, M., Ocbina, P. J., and Anderson, K. V. (2009). Mouse kif7/costal2
is a cilia-associated protein that regulates sonic hedgehog signaling. Proc Natl
Acad Sci U S A, 106(32):13377–82.
Liu, A. and Joyner, A. L. (2001). En and gbx2 play essential roles downstream of fgf8
in patterning the mouse mid/hindbrain region. Development, 128(2):181–91.
Liu, P., Barkley, L. R., Day, T., Bi, X., Slater, D. M., Alexandrow, M. G., Nasheuer,
H. P., and Vaziri, C. (2006a). The chk1-mediated s-phase checkpoint targets
initiation factor cdc45 via a cdc25a/cdk2-independent mechanism. J Biol Chem,
281(41):30631–44.
Liu, Q., Guntuku, S., Cui, X. S., Matsuoka, S., Cortez, D., Tamai, K., Luo, G.,
Carattini-Rivera, S., DeMayo, F., Bradley, A., Donehower, L. A., and Elledge, S. J.
(2000). Chk1 is an essential kinase that is regulated by atr and required for the
g(2)/m dna damage checkpoint. Genes Dev, 14(12):1448–59.
Liu, S., Bekker-Jensen, S., Mailand, N., Lukas, C., Bartek, J., and Lukas, J. (2006b).
Claspin operates downstream of topbp1 to direct atr signaling towards chk1
activation. Mol Cell Biol, 26(16):6056–64.
Liu, X., Kim, C. N., Yang, J., Jemmerson, R., and Wang, X. (1996). Induction of
apoptotic program in cell-free extracts: requirement for datp and cytochrome c.
Cell, 86(1):147–57.
Lizarraga, S. B., Margossian, S. P., Harris, M. H., Campagna, D. R., Han, A. P.,
Blevins, S., Mudbhary, R., Barker, J. E., Walsh, C. A., and Fleming, M. D. (2010).
Cdk5rap2 regulates centrosome function and chromosome segregation in neuronal
progenitors. Development, 137(11):1907–17.
Logue, S. E. and Martin, S. J. (2008). Caspase activation cascades in apoptosis.
Biochem Soc Trans, 36(Pt 1):1–9.
60
Lopes, M., Cotta-Ramusino, C., Pellicioli, A., Liberi, G., Plevani, P., Muzi-Falconi,
M., Newlon, C. S., and Foiani, M. (2001). The dna replication checkpoint response
stabilizes stalled replication forks. Nature, 412(6846):557–61.
Lopes, M., Foiani, M., and Sogo, J. M. (2006). Multiple mechanisms control
chromosome integrity after replication fork uncoupling and restart at irreparable
uv lesions. Mol Cell, 21(1):15–27.
Lovejoy, C. A., Xu, X., Bansbach, C. E., Glick, G. G., Zhao, R., Ye, F., Sirbu, B. M.,
Titus, L. C., Shyr, Y., and Cortez, D. (2009). Functional genomic screens identify
cinp as a genome maintenance protein. Proc Natl Acad Sci U S A, 106(46):19304–9.
Lukas, C., Bartkova, J., Latella, L., Falck, J., Mailand, N., Schroeder, T., Sehested,
M., Lukas, J., and Bartek, J. (2001). Dna damage-activated kinase chk2 is
independent of proliferation or diﬀerentiation yet correlates with tissue biology.
Cancer Res, 61(13):4990–3.
Lukas, C., Melander, F., Stucki, M., Falck, J., Bekker-Jensen, S., Goldberg, M.,
Lerenthal, Y., Jackson, S. P., Bartek, J., and Lukas, J. (2004). Mdc1 couples dna
double-strand break recognition by nbs1 with its h2ax-dependent chromatin
retention. EMBO J, 23(13):2674–83.
MacDonald, T. J., Rood, B. R., Santi, M. R., Vezina, G., Bingaman, K., Cogen, P. H.,
and Packer, R. J. (2003). Advances in the diagnosis, molecular genetics, and
treatment of pediatric embryonal cns tumors. Oncologist, 8(2):174–86.
MacFarlane, M., Merrison, W., Dinsdale, D., and Cohen, G. M. (2000). Active
caspases and cleaved cytokeratins are sequestered into cytoplasmic inclusions in
trail-induced apoptosis. J Cell Biol, 148(6):1239–54.
Mailand, N., Falck, J., Lukas, C., Syljuasen, R. G., Welcker, M., Bartek, J., and
Lukas, J. (2000). Rapid destruction of human cdc25a in response to dna damage.
Science, 288(5470):1425–9.
Majewski, F. and Goecke, T. (1982). Studies of microcephalic primordial dwarfism i:
approach to a delineation of the seckel syndrome. Am J Med Genet, 12(1):7–21.
Maloverjan, A. and Piirsoo, M. (2012). Mammalian homologues of drosophila fused
kinase. Vitam Horm, 88:91–113.
Manto, M. (2008). The cerebellum, cerebellar disorders, and cerebellar research–two
centuries of discoveries. Cerebellum, 7(4):505–16.
Mao, J., Ligon, K. L., Rakhlin, E. Y., Thayer, S. P., Bronson, R. T., Rowitch, D., and
McMahon, A. P. (2006). A novel somatic mouse model to survey tumorigenic
potential applied to the hedgehog pathway. Cancer Res, 66(20):10171–8.
61
Marjanovic, M., Sanchez-Huertas, C., Terre, B., Gomez, R., Scheel, J. F., Pacheco, S.,
Knobel, P. A., Martinez-Marchal, A., Aivio, S., Palenzuela, L., Wolfrum, U.,
McKinnon, P. J., Suja, J. A., Roig, I., Costanzo, V., Luders, J., and Stracker, T. H.
(2015). Cep63 deficiency promotes p53-dependent microcephaly and reveals a role
for the centrosome in meiotic recombination. Nat Commun, 6:7676.
Marshall, G. M., Carter, D. R., Cheung, B. B., Liu, T., Mateos, M. K., Meyerowitz,
J. G., and Weiss, W. A. (2014). The prenatal origins of cancer. Nat Rev Cancer,
14(4):277–89.
Martinez, S., Andreu, A., Mecklenburg, N., and Echevarria, D. (2013). Cellular and
molecular basis of cerebellar development. Front Neuroanat, 7:18.
Masai, H., Matsumoto, S., You, Z., Yoshizawa-Sugata, N., and Oda, M. (2010).
Eukaryotic chromosome dna replication: where, when, and how? Annu Rev
Biochem, 79:89–130.
Massari, M. E. and Murre, C. (2000). Helix-loop-helix proteins: regulators of
transcription in eucaryotic organisms. Mol Cell Biol, 20(2):429–40.
Matsuoka, S., Ballif, B. A., Smogorzewska, A., McDonald, E. R., r., Hurov, K. E., Luo,
J., Bakalarski, C. E., Zhao, Z., Solimini, N., Lerenthal, Y., Shiloh, Y., Gygi, S. P.,
and Elledge, S. J. (2007). Atm and atr substrate analysis reveals extensive protein
networks responsive to dna damage. Science, 316(5828):1160–6.
McIntyre, R. E., Lakshminarasimhan Chavali, P., Ismail, O., Carragher, D. M.,
Sanchez-Andrade, G., Forment, J. V., Fu, B., Del Castillo Velasco-Herrera, M.,
Edwards, A., van der Weyden, L., Yang, F., Sanger Mouse Genetics, P.,
Ramirez-Solis, R., Estabel, J., Gallagher, F. A., Logan, D. W., Arends, M. J., Tsang,
S. H., Mahajan, V. B., Scudamore, C. L., White, J. K., Jackson, S. P., Gergely, F.,
and Adams, D. J. (2012). Disruption of mouse cenpj, a regulator of centriole
biogenesis, phenocopies seckel syndrome. PLoS Genet, 8(11):e1003022.
McKusick, V. A., Mahloudji, M., Abbott, M. H., Lindenberg, R., and Kepas, D. (1967).
Seckel’s bird-headed dwarfism. N Engl J Med, 277(6):279–86.
McManamy, C. S., Pears, J., Weston, C. L., Hanzely, Z., Ironside, J. W., Taylor, R. E.,
Grundy, R. G., Cliﬀord, S. C., Ellison, D. W., and Clinical Brain Tumour, G. (2007).
Nodule formation and desmoplasia in medulloblastomas-defining the
nodular/desmoplastic variant and its biological behavior. Brain Pathol,
17(2):151–64.
McNeil, D. E., Cote, T. R., Clegg, L., and Rorke, L. B. (2002). Incidence and trends in
pediatric malignancies medulloblastoma/primitive neuroectodermal tumor: a seer
update. surveillance epidemiology and end results. Med Pediatr Oncol,
39(3):190–4.
62
Meek, D. W. (2004). The p53 response to dna damage. DNA Repair (Amst),
3(8-9):1049–56.
Meissirel, C., Ruiz de Almodovar, C., Knevels, E., Coulon, C., Chounlamountri, N.,
Segura, I., de Rossi, P., Vinckier, S., Anthonis, K., Deleglise, B., de Mol, M., Ali, C.,
Dassonville, K., Loyens, E., Honnorat, J., Michotte, Y., Rogemond, V., Smolders, I.,
Voets, T., Vivien, D., Vanden Berghe, P., Van den Bosch, L., Robberecht, W.,
Chedotal, A., Oliviero, S., Dewerchin, M., Schmucker, D., Thomasset, N., Salin, P.,
and Carmeliet, P. (2011). Vegf modulates nmda receptors activity in cerebellar
granule cells through src-family kinases before synapse formation. Proc Natl Acad
Sci U S A, 108(33):13782–7.
Mellor, J. R., Merlo, D., Jones, A., Wisden, W., and Randall, A. D. (1998). Mouse
cerebellar granule cell diﬀerentiation: electrical activity regulates the gabaa
receptor alpha 6 subunit gene. J Neurosci, 18(8):2822–33.
Methot, N. and Basler, K. (2000). Suppressor of fused opposes hedgehog signal
transduction by impeding nuclear accumulation of the activator form of cubitus
interruptus. Development, 127(18):4001–10.
Michalak, E. M., Villunger, A., Adams, J. M., and Strasser, A. (2008). In several cell
types tumour suppressor p53 induces apoptosis largely via puma but noxa can
contribute. Cell Death Diﬀer, 15(6):1019–29.
Minn, A. J., Velez, P., Schendel, S. L., Liang, H., Muchmore, S. W., Fesik, S. W., Fill,
M., and Thompson, C. B. (1997). Bcl-x(l) forms an ion channel in synthetic lipid
membranes. Nature, 385(6614):353–7.
Miralbell, R., Lomax, A., Bortfeld, T., Rouzaud, M., and Carrie, C. (1997). Potential
role of proton therapy in the treatment of pediatric medulloblastoma/primitive
neuroectodermal tumors: reduction of the supratentorial target volume. Int J
Radiat Oncol Biol Phys, 38(3):477–84.
Mirkin, E. V. and Mirkin, S. M. (2007). Replication fork stalling at natural
impediments. Microbiol Mol Biol Rev, 71(1):13–35.
Miyashita, T., Krajewski, S., Krajewska, M., Wang, H. G., Lin, H. K., Liebermann,
D. A., Hoﬀman, B., and Reed, J. C. (1994). Tumor suppressor p53 is a regulator of
bcl-2 and bax gene expression in vitro and in vivo. Oncogene, 9(6):1799–805.
Miyata, T., Maeda, T., and Lee, J. E. (1999). Neurod is required for diﬀerentiation of
the granule cells in the cerebellum and hippocampus. Genes Dev, 13(13):1647–52.
Mokrani-Benhelli, H., Gaillard, L., Biasutto, P., Le Guen, T., Touzot, F., Vasquez, N.,
Komatsu, J., Conseiller, E., Picard, C., Gluckman, E., Francannet, C., Fischer, A.,
Durandy, A., Soulier, J., de Villartay, J. P., Cavazzana-Calvo, M., and Revy, P.
(2013). Primary microcephaly, impaired dna replication, and genomic instability
caused by compound heterozygous atr mutations. Hum Mutat, 34(2):374–84.
63
Molenaar, W. M. and Trojanowski, J. Q. (1994). Primitive neuroectodermal tumors of
the central nervous system in childhood: tumor biological aspects. Crit Rev Oncol
Hematol, 17(1):1–25.
Mukherjee, B., Kessinger, C., Kobayashi, J., Chen, B. P., Chen, D. J., Chatterjee, A.,
and Burma, S. (2006). Dna-pk phosphorylates histone h2ax during apoptotic dna
fragmentation in mammalian cells. DNA Repair (Amst), 5(5):575–90.
Mulhern, R. K., Kepner, J. L., Thomas, P. R., Armstrong, F. D., Friedman, H. S., and
Kun, L. E. (1998). Neuropsychologic functioning of survivors of childhood
medulloblastoma randomized to receive conventional or reduced-dose craniospinal
irradiation: a pediatric oncology group study. J Clin Oncol, 16(5):1723–8.
Murga, M., Bunting, S., Montana, M. F., Soria, R., Mulero, F., Canamero, M., Lee, Y.,
McKinnon, P. J., Nussenzweig, A., and Fernandez-Capetillo, O. (2009). A mouse
model of atr-seckel shows embryonic replicative stress and accelerated aging. Nat
Genet, 41(8):891–8.
Murre, C., McCaw, P. S., Vaessin, H., Caudy, M., Jan, L. Y., Jan, Y. N., Cabrera,
C. V., Buskin, J. N., Hauschka, S. D., Lassar, A. B., and et al. (1989). Interactions
between heterologous helix-loop-helix proteins generate complexes that bind
specifically to a common dna sequence. Cell, 58(3):537–44.
Myers, J. S. and Cortez, D. (2006). Rapid activation of atr by ionizing radiation
requires atm and mre11. J Biol Chem, 281(14):9346–50.
Nakano, K. and Vousden, K. H. (2001). Puma, a novel proapoptotic gene, is induced
by p53. Mol Cell, 7(3):683–94.
Nam, E. A. and Cortez, D. (2011). Atr signalling: more than meeting at the fork.
Biochem J, 436(3):527–36.
NCI (2010). Cancer prevalence and cost of care projections. Report, National Cancer
Institute.
Netter, F. H. (2011). Atlas of human anatomy. Sanders-Elsevier, Philadelphia, PA, 5
edition.
Nghiem, P., Park, P. K., Kim Ys, Y. S., Desai, B. N., and Schreiber, S. L. (2002). Atr is
not required for p53 activation but synergizes with p53 in the replication
checkpoint. J Biol Chem, 277(6):4428–34.
Nicot, A., Lelievre, V., Tam, J., Waschek, J. A., and DiCicco-Bloom, E. (2002).
Pituitary adenylate cyclase-activating polypeptide and sonic hedgehog interact to
control cerebellar granule precursor cell proliferation. J Neurosci, 22(21):9244–54.
Nieduszynski, C. A., Blow, J. J., and Donaldson, A. D. (2005). The requirement of
yeast replication origins for pre-replication complex proteins is modulated by
transcription. Nucleic Acids Res, 33(8):2410–20.
64
Northcott, P. A., Dubuc, A. M., Pfister, S., and Taylor, M. D. (2012). Molecular
subgroups of medulloblastoma. Expert Rev Neurother, 12(7):871–84.
Nunez, E., Stuardo, M. C., and Frias, J. (1971). [seckel’s syndrome]. Rev Chil
Pediatr, 42(2):117–9.
Nusslein-Volhard, C. and Wieschaus, E. (1980). Mutations aﬀecting segment number
and polarity in drosophila. Nature, 287(5785):795–801.
O’Connor, L., Strasser, A., O’Reilly, L. A., Hausmann, G., Adams, J. M., Cory, S., and
Huang, D. C. (1998). Bim: a novel member of the bcl-2 family that promotes
apoptosis. EMBO J, 17(2):384–95.
Oda, E., Ohki, R., Murasawa, H., Nemoto, J., Shibue, T., Yamashita, T., Tokino, T.,
Taniguchi, T., and Tanaka, N. (2000). Noxa, a bh3-only member of the bcl-2 family
and candidate mediator of p53-induced apoptosis. Science, 288(5468):1053–8.
O’Driscoll, M., Ruiz-Perez, V. L., Woods, C. G., Jeggo, P. A., and Goodship, J. A.
(2003). A splicing mutation aﬀecting expression of ataxia-telangiectasia and
rad3-related protein (atr) results in seckel syndrome. Nat Genet, 33(4):497–501.
Ogi, T., Walker, S., Stiﬀ, T., Hobson, E., Limsirichaikul, S., Carpenter, G., Prescott,
K., Suri, M., Byrd, P. J., Matsuse, M., Mitsutake, N., Nakazawa, Y., Vasudevan, P.,
Barrow, M., Stewart, G. S., Taylor, A. M., O’Driscoll, M., and Jeggo, P. A. (2012).
Identification of the first atrip-deficient patient and novel mutations in atr define a
clinical spectrum for atr-atrip seckel syndrome. PLoS Genet, 8(11):e1002945.
Oliver, T. G., Grasfeder, L. L., Carroll, A. L., Kaiser, C., Gillingham, C. L., Lin, S. M.,
Wickramasinghe, R., Scott, M. P., and Wechsler-Reya, R. J. (2003). Transcriptional
profiling of the sonic hedgehog response: a critical role for n-myc in proliferation of
neuronal precursors. Proc Natl Acad Sci U S A, 100(12):7331–6.
Olson, J. M., Asakura, A., Snider, L., Hawkes, R., Strand, A., Stoeck, J., Hallahan,
A., Pritchard, J., and Tapscott, S. J. (2001). Neurod2 is necessary for development
and survival of central nervous system neurons. Dev Biol, 234(1):174–87.
Ou, Y. Y., Mack, G. J., Zhang, M., and Rattner, J. B. (2002). Cep110 and ninein are
located in a specific domain of the centrosome associated with centrosome
maturation. J Cell Sci, 115(Pt 9):1825–35.
Packer, R. J., Gajjar, A., Vezina, G., Rorke-Adams, L., Burger, P. C., Robertson, P. L.,
Bayer, L., LaFond, D., Donahue, B. R., Marymont, M. H., Muraszko, K., Langston,
J., and Sposto, R. (2006). Phase iii study of craniospinal radiation therapy followed
by adjuvant chemotherapy for newly diagnosed average-risk medulloblastoma. J
Clin Oncol, 24(25):4202–8.
Packer, R. J., Goldwein, J., Nicholson, H. S., Vezina, L. G., Allen, J. C., Ris, M. D.,
Muraszko, K., Rorke, L. B., Wara, W. M., Cohen, B. H., and Boyett, J. M. (1999).
65
Treatment of children with medulloblastomas with reduced-dose craniospinal
radiation therapy and adjuvant chemotherapy: A children’s cancer group study. J
Clin Oncol, 17(7):2127–36.
Packer, R. J., Sutton, L. N., Goldwein, J. W., Perilongo, G., Bunin, G., Ryan, J.,
Cohen, B. H., D’Angio, G., Kramer, E. D., Zimmerman, R. A., and et al. (1991).
Improved survival with the use of adjuvant chemotherapy in the treatment of
medulloblastoma. J Neurosurg, 74(3):433–40.
Packer, R. J. and Vezina, G. (2008). Management of and prognosis with
medulloblastoma: therapy at a crossroads. Arch Neurol, 65(11):1419–24.
Paixao, S., Colaluca, I. N., Cubells, M., Peverali, F. A., Destro, A., Giadrossi, S.,
Giacca, M., Falaschi, A., Riva, S., and Biamonti, G. (2004). Modular structure of
the human lamin b2 replicator. Mol Cell Biol, 24(7):2958–67.
Pan, G., O’Rourke, K., and Dixit, V. M. (1998). Caspase-9, bcl-xl, and apaf-1 form a
ternary complex. J Biol Chem, 273(10):5841–5.
Pappas, D. L., J., Frisch, R., and Weinreich, M. (2004). The nad(+)-dependent sir2p
histone deacetylase is a negative regulator of chromosomal dna replication. Genes
Dev, 18(7):769–81.
Paques, F. and Haber, J. E. (1999). Multiple pathways of recombination induced by
double-strand breaks in saccharomyces cerevisiae. Microbiol Mol Biol Rev,
63(2):349–404.
Parsons, D. W., Li, M., Zhang, X., Jones, S., Leary, R. J., Lin, J. C., Boca, S. M.,
Carter, H., Samayoa, J., Bettegowda, C., Gallia, G. L., Jallo, G. I., Binder, Z. A.,
Nikolsky, Y., Hartigan, J., Smith, D. R., Gerhard, D. S., Fults, D. W., VandenBerg,
S., Berger, M. S., Marie, S. K., Shinjo, S. M., Clara, C., Phillips, P. C., Minturn,
J. E., Biegel, J. A., Judkins, A. R., Resnick, A. C., Storm, P. B., Curran, T., He, Y.,
Rasheed, B. A., Friedman, H. S., Keir, S. T., McLendon, R., Northcott, P. A., Taylor,
M. D., Burger, P. C., Riggins, G. J., Karchin, R., Parmigiani, G., Bigner, D. D., Yan,
H., Papadopoulos, N., Vogelstein, B., Kinzler, K. W., and Velculescu, V. E. (2011).
The genetic landscape of the childhood cancer medulloblastoma. Science,
331(6016):435–9.
Pasero, P., Bensimon, A., and Schwob, E. (2002). Single-molecule analysis reveals
clustering and epigenetic regulation of replication origins at the yeast rdna locus.
Genes Dev, 16(19):2479–84.
Pei, Y., Moore, C. E., Wang, J., Tewari, A. K., Eroshkin, A., Cho, Y. J., Witt, H.,
Korshunov, A., Read, T. A., Sun, J. L., Schmitt, E. M., Miller, C. R., Buckley, A. F.,
McLendon, R. E., Westbrook, T. F., Northcott, P. A., Taylor, M. D., Pfister, S. M.,
Febbo, P. G., and Wechsler-Reya, R. J. (2012). An animal model of myc-driven
medulloblastoma. Cancer Cell, 21(2):155–67.
66
Peng, C. Y., Graves, P. R., Thoma, R. S., Wu, Z., Shaw, A. S., and Piwnica-Worms, H.
(1997). Mitotic and g2 checkpoint control: regulation of 14-3-3 protein binding by
phosphorylation of cdc25c on serine-216. Science, 277(5331):1501–5.
Perciavalle, R. M., Stewart, D. P., Koss, B., Lynch, J., Milasta, S., Bathina, M.,
Temirov, J., Cleland, M. M., Pelletier, S., Schuetz, J. D., Youle, R. J., Green, D. R.,
and Opferman, J. T. (2012). Anti-apoptotic mcl-1 localizes to the mitochondrial
matrix and couples mitochondrial fusion to respiration. Nat Cell Biol,
14(6):575–83.
Perciavalle, V., Bosco, G., and Poppele, R. (1995). Correlated activity in the
spinocerebellum is related to spinal timing generators. Brain Res, 695(2):293–7.
Perfettini, J. L., Kroemer, R. T., and Kroemer, G. (2004). Fatal liaisons of p53 with
bax and bak. Nat Cell Biol, 6(5):386–8.
Pichierri, P., Rosselli, F., and Franchitto, A. (2003). Werner’s syndrome protein is
phosphorylated in an atr/atm-dependent manner following replication arrest and
dna damage induced during the s phase of the cell cycle. Oncogene,
22(10):1491–500.
Pietsch, T., Waha, A., Koch, A., Kraus, J., Albrecht, S., Tonn, J., Sorensen, N.,
Berthold, F., Henk, B., Schmandt, N., Wolf, H. K., von Deimling, A., Wainwright,
B., Chenevix-Trench, G., Wiestler, O. D., and Wicking, C. (1997).
Medulloblastomas of the desmoplastic variant carry mutations of the human
homologue of drosophila patched. Cancer Res, 57(11):2085–8.
Poli, J., Tsaponina, O., Crabbe, L., Keszthelyi, A., Pantesco, V., Chabes, A.,
Lengronne, A., and Pasero, P. (2012). dntp pools determine fork progression and
origin usage under replication stress. EMBO J, 31(4):883–94.
Pomeroy, S. L., Tamayo, P., Gaasenbeek, M., Sturla, L. M., Angelo, M., McLaughlin,
M. E., Kim, J. Y., Goumnerova, L. C., Black, P. M., Lau, C., Allen, J. C., Zagzag, D.,
Olson, J. M., Curran, T., Wetmore, C., Biegel, J. A., Poggio, T., Mukherjee, S.,
Rifkin, R., Califano, A., Stolovitzky, G., Louis, D. N., Mesirov, J. P., Lander, E. S.,
and Golub, T. R. (2002). Prediction of central nervous system embryonal tumour
outcome based on gene expression. Nature, 415(6870):436–42.
Pons, S., Trejo, J. L., Martinez-Morales, J. R., and Marti, E. (2001). Vitronectin
regulates sonic hedgehog activity during cerebellum development through creb
phosphorylation. Development, 128(9):1481–92.
Prado, F. and Aguilera, A. (2005). Impairment of replication fork progression
mediates rna polii transcription-associated recombination. EMBO J,
24(6):1267–76.
Qvist, P., Huertas, P., Jimeno, S., Nyegaard, M., Hassan, M. J., Jackson, S. P., and
Borglum, A. D. (2011). Ctip mutations cause seckel and jawad syndromes. PLoS
Genet, 7(10):e1002310.
67
Raﬀel, C. (2004). Medulloblastoma: molecular genetics and animal models.
Neoplasia, 6(4):310–22.
Ragland, R. L., Patel, S., Rivard, R. S., Smith, K., Peters, A. A., Bielinsky, A. K., and
Brown, E. J. (2013). Rnf4 and plk1 are required for replication fork collapse in
atr-deficient cells. Genes Dev, 27(20):2259–73.
Rasheed, B. K. and Bigner, S. H. (1991). Genetic alterations in glioma and
medulloblastoma. Cancer Metastasis Rev, 10(4):289–99.
Ray, A., Ho, M., Ma, J., Parkes, R. K., Mainprize, T. G., Ueda, S., McLaughlin, J.,
Bouﬀet, E., Rutka, J. T., and Hawkins, C. E. (2004). A clinicobiological model
predicting survival in medulloblastoma. Clin Cancer Res, 10(22):7613–20.
Reitsema, T., Klokov, D., Banath, J. P., and Olive, P. L. (2005). Dna-pk is responsible
for enhanced phosphorylation of histone h2ax under hypertonic conditions. DNA
Repair (Amst), 4(10):1172–81.
Rieﬀ, H. I., Raetzman, L. T., Sapp, D. W., Yeh, H. H., Siegel, R. E., and Corfas, G.
(1999). Neuregulin induces gaba(a) receptor subunit expression and neurite
outgrowth in cerebellar granule cells. J Neurosci, 19(24):10757–66.
Ris, M. D., Packer, R., Goldwein, J., Jones-Wallace, D., and Boyett, J. M. (2001).
Intellectual outcome after reduced-dose radiation therapy plus adjuvant
chemotherapy for medulloblastoma: a children’s cancer group study. J Clin Oncol,
19(15):3470–6.
Riva, D. and Giorgi, C. (2000a). The cerebellum contributes to higher functions
during development: evidence from a series of children surgically treated for
posterior fossa tumours. Brain, 123 ( Pt 5):1051–61.
Riva, D. and Giorgi, C. (2000b). The contribution of the cerebellum to mental and
social functions in developmental age. Fiziol Cheloveka, 26(1):27–31.
Robinson, G. W., Orr, B. A., Wu, G., Gururangan, S., Lin, T., Qaddoumi, I., Packer,
R. J., Goldman, S., Prados, M. D., Desjardins, A., Chintagumpala, M., Takebe, N.,
Kaste, S. C., Rusch, M., Allen, S. J., Onar-Thomas, A., Stewart, C. F., Fouladi, M.,
Boyett, J. M., Gilbertson, R. J., Curran, T., Ellison, D. W., and Gajjar, A. (2015).
Vismodegib exerts targeted eﬃcacy against recurrent sonic hedgehog-subgroup
medulloblastoma: Results from phase ii pediatric brain tumor consortium studies
pbtc-025b and pbtc-032. J Clin Oncol, 33(24):2646–54.
Robles, A. I., Bemmels, N. A., Foraker, A. B., and Harris, C. C. (2001). Apaf-1 is a
transcriptional target of p53 in dna damage-induced apoptosis. Cancer Res,
61(18):6660–4.
Rorke, L. B. (1983). The cerebellar medulloblastoma and its relationship to primitive
neuroectodermal tumors. J Neuropathol Exp Neurol, 42(1):1–15.
68
Roussel, M. F. and Hatten, M. E. (2011). Cerebellum development and
medulloblastoma. Curr Top Dev Biol, 94:235–82.
Roussel, M. F. and Robinson, G. W. (2013). Role of myc in medulloblastoma. Cold
Spring Harb Perspect Med, 3(11).
Rubin, J. B., Choi, Y., and Segal, R. A. (2002). Cerebellar proteoglycans regulate
sonic hedgehog responses during development. Development, 129(9):2223–32.
Rubinstein, L. J. (1985). Embryonal central neuroepithelial tumors and their
diﬀerentiating potential. a cytogenetic view of a complex neuro-oncological
problem. J Neurosurg, 62(6):795–805.
Rutka, J. T. (1997). Medulloblastoma. Clin Neurosurg, 44:571–85.
Sakahira, H., Enari, M., and Nagata, S. (1998). Cleavage of cad inhibitor in cad
activation and dna degradation during apoptosis. Nature, 391(6662):96–9.
Saleh-Gohari, N., Bryant, H. E., Schultz, N., Parker, K. M., Cassel, T. N., and
Helleday, T. (2005). Spontaneous homologous recombination is induced by
collapsed replication forks that are caused by endogenous dna single-strand
breaks. Mol Cell Biol, 25(16):7158–69.
Salsano, E., Pollo, B., Eoli, M., Giordana, M. T., and Finocchiaro, G. (2004).
Expression of math1, a marker of cerebellar granule cell progenitors, identifies
diﬀerent medulloblastoma sub-types. Neurosci Lett, 370(2-3):180–5.
Santamaria, D., de la Cueva, G., Martinez-Robles, M. L., Krimer, D. B., Hernandez,
P., and Schvartzman, J. B. (1998). Dnab helicase is unable to dissociate rna-dna
hybrids. its implication in the polar pausing of replication forks at cole1 origins. J
Biol Chem, 273(50):33386–96.
Santamaria, D., Hernandez, P., Martinez-Robles, M. L., Krimer, D. B., and
Schvartzman, J. B. (2000). Premature termination of dna replication in plasmids
carrying two inversely oriented cole1 origins. J Mol Biol, 300(1):75–82.
Sartori, A. A., Lukas, C., Coates, J., Mistrik, M., Fu, S., Bartek, J., Baer, R., Lukas,
J., and Jackson, S. P. (2007). Human ctip promotes dna end resection. Nature,
450(7169):509–14.
Sauk, J. J., Litt, R., Espiritu, C. E., and Delaney, J. R. (1973). Familial bird-headed
dwarfism (seckel’s syndrome). J Med Genet, 10(2):196–8.
Savill, J. and Fadok, V. (2000). Corpse clearance defines the meaning of cell death.
Nature, 407(6805):784–8.
Sax, J. K., Fei, P., Murphy, M. E., Bernhard, E., Korsmeyer, S. J., and El-Deiry, W. S.
(2002). Bid regulation by p53 contributes to chemosensitivity. Nat Cell Biol,
4(11):842–9.
69
Schaarschmidt, D., Baltin, J., Stehle, I. M., Lipps, H. J., and Knippers, R. (2004). An
episomal mammalian replicon: sequence-independent binding of the origin
recognition complex. EMBO J, 23(1):191–201.
Schmahmann, J. D. (1991). An emerging concept. the cerebellar contribution to
higher function. Arch Neurol, 48(11):1178–87.
Schroeder, K. and Gururangan, S. (2014). Molecular variants and mutations in
medulloblastoma. Pharmgenomics Pers Med, 7:43–51.
Schuller, U., Heine, V. M., Mao, J., Kho, A. T., Dillon, A. K., Han, Y. G., Huillard, E.,
Sun, T., Ligon, A. H., Qian, Y., Ma, Q., Alvarez-Buylla, A., McMahon, A. P.,
Rowitch, D. H., and Ligon, K. L. (2008). Acquisition of granule neuron precursor
identity is a critical determinant of progenitor cell competence to form shh-induced
medulloblastoma. Cancer Cell, 14(2):123–34.
Seckel, H. P. G. (1960). Bird-headed dwarfs: studies in developmental anthrolopology
including human proportions. S. Karger, Basel, Switzerland.
Shaheen, R., Faqeih, E., Ansari, S., Abdel-Salam, G., Al-Hassnan, Z. N., Al-Shidi, T.,
Alomar, R., Sogaty, S., and Alkuraya, F. S. (2014). Genomic analysis of primordial
dwarfism reveals novel disease genes. Genome Res, 24(2):291–9.
Shanske, A., Caride, D. G., Menasse-Palmer, L., Bogdanow, A., and Marion, R. W.
(1997). Central nervous system anomalies in seckel syndrome: report of a new
family and review of the literature. Am J Med Genet, 70(2):155–8.
Shen, T. and Huang, S. (2012). The role of cdc25a in the regulation of cell
proliferation and apoptosis. Anticancer Agents Med Chem, 12(6):631–9.
Shiloh, Y. (2003). Atm and related protein kinases: safeguarding genome integrity.
Nat Rev Cancer, 3(3):155–68.
Shiloh, Y. (2006). The atm-mediated dna-damage response: taking shape. Trends
Biochem Sci, 31(7):402–10.
Shiloh, Y. and Ziv, Y. (2013). The atm protein kinase: regulating the cellular
response to genotoxic stress, and more. Nat Rev Mol Cell Biol, 14(4):197–210.
Shimada, M., Niida, H., Zineldeen, D. H., Tagami, H., Tanaka, M., Saito, H., and
Nakanishi, M. (2008). Chk1 is a histone h3 threonine 11 kinase that regulates dna
damage-induced transcriptional repression. Cell, 132(2):221–32.
Shimuta, K., Nakajo, N., Uto, K., Hayano, Y., Okazaki, K., and Sagata, N. (2002).
Chk1 is activated transiently and targets cdc25a for degradation at the xenopus
midblastula transition. EMBO J, 21(14):3694–703.
Shin, M. H., Yuan, M., Zhang, H., Margolick, J. B., and Kai, M. (2012).
Atm-dependent phosphorylation of the checkpoint clamp regulates repair
pathways and maintains genomic stability. Cell Cycle, 11(9):1796–803.
70
Shiozaki, E. N., Chai, J., Rigotti, D. J., Riedl, S. J., Li, P., Srinivasula, S. M.,
Alnemri, E. S., Fairman, R., and Shi, Y. (2003). Mechanism of xiap-mediated
inhibition of caspase-9. Mol Cell, 11(2):519–27.
Sir, J. H., Barr, A. R., Nicholas, A. K., Carvalho, O. P., Khurshid, M., Sossick, A.,
Reichelt, S., D’Santos, C., Woods, C. G., and Gergely, F. (2011). A primary
microcephaly protein complex forms a ring around parental centrioles. Nat Genet,
43(11):1147–53.
Sirachainan, N., Nuchprayoon, I., Thanarattanakorn, P., Pakakasama, S., Lusawat,
A., Visudibhan, A., Dhanachai, M., Larbcharoensub, N., Amornfa, J., Shotelersuk,
K., Katanyuwong, K., Tangkaratt, S., and Hongeng, S. (2011). Outcome of
medulloblastoma in children treated with reduced-dose radiation therapy plus
adjuvant chemotherapy. J Clin Neurosci, 18(4):515–9.
Sirbu, B. M., Couch, F. B., Feigerle, J. T., Bhaskara, S., Hiebert, S. W., and Cortez, D.
(2011). Analysis of protein dynamics at active, stalled, and collapsed replication
forks. Genes Dev, 25(12):1320–7.
Skousen, G. J., Wardinsky, T., and Chenaille, P. (1996). Medulloblastoma in patient
with rubinstein-taybi syndrome. Am J Med Genet, 66(3):367.
Slee, E. A., Adrain, C., and Martin, S. J. (2001). Executioner caspase-3, -6, and -7
perform distinct, non-redundant roles during the demolition phase of apoptosis. J
Biol Chem, 276(10):7320–6.
Smith, E., Dejsuphong, D., Balestrini, A., Hampel, M., Lenz, C., Takeda, S.,
Vindigni, A., and Costanzo, V. (2009). An atm- and atr-dependent checkpoint
inactivates spindle assembly by targeting cep63. Nat Cell Biol, 11(3):278–85.
Smith, J., Tho, L. M., Xu, N., and Gillespie, D. A. (2010). The atm-chk2 and atr-chk1
pathways in dna damage signaling and cancer. Adv Cancer Res, 108:73–112.
Smoll, N. R. and Drummond, K. J. (2012). The incidence of medulloblastomas and
primitive neurectodermal tumours in adults and children. J Clin Neurosci,
19(11):1541–4.
Sogo, J. M., Lopes, M., and Foiani, M. (2002). Fork reversal and ssdna accumulation
at stalled replication forks owing to checkpoint defects. Science,
297(5581):599–602.
Solecki, D. J., Liu, X. L., Tomoda, T., Fang, Y., and Hatten, M. E. (2001). Activated
notch2 signaling inhibits diﬀerentiation of cerebellar granule neuron precursors
by maintaining proliferation. Neuron, 31(4):557–68.
Sorensen, C. S., Hansen, L. T., Dziegielewski, J., Syljuasen, R. G., Lundin, C.,
Bartek, J., and Helleday, T. (2005). The cell-cycle checkpoint kinase chk1 is
required for mammalian homologous recombination repair. Nat Cell Biol,
7(2):195–201.
71
Sorensen, C. S., Syljuasen, R. G., Falck, J., Schroeder, T., Ronnstrand, L., Khanna,
K. K., Zhou, B. B., Bartek, J., and Lukas, J. (2003). Chk1 regulates the s phase
checkpoint by coupling the physiological turnover and ionizing radiation-induced
accelerated proteolysis of cdc25a. Cancer Cell, 3(3):247–58.
Sotelo, C. (2015). Molecular layer interneurons of the cerebellum: developmental
and morphological aspects. Cerebellum, 14(5):534–56.
Stanton, B. Z. and Peng, L. F. (2010). Small-molecule modulators of the sonic
hedgehog signaling pathway. Mol Biosyst, 6(1):44–54.
Stiﬀ, T., Walker, S. A., Cerosaletti, K., Goodarzi, A. A., Petermann, E., Concannon,
P., O’Driscoll, M., and Jeggo, P. A. (2006). Atr-dependent phosphorylation and
activation of atm in response to uv treatment or replication fork stalling. EMBO J,
25(24):5775–82.
Stommel, J. M. and Wahl, G. M. (2004). Accelerated mdm2 auto-degradation induced
by dna-damage kinases is required for p53 activation. EMBO J, 23(7):1547–56.
Sugio, Y., Tsukahara, M., and Kajii, T. (1993). Two japanese cases with
microcephalic primordial dwarfism: classical seckel syndrome and osteodysplastic
primordial dwarfism type ii. Jpn J Hum Genet, 38(2):209–17.
Sun, H. Q., Yamamoto, M., Mejillano, M., and Yin, H. L. (1999). Gelsolin, a
multifunctional actin regulatory protein. J Biol Chem, 274(47):33179–82.
Suzuki, Y., Nakabayashi, Y., Nakata, K., Reed, J. C., and Takahashi, R. (2001).
X-linked inhibitor of apoptosis protein (xiap) inhibits caspase-3 and -7 in distinct
modes. J Biol Chem, 276(29):27058–63.
Syljuasen, R. G., Sorensen, C. S., Hansen, L. T., Fugger, K., Lundin, C., Johansson,
F., Helleday, T., Sehested, M., Lukas, J., and Bartek, J. (2005). Inhibition of
human chk1 causes increased initiation of dna replication, phosphorylation of atr
targets, and dna breakage. Mol Cell Biol, 25(9):3553–62.
Szalay, G. C. (1964). Intrauterine growth retardation versus silver’s syndrome. J
Pediatr, 64:234–40.
Takayama, Y., Kamimura, Y., Okawa, M., Muramatsu, S., Sugino, A., and Araki, H.
(2003). Gins, a novel multiprotein complex required for chromosomal dna
replication in budding yeast. Genes Dev, 17(9):1153–65.
Takeuchi, Y., Horiuchi, T., and Kobayashi, T. (2003). Transcription-dependent
recombination and the role of fork collision in yeast rdna. Genes Dev,
17(12):1497–506.
Tan, Y., Raychaudhuri, P., and Costa, R. H. (2007). Chk2 mediates stabilization of
the foxm1 transcription factor to stimulate expression of dna repair genes. Mol
Cell Biol, 27(3):1007–16.
72
Tassan, J. P., Jaquenoud, M., Fry, A. M., Frutiger, S., Hughes, G. J., and Nigg, E. A.
(1995). In vitro assembly of a functional human cdk7-cyclin h complex requires
mat1, a novel 36 kda ring finger protein. EMBO J, 14(22):5608–17.
Taylor, M. D., Mainprize, T. G., and Rutka, J. T. (2000). Molecular insight into
medulloblastoma and central nervous system primitive neuroectodermal tumor
biology from hereditary syndromes: a review. Neurosurgery, 47(4):888–901.
Taylor, M. D., Northcott, P. A., Korshunov, A., Remke, M., Cho, Y. J., Cliﬀord, S. C.,
Eberhart, C. G., Parsons, D. W., Rutkowski, S., Gajjar, A., Ellison, D. W., Lichter,
P., Gilbertson, R. J., Pomeroy, S. L., Kool, M., and Pfister, S. M. (2012). Molecular
subgroups of medulloblastoma: the current consensus. Acta Neuropathol,
123(4):465–72.
Tempe, D., Casas, M., Karaz, S., Blanchet-Tournier, M. F., and Concordet, J. P.
(2006). Multisite protein kinase a and glycogen synthase kinase 3beta
phosphorylation leads to gli3 ubiquitination by scfbetatrcp. Mol Cell Biol,
26(11):4316–26.
Thanasoula, M., Escandell, J. M., Suwaki, N., and Tarsounas, M. (2012). Atm/atr
checkpoint activation downregulates cdc25c to prevent mitotic entry with
uncapped telomeres. EMBO J, 31(16):3398–410.
Thangavel, S., Berti, M., Levikova, M., Pinto, C., Gomathinayagam, S., Vujanovic,
M., Zellweger, R., Moore, H., Lee, E. H., Hendrickson, E. A., Cejka, P., Stewart, S.,
Lopes, M., and Vindigni, A. (2015). Dna2 drives processing and restart of reversed
replication forks in human cells. J Cell Biol, 208(5):545–62.
Therond, P. P., Knight, J. D., Kornberg, T. B., and Bishop, J. M. (1996).
Phosphorylation of the fused protein kinase in response to signaling from
hedgehog. Proc Natl Acad Sci U S A, 93(9):4224–8.
Thompson, E. and Pembrey, M. (1985). Seckel syndrome: an overdiagnosed
syndrome. J Med Genet, 22(3):192–201.
Tibbetts, R. S., Brumbaugh, K. M., Williams, J. M., Sarkaria, J. N., Cliby, W. A.,
Shieh, S. Y., Taya, Y., Prives, C., and Abraham, R. T. (1999). A role for atr in the
dna damage-induced phosphorylation of p53. Genes Dev, 13(2):152–7.
Tibbetts, R. S., Cortez, D., Brumbaugh, K. M., Scully, R., Livingston, D., Elledge,
S. J., and Abraham, R. T. (2000). Functional interactions between brca1 and the
checkpoint kinase atr during genotoxic stress. Genes Dev, 14(23):2989–3002.
Timmann, D. and Daum, I. (2007). Cerebellar contributions to cognitive functions: a
progress report after two decades of research. Cerebellum, 6(3):159–62.
Toledo, L. I., Altmeyer, M., Rask, M. B., Lukas, C., Larsen, D. H., Povlsen, L. K.,
Bekker-Jensen, S., Mailand, N., Bartek, J., and Lukas, J. (2013). Atr prohibits
73
replication catastrophe by preventing global exhaustion of rpa. Cell,
155(5):1088–103.
Tomlinson, F. H., Scheithauer, B. W., and Jenkins, R. B. (1992a). Medulloblastoma:
Ii. a pathobiologic overview. J Child Neurol, 7(3):240–52.
Tomlinson, F. H., Scheithauer, B. W., Meyer, F. B., Smithson, W. A., Shaw, E. G.,
Miller, G. M., and Groover, R. V. (1992b). Medulloblastoma: I. clinical, diagnostic,
and therapeutic overview. J Child Neurol, 7(2):142–55.
Tone, S., Sugimoto, K., Tanda, K., Suda, T., Uehira, K., Kanouchi, H., Samejima, K.,
Minatogawa, Y., and Earnshaw, W. C. (2007). Three distinct stages of apoptotic
nuclear condensation revealed by time-lapse imaging, biochemical and electron
microscopy analysis of cell-free apoptosis. Exp Cell Res, 313(16):3635–44.
Topiwala, K., Fahmi, T., Savenka, A. . V., Apostolov, E. O., and Basnakian, A. G.
(2013). Dnase activity in kidney cell pyknosis induced by serum deprivation. The
FASEB Journal, 27(1):1.
Trenz, K., Errico, A., and Costanzo, V. (2008). Plx1 is required for chromosomal dna
replication under stressful conditions. EMBO J, 27(6):876–85.
Tsujimoto, Y. (1989). Stress-resistance conferred by high level of bcl-2 alpha protein
in human b lymphoblastoid cell. Oncogene, 4(11):1331–6.
Tsujimoto, Y. (1998). Role of bcl-2 family proteins in apoptosis: apoptosomes or
mitochondria? Genes Cells, 3(11):697–707.
Vaillant, C. and Monard, D. (2009). Shh pathway and cerebellar development.
Cerebellum, 8(3):291–301.
Vaudry, D., Basille, M., Anouar, Y., Fournier, A., Vaudry, H., and Gonzalez, B. J.
(1998). The neurotrophic activity of pacap on rat cerebellar granule cells is
associated with activation of the protein kinase a pathway and c-fos gene
expression. Ann N Y Acad Sci, 865:92–9.
Vaux, D. L., Cory, S., and Adams, J. M. (1988). Bcl-2 gene promotes haemopoietic cell
survival and cooperates with c-myc to immortalize pre-b cells. Nature,
335(6189):440–2.
Viguera, E., Hernandez, P., Krimer, D. B., Boistov, A. S., Lurz, R., Alonso, J. C., and
Schvartzman, J. B. (1996). The cole1 unidirectional origin acts as a polar
replication fork pausing site. J Biol Chem, 271(37):22414–21.
Virchow, R. L. C. (1892). Vorstellung des knaben dobos. Berliner Klinische
Wochenschrift, 29(21):1.
74
von Hoﬀ, K., Hartmann, W., von Bueren, A. O., Gerber, N. U., Grotzer, M. A., Pietsch,
T., and Rutkowski, S. (2010). Large cell/anaplastic medulloblastoma: outcome
according to myc status, histopathological, and clinical risk factors. Pediatr Blood
Cancer, 54(3):369–76.
Voogd, J. and Glickstein, M. (1998). The anatomy of the cerebellum. Trends
Neurosci, 21(9):370–5.
Vorechovsky, I., Tingby, O., Hartman, M., Stromberg, B., Nister, M., Collins, V. P.,
and Toftgard, R. (1997). Somatic mutations in the human homologue of drosophila
patched in primitive neuroectodermal tumours. Oncogene, 15(3):361–6.
Wallace, V. A. (1999). Purkinje-cell-derived sonic hedgehog regulates granule neuron
precursor cell proliferation in the developing mouse cerebellum. Curr Biol,
9(8):445–8.
Walsh, J. G., Cullen, S. P., Sheridan, C., Luthi, A. U., Gerner, C., and Martin, S. J.
(2008). Executioner caspase-3 and caspase-7 are functionally distinct proteases.
Proc Natl Acad Sci U S A, 105(35):12815–9.
Walter, A. W., Mulhern, R. K., Gajjar, A., Heideman, R. L., Reardon, D., Sanford,
R. A., Xiong, X., and Kun, L. E. (1999). Survival and neurodevelopmental outcome
of young children with medulloblastoma at st jude children’s research hospital. J
Clin Oncol, 17(12):3720–8.
Walworth, N., Davey, S., and Beach, D. (1993). Fission yeast chk1 protein kinase
links the rad checkpoint pathway to cdc2. Nature, 363(6427):368–71.
Wang, J., Gong, Z., and Chen, J. (2011). Mdc1 collaborates with topbp1 in dna
replication checkpoint control. J Cell Biol, 193(2):267–73.
Wang, L., Lin, C. M., Brooks, S., Cimbora, D., Groudine, M., and Aladjem, M. I.
(2004). The human beta-globin replication initiation region consists of two
modular independent replicators. Mol Cell Biol, 24(8):3373–86.
Wang, V. Y. and Zoghbi, H. Y. (2001). Genetic regulation of cerebellar development.
Nat Rev Neurosci, 2(7):484–91.
Ward, I. M. and Chen, J. (2001). Histone h2ax is phosphorylated in an atr-dependent
manner in response to replicational stress. J Biol Chem, 276(51):47759–62.
Wechsler-Reya, R. and Scott, M. P. (2001). The developmental biology of brain
tumors. Annu Rev Neurosci, 24:385–428.
Wechsler-Reya, R. J. (2001). Caught in the matrix: how vitronectin controls neuronal
diﬀerentiation. Trends Neurosci, 24(12):680–2.
Wechsler-Reya, R. J. and Scott, M. P. (1999). Control of neuronal precursor
proliferation in the cerebellum by sonic hedgehog. Neuron, 22(1):103–14.
75
Weinberg, R. (2013). The Biology of Cancer. Taylor and Francis Group, New York,
NY, 2nd edition.
Wetmore, C., Eberhart, D. E., and Curran, T. (2000). The normal patched allele is
expressed in medulloblastomas from mice with heterozygous germ-line mutation
of patched. Cancer Res, 60(8):2239–46.
Willis, J., Patel, Y., Lentz, B. L., and Yan, S. (2013). Ape2 is required for atr-chk1
checkpoint activation in response to oxidative stress. Proc Natl Acad Sci USA,
110(26):10592–7.
Willis, S. N., Chen, L., Dewson, G., Wei, A., Naik, E., Fletcher, J. I., Adams, J. M.,
and Huang, D. C. (2005). Proapoptotic bak is sequestered by mcl-1 and bcl-xl, but
not bcl-2, until displaced by bh3-only proteins. Genes Dev, 19(11):1294–305.
Willis, S. N., Fletcher, J. I., Kaufmann, T., van Delft, M. F., Chen, L., Czabotar, P. E.,
Ierino, H., Lee, E. F., Fairlie, W. D., Bouillet, P., Strasser, A., Kluck, R. M., Adams,
J. M., and Huang, D. C. (2007). Apoptosis initiated when bh3 ligands engage
multiple bcl-2 homologs, not bax or bak. Science, 315(5813):856–9.
Wolter, K. G., Hsu, Y. T., Smith, C. L., Nechushtan, A., Xi, X. G., and Youle, R. J.
(1997). Movement of bax from the cytosol to mitochondria during apoptosis. J Cell
Biol, 139(5):1281–92.
Woo, R. A. and Poon, R. Y. (2003). Cyclin-dependent kinases and s phase control in
mammalian cells. Cell Cycle, 2(4):316–24.
Woodward, A. M., Gohler, T., Luciani, M. G., Oehlmann, M., Ge, X., Gartner, A.,
Jackson, D. A., and Blow, J. J. (2006). Excess mcm2-7 license dormant origins of
replication that can be used under conditions of replicative stress. J Cell Biol,
173(5):673–83.
Wu, G., Chai, J., Suber, T. L., Wu, J. W., Du, C., Wang, X., and Shi, Y. (2000).
Structural basis of iap recognition by smac/diablo. Nature, 408(6815):1008–12.
Wu, X., Shell, S. M., Liu, Y., and Zou, Y. (2007). Atr-dependent checkpoint modulates
xpa nuclear import in response to uv irradiation. Oncogene, 26(5):757–64.
Wurstle, M. L., Laussmann, M. A., and Rehm, M. (2012). The central role of initiator
caspase-9 in apoptosis signal transduction and the regulation of its activation and
activity on the apoptosome. Exp Cell Res, 318(11):1213–20.
Wyrick, J. J., Aparicio, J. G., Chen, T., Barnett, J. D., Jennings, E. G., Young, R. A.,
Bell, S. P., and Aparicio, O. M. (2001). Genome-wide distribution of orc and mcm
proteins in s. cerevisiae: high-resolution mapping of replication origins. Science,
294(5550):2357–60.
76
Xu, H., Yang, Y., Tang, X., Zhao, M., Liang, F., Xu, P., Hou, B., Xing, Y., Bao, X., and
Fan, X. (2013). Bergmann glia function in granule cell migration during
cerebellum development. Mol Neurobiol, 47(2):833–44.
Yamasaki, T., Kawaji, K., Ono, K., Bito, H., Hirano, T., Osumi, N., and Kengaku, M.
(2001). Pax6 regulates granule cell polarization during parallel fiber formation in
the developing cerebellum. Development, 128(16):3133–44.
Yang, E., Zha, J., Jockel, J., Boise, L. H., Thompson, C. B., and Korsmeyer, S. J.
(1995). Bad, a heterodimeric partner for bcl-xl and bcl-2, displaces bax and
promotes cell death. Cell, 80(2):285–91.
Yang, J., Liu, X., Bhalla, K., Kim, C. N., Ibrado, A. M., Cai, J., Peng, T. I., Jones,
D. P., and Wang, X. (1997). Prevention of apoptosis by bcl-2: release of cytochrome
c from mitochondria blocked. Science, 275(5303):1129–32.
Yang, X. W., Wynder, C., Doughty, M. L., and Heintz, N. (1999). Bac-mediated
gene-dosage analysis reveals a role for zipro1 (ru49/zfp38) in progenitor cell
proliferation in cerebellum and skin. Nat Genet, 22(4):327–35.
Yang, X. W., Zhong, R., and Heintz, N. (1996). Granule cell specification in the
developing mouse brain as defined by expression of the zinc finger transcription
factor ru49. Development, 122(2):555–66.
Yang, Z. J., Ellis, T., Markant, S. L., Read, T. A., Kessler, J. D., Bourboulas, M.,
Schuller, U., Machold, R., Fishell, G., Rowitch, D. H., Wainwright, B. J., and
Wechsler-Reya, R. J. (2008). Medulloblastoma can be initiated by deletion of
patched in lineage-restricted progenitors or stem cells. Cancer Cell, 14(2):135–45.
Yigit, G., Brown, K. E., Kayserili, H., Pohl, E., Caliebe, A., Zahnleiter, D., Rosser, E.,
Bogershausen, N., Uyguner, Z. O., Altunoglu, U., Nurnberg, G., Nurnberg, P.,
Rauch, A., Li, Y., Thiel, C. T., and Wollnik, B. (2015). Mutations in cdk5rap2 cause
seckel syndrome. Mol Genet Genomic Med, 3(5):467–80.
Yokota, N., Aruga, J., Takai, S., Yamada, K., Hamazaki, M., Iwase, T., Sugimura, H.,
and Mikoshiba, K. (1996). Predominant expression of human zic in cerebellar
granule cell lineage and medulloblastoma. Cancer Res, 56(2):377–83.
Yoo, H. Y., Kumagai, A., Shevchenko, A., Shevchenko, A., and Dunphy, W. G. (2007).
Ataxia-telangiectasia mutated (atm)-dependent activation of atr occurs through
phosphorylation of topbp1 by atm. J Biol Chem, 282(24):17501–6.
Yoo, H. Y., Kumagai, A., Shevchenko, A., Shevchenko, A., and Dunphy, W. G. (2009).
The mre11-rad50-nbs1 complex mediates activation of topbp1 by atm. Mol Biol
Cell, 20(9):2351–60.
Yoo, H. Y., Shevchenko, A., Shevchenko, A., and Dunphy, W. G. (2004). Mcm2 is a
direct substrate of atm and atr during dna damage and dna replication checkpoint
responses. J Biol Chem, 279(51):53353–64.
77
Zadorozny, E. V., Little, J. C., and Kalderon, D. (2015). Contributions of costal
2-fused interactions to hedgehog signaling in drosophila. Development,
142(5):931–42.
Zhang, C., Zhu, Q., and Hua, T. (2010). Aging of cerebellar purkinje cells. Cell Tissue
Res, 341(3):341–7.
Zhao, H., Watkins, J. L., and Piwnica-Worms, H. (2002). Disruption of the checkpoint
kinase 1/cell division cycle 25a pathway abrogates ionizing radiation-induced s and
g2 checkpoints. Proc Natl Acad Sci U S A, 99(23):14795–800.
Zheng, L., Zhou, M., Guo, Z., Lu, H., Qian, L., Dai, H., Qiu, J., Yakubovskaya, E.,
Bogenhagen, D. F., Demple, B., and Shen, B. (2008). Human dna2 is a
mitochondrial nuclease/helicase for eﬃcient processing of dna replication and
repair intermediates. Mol Cell, 32(3):325–36.
Zheng, Y., Mennella, V., Marks, S., Wildonger, J., Elnagdi, E., Agard, D., and
Megraw, T. L. (2016). The seckel syndrome and centrosomal protein ninein
localizes asymmetrically to stem cell centrosomes but is not required for normal
development, behavior, or dna damage response in drosophila. Mol Biol Cell,
27(11):1740–52.
Zine, A. and de Ribaupierre, F. (2002). Notch/notch ligands and math1 expression
patterns in the organ of corti of wild-type and hes1 and hes5 mutant mice. Hear
Res, 170(1-2):22–31.
Zou, L., Cortez, D., and Elledge, S. J. (2002). Regulation of atr substrate selection by
rad17-dependent loading of rad9 complexes onto chromatin. Genes Dev,
16(2):198–208.
Zou, L. and Elledge, S. J. (2003). Sensing dna damage through atrip recognition of
rpa-ssdna complexes. Science, 300(5625):1542–8.
Zurawel, R. H., Chiappa, S. A., Allen, C., and Raﬀel, C. (1998). Sporadic
medulloblastomas contain oncogenic beta-catenin mutations. Cancer Res,
58(5):896–9.
78
CHAPTER 2: FAMILIAL MICROCEPHALIC DISORDERS SUGGEST NEW
APPROACHES TO BRAIN TUMOR TREATMENT1
Overview
Current brain tumor treatments that rely on inducing DNA damage through
radiation and chemotherapy are limited in eﬃcacy and produce excessive side eﬀects.
Many types of brain tumors, including glioblastoma and other high grade gliomas,
frequently develop resistance to radiation and chemotherapy. While
medulloblastoma, the most common malignant brain tumor in children, is often
cured by conventional therapy, survivors suﬀer treatment-induced cognitive
impairment, hearing loss, early strokes, and growth failure. New therapies for
primary brain tumors are thus urgently needed.
Brain tumors arise from mutations in diverse stem and progenitor cells that
ultimately originate from the neuroectoderm. Familial microcephaly also develops in
response to genetic mutations in these cell types, but with the opposite result: limited
brain growth due to hypoproliferation, premature senescence, and/or apoptosis.
Some brain tumors retain many similarities to their neuroectoderm-derived stem or
progenitor cell of origin. These tumors may therefore be susceptible to disruptions in
genes that are mutated in microcephaly. The potential for the products of
microcephaly genes to be therapeutic targets in brain tumors is highlighted by recent
literature on KIF11/EG5, ASPM, CDK6, and ATR. Treatments that disrupt these
targets may open new avenues for brain tumor therapy.
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Introduction
Strict control of neural stem and progenitor cell proliferation prevents both
developmental malformation resulting from hypo-proliferation and tumor formation
resulting from hyper-proliferation. Microcephaly is a neurodevelopmental disorder
defined by reduced head size due to impaired brain development, or microencephaly.
A broad and diverse host of causes have been identified for microcephaly, ranging
from genetic conditions to fetal trauma to maternal exposures. In general, the
common link between these sources is that pathogenesis involves insuﬃcient
proliferation of neural stem or progenitor cells, premature neuronal diﬀerentiation
or senescence, and/or inappropriate cell death (Jamuar and Walsh, 2015). Familial
microcephaly and congenital microcephalic disorders thus identify genes that are
vital in proper brain development. Specifically, these hereditary conditions reveal
how certain gene products critically regulate processes necessary for the normal
expansion and survival of neural stem and progenitor cells.
Improved understanding of the basic biology of neural stem and progenitor cells
is important for the study of brain tumors. Whereas microcephaly is a consequence
of failed stem/progenitor expansion, brain tumors can form in response to mutations
in these cells that lead to over-expansion. The most common primary, malignant
tumors of the brain are glioblastoma in adults and medulloblastoma in children. The
cell of origin for glioblastoma is still under investigation but candidates include
Nestin+ neural stem cells, multipotent progenitors of the subventricular zone (SVZ),
or lineage-restricted progenitors that give rise to astrocytes or oligodendrocytes
(Alcantara Llaguno et al., 2009; Holland et al., 2000; Gibson et al., 2010; Lindberg
et al., 2009). For medulloblastoma, the cell of origin is either a neural stem cell of the
cerebellar ventricular zone (CVZ) or a progenitor cell of the cerebellum or rhombic
lip, depending on the molecular subgroup (Gibson et al., 2010; Gilbertson and
Ellison, 2008; Northcott et al., 2012). With both glioblastoma and medulloblastoma,
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either a majority or a distinct population of tumor cells retain genetic and molecular
characteristics of the stem/progenitor cell of origin (Alderton, 2011; Baryawno et al.,
2010; Dirks, 2008; Modrek et al., 2014; Schuller et al., 2008; Zong et al., 2012).
Therefore, proteins that regulate growth and survival in neural stem/progenitor cells
should retain their function in brain tumors. Familial microcephaly and congenital
microcephalic disorders identify these proteins, which may be attractive targets for
brain tumor treatment.
In this review, we focus on four genes that are each mutated in a diﬀerent form of
hereditary microcephaly and either over-expressed or uniquely important in a
primary brain tumor: KIF11, ASPM, CDK6, and ATR. Interestingly, the products of
these genes all exert some form of control over mitotic entry or progression,
underscoring the particular importance of mitosis for normal brain development and
tumor formation. For each of the four candidates, preclinical studies have
demonstrated eﬃcacy in targeting the gene products for attenuating tumorigenesis
in glioblastoma and/or medulloblastoma. These examples ultimately highlight the
importance of studying normal brain development for understanding the
pathogenesis and treatment of brain tumors.
KIF11 is mutated in primary microcephaly and upregulated in glioma
A recent report identified KIF11 (Kines family member 11) mutations as
responsible for a form of primary, autosomal dominant microcephaly (Ostergaard
et al., 2012). Examination of ten families found diverse KIF11 mutations that were
associated with microcephaly, chorioretinopathy, and/or lymphedema. All of the
mutations were predicted to alter the KIF11 protein product, EG5 (KSP, Kinesin
spindle protein), which is a bipolar molecular motor protein of the kinesin family.
KIF11 expression begins as early in mammalian development as the blastula stage
and EG5 is required for initial cleavage events in embryogenesis (Castillo and
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Justice, 2007). As a result, Kif11-null mice perish prior to gastrulation (Chauviere
et al., 2008).
Beyond embryogenesis, EG5 interacts crucially with microtubules of the mitotic
spindle during mitosis (Kapoor et al., 2000; Sawin and Mitchison, 1995; Valentine
et al., 2006). Chromatid separation in mitosis requires formation of a bipolar spindle
apparatus with two centrosomes located on opposite sides of the nucleus (Fig. 2.1A).
The heterotetrameric shape and plus-end-directed motor activity of EG5 allow it to
crosslink antiparallel microtubules and push apart the duplicated centrosomes in
prophase (Kashina et al., 1997; Sawin et al., 1992). Continued EG5 activity into
prometaphase completes establishment of a bipolar mitotic spindle that is capable of
pulling apart sister chromatids (Blangy et al., 1995; Kashina et al., 1996). Indeed,
early studies of EG5 disruption with the small molecule inhibitor Monastrol resulted
in monoasters with radial spokes of microtubules surrounded by a band of
duplicated, unsegregated chromosomes (Kapoor et al., 2000; Mayer et al., 1999).
Formation of this aberrant structure in turn leads to activation of the spindle
assembly checkpoint via MAD2 (Mitotic arrest-deficient 2) and subsequent mitotic
arrest (Kapoor et al., 2000; Chin and Herbst, 2006). Prolonged mitotic arrest
triggers the cell death program through the intrinsic apoptotic pathway involving
activation of Caspase-3 (Valensin et al., 2009). The exact mechanism, however, for
how mitotic arrest actually leads to apoptosis is an area of active investigation. One
theory proposes that prolonged mitotic arrest produces cellular stress, which induces
activation of Caspases-9 and -7 and the caspase-activated DNase (Orth et al., 2012).
This nuclease damages the DNA of arrested cells, triggering full engagement of the
p53-dependent apoptotic pathway.
Although it is still unclear how exactly KIF11 mutation leads to microcephaly, it
follows that based on the known mechanism of EG5 and the consequences of its
inhibition in other cells, that reduced EG5 activity could lead to reduced
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proliferation and increased apoptosis in mitotically active neural stem and
progenitor cells. In the developing zebra fish nervous system, eg5 inhibition was
found to attenuate the rate of proliferation and aggravate the rate of cell death in
neural stem and progenitor cells (Johnson et al., 2014). KIF11 mutations that reduce
rather than completely abrogate EG5 activity could reasonably produce microcephaly
through an identical mechanism.
Importantly, while EG5 is essential to the microtubules of mitosis and its
inhibition can lead to apoptosis, EG5 function is limited to mitosis (Kapoor et al.,
2000; Sawin and Mitchison, 1995; Mayer et al., 1999). That is, EG5 does not seem
important in non-mitotic microtubules, which are required for diverse cellular
processes, including axonal transport in the central nervous system (Conde and
Caceres, 2009). Thus, KIF11/EG5 inhibitors may disrupt the mitotic spindle without
producing the neurotoxicity of microtubule-directed agents such as vinca alkaloids
(Vinblastine and Vincristine) and taxanes (Paclitaxel and Docetaxel) (Grisold et al.,
2012; Marcus et al., 2005). Overexpression of KIF11 has been identified in bladder
and pancreatic cancers and its expression was correlated with higher clinical grades
and stages (Ding et al., 2011; Liu et al., 2010). A 2015 study found KIF11
upregulation in human glioblastoma (Venere et al., 2015). KIF11/EG5 inhibition by
the small molecule inhibitor Ispinesib reduced the proliferation of neural stem-like
glioblastoma cells in vitro and in mouse xenograft models by preventing mitotic
progression. Ispenisib treatment increased the survival of mice with glioblastoma
from 24 to 36 days.
KIF11/EG5 inhibitors have not yet been tested for primary brain cancers in
clinical trials in the United States. However, several small molecule EG5 inhibitors
are being tested in patients with various other cancers, including Ispinesib (SB-
715992), Litronesib (LY-2523355), Filanesib (ARRY-520), SB-743921, 4SC-205,
AZD-4877, MK-0731, and ARQ-621 (Table 2.1). For all of these agents, patients
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experienced minimal neurotoxicity, as predicted – neutropenia and leukopenia were
the most common side eﬀects since mitotic inhibition targets all rapidly dividing cells
(Knight and Parrish, 2008). Unfortunately, EG5 inhibition as monotherapy has
mostly had limited benefit in the cancers in which it has been tested due to the short
half-life of many of the inhibitors, which prevented targeting relatively slower cycling
neoplastic cells in the tested cancers (Huszar et al., 2009). ARRY-520 and 4SC-205
have shown longer half-life, but in general, EG5 inhibitors are being tested in
combination with other chemotherapeutics (Khoury et al., 2012). Regardless of these
findings in other cancers, EG5 inhibition could potentially still hold great promise
even as monotherapy for glioblastoma since the cancer cells of glioblastoma are
highly proliferative, which should allow even short half-life inhibitors to exert a
potent eﬀect. Moreover, the recent reports on EG5 inhibition in preclinical models of
glioblastoma (Valensin et al., 2009; Venere et al., 2015) are encouraging and
recommend further exploration of inhibiting EG5 for the treatment of high grade
gliomas.
ASPM is mutated in primary microcephaly and upregulated in glioma and
medulloblastoma
Like EG5, ASPM (Abnormal spindle microtubule assembly) has a role in
orienting and maintaining the mitotic spindle, and it is especially important in
neural stem/progenitor cells (Kouprina et al., 2005; Zhong et al., 2005). ASPM is a
microtubule minus-end-associated protein that is found at the mitotic spindle poles
from prophase through telophase (Kouprina et al., 2005; Higgins et al., 2010). In
vitro studies in non-neural human cells demonstrated that ASPM is required for cell
division and that cytokinesis fails in its absence (Higgins et al., 2010). In Drosophila
neuroblasts, the ASPM homolog asp is required for proper completion of mitosis and
its disruption leads to mitotic arrest at metaphase (do Carmo Avides and Glover,
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1999). In contrast, loss of ASPM in mammalian neural stem and progenitor cells
does not prevent mitotic progression (Fish et al., 2006; Pulvers et al., 2010; Williams
et al., 2015). Rather, ASPM is thought to control symmetric divisions in epithelial
stem cells of the neuroectoderm and its acute inhibition by RNA-i led to increased
asymmetric divisions that depleted the stem cell population (Fish et al., 2006). A
conflicting report by the same group found no such changes to the proportion of
symmetric versus asymmetric neuroepithelial divisions when Aspm was mutated,
but the authors suggested that this discrepancy could be due to partially preserved
ASPM function with the mutation and/or a diﬀerence between acute inhibition and
gradual acclimation (Pulvers et al., 2010). In the more lineaged-committed
cerebellar granule neuron progenitor (CGNP), ASPM mediates cell cleavage plane
orientation (Williams et al., 2015). Conditional Aspm deletion in CGNPs led to a
relative increase in the proportion of divisions oriented transverse to the pial surface
in the external granule layer (EGL) of the early postnatal mouse cerebellum,
consistent with inappropriately increased progenitor cell cycle exit and
diﬀerentiation (Fig. 2.1B).
Mutations in ASPM are the most common cause of familial microcephaly (Bond
et al., 2002; Roberts et al., 2002). Nearly all of the identified mutations lead to ASPM
truncation (Bond et al., 2002; Roberts et al., 2002), and although the mutations
aﬀect all tissues, it is still unclear why ASPM is particularly important to neural
stem/progenitor cells compared to other proliferating cells (Kouprina et al., 2005;
Luers et al., 2002). Indeed, Aspm-null mice develop microcephaly and hypogonadism,
but other tissues seem relatively unaﬀected (Pulvers et al., 2010; Fujimori et al.,
2014). Research into the molecular function of ASPM indicates that microcephaly
associated with ASPM mutation is due at least in part to impaired self-renewal of
neural stem and progenitor cells (Fish et al., 2006; Pulvers et al., 2010; Williams
et al., 2015). In addition, apoptosis from ASPM loss may be important in generating
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microcephaly through cerebellar hypoplasia (Williams et al., 2015), but cell death
does not appear to occur in ASPM-inhibited neuroepithelial cells (Pulvers et al.,
2010). Altogether, these studies emphasize the disproportionate importance of
ASPM in the developing brain compared to other tissues and demonstrate how
ASPM disruption decreases proliferation and increases cell death in neural
stem/progenitor cells.
In contrast to microcephaly, ASPM expression is increased in malignant gliomas
(Horvath et al., 2006; Hagemann et al., 2008; Bikeye et al., 2010). In an early study
using 120 patient samples of glioblastoma, an unbiased screen identified ASPM as
being significantly overexpressed (Horvath et al., 2006). A separate study using
RT-PCR and immunohistochemistry on tumor samples from 15 patients with
low-grade (II) astrocytoma and 15 patients with glioblastoma showed that ASPM
mRNA and protein were low in the astrocytomas but much higher in glioblastomas
(Hagemann et al., 2008). Similar results were obtained from 175 patient glioma
samples, representing 8 grade II, 75 grade III, and 92 grade IV gliomas – ASPM
mRNA and protein levels increased with tumor grade and were also higher in
recurrent tumors (Bikeye et al., 2010). siRNA knockdown of ASPM in glioblastoma
cell lines reduced proliferation, increased cell death, and sensitized cells to DNA
damaging agents like X-rays and Cisplatin (Bikeye et al., 2010; Horvath et al., 2006;
Kato et al., 2011). ASPM is also upregulated in medulloblastoma (Vulcani-Freitas
et al., 2011). In a primary mouse model of medulloblastoma, conditional Aspm
deletion was found to increase DNA damage in tumors and attenuate overall
tumorigenesis (Williams et al., 2015). Further research in in vivo systems is needed
to illuminate the exact mechanism by which ASPM disruption reduces tumor
formation or destroys tumors. Nonetheless, these studies highlight the shared
dependence of neural stem/progenitor and brain tumor cells on ASPM. Despite these
promising findings, there are currently no ASPM inhibitors in clinical trials in the
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US.
CDK6 is mutated in primary microcephaly and upregulated in glioma and
medulloblastoma
Data collected on eight generations of a large, consanguineous family in which 10
individuals had apparent primary, autosomal recessive microcephaly found
recurrent mutations in CDK6 (Cyclin-dependent kinase 6) (Hussain et al., 2013).
CDK6 protein levels were not reduced in the microcephalic patients, however its
function and behavior were altered. In control human fibroblasts, CDK6 associated
with centrosomes in mitosis – this association was absent in CDK6 mutant
fibroblasts, which displayed abnormal mitotic spindle alignment and supernumerary
centrosomes that persisted into interphase. Mutant patient fibroblasts had
abnormal cell polarity and reduced cell motility in vitro (Fig. 2.1C). While these
observations have yet to be confirmed directly in neural stem or progenitor cells, the
authors did detect CDK6 by immunofluorescence in neuroepithelial and neural
progenitor cells of the embryonic mouse brain. They hypothesized that microcephaly
was a consequence of increased neural stem/ progenitor apoptosis and decreased cell
proliferation due to reduced RB (Retinoblastoma) phosphorylation, which were seen
in the mutant fibroblasts.
The most well-studied role for CDK6 is in control of the cell cycle. CDK6 interacts
with Cyclin D in G1-phase to phosphorylate RB (Meyerson and Harlow, 1994). This
phosphorylation allows cell cycle progression from G1- to S-phase (Sherr et al., 2016;
Tigan et al., 2016). Cyclin D binding is required for CDK6 activity, and the levels of
this cyclin are controlled by growth factors and mitogens (Sherr and Roberts, 1999).
In turn, CDK6 levels are thought to be regulated by p21 (CIP1, CDK-interacting
protein 1), p27 (KIP1, Kinesin-like protein 1), and p57 (KIP2), which may control
CDK6 assembly and nuclear translocation (Blain et al., 1997; Cheng et al., 1998;
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LaBaer et al., 1997). Besides Cyclin D, CDK6 activity is also regulated by its
inhibitors p15 (INK4B, Inhibitor of CDK4 B), p16 (INK4A), p18 (INK4C), and p19
(INK4D) (Ruas and Peters, 1998).
Tight control of CDK6’s cell cycle activity is imperative as it is expressed at some
point in almost all tissues. Nevertheless, CDK6 has a homolog in mammals, CDK4,
that is able to carry out many of the same functions (Bates et al., 1994; Lucas et al.,
1995). Indeed, Cdk6-null mice are viable and mostly develop normally, but suﬀer
from anemia and defective T-cell maturation (Hu et al., 2009; Malumbres et al.,
2004). Cdk4-null mice are also viable and instead experience pancreatic and
pituitary hypoplasia (Rane et al., 1999; Tsutsui et al., 1999). In contrast, loss of both
Cdk4 and Cdk6 results in embryonic lethality, underscoring redundant roles for
CDK4 and CDK6 (Malumbres et al., 2004). The distinct phenotypes of the two null
mice, however, suggest some non-overlapping functions for the kinases. Apart from a
role in hematopoiesis, CDK6 may regulate the apoptotic program (Nagasawa et al.,
2001). Cultured mouse embryonic fibroblasts overexpressing Cdk6 upregulated Tp53
and subsequent exposure to ultraviolet (UV) irradiation caused rapid, widespread,
BAX (BCL2 (B-cell lymphoma 2)-associated X)-mediated apoptosis.
In the central nervous system (CNS), Cdk6 expression is high in cortical
progenitor and striatal stem cells and decreases once the cells cease proliferating
and diﬀerentiate (Ferguson et al., 2000). Cdk6 disruption prolonged G1-phase in
these cells and inhibited entry into S-phase, inhibiting their proliferation. G1-phase
lengthening has been shown in mouse neuroepithelial cells to induce premature
diﬀerentiation, explaining the decreased proliferation associated with Cdk6
disruption (Calegari and Huttner, 2003). Juvenile mice lacking Cdk6 similarly had
precursor cells in the SVZ and subgranular zone of the dentate gyrus that
experienced prolonged G1-phase, premature cell cycle exit, and attenuated
proliferation (Beukelaers et al., 2011). A final putative role for CDK6 in the CNS is
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suggested by an experiment where astrocytes from neonatal mice that were induced
to overexpress Cdk6 in vitro appeared more bi-polar and fibroblast-like than normal,
multi-polar astrocytes (Ericson et al., 2003).
CDK6 upregulation is found in several types of tumors, including malignant
glioma and medulloblastoma (Costello et al., 1997; Mendrzyk et al., 2005; Lam et al.,
2000; Tadesse et al., 2015). In gliomas, CDK6 expression increases with higher
tumor grade and is correlated with a worse prognosis (Li et al., 2012; Chen et al.,
2013). siRNA knockdown of CDK6 in cultured glioblastoma cells reduced
proliferation and increased apoptosis following treatment with Temozolomide (Chen
et al., 2013). Two miRNAs, miRNA-495 and miRNA-340, have been identified that
suppress CDK6 activity (Li et al., 2012, 2015). They are both downregulated in
human glioblastoma and their expression was found to arrest tumor cells in G1,
leading to less proliferation. SUMO1 (Small, ubiquitin-like modifier 1) has also
recently been identified to interact with CDK6 in glioblastoma by preventing its
degradation in order to permit tumor cell hyper-proliferation (Bellail et al., 2014). As
in glioblastoma, CDK6 inhibition in medulloblastoma cell lines was found to induce
G1 arrest due to RB hypo-phosphorylation, attenuating cell proliferation (Whiteway
et al., 2013). Moreover, CDK6 inhibition significantly limited the survival of
medulloblastoma cells exposed to radiation. The role of CDK6 in mitotic progression,
as suggested by microcephaly, has yet to be investigated in these cancers.
A multitude of CDK6 inhibitors, though not all specific for CDK6, have been
tested in clinical trials over the past twenty years for a variety of cancers (Asghar
et al., 2015). Few, however, have been tried in primary brain cancers (Table 2.2).
The CDK4/6 inhibitor Palbociclib (PD-0332991) has the most ongoing clinical trials
for mostly breast cancers, but also several for primary or metastatic brain tumors.
Ribociclib (LEE-011), another CDK4/6 inhibitor, has active Phase I/II clinical trials
for gliomas. Finally, Abemaciclib (LY-2835219), also a CDK4/6 inhibitor, has one
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active Phase I trial for children with diﬀuse intrinsic pontine glioma. Early results
with these agents as monotherapy in non-brain cancers have shown good clinical
outcomes, with neutropenia and some gastrointestinal toxicity as the most common
limiting side eﬀects. However, anti-tumor eﬀects have generally been modest and not
all cancers are responsive. Further research will reveal the feasibility of targeting
CDK6 in humans to treat primary brain tumors.
ATR is mutated in Seckel syndrome and plays an important role in
medulloblastoma tumorigenesis
ATR (Ataxia-telangiectasia and Rad3-related) is a serine/threonine kinase that
activates substrates involved in DNA repair, cell cycle arrest, and apoptosis
(Abraham, 2001). Specifically, ATR responds to the presence of single-stranded DNA
(ssDNA), which forms as a normal part of DNA replication and pathologically as a
result of DNA damage (Cimprich and Cortez, 2008). In vitro studies demonstrate
that in undamaged dividing cells, ATR checks genomic integrity at S-phase and
slows cell cycle progression to prevent replication stress from causing DNA damage
(Shiloh, 2001). Conversely, ssDNA resultant from DNA damage can cause ATR
activation in all phases of the cell cycle (Shiloh, 2003; Germann et al., 2014; Gray
et al., 2013). The presence of DNA damage prompts ATR to act in two possible ways
– cell cycle arrest and DNA repair if the damage is minimal, or apoptosis if the
damage is extensive (Smith et al., 2010). Yet, whether DNA damage from ATR
deficiency occurs in specific areas of the genome or is randomly distributed is not well
understood. Moreover, although ATR can promote apoptosis, loss of ATR is actually
associated with increased cell death due to the greater role of ATR in mitigating
DNA damage and preventing cell death (Yang et al., 2003). There is some debate as
to how cell death proceeds from ATR deficiency. Cleaved Caspase-3 (cC3) activation
in Atr-deleted cells indicates that cell death occurs via apoptosis (Myers et al., 2009;
90
Heﬀernan et al., 2009). In contrast to typical apoptosis after genotoxic stress,
however, ATR-deficient cell death has been suggested to be p53-independent
(Heﬀernan et al., 2009; Lee et al., 2012). This is unexpected given the pivotal role of
p53 in bridging DNA damage with apoptosis (Oﬀer et al., 2002; Roos and Kaina,
2006; Wang, 2001).
The role of ATR in proliferating cells is especially important due to its ability to
relieve physiologic replicative stress, which would otherwise cause DNA damage
(Paulsen and Cimprich, 2007). Complete loss of ATR is embryonic lethal in mice, as
widespread chromosome fragmentation precipitates caspase-mediated apoptosis
(Brown and Baltimore, 2000). In the brain, ATR is essential to cerebellar growth,
where proliferation of CGNPs continues longer than almost all other neural cell
types (Carletti and Rossi, 2008). Conditional deletion of Atr in the embryonic mouse
CNS was found to almost exclusively aﬀect two areas of the developing brain – the
ganglionic eminence, which produces cortical, striatal, and olfactory cells, and the
nascent cerebellum (Lee et al., 2012). Neural stem cells of the embryonic brain
required ATR for normal proliferation and expansion, and its loss resulted in
microcephaly, with especially prominent cerebellar hypoplasia, and early postnatal
lethality. In the absence of ATR, neural stem cell populations of the embryonic
ganglionic eminence and nascent cerebellum experienced extensive DNA damage
that led to either apoptosis or impaired proliferation, respectively. Interestingly,
inactivation of p53 neither significantly rescued nor exacerbated the ATR phenotype,
despite partial attenuation of apoptosis in the forebrain, leading the authors to
conclude that neuropathology from ATR loss is not p53-dependent.
The function of ATR appears to be slightly diﬀerent in more lineage-committed
neural progenitors at later stages of development. Our group has found that Atr
deletion in CGNPs causes chromosomal damage and widespread apoptosis but no
defect in proliferation at the early postnatal stage, when CGNP proliferation is
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maximal (Lang et al., 2016). Cerebellar hypoplasia was partially rescued by
co-deletion of either Bax and Bak or p53. However, in the Atr/Bax/Bak-deleted
mice, pathology persisted due to continued activation of p53 by ATM in CGNPs,
leading to p21-mediated cell cycle arrest and premature cell cycle exit. CGNPs in
Atr/p53-deleted mice experienced caspase-independent cell death that likely induced
cerebellar hypoplasia. Furthermore, ATR loss was found to increase the fraction of
CGNPs in M-phase, suggesting an important role for ATR in mediating mitotic entry
in CGNPs. This checkpoint role is supported by the finding that Atr deletion
significantly increased the fraction of CGNPs with a spectrum of chromosomal
abnormalities (Fig. 2.1D). Finally, sequencing and pathway analyses demonstrated
the critical importance of p53 in mediating the response to ATR loss in CGNPs.
While ATR may have slightly diﬀerent functions in neural stem cells compared to
neural progenitors, the impact of its loss in these cell types clearly demonstrates its
importance in brain development. This importance is highlighted by the congenital
disorder Seckel syndrome, which is caused by hypomorphic mutations in ATR and
characterized by intrauterine growth restriction, cryptorchidism, distinctive facies,
pancytopenia, and microcephaly (Goodship et al., 2000; O’Driscoll et al., 2003).
Research into the pathogenesis of Seckel syndrome, and especially the eﬀect of ATR
deletion on neural stem/progenitor cells, as discussed above, has implications for
developing novel brain cancer therapeutics. The unique requirement of cerebellar
progenitors for ATR (Lee et al., 2012; Lang et al., 2016) suggests that ATR may be an
eﬀective therapeutic target for the cerebellar cancer medulloblastoma (Amakye
et al., 2013). Activating mutations in the SHH signaling pathway are responsible for
25% of human medulloblastoma (Wechsler-Reya and Scott, 2001), and CGNPs are
thought to be the cells of origin for this molecular subset (Schuller et al., 2008;
Wechsler-Reya and Scott, 1999; Fernandez et al., 2009; Kim et al., 2003; Dey et al.,
2012; Mao et al., 2006). Indeed, genetically engineered mice with neuronal
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hyper-activation of the Sonic hedgehog (SHH) pathway reproducibly develop
cerebellar tumors that resemble human medulloblastoma (Pietsch et al., 1997; Dey
et al., 2012; Mao et al., 2006). As with other types of cancer cells, medulloblastoma
cells suﬀer from genetic instability owing to rapid rounds of proliferation (Blow and
Gillespie, 2008; Negrini et al., 2010; Kool et al., 2014). Radiation and chemotherapy,
the current standard of care for medulloblastoma, take advantage of this genomic
instability by further damaging the DNA of neoplastic cells – enough to push them
towards cell death (Roos and Kaina, 2006; Herr and Debatin, 2001). However,
radiation can be extremely toxic to the normal brain, and chemotherapy damages
healthy, endogenous dividing cells such as found in the GI tract and bone marrow
(Barnett et al., 2009). These eﬀects can be particularly devastating in young patients.
We have found that Atr deletion in two diﬀerent mouse models of
medulloblastoma either significantly reduced tumorigenesis or completely abrogated
tumor formation (Lang et al., 2016). Our group is currently testing pharmacological
ATR inhibition in mice with established medulloblastoma using the novel ATR
inhibitor pVE-822, in which the small molecule ATR inhibitor VE-822 is packaged in
polymeric micelle nanoparticles. Preliminary results show that pVE-822 delivered
by intraperitoneal injection eﬀectively crosses the blood-brain barrier and induces
DNA damage and apoptosis in neonatal wild-type mice. In medulloblastoma-bearing
mice, pVE-822 treatment increased tumor DNA damage and reduced tumor size.
Ongoing research aims to determine whether pVE-822 produces a survival benefit in
mice with medulloblastoma and how pVE-822 may be combined with other therapies
to improve treatment outcomes. At this time, the ATR inhibitor VX-970 (VE-822) is
in Phase I clinical trials with radiation therapy for secondary brain cancer
(metastases from non-small cell lung cancer (NSCLC)). VX-970 is also being actively
tested in Phase I and II trials for other non-brain malignancies (Table 2.3). In
addition, the ATR inhibitor AZD-6738 is currently in Phase I trials for solid tumors
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refractory to other therapies.
A particular benefit of ATR inhibition for the treatment of brain cancers is that in
the adult brain, ATR seems to be dispensable for the survival and function of
post-mitotic neurons (Lang et al., 2016; Kemp and Sancar, 2016; Ruzankina et al.,
2007). It has been shown in mice, however, that ATR is still required for normal
proliferation of remaining neural stem cell populations, such as in the hippocampus,
in the adult mouse brain (Onksen et al., 2011). Of course, with medulloblastoma,
since most patients are young with still-developing brains, ATR inhibitors may
produce greater toxicity than in adults. Yet, our findings in neonatal and juvenile
medulloblastoma-bearing mice suggest fairly minimal CNS toxicity. In gliomas,
although ATR upregulation has yet to be reported, the deleterious eﬀect of ATR
disruption in the neural stem cells from which gliomas may derive supports
investigating ATR inhibition in these tumors. Here especially, the apparent CNS
tolerability for ATR loss intimates the possible improved therapeutic benefit of ATR
inhibition over traditional chemotherapy.
Discussion
The summary presented here highlights how insights from developmental
disorders can inform advances in cancer therapeutics. Using the brain as an
example, we make the case that molecules downregulated in microcephaly may be
attractive targets for brain tumor treatment, where they may be upregulated, and
since the two conditions lie on opposite ends of the same spectrum of proliferation
regulation. Of the four discussed proteins, three – KIF11/EG5, ASPM, and CDK6 –
have been shown to play a role in orienting the mitotic spindle in neural stem and
progenitor cells (Sawin and Mitchison, 1995; Kapoor et al., 2000; Kouprina et al.,
2005; Zhong et al., 2005; Hussain et al., 2013). Indeed, the primary role of EG5 and
ASPM seems to be in spindle maintenance (Valentine et al., 2006; Sawin et al., 1992;
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Higgins et al., 2010), while CDK6 is better recognized for controlling the G1-S
checkpoint and has only recently been implicated in spindle assembly in neural
stem/progenitor cells (Hussain et al., 2013; Sherr et al., 2016; Tigan et al., 2016).
Like CDK6, ATR has been most extensively studied for its non-mitotic functions,
such as restarting stalled replication forks and responding to DNA damage
(Abraham, 2001; Cimprich and Cortez, 2008; Shiloh, 2003). Our group has shown
that, as with EG5, ASPM, and CDK6, ATR also has an important function related to
mitosis in neural stem/progenitors in that it seems to control mitotic entry in CGNPs
(Lang et al., 2016).
That four genes mutated in microcephalic disorders code for proteins involved
with mitosis is not necessarily surprising since primary microcephaly has been
described as essentially a mitotic disorder (Faheem et al., 2015). Rather, the
examples we have presented emphasize the similar molecular dependencies between
neural stem/progenitor cells and brain cancer cells and suggest that the
disproportionate importance of mitosis in neural stem/progenitor cells should provide
incentive to more intensively study mitotic inhibition as targeted treatment for brain
cancers. With high-grade gliomas, evidence suggests that populations of neural stem
or progenitor-like cells maintain tumor growth, and these cells are resistant to
radiation and alkylating chemotherapy (Venere et al., 2015, 2011). Yet, the similarity
of these tumor cells to neural stem/progenitor cells implies that they too may rely on
mitotically active microcephaly proteins, and a variety of experiments have certainly
shown this to be the case (Venere et al., 2015; Bikeye et al., 2010; Hagemann et al.,
2008; Horvath et al., 2006; Chen et al., 2013; Li et al., 2012, 2015). Thus, inhibition
of microcephaly proteins like EG5, ASPM, and CDK6 may not only eﬃciently target
malignant glioma cells, but also produce reduced neurotoxicity due to the relative
absence of neural stem/progenitor cells in the developed brain outside of tumors.
Likewise, in medulloblastoma, tumor cells often bear resemblance to cerebellar
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stem/progenitor cells (Wang and Wechsler-Reya, 2014). The mitotic spindle proteins
ASPM and CDK6 are upregulated in medulloblastoma and their disruption has been
shown to impair tumor growth (Williams et al., 2015; Vulcani-Freitas et al., 2011;
Mendrzyk et al., 2005; Whiteway et al., 2013). Although ATR has not been shown to
be upregulated in human medulloblastoma, it clearly plays a pivotal role in CGNP
survival and is required for tumorigenesis in the SHH subgroup of medulloblastoma
(Lang et al., 2016). Current standard-of-care for children with medulloblastoma
involves surgical resection of the primary mass accompanied by radiation and
chemotherapy, all of which can have substantial deleterious eﬀects on the still-
developing CNS (Roos and Kaina, 2006; Herr and Debatin, 2001; Barnett et al.,
2009). Here again, targeted therapy against microcephaly proteins may produce
substantial therapeutic benefit with relatively lower toxicity, as has been suggested
by studies of ATR inhibition (Lang et al., 2016; Kemp and Sancar, 2016).
A concern might be that while the four discussed proteins, and mitotic regulators
in general, may be viable targets for monotherapy, inhibitors of such molecules may
not synergize well with other chemotherapeutics since blocking mitosis would halt
cell cycle progression and most existing chemotherapeutic agents disrupt cycling
cells (Roberts et al., 2012; Dean et al., 2012). In the cases of ASPM and ATR
inhibition, neural stem/progenitor cells continue to cycle, at least initially, and their
disrupted expansion was due to processes other than solely cell cycle arrest (Fish
et al., 2006; Pulvers et al., 2010; Williams et al., 2015; Lang et al., 2016). Another
consideration for inhibiting some of these targets is that proteins like EG5, CDK6,
and ATR function in many tissues and organs. Systemic administration of inhibitors
against these molecules may produce non-neural toxicities, which must be studied,
and raises the possibility of need for direct tumoral delivery.
Apart from KIF11, ASPM, CDK6, and ATR, several other genes that are mutated
in microcephalic disorders may be viable candidates for cancer therapy (Table 2.4).
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NBS1 (NBN, Nibrin; p95) is mutated in Nijmegen breakage syndrome (NBS), which
is characterized by growth impairment, immunodeficiency, radiation sensitivity,
microcephaly, and, paradoxically, predisposition to malignancies like lymphoma,
rhabdomyosarcoma, glioma, and medulloblastoma (Digweed and Sperling, 2004).
The protein coded by this gene senses DNA double-strand breaks (DSBs) and
mediates S-phase arrest and DNA repair through ATM (Ataxia-telangiectasia
mutated) and BRCA1 (Breast cancer 1) (Branzei and Foiani, 2008; Lim et al., 2000;
Zhu et al., 2000). L1CAM (L1 cell adhesion molecule) regulates NBS1 expression and
activity and L1CAM expression is associated with a worse prognosis in glioma
(Izumoto et al., 1996; Suzuki et al., 2005). Disruption of L1CAM and NBS1 were
found to increase the radiation sensitivity of stem-like cells in glioblastoma (Cheng
et al., 2011). However, considering the importance of NBS1 in DSB repair, NBS1
inhibition may have limited therapeutic use, especially considering that its mutation
actually increases the frequency of brain tumors.
Mutations in IGF1R (Insulin-like growth factor 1 receptor) have been identified in
patients with microcephaly and general pre- and post-natal growth impairment
(Abuzzahab et al., 2003; Juanes et al., 2015; Walenkamp et al., 2006). IGF1R is a
receptor tyrosine kinase that is broadly expressed in almost all tissues and mediates
cell proliferation through IGF1 signaling, ensuring adequate growth of many organs,
including the brain (Klammt et al., 2008). As in humans, mice carrying mutations in
Igf1r experience growth failure and microcephaly, although complete loss of IGF1R is
embryonic lethal due to respiratory failure (Baker et al., 1993; Liu et al., 1993). In
the CNS, IGF1R is indispensable for the expansion of neural stem and progenitor
cells, including CGNPs, during development (Ziegler et al., 2015; de Pablo and de la
Rosa, 1995). It continues to be important in mature neurons, ensuring their survival
and promoting synaptogenesis (Joseph D’Ercole and Ye, 2008). Some research has
suggested that signaling through IGF1R may contribute to the genesis of
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medulloblastoma and increased IGF1R expression has been found in a set of human
medulloblastoma samples (Del Valle et al., 2002). A recent report has described
increased IGF1 presence in the CSF of patients with metastatic medulloblastoma,
and the authors proposed targeting IGF1R as a novel treatment for advanced
medulloblastoma (Svalina et al., 2016). Many IGF1R inhibitors exist, but thus far,
they have had mixed success in clinical trials as anti-tumor therapies, with the broad
biological role of IGF1R possibly limiting the therapeutic index (Chen and Sharon,
2013).
Aicardi-Goutieres syndrome is a congenital disorder that develops in response to
hyper-activation of the immune system that primarily leads to postnatal
microcephaly and widespread skin lesions (Aicardi and Goutieres, 1984; Bonnemann
and Meinecke, 1992; Lanzi et al., 2003). Genetic studies have identified several genes
that may contribute to this condition, including TREX1 (Three prime repair
exonuclease 1), which codes for a 3’ exonuclease involved in DNA proofreading and
repair (Crow et al., 2006a,b; Rice et al., 2009, 2012, 2014). Decreased TREX1
function allows for the intracellular accumulation of DNA fragments that would
normally be degraded, essentially mimicking an eﬀect of viral infection, thereby
stimulating a prolonged immune response (Ishii and Akira, 2005; Lehtinen et al.,
2008; Yang et al., 2007). Inappropriate activation of the immune response is thought
to be neurotoxic, either directly or indirectly, and thus cause microcephaly (Peschke
et al., 2016). Since TREX1 dysfunction increases immune-mediated neurotoxicity,
one group has suggested that TREX1-mutated lymphocytes could impede cancer
growth (Pulliero et al., 2012). The authors cultured neuroblastoma, a cancer of the
peripheral nervous system, cells in the presence of TREX1-mutated T-cells and saw
that tumor cell growth was significantly inhibited. This study illustrates how
insights from microcephalic disorders can even inform development of novel cancer
immunotherapies.
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Another possible target for cancer therapy is WDR62 (WD repeat domain 62),
which is mutated in primary, autosomal recessive microcephaly (Bastaki et al., 2016;
Bhat et al., 2011; Kousar et al., 2011). Patients with WDR62 mutations have
microcephaly, pachygyria, polymicrogyria, gyral thickening, microlissencephaly, and
cortical dysplasia (Bilguvar et al., 2010; Murdock et al., 2011). Interestingly, WDR62
has a similar function to ASPM, so microcephaly may proceed from dysregulation of
analogous mechanisms. In Drosophila, the WDR62 ortholog cg7337 was described as
a microtubule-associated protein that stabilizes interphase microtubules in
neuroblasts, regulates their mitotic entry, and ensures proper mitotic centrosome
positioning and spindle orientation (Ramdas Nair et al., 2016). Similarly, in
mammalian cells, WDR62 has been found to co-localize with ASPM to mitotic
spindle poles in proliferating neural precursor cells (Nicholas et al., 2010; Yu et al.,
2010). Wdr62 deletion in mice leads to mitotic arrest in neural stem and progenitor
cells as a consequence of spindle instability and activation of the spindle assembly
checkpoint, which ultimately results in cell death (Chen et al., 2014). It has also
been shown that deficiency of WDR62 in cortical progenitors can induce premature
diﬀerentiation (Xu et al., 2014). Thus far, one study has found a link between
WDR62 and cancer (Zhang et al., 2013). WDR62 protein levels were increased in 6
ovarian cancer cell lines and ovarian tumor samples from 75 patients, with greater
expression in more advanced cancers. Similar to CDK6 depletion, overexpression of
WDR62 was associated in tumor samples with supernumerary centrosomes,
suggesting that CDK6 and WDR62 may have opposing roles in mitotic spindle
organization (Hussain et al., 2013). More research is needed to determine if WDR62
is also upregulated in other cancers, but nonetheless, its similar role to ASPM in
neural stem/progenitor cells includes it as a possible target for brain cancer therapy.
One recent report has implicated SASS6 (SAS6 centriolar assembly protein)
mutations as being responsible for a form of primary, autosomal recessive
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microcephaly (Khan et al., 2014). Three members of a consanguineous Pakistani
family were aﬀected with microcephaly and found to have missense mutations in
SASS6. The protein coded by this gene, SAS6 (Spindle assembly abnormal protein 6
homolog), regulates centrosome cohesion, assembly, and duplication
(Rodrigues-Martins et al., 2007). Mutation in CEP135 (Centrosomal protein 135)
has also been linked to human microcephaly, and its protein product is believed to
directly interact with SAS6 to regulate centrosome activity (Hussain et al., 2012; Lin
et al., 2013). To date, only one report has suggested SASS6 over-expression in
human cancers (Shinmura et al., 2015). The authors found SASS6 mRNA and
protein to be increased in a panel of colorectal cancer samples, and SASS6
overexpression in colorectal cancer cells was seen to precipitate mitotic chromosomal
abnormalities. Probing of the cancer genome atlas also revealed slightly increased
SAS6 levels in bladder urothelial carcinoma, breast invasive carcinoma, head and
neck squamous cell carcinoma, kidney renal clear cell carcinoma, lung
adenocarcinoma, lung squamous cell carcinoma, prostate carcinoma, and uterine
corpus endometrial carcinoma. Despite the paucity of research on SAS6, that it is a
centrosome-associated protein disrupted in microcephaly like EG5, ASPM, CDK6,
and WDR62 hints at its importance in neural stem/progenitor cells, which could
make it a viable target for brain tumor treatment.
CENPE (Centromere protein E) is a centromere kinetochore-associated protein
that accumulates in G2-phase and has activity in M-phase (Gudimchuk et al., 2013;
Kim et al., 2010; Yen et al., 1991). The microtubule-dependent motor activity of
CENPE allows it to align chromosomes in prometaphase (Cai et al., 2009; Kim et al.,
2008). Depletion of CENPE results in chromosomal instability and mitotic arrest
(Putkey et al., 2002; Yao et al., 2000). Mutation of the CENPE gene has been
described in two siblings with microcephalic primordial dwarfism (Mirzaa et al.,
2014). Although CENPE expression was not reduced in the patients cells, its activity
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was altered, as the protein failed to accumulate in mitosis. Lymphoid cells from
these patients were found to display mitotic spindle abnormalities (monopolar and
multipolar), altered chromosome segregation, and mitotic arrest. While CENPE
function is disrupted in microcephaly, its expression has been found to be increased
in triple-negative breast cancers (Kung et al., 2014). siRNA knockdown and small
molecule inhibition of CENPE were found to inhibit proliferation of triple-negative
breast cancer cell lines and reduce tumor growth in a breast cancer xenograft model.
Similarly, CENPE inhibition has been shown to reduce the viability of pancreatic
carcinoma cell lines (Henderson et al., 2009). A high-throughput screen identified a
novel CENPE inhibitor that induced mitotic arrest and apoptosis in these cells.
Furthermore, CENPE inhibition had a strong anti-tumor eﬀect on colon
adenocarcinomas xenografted onto mice – treatment increased mitotic arrest that
led to apoptosis (Wood et al., 2010). Another broad screen described sensitivity to
CENPE inhibition in multiple types of cancer cell lines (Ohashi et al., 2015), and
indeed, targeting CENPE for cancer treatment has gained attention (Wacker and
Kapoor, 2010). Several CENPE inhibitors are being explored in preclinical trials,
and one, GSK-923295, has completed Phase I clinical trials for refractory cancers.
The similar molecular function of CENPE to EG5 supports research into its
inhibition in treating malignant gliomas.
Cornelia de Lange syndrome is a congenital disorder that presents with a
spectrum of abnormalities, including growth failure, hypertrichosis, hearing
impairment, cleft palate, visual defects, cardiac abnormalities, seizures, and
microcephaly (Ireland et al., 1993; Jackson et al., 1993). Underlying etiology involves
mutation of the NIPBL (Nipped-B-like) gene in most cases, although mutations in
SMC1A (Structural maintenance of chromosomes 1A), SMC3, and HDAC8 (Histone
deacetylase 8) have also been reported (Deardorﬀ et al., 2007; Krantz et al., 2004;
Musio et al., 2006; Tonkin et al., 2004). All four genes code for cohesin proteins that
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hold together sister chromatids after replication until their separation in mitosis,
and disruption of at least NIPBL leads to mitotic arrest (Peters et al., 2008; Watrin
et al., 2006). Studies in the developing CNS of zebrafish have shown that loss of the
nipblb paralog promoted neural stem and progenitor cell apoptosis with concomitant
reduced activity in the Wnt (Wingless-related integration site) signaling pathway
(Pistocchi et al., 2013). These findings suggest that pathogenesis of the
microcephalic component of Cornelia de Lange syndrome may be a result of NIPBL
disruption leading to prolonged mitotic arrest that triggers apoptosis in neural stem/
progenitor cells. On the other hand, upregulation of NIPBL has been described in
tumor samples from patients with NSCLC, where its expression was correlated with
worse pathologic features (Xu et al., 2015). NIPBL was also upregulated in NSCLC
cell lines and its disruption promoted apoptosis, as with neural stem cells, and
increased sensitivity to Paclitaxel and Gemcitabine. An oncogenic or therapeutic role
in brain cancer has yet to be described.
A final candidate for novel brain cancer therapy is MECP2 (Methyl CpG-binding
protein 2), a transcriptional regulator with a prominent role in the brain
(Shahbazian et al., 2002b). Mutations inMECP2 are responsible for the X-linked
neurodevelopmental disorder Rett syndrome, which presents around one-year of age
as autism-like behaviors, motor deficits, GI disturbances, and sometimes
microcephaly (Shahbazian and Zoghbi, 2002; Shahbazian et al., 2002a; Jacob et al.,
2009). The pathogenesis of Rett syndrome is still not entirely clear, as the functions
of MECP2 have yet to be fully elucidated (Guy et al., 2011). Nevertheless, the timing
of symptoms in Rett syndrome suggests that MECP2 predominantly functions in
neurons rather than neural stem or progenitor cells, and MECP2 has been shown to
be important in synaptic function and neurotransmission (Armstrong, 2001;
Armstrong et al., 1995; Armstrong, 2005). A recent study in zebrafish, however,
found mecp2 to be important in promoting neural stem cell diﬀerentiation, and its
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depletion increased the proportion of nestin+ stem cells in embryonic development
(Gao et al., 2015). With regards to tumorigenesis, MECP2 silencing in prostate
cancer cell lines was found to both decrease proliferation and increase apoptosis
(Yaqinuddin et al., 2008). A separate study demonstrated human prostate cancer cell
proliferation was dramatically attenuated by MECP2 disruption and that ectopic
MECP2 expression actually promoted prostate cancer proliferation (Bernard et al.,
2006). These opposing eﬀects of MECP2 in neural stem cells versus prostate cancer
cells raise concerns as to its viability as a cancer therapeutic, especially for stem/
progenitor-derived brain cancers. Even as treatment for non-brain malignancies,
inhibiting MECP2 may produce severely limiting neurotoxicity, which is supported
by the observation that Rett syndrome is a postnatal condition and therefore MECP2
must be vitally important in post-mitotic neurons.
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Table 2.4: Genes mutated in microcephalic disorders code for products that may be  
attractive targets for brain cancer therapies. 
Gene 
of 
interest 
Protein function Associated microcephalic disorder Suggested roles in cancer 
KIF11 
Mitotic spindle 
organization through 
microtubule association 
Decreased function in 
primary, autosomal 
dominant microcephaly 
Increased expression in 
bladder urothelial 
carcinoma, pancreatic 
adenocarcinoma, and 
glioblastoma: disruption 
reduces proliferation 
ASPM 
Mitotic spindle 
organization through 
microtubule association 
Decreased function in 
primary, autosomal 
recessive microcephaly 
Increased expression in 
glioblastoma and 
medulloblastoma: disruption 
reduces tumorigenesis 
CDK6 
G1-S checkpoint 
regulation and possibly 
mitotic spindle 
organization 
Decreased function in 
primary, autosomal 
recessive microcephaly 
Increased expression in 
many cancers, including 
glioblastoma and 
medulloblastoma: disruption 
reduces proliferation 
ATR 
DNA damage response 
and possibly M-phase 
checkpoint regulation 
Decreased function in 
Seckel syndrome 
Disruption reduces 
medulloblastoma 
tumorigenesis 
NBS1 DNA damage response 
Decreased function in 
Nijmegen breakage 
syndrome 
Disruption increases 
radiation sensitivity in 
glioblastoma cells 
IGF1R 
Mutli-tissue cell 
proliferation and survival; 
CNS synaptogenesis 
Decreased function in 
primary, autosomal 
recessive microcephaly 
Increased expression in 
medulloblastoma, 
especially metastatic 
TREX1 DNA proofreading and repair 
Decreased function in 
Aicardi-Goutieres 
syndrome 
Disruption in T-cells 
increases immune-
mediated killing of 
neuroblastoma cells 
WDR62 
Mitotic spindle 
organization through 
microtubule association 
Decreased function in 
primary, autosomal 
recessive microcephaly 
Increased expression in 
ovarian cancer 
SASS6 
Centrosome cohesion, 
assembly, and 
duplication 
Decreased function in 
primary, autosomal 
recessive microcephaly 
Increased expression in 
colorectal cancer 
CENPE Mitotic chromosome alignment 
Decreased function in 
microcephalic primordial 
dwarfism 
Disruption reduces viability 
of triple-negative breast 
cancer, pancreatic 
carcinoma, and colon 
adenocarcinoma cells 
NIPBL Sister chromatid cohesion 
Decreased function in 
Cornelia de Lange 
syndrome 
Increased expression in 
non-small cell lung cancer: 
disruption induces 
apoptosis 
MECP2 
Transcriptional 
repression and 
neurotransmission 
Decreased function in 
Rett syndrome 
Disruption reduces 
proliferation in prostate 
cancer cells 
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Figure 2.1: Microcephalic disorders are characterized by disruptions in
mitotic regulators, which could be targeted for brain cancer therapy. (A)
EG5/KIF11 is a heterotetrameric, plus-end-directed microtubule motor protein that
pushes apart the duplicated centrosomes to create a bipolar mitotic spindle in
prophase and prometaphase, which allows for separation of sister chromatids (left).
In the absence of EG5/KIF11, the centrosomes fail to separate, resulting in the
formation of a monoaster, which triggers mitotic arrest that can lead to apoptosis
(right). (B) ASPM is a microtubule minus-end-associated protein found at mitotic
spindle poles that has been implicated in both mediating symmetric cell divisions
and orienting the cell division plane in neural stem and progenitor cells (left). The
absence of ASPM creates more asymmetric divisions and altered division planes,
both of which can promote diﬀerentiation over continued proliferation (right). (C)
One report has found that CDK6 associates with mitotic centrosomes, possibly
mediating centrosome duplication, spindle assembly, and cellular motility (left). The
CDK6 mutation associated with mirocephalic patients did not reduce CDK6 protein
levels but rather altered its function and behavior such that it no longer associated
with centrosomes, which led to supernumerary centrosomes, inappropriate mitotic
spindle alignment, abnormal cellular polarity, and reduced cell motility (right). (D)
In CGNPs, endogenous, replication-associated DNA damage activates the DNA
damage response protein ATR, which recognizes single-stranded DNA coated by RPA
at stalled replication forks, simplified here. Activated ATR can promote G2/M arrest
by barring mitotic entry through preventing CDK1/CDC2 activation and by targeting
CEP63 to block assembly of the mitotic spindle (left). Absence of ATR both limits
DNA repair and permits mitotic entry in CGNPs. Progression through mitosis
exacerbates DNA damage in the form of severe chromosomal aberrations.
Overwhelming DNA damage causes ATM to activate p53, which primarily induces
apoptosis in postnatal CGNPs.
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CHAPTER 3: ATR MAINTAINS CHROMOSOMAL INTEGRITY DURING
POSTNATAL CEREBELLAR NEUROGENESIS AND IS REQUIRED FOR
MEDULLOBLASTOMA FORMATION2
Overview
Microcephaly and medulloblastoma may both result from mutations that
compromise genomic stability. We report that ATR, which is mutated in the
microcephalic disorder Seckel syndrome, sustains cerebellar growth by maintaining
chromosomal integrity during postnatal neurogenesis. Atr deletion in cerebellar
granule neuron progenitors (CGNPs) induced proliferation-associated DNA damage,
p53 activation, apoptosis and cerebellar hypoplasia in mice. Co-deletions of either
p53 or Bax and Bak prevented apoptosis in Atr-deleted CGNPs, but failed to fully
rescue cerebellar growth. ATR-deficient CGNPs had impaired cell cycle checkpoint
function and continued to proliferate, accumulating chromosomal abnormalities.
RNA-Seq demonstrated that the transcriptional response to ATR-deficient
proliferation was highly p53-dependent and markedly attenuated by p53 co-deletion.
Acute ATR inhibition in vivo by nanoparticle-formulated VE-822 reproduced the
developmental disruptions seen with Atr deletion. Genetic deletion of Atr blocked
tumorigenesis in medulloblastoma-prone SmoM2 mice. Our data show that
p53-driven apoptosis and cell cycle arrest – and, in the absence of p53, non-apoptotic
cell death – redundantly limit growth in ATR-deficient progenitors. These
mechanisms may be exploited for treatment of CGNP-derived medulloblastoma
using ATR inhibition.
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Introduction
Appropriate brain development requires genomic fidelity. Diverse mutations that
increase DNA damage can restrict brain growth, causing microcephaly (Lee and
McKinnon, 2007; McMahon et al., 2014; Orii et al., 2006; Rosin et al., 2015; Williams
et al., 2015). Combined with p53 deletion, mutations in DNA repair genes may
produce unrestricted growth in medulloblastoma (Frappart et al., 2009; Lee and
McKinnon, 2002; Tong et al., 2003), a malignant tumor of neural progenitors. The
serine/threonine kinase ATR (Ataxia Telangiectasia and Rad3-related protein)
mitigates proliferation-associated DNA damage (Brown and Baltimore, 2000) and
has been implicated in microcephaly in Seckel syndrome (O’Driscoll et al., 2003). In
mice, conditional deletion of Atr throughout the CNS during embryonic development
similarly induces microcephaly, but particularly aﬀects the cerebellum and
ganglionic eminence (Lee et al., 2012). The precise mechanisms that cause DNA
damage to impair growth specifically in the brain are unknown. We investigated the
processes that restrict growth when Atr is deleted in the cerebellum in order to shed
light on the pathogenesis of microcephaly associated with DNA damage and to
determine whether the reliance of neural progenitors on ATR persists in progenitor-
derived medulloblastoma.
Cerebellar growth depends on the postnatal proliferation of cerebellar granule
neuron progenitors (CGNPs) in the external granular layer (EGL) along the outside
of the cerebellum, which peaks between postnatal day (P) 5 and 7 (Hatten and
Heintz, 1995). Although Atr deletion in Nestin (NES)+ progenitors blocks cerebellar
development prior to postnatal neurogenesis (Lee et al., 2012), the specific cellular
processes restricting the growth of ATR-deficient progenitors have not been
discerned. In vitro, ATR reduces DNA damage during proliferation by stabilizing
stalled replication forks and by arresting the cell cycle to allow for DNA repair
(Cimprich and Cortez, 2008). Replication fork collapse following ATR disruption
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produces DNA double-strand breaks (DSBs), which are considered the most toxic
form of DNA damage (Couch et al., 2013). ATR also maintains S- and G2-phase
checkpoints by phosphorylating CHK1 (CHEK1) in response to DNA damage (Smith
et al., 2010). Determining how these functions combine in vivo to sustain neural
progenitors is essential to understanding both the pathogenesis of Seckel syndrome
and the requirement for ATR in brain development.
We found that ATR-deficient CGNPs continued to proliferate despite
accumulating DNA damage, which induced population-wide, p53-dependent
apoptosis. Blocking apoptosis in ATR-deficient CGNPs through co-deletion of the key
apoptotic mediators Bax and Bak (Bak1) or co-deletion of p53 (Tp53) did not fully
rescue the resulting cerebellar hypoplasia. Rather, premature cell cycle exit in Atr/
Bax/Bak mutants or non-apoptotic cell death in Atr/p53 mutants redundantly
limited CGNP population growth. Atr-deleted CGNPs also demonstrated diverse
chromosomal abnormalities that were intensified by restriction of apoptosis. CGNPs
are the cells of origin for Sonic hedgehog (SHH) subgroup medulloblastomas; we
found that Atr deletion blocked the tumorigenic eﬀect of constitutive SHH activation
in transgenic SmoM2 mice. These investigations define a crucial role for ATR in
maintaining genomic integrity during brain development and suggest that ATR
dependence might be exploited for medulloblastoma therapy.
Results
Atr deletion induces CGNP apoptosis and cerebellar hypoplasia
To analyze ATR function in CGNPs, we generated mice with conditional Atr
deletion (Brown and Baltimore, 2003) in the MATH1 lineage. Math1 (Atoh1) is
expressed by CGNPs in a rostrocaudal progression beginning at the anterior
margins of the cerebellar cortex at embryonic day (E) 12.5 (Hatten and Roussel,
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2011). We crossed theMath1-Cre and AtrloxP/loxP mouse lines to generate
Math1-Cre; AtrloxP/loxP (AtrM-cre ) mice.
AtrM-cre mice were viable and fertile, but by P12 displayed tremor and ataxia,
suggesting impaired postnatal neurogenesis. These animals were born with
hindbrains of normal appearance, with the EGL spread over the primordial
cerebellum. By P3, however, the EGL in AtrM-cre mice was noticeably thinner and
less foliated than inMath1-Cre littermate controls with intact Atr (Math1-Cre;
Atr+/+ orMath1-Cre;AtrloxP/+). Cerebellar hypoplasia in AtrM-cre mice became
progressively more apparent with age (Fig. 3.1A).
We noted sparing of the posterior regions of the cerebellum in AtrM-cre mice (Fig.
3.1A, middle row). To determine if this sparing was the result of incomplete
recombination in these regions or was due to reduced dependence on ATR, we used
hGFAP-Cre to delete Atr throughout the CGNP population. hGFAP-Cre mice express
Cre recombinase in neural stem cells, targeting all cells of the cerebellum except the
Purkinje cells (Andrae et al., 2001). In the resulting hGFAP-Cre;AtrloxP/loxP (AtrG-cre
) mice, we found hypoplasia across the entire EGL. The EGL was thinned by P0 and
completely lost by P7. These mice showed more severe tremor and died by P18 (Fig.
3.1A, bottom row; Fig. 3.S1A,B).
To understand the cause of cerebellar hypoplasia in Atr mutants, we analyzed
patterns of proliferation, DNA damage and apoptosis in AtrM-cre and AtrG-cre mice by
immunohistochemistry (IHC). Although prior studies showed that deletion of Atr in
Nes-expressing progenitors blocks the prenatal proliferation of CGNP precursors
(Lee et al., 2012), we observed no reduction in the postnatal proliferation of CGNPs
in P3 AtrM-cre or P0 AtrG-cre cerebella, as demonstrated by the fraction of EGL cells
expressing the mitosis marker phosphorylated histone H3 (pH3) (Fig. 3.1B,C, Fig.
3.S1C) or the cycling cell marker proliferating cell nuclear antigen (PCNA) (Fig.
3.S3D). However, we found significantly increased DNA damage as demonstrated by
132
phosphorylated histone H2A.X (H2A.X), increased activation of the cellular DNA
damage response as shown by phosphorylated ATM (p-ATM) and p53 (p-p53), and
increased apoptosis as shown by the levels of cleaved Caspase-3 (cC3) (Fig. 3.1B,C,
Fig. 3.S1C,D). Atr-deleted CGNPs therefore proliferate robustly, but accrue
extensive DNA damage and undergo apoptosis.
Deletion of Bax and Bak prevents cell death in Atr-mutant CGNPs
Extensive apoptosis complicated further analysis of ATR-deficient CGNPs. Prior
studies showed that deletion of the apoptosis gatekeeper Bax is suﬃcient to stabilize
CGNPs with radiation-induced or proliferation-associated DNA damage (Chong
et al., 2000; Garcia et al., 2013; Williams et al., 2015). We found, however, that
apoptosis of Atr-deleted CGNPs and cerebellar hypoplasia were not prevented by Bax
co-deletion inMath1-Cre;AtrloxP/loxP ;BaxloxP/loxP (Atr;BaxM-cre ) animals (Fig.
3.2A, Fig. 3.S2A,B). Co-deletion of Atr and the Bax homolog Bak also failed to
stabilize the CGNP population inMath1-Cre;AtrloxP/loxP ;Bak-/- (Atr;BakM-cre ) mice
(Fig. 3.S2A,B). However, combining genetic deletion of both Bax and Bak in ATR-
deficient mice (Math1-Cre;AtrloxP/loxP ;BaxloxP/loxP ;Bak-/- , or Atr;Bax;BakM-cre )
eﬀectively prevented CGNP apoptosis, partially rescuing cerebellar growth (Fig.
3.2A,B, Fig. 3.S2A,C). TUNEL staining did not detect non-apoptotic cell death in
Atr;Bax;BakM-cre cerebella that might have been missed by cC3 studies (Fig.
3.2B,D). These data show that Atr deletion in CGNPs, in contrast to other
pro-apoptotic stimuli such as radiation, activated both BAX- and BAK-driven
apoptosis.
We compared markers of proliferation, DNA damage and the DNA damage
response in CGNPs of P3 Atr;BaxM-cre , Atr;Bax;BakM-cre , and Atr-intactMath1-Cre;
BaxloxP/loxP ;Bak-/- (Bax;BakM-cre ) controls by IHC. The fractions of pH3+ and
PCNA+ CGNPs were similar in Atr-mutant and Atr-intact genotypes (Fig. 3.2D,
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Fig. 3.S2C, Fig. 3.S3C,D). CGNPs in Atr;BaxM-cre and Atr;Bax;BakM-cre mice
showed similar levels of H2A.X. However, p-ATM, p-p53, and the cell cycle inhibitor
p21 (CDKN1A) were all markedly increased in Atr;Bax;BakM-cre CGNPs (Fig.
3.2B,D, Fig. 3.S2B,C). Apoptosis-disabled, ATR-deficient CGNPs were thus able to
activate p53 without undergoing cell death.
Atr- and p53-double-mutant CGNPs undergo caspase-independent cell
death
To determine the functional significance of p53 activation in CGNPs of AtrM-cre
mice, we examined the phenotype ofMath1-Cre;AtrloxP/loxP ;p53loxP/loxP
(Atr;p53M-cre ) mice. p53 deletion prevents CGNP apoptosis after radiation-induced
DNA damage (Herzog et al., 1998). p53 deletion did not completely rescue cerebellar
hypoplasia in Atr mutants (Fig. 3.2A, Fig. 3.S3A), despite eﬀective suppression of
the p53 axis, as demonstrated by the absence of p21 and p53 activation (Fig.
3.2C,D). The fraction of pH3+ and PCNA+ CGNPs in Atr;p53M-cre mice did not diﬀer
from Atr- intact controls at P3 (Fig. 3.2D, Fig. 3.S3B,D). Atr;p53M-cre CGNPs
accumulated significantly more DNA damage than AtrM-cre or Atr;Bax;BakM-cre
CGNPs (Fig. 3.2D). This increased level of DNA damage did not trigger activation of
Caspase-3 (Fig. 3.2D). However, TUNEL staining demonstrated that cell death had
occurred without caspase activation (Fig. 3.2C,D).
Atr;p53M-cre CGNPs showed abnormal morphologies that were diﬀerent from the
pyknotic nuclei found in the AtrM-cre EGL. These features included giant,
multinucleated cells and cells with micronuclei (Fig. 3.S3E), consistent with
published descriptions of p53-deficient cancer cells undergoing necrosis after DNA
damage (Vakifahmetoglu et al., 2008). To examine whether Atr;p53M-cre CGNPs
were dying through regulated necrosis, we compared the phosphorylation of MLKL,
an essential step in the necroptosis pathway (Cai et al., 2014). We found scattered
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CGNPs showing phosphorylated MLKL (p-MLKL) inMath1-Cre, p53M-cre , and
Atr;p53M-cre mice, but no increase in the Atr;p53M-cre genotype (Fig. 3.S3F). Thus,
ATR/p53-deficient CGNPs undergo cell death without evidence of activating the
apoptotic or necroptotic pathways.
Accelerated cell cycle exit in Atr;Bax;BakM-cre CGNPs
To account for the incomplete rescue of cerebellar growth in Atr;Bax;BakM-cre and
Atr;p53M-cre mice despite the prevention of CGNP apoptosis, we investigated CGNP
proliferation over time. We compared the mitotic rate of AtrM-cre , Atr;Bax;BakM-cre ,
and Atr;p53M-cre CGNPs in the EGL with Atr-intact controls at P3, P5 and P7. We
first determined that EGL mitotic rates did not vary significantly between the
Atr-intactMath1-Cre, Bax;BakM-cre , and p53M-cre control genotypes, allowing us to
pool controls (Fig. 3.S3G). The mitotic rates of AtrM-cre CGNPs did not diﬀer from
controls with any statistical significance at P3, P5 or P7: both groups showed a small
decrease in proliferation by P7 (Fig. 3.2E). By contrast, the proliferation rate of
Atr;Bax;BakM-cre CGNPs decreased markedly from P3 to P5 and from P5 to P7, and
was significantly lower than in controls at both P5 and P7. These data show that
non-proliferating cells were increased in the P5 and P7 EGL of Atr;Bax;BakM-cre
mice but not in AtrM-cre mice with intact apoptosis. This increased cell cycle exit at
P5 and P7 was p53-dependent, as the mitotic rate of apoptosis-disabled Atr;p53M-cre
CGNPs was significantly higher than the Atr;Bax;BakM-cre CGNP mitotic rate at
both P5 and P7.
We noted clusters of cells in P20 Atr;Bax;BakM-cre cerebella in the typically
depopulated region where the EGL had been. These cells expressed the neuronal
marker NEUN (RBFOX3) (Fig. 3.2F) and were PCNA- (data not shown), identifying
them as diﬀerentiated neurons. The location of these neurons suggests that they
derive from CGNPs, and similar ectopic neurons were not seen in AtrM-cre ,
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Atr;p53M-cre , or Atr-intact control cerebella. These observations provide evidence
that premature, p53/p21-driven CGNP cell cycle exit after P3 limits the rescue eﬀect
of disabled apoptosis in Atr;Bax;BakM-cre cerebella.
Cell cycle checkpoint failure in ATR-deficient CGNPs with DNA damage
ATR coordinates the cellular response to replication stress by activating cell cycle
checkpoints (Abraham, 2001). Our studies of cerebellar sections indicated that Atr-
deleted CGNPs continue to proliferate after developing detectable DNA damage. To
assess checkpoint function in Atr-mutants, we used fluorescence-activated cell
sorting (FACS) to analyze freshly isolated CGNPs from the cerebella of P3 mice with
and without Atr deletion, including AtrM-cre , Atr;Bax;BakM-cre , and Atr;p53M-cre
knockout genotypes as well asMath1-Cre, Bax;BakM-cre , and p53M-cre controls. All
cells were stained for DNA content (FxCycle Violet), H2A.X, and pH3.
Atr-deleted genotypes showed a strongly H2A.X+ subpopulation that was not
seen in controls (Fig. 3.S4A). To generate Atr-intact CGNPs with comparable DNA
damage, we subjected P3 wild-type (WT) mice to X-ray radiation (2Gy) and then
isolated and analyzed CGNPs 2hr. later. These WT, irradiated CGNPs showed
H2A.X staining that was comparable in intensity to the H2A.X+ CGNPs in
Atr-deleted mice (Fig. 3.S4A). DNA content staining eﬀectively identified cells at
G1-, S-, and G2/M-phases (Fig. 3.S4A), and pH3 staining distinguished G2- from
M-phase (Fig. 3.S4B). We found no statistically significant diﬀerences in cell cycle
distribution between non-irradiated control genotypes (Fig. 3.S4C), and these
controls were pooled for further analysis.
Without H2A.X selection, comparison of P3 CGNP cell cycle distribution
between controls and Atr-deleted genotypes showed a significant diﬀerence only in
the Atr;Bax;BakM-cre CGNPs. These cells showed enrichment of G2- at the expense
of G1-phase (Fig. 3.3A), consistent with either delayed progression or G2 arrest.
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However, comparing the H2A.X+ subsets from Atr-deleted genotypes and irradiated,
WT mice, we noted marked diﬀerences in M-phase. All three Atr-deleted genotypes
demonstrated CGNPs that were both H2A.X+ and pH3+ (Fig. 3.3B). By contrast,
pH3+ CGNPs were almost undetectable in the irradiated, WT mice (Fig. 3.3B).
FACS results were confirmed by dual immunofluorescence (IF) for pH3 and
H2A.X or phospho-53BP1 (p-53BP1; 53BP1 is also known as TP53BP1), another
marker of DNA damage (Fig. 3.3C). First, in WT, non-irradiated controls, pH3+ cells
were always negative for H2A.X and p-53BP1. Second, in irradiated, WT mice,
CGNPs that were H2A.X+ or p-53BP1+ were never pH3+. Finally, in all Atr-deleted
genotypes, H2A.X+/pH3+ and p-53BP1+/pH3+ cells were common (Fig. 3.3C). The
H2A.X+/pH3+ CGNPs in Atr-deleted genotypes either entered M-phase with DNA
damage or persisted in M-phase after acquiring DNA damage. These data do not
conclusively show whether H2A.X+, Atr-deleted CGNPs are able to complete
mitosis. However, Atr deletion clearly permitted cells with DNA damage to be mitotic
– a condition that is not seen in Atr-intact CGNPs.
Additionally, in each of the Atr-deleted genotypes, we found that H2A.X+ CGNPs
were distributed across all phases of the cell cycle, with relative enrichment in S-,
G2-, and M-phases, compared with H2A.X+ CGNPs from irradiated, WT mice (Fig.
3.3D). Consistent with these data, IF studies showed colocalization of H2A.X with
markers of G1- (Cyclin D1), S- (BrdU), and G2- (Cyclin B1) phases (Fig. 3.S4D) in
AtrM-cre cerebella. G1 depletion in Atr-deleted, H2A.X+ CGNPs could indicate
either loss of H2A.X phosphorylation in G1 cells through DNA repair, or slowed
return of H2A.X+ cells to G1. The abundance of H2A.X+ cells in each phase of the
cell cycle, however, suggests that CGNPs with Atr deletion and DNA damage can
progress through the cell cycle and, in the case of Atr;Bax;BakM-cre , have not all
permanently arrested by P3. Altogether, at this single time point, most ATR-
deficient CGNPs did not show evidence of impaired cell cycle function. However, Atr
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deletion increased the fraction of CGNPs with DNA damage and altered the barriers
that normally prevent them from undergoing mitosis.
FACS data confirmed the increased cell death seen in AtrM-cre and Atr;p53M-cre
CGNPs, which both showed increased sub-G1 fractions. We did not detect an
increase in sub-G1 H2A.X+ CGNPs in Atr;Bax;BakM-cre cerebella (Fig. 3.3E).
These increases in sub-G1 fractions are consistent with our observations of apoptotic
cell death in the AtrM-cre genotype and non-apoptotic cell death in the Atr;p53M-cre
genotype.
ATR protects CGNP chromosome integrity
Our finding of impaired checkpoint function suggested that genomic fidelity
might be impaired in Atr-deleted CGNPs. In vitro studies have shown incomplete
DNA replication and chromosomal fragmentation in Atr-mutant cells (Brown and
Baltimore, 2000). To determine if chromosomal damage accumulates in ATR-
deficient cells in vivo and to quantify the damage, we karyotyped Atr-deleted CGNPs
freshly harvested from P3 cerebella. We dissociated CGNPs from AtrM-cre ,
Atr;Bax;BakM-cre , and Atr;p53M-cre mice andMath1-Cre, Bax;BakM-cre , and
p53M-cre controls. Dissociated cells were treated ex vivo with Colcemid, and
metaphase spreads were analyzed by conventional karyotyping and spectral
karyotyping (SKY). We noted frequent chromosome breaks in all Atr-mutant
genotypes and a spectrum of abnormalities, including dicentric chromosomes,
end-to-end fusions, deletions, translocations, and whole chromosome gains or losses
(Fig. 3.4A). In addition, Atr;p53M-cre CGNP chromosomes showed segregation
defects (premature sister chromatid separation). These abnormalities were not
detected in controls (AtrM-cre 35%, P<0.01; Atr;Bax;BakM-cre 48%, P<0.01;
Atr;p53M-cre 49%, P<0.01; Student’s t-test).
For statistical analysis, we divided metaphases with varying degrees of
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chromosomal damage into four bins: 1-10 chromosome breaks/cell; >10 chromosome
breaks/cell and <50% chromosomes fragmented (Mild); >10 chromosome breaks/cell,
>50% chromosomes fragmented, and some preserved chromosome morphology
(Moderate); and >10 chromosome breaks/cell, >50% chromosomes fragmented, and
complete loss of chromosome morphology (Severe) (Fig. 3.4B). In all Atr-deleted
genotypes, the frequencies of cells with all degrees of chromosomal damage were
increased, but the increases in AtrM-cre cells with Moderate and Severe damage were
not statistically significant. Moderate and Severe damage, however, were particularly
enriched in the apoptosis-incompetent Atr;Bax;BakM-cre and Atr;p53M-cre genotypes
(Fig. 3.4C). These data show that CGNPs require ATR to maintain chromosomal
integrity during proliferation, and that apoptosis limits the accumulation of genetic
abnormalities by removing damaged cells from the population. Karyotype analyses
also reaﬃrm that CGNPs with damaged DNA progress to M-phase in Atr-mutants.
Transcriptomic adaptations to ATR deficiency are predominantly p53-
driven
We used RNA-Seq to determine the transcriptomic alterations induced by
proliferation-associated DNA damage in the absence of Atr. Despite a wide body of
literature on the cellular consequences of ATR loss, the impact on the transcriptome
had not previously been reported. The prolonged survival of Atr-deleted CGNPs in
Atr;Bax;BakM-cre and Atr;p53M-cre mice allowed us to analyze mRNA abundance
without losing cells with DNA damage from the population through cell death. We
isolated and purified total RNA for RNA-Seq analysis from the cerebella of apoptosis-
incompetent, ATR-deficient P3 mice (Atr;Bax;BakM-cre and Atr;p53M-cre ) and
corresponding age-matched controls (Bax;BakM-cre and p53M-cre ). The abundance of
mRNAs may be altered by changes in either production or degradation. ATR has
been implicated in RNA processing (Chandris et al., 2010), and Atr deletion may
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alter both gene transcription and mRNA stability. Our data thus identify
transcriptomic, rather than transcriptional changes.
We noted that Atr deletion evoked a richer, more complex pattern of
transcriptomic changes in the Bax/Bak-co-deleted background compared with the
p53-co-deleted background. Principal component analysis (PCA) demonstrated that
the second component of variation explained 16% of variance in global gene
expression, and separated Atr;Bax;BakM-cre from Bax;BakM-cre (P=4.41x10-7,
Hotelling’s t-square test) but not Atr;p53M-cre from p53M-cre (P=0.20, Hotelling’s
t-square test) (Fig. 3.5A). This diﬀerence in separation on PCA indicates that
p53-deleted CGNPs are more restricted in their transcriptomic response to ATR
deficiency. Consistent with reduced transcriptional responsiveness with Atr/p53-
co-deletion, the number of genes diﬀerentially expressed in Atr;Bax;BakM-cre
cerebella compared with controls was significantly greater than in Atr;p53M-cre
cerebella compared with controls (P=2.8x10-52, Fisher’s exact test). Using a false
discovery rate (FDR) of <0.01 and considering only genes meeting a fold-change (FC)
criterion of |log2(knockout/control)|>1.5, we identified 339 genes diﬀerentially
expressed by ATR-deficient cells in the Bax/Bak-deleted background, as compared
with 56 genes diﬀerentially expressed by ATR-deficient cells in the p53-deleted
background, with 9 genes represented in both sets (Fig. 3.5B, Tables 3.S1 and
3.S2). This overlap demonstrates a high degree of correspondence between the gene
sets (P=2.0x10-8, hypergeometric test). However, P-values for diﬀerentially expressed
genes were consistently smaller in the p53-deleted comparison, as visualized in plots
of FC versus significance (Fig. 3.5C), indicating an overall smaller transcriptomic
eﬀect of Atr deletion in the absence of p53. Expression microarray analysis
comparing mRNA from Atr;Bax;BakM-cre versus Bax;BakM-cre cerebella defined a
gene set that corresponded well with the diﬀerential gene set defined by RNA-Seq
(Fig. 3.S5A). By contrast, microarray analysis was unable to identify any
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diﬀerentially expressed genes in the Atr;p53M-cre versus p53M-cre comparison,
consistent with an overall low signal-to-noise ratio in the absence of p53.
Pathway analysis of the 339 genes diﬀerentially expressed in Atr;Bax;BakM-cre
CGNPs demonstrated a strong correspondence between these genes and the
molecular signature of p53-dependent transcription. Activation of p53 can induce
both apoptosis and cell cycle arrest (Zuckerman et al., 2009), and we noted that
regulators of both processes were enriched in the Atr;Bax;BakM-cre gene set (Table
3.1). By contrast, we did not identify any pattern in Atr;p53M-cre CGNPs that could
be attributed to a specific transcriptional regulator (Table 3.S3) and, consistent with
the lack of increased MLKL activation, we found no elevation of necroptosis-
associated genes such as RIP kinases.
We used IF to determine the protein expression patterns of Trophinin (TRO),
which was among the 9 genes identified as diﬀerentially expressed in both Atr-
deleted genotypes, and for which we were able to obtain eﬀective antibodies.
Examining Bax;BakM-cre and p53M-cre control brains, we found that TRO was
expressed in all diﬀerentiated neurons of the brain, but absent in progenitor regions
(Fig. 3.5D). In Atr-deleted Atr;Bax;BakM-cre and Atr;p53M-cre cerebella, however,
TRO was detected within the CGNP layer (EGL), indicating upregulation of the
protein as well as the RNA.
From the larger set of 124 genes that were upregulated in the Atr-mutant
cerebella of both p53-deleted and Bax/Bak-deleted backgrounds with FDR<0.01,
irrespective of FC, we selected Eif4ebp1 for further analysis. EIF4EBP1 is known to
regulate protein translation downstream of mTOR (Fingar et al., 2002), a PIKK
kinase homologous to ATR (Lovejoy and Cortez, 2009). Atr-deleted CGNPs
demonstrated marked upregulation of EIF4EBP1 protein. In control cerebella,
EIF4EBP1 was limited to a subset of CGNPs at the outer margin of the EGL,
whereas in Atr-deleted cerebella EIF4EBP1 was detected throughout the EGL (Fig.
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3.5D). Our in situ IF data, along with our microarray results, thereby validate our
RNA-Seq findings.
We further examined our RNA-Seq data to determine whether Atr deletion
produced recurrent point mutations or other changes in RNA sequence. We did not
detect a significant change in mismatch rate associated with Atr deletion (Fig.
3.S5B). Fusion transcript detection software suggested a small number of fusion
products, only one of which, with unknown biological function, emerged with
statistical significance (Fig. 3.S5C). Together with our karyotype analysis, these
data suggest that, although Atr deletion significantly altered chromosome structure,
it did not substantially increase the rate of point mutations or recurrent fusion
transcripts.
ATR is required for medulloblastoma tumorigenesis
Prior studies have shown that deletion of diverse DNA repair pathway genes,
combined with p53 deletion, induces medulloblastoma in mice (Frappart et al., 2007,
2009; Holcomb et al., 2006; Lee and McKinnon, 2002). To determine if Atr mutation
predisposes mice to medulloblastoma, we followed the viability and neurologic
function of 12 Atr;p53M-cre and 12 Atr;Bax;BakM-cre mice for more than 300 days
(supplementary Materials and Methods). These mice showed no progressive
neurological changes or other evidence of tumorigenesis, and their cerebella
remained hypoplastic (data not shown). The absence of tumors despite impaired
genomic stability and p53 deletion suggests that medulloblastoma tumorigenesis,
like postnatal neurogenesis, might require ATR function.
We directly tested this suggested requirement for ATR in medulloblastoma
tumorigenesis by deleting Atr in tumor-prone hGFAP-Cre;SmoM2 (SmoM2G-cre )
mice (Schuller et al., 2008). CGNPs in SmoM2G-cre mice with intact Atr gave rise to
medulloblastoma with 100% frequency by P7, causing the mice to die from tumor
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progression by P20 (Fig. 3.6A). By contrast, Atr deletion in SmoM2;AtrG-cre animals
completely blocked tumor formation, as seen and quantified by Hematoxylin and
Eosin (H&E) staining and by IF for PCNA, which marks proliferating tumor cells
(Fig. 3.6A). The inability of Atr-deleted CGNPs in SmoM2;AtrG-cre mice to give rise
to tumors suggests that ATR inhibition might eﬀectively restrict medulloblastoma
growth.
ATR inhibitor administered in vivo induces DNA damage specifically in
CGNPs
To determine whether acute disruption of ATR function during postnatal
neurogenesis in WT mice would recapitulate conditional Atr deletion, we developed a
novel formulation of the small molecule ATR inhibitor VE-822 (pVE-822) (Charrier
et al., 2011; Fokas et al., 2012). We first demonstrated that VE-822 induces DNA
damage and apoptosis in isolated CGNPs in vitro in a time- and dose-dependent
manner (Fig. 3.S6A). To enhance delivery of VE-822 across the blood-brain barrier,
we encapsulated VE-822 in poly(2-oxazoline) micelles, generating pVE-822 (Fig.
3.S6B,C). We found that pVE-822, administered by intraperitoneal (IP) injection,
induced H2A.X and cC3 in the EGL, without aﬀecting the surrounding
diﬀerentiated neurons in the cerebellum or cortical neurons (Fig. 3.6B,C). As with
Atr deletion, acute ATR inhibition by pVE-822 promoted upregulation of EIF4EBP1
in CGNPs, demonstrating that EIF4EBP1 is an eﬀective biomarker of ATR
disruption (Fig. 3.6D). These results show that pVE-822 eﬀectively crosses the
blood-brain barrier in bioactive concentrations after IP administration, and that
acute, global loss of ATR function specifically disrupts CGNPs. The absence of
neuronal toxicity associated with pVE-822 administration is consistent with recent
literature demonstrating that ATR inhibition does not damage non-proliferating,
diﬀerentiated neurons (Kemp and Sancar, 2016).
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Discussion
Our data show that ATR is required to mitigate endogenous DNA damage during
postnatal CGNP proliferation in order to maintain genomic stability. A prior study
that deleted Atr using Nes-Cre, which is expressed by E9.5 with an eﬀect by E10.5,
found that embryonic CGNP precursors exit the cell cycle prematurely, blocking
cerebellar development before postnatal CGNP proliferation (Lee et al., 2012). By
contrast, in AtrG-cre and AtrM-cre mice, where Cre expression does not occur until
E11.5 and E12.5 (Andrae et al., 2001; Machold and Fishell, 2005), respectively,
CGNPs proliferated normally in the postnatal period and the eﬀect of Atr deletion
was not observed until P0 and P3, respectively. Postnatal proliferation in Atr-deleted
CGNPs produced widespread DNA damage that activated ATM and p53 and induced
apoptosis, resulting in cerebellar hypoplasia.
Blocking apoptosis by co-deletion of Bax and Bak or p53 did not fully rescue
cerebellar hypoplasia. Cerebellar growth failure persisted despite attenuation of
apoptosis due to inappropriate cell cycle exit and diﬀerentiation in Atr;Bax;BakM-cre
CGNPs or caspase-independent cell death in Atr;p53M-cre CGNPs. Karyotype
analysis showed that Atr-deleted CGNPs developed extensive chromosomal
abnormalities, and RNA-Seq analysis revealed the p53 pathway to be the
predominant driver of the transcriptomic response to ATR-deficient proliferation.
Atr deletion in medulloblastoma-prone mice (SmoM2;AtrG-cre ) completely
abrogated tumor formation, suggesting a therapeutic potential for ATR inhibition as
a novel treatment for medulloblastoma. The anti-tumor eﬀect of targeting ATR
might be magnified in our model, as early deletion of Atr by hGFAP-Cre depletes the
pool of CGNPs from which tumors may originate. However, CGNPs were present in
P0 AtrG-cre mice (Fig. 3.1A), and SmoM2 expression consistently failed to induce
tumor growth from these cells in SmoM2;AtrG-cre animals. Future work will assess
the therapeutic potential of the ATR inhibitor pVE-822 in mice with established
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medulloblastoma. Indeed, we have already shown here that acute, in vivo ATR
inhibition by pVE-822 in WT mice reproduces the eﬀects of conditional Atr deletion.
Taken together, these results define a crucial role for ATR in maintaining genomic
integrity in rapidly proliferating neural progenitors and in medulloblastoma cells.
The finding that 5-9% of Atr-deleted CGNPs were cC3+ demonstrates a strong
induction of apoptosis. Unlike CGNP death after radiation, the death of these cells is
not expected to be a synchronous process. Moreover, dying cells are cC3+ for only a
limited time because they are rapidly cleared by phagocytosis and cC3 is known to
have a short half-life (Elliott and Ravichandran, 2010; Walsh et al., 2011). Detecting
5-9% of cells expressing cC3 thus indicates a high rate of cell death.
Apoptosis in Atr-deleted CGNPs, in contrast to irradiated Atr-intact CGNPs
(Chong et al., 2000; Williams et al., 2015), was not prevented by co-deletion of Bax,
but was prevented by co-deletion of both Bax and Bak. In other cell types, BAK-
driven apoptosis can be activated by genotoxic stress during mitosis (Chu et al.,
2012; Flores et al., 2012). Atr-deleted CGNPs with DNA damage were markedly
more prone to be mitotic than irradiated CGNPs in Atr-intact mice. The mitosis of
Atr-deleted CGNPs with DNA damage might activate BAK-driven apoptosis that is
not activated by radiation in WT mice.
The dependence of CGNPs on ATR to prevent DNA damage suggests that these
cells are particularly prone to endogenous replication stress. ATR is activated in
response to stalled DNA replication forks (Nam and Cortez, 2011), which can be
caused by exogenous (Harley et al., 2016; Harper et al., 2010) or endogenous (Willis
et al., 2013) factors. We have previously shown that normal CGNP proliferation
produces endogenous DNA damage, detectable as small H2A.X+ foci (Williams
et al., 2015). We now show that ATR mitigates endogenous, proliferation-associated
DNA damage in CGNPs in order to maintain replication fidelity.
To account for the phenotype of Atr deletion we propose a model in which: (1)
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rapid proliferation promotes replication fork stalling from endogenous sources
(Mirkin and Mirkin, 2007); (2) absence of ATR prolongs and collapses forks with
consequent formation of DSBs (Couch et al., 2013); (3) ATM is activated and
recruited to sites of DSBs (Shiloh, 2003); and (4) p-ATM activates p53, which
ultimately induces apoptosis (Shiloh and Ziv, 2013) through BAX and BAK, and cell
cycle arrest through p21 (Fig. 3.7). Because DNA damage and apoptosis occur
throughout the entire CGNP population, cerebellar growth is eﬀectively halted.
Apoptosis functions to cull CGNPs that acquire chromosomal abnormalities; thus,
disabling apoptosis in ATR-deficient mice increases chromosomal fragmentation.
p21 upregulation in Atr;Bax;BakM-cre CGNPs demonstrates that p53-induced cell
cycle exit acts as an additional barrier to the propagation of genomic abnormalities
in apoptosis-incompetent, Atr-deleted CGNPs. Genomic stability in CGNPs may be
particularly important for preventing their rapid postnatal proliferation from
degenerating into tumorigenesis. Medulloblastoma, the most common malignant
pediatric brain tumor, arises from hindbrain neural progenitors including CGNPs
(Yang et al., 2008). Chromosome damage has been observed in medulloblastoma,
frequently in association with p53 mutation (Rausch et al., 2012). Importantly,
despite severe chromosomal abnormalities in Atr;Bax;BakM-cre and Atr;p53M-cre
mice, we never observed tumor formation. Indeed, we found that medulloblastoma
tumorigenesis, like cerebellar development, requires ATR.
Since the physiological requirement for ATR in neural progenitors is
recapitulated in the pathological growth of medulloblastoma, ATR may be a
promising target for novel anti-tumor therapy. pVE-822 eﬀectively crosses the
blood-brain barrier in bioactive concentrations and induces DNA damage in
proliferating cells. By damaging DNA in proliferating cells, pVE-822 might have a
similar toxicity to conventional chemotherapeutic agents such as etoposide. An
advantage of ATR inhibition over standard chemotherapy, however, is suggested by
146
our data showing that Atr deletion kills cells even in the absence of p53. Whether the
activity of pVE-822 against proliferating, non-tumor cells will limit its therapeutic
potential remains to be tested.
Materials and Methods
Mice
We generated AtrM-cre and AtrG-cre mice by crossing AtrloxP/loxP (Brown and
Baltimore, 2003) mice with theMath1-Cre (Jackson Labs, stock 011104) (Matei
et al., 2005) and hGFAP-Cre (Jackson Labs, stock 012886) (Zhuo et al., 2001) mouse
lines, respectively. BaxloxP/loxP ;Bak-/- mice (Takeuchi et al., 2005) were obtained
from Jackson Labs (stock 006329). To generate mice with co-deletion of
Atr/Bax/Bak, Atr/Bax, Atr/Bak, and Bax/Bak, we crossed AtrM-cre and
BaxloxP/loxP ;Bak-/- animals, intercrossed the progeny, and selected mice of
Atr;Bax;BakM-cre , Atr;BaxM-cre , Atr;BakM-cre , and Bax;BakM-cre genotypes. We
generated Atr;p53M-cre mice by crossing AtrM-cre with p53loxP/loxP mice (Jonkers
et al., 2001) provided by the NCI (strain 01XC2). Medulloblastoma-prone animals
with and without Atr deletion were born from the cross between hGFAP-Cre;
AtrloxP/+ and SmoM2loxP/loxP;AtrloxP/loxP , in which tumorigenesis is induced by
deletion of a loxP-flanked Stop cassette between the Smo promoter and coding region
(Schuller et al., 2008). All mice were of speciesMus musculus and crossed into the
C57BL/6 background through at least five generations. We used equal numbers of
male and female mice, as we did not observe any diﬀerences based on sex. Numbers
(n) in figures indicate biological replicates, which were determined so as to measure
a 25% diﬀerence in means with power=80% and =0.05. Animal use was in keeping
with the policies of the University of North Carolina at Chapel Hill Institutional
Animal Use and Care Committee. P3 mice of the indicated genotypes received 2 Gy
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whole-body X-ray irradiation and were sacrificed 2 hr later.
Immunostaining of cerebellar sections
Mouse brains were processed and immunostained as previously described
(Gershon et al., 2013). Primary antibodies are listed in the supplementary Materials
and Methods. Secondary antibodies of the indicated fluorophores were used at
1:2000 for IF. Cell death was detected by TUNEL assay [ThermoFisher Scientific
(TFS) C10617] (Galluzzi et al., 2009). DAPI and Hematoxylin were used as nuclear
counterstains. BrdU analysis is described in the supplementary Materials and
Methods.
Quantification of immunostaining
Stained slides were digitally imaged and positively-stained cells were counted
using Aperio Software (Aperio Technologies) for chromogen-stained slides or Tissue
Studio (Definiens) for fluorescence, as previously described (Williams et al., 2015).
The entire EGL region in each section was manually annotated and used for
quantifications, which were normalized to the total number of nucleated cells in the
designated region. The measurement of cerebellar cellularity is described in the
supplementary Materials and Methods.
CGNP isolation
CGNPs from P3 Atr-deleted mice and controls were isolated as previously
described (Lee et al., 2009). Briefly, we separated cerebella from the rest of the brain,
removed the meninges, and dissociated the tissue in 20 units/ml papain
(Worthington Biochemical Corporation PDS) at 37C for 15 min. CGNPs were then
purified from the dissociated cerebellar tissue by successive rounds of centrifugation,
discontinuous density gradient, and mesh filtering.
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Flow cytometry
Flow cytometry on ATR-deficient CGNPs was performed by first fixing and
permeabilizing (TFS GAS-004) isolated CGNPs suspended in HBSS containing 33
mM glucose, as previously described (Stahl et al., 2008). CGNPs were then stained
successively for DNA damage with e660-conjugated anti-H2A.X Ser139
(eBioscience 50-9865) at 1:10, for M-phase with 488-conjugated anti-pH3 (Cell
Signaling Technology 9708) at 1:25, and for DNA content with FxCycle Violet (TFS
F-10347) at 1:50. Technical controls included no stain, single-stained and
fluorescence-minus-one samples. FACS was performed on an LSR Fortessa (BD
Biosciences). For all experiments, 10,000-50,000 cells were counted. Analysis of
FACS data was performed using FlowJo v10.0.8 (FlowJo).
Cytogenetic analysis
Cytogenetic analysis was performed on Atr-deleted CGNP metaphase spreads.
Freshly isolated CGNPs from P3 animals were treated for 30 min with 100 nM
Colcemid (TFS 15210-040) in Neurobasal-A Medium (TFS 10888-022) supplemented
with 1x GlutaMAX-I (TFS 35050), 1x penicillin-streptomycin and 25 mM KCl at 37C
to block cell cycle progression in M-phase. CGNPs were then were resuspended in 75
mM KCl, incubated at 37C for 5 min, and fixed in methanol:acetic acid (3:1). The
fixed cell suspension was dropped onto slides, stained in 0.08 g/ml DAPI in 2x SSC
for 3 min, and mounted in antifade solution (Vector Laboratories H-1200). The
stained slides were scanned using a Zeiss Axioplan 2i epifluorescence microscope
equipped with a megapixel CCD camera (CV-M4+CL, JAI) controlled by Isis 5.2
imaging software (Metasystems International). Chromatid breaks were counted as
single-break events, tri-radials and quadri-radials as two-break events each, and
other complex chromatid exchanges were converted into the minimum number of
breaks required for their theoretical reconstruction. Chromosome aberrations
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(fragments, rings, dicentric/tricentrics and large marker chromosomes) were
recorded and the breaks required for these rearrangements were not added to the
frequency of chromatid breaks.
Mutation analysis
The frequency of mismatches or of transcript fusions associated with Atr deletion
were determined as described in the supplementary Materials and Methods.
Western blot
P3 WT CGNPs subject to VE-822 or vehicle were analyzed for H2A.X and cC3
(with -actin loading control) by western blot as described in the supplementary
Materials and Methods.
Spectral karyotyping
Metaphase spreads from the fixed cell suspensions were hybridized with SKY
painting probes according to the manufacturer’s protocol (Applied Spectral Imaging).
SKY images were acquired with an SD300 Spectracube (Applied Spectral Imaging)
mounted on a Nikon Eclipse E800 microscope using a custom-designed optical filter
(SKY-1) (Chroma Technology). For each sample, a minimum of 20, but usually 50,
metaphases were captured and fully karyotyped. The breakpoints on the SKY-
painted chromosomes were determined by comparison with the corresponding DAPI
karyotype and chromosomal abnormalities were described according to (ISCN, 2013).
RNA-Seq and diﬀerential expression analysis
For RNA-Seq analysis, total RNA was purified using the RNeasy Mini Kit
(Qiagen 74104) from freshly dissected whole P3 cerebella. RNA quality and quantity
were assessed by spectrophotometry and capillary gel electrophoresis. We generated
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stranded mRNA libraries using an Illumina TruSeq Stranded mRNA Library Prep
Kit (Illumina RS-122-2101). 60 ng/l poly(A)-selected RNA from each sample was
run in two lanes of a HiSeq 2000 sequencing instrument (Illumina) for 100 cycles of
multiplexed paired-end reads.
We performed read pseudo-alignment and quantification using Kallisto v0.42.4
(Bray et al., 2016) with 200 bootstraps/paired-end read, aligning against the mouse
mm9 genomic assembly, GRCm38 transcriptome definition. Downstream analysis
was performed using the edgeR v3.12.0 software package (Robinson et al., 2010) in
R-Studio v0.99.491 with R v2.11.1 (Team, 2014). To assess diﬀerential expression,
we used a general linear model in edgeR comparing Atr-deleted with control, setting
the minimum counts per million at 2 and requiring greater than half the samples to
pass the count threshold for a given transcript. Microarray validation is detailed in
the supplementary Materials and Methods.
Pathway analysis
Biological pathway enrichment was determined by comparing transcriptomic data
with Kyoto Encyclopedia of Genes and Genomes v77.1 (Kanehisa and Goto, 2000),
WikiPathways (Kutmon et al., 2016) and Gene Ontology v1.2 (Ashburner et al., 2000)
databases using EnrichNet v1.1 (Glaab et al., 2012), Panther v10.0 (Mi et al., 2013),
and WebGestalt (Wang et al., 2013). Only genes above the diﬀerential expression
significance threshold of log2(FC)>1.5 and FDR<0.01 were used in pathway analysis.
pVE-822 in vivo administration
For in vivo studies, WT mice were subject to IP injection with 60 mg/kg pVE-822
(see supplementary Materials and Methods for formulation) or an equal volume
of vehicle every 12 hr for 3 total injections from P3-5. 12 hr following the final
injection, animals were sacrificed and brains were prepared for immunostaining.
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Supplementary Materials and Methods
Measurement of cerebellar cellularity
Cerebellar cellularity was defined as the IGL density (cells/mm2) as measured on
H&E-stained, sagittal brain sections. We measured statistical significance using the
2-sided independent samples t-test assuming unequal variances in SPSS Statistics
23 (IBM, Armonk, NY).
Survival analysis
Atr-deleted and control mice were followed for event-free survival. Animals were
sacrificed either at the censure age of 300 days-old or at observation of severe weight
loss, marked diﬃculty ambulating, and/or significantly diminished physical activity.
BrdU injection
To label cells in S-phase, 200 mg/kg BrdU (BD Biosciences 550891) dissolved in
HBSS was administered by IP injection to mice of the indicated genotypes 2 hr
before harvest.
Microarray validation
Total RNA was purified using the RNeasy Mini Kit (Qiagen 74104, Hilden,
Germany) from freshly-dissected whole P3 cerebella. RNA quality and quantity were
assessed by spectrophotometry and capillary gel electrophoresis. 500 ng of RNA from
each sample was run on an Aﬀymetrix GeneChip Mouse Transcriptome Assay 1.0
(Aﬀymetrix, Santa Clara, CA). Diﬀerential gene expression was analyzed in Partek
Genomics Suite (Partek Inc., Chesterfield, MO) using RMA normalization and
significance thresholds of FDR<0.01 and |Log2(FC)|>1.5. Data available at GEO:
GSE85394.
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Mutation analysis
Mismatch error rate was calculated from the set of all mutations/mismatches
after MapSplice v2.2.0 (Wang et al., 2010) alignment to the mouse mm9 genomic
assembly. Mismatches were captured using the bcftools -A" option to keep all
possible alternate alleles at variant sites. Neighboring nucleotides of each mismatch
were collected using a custom software. The frequency of all 96 possible trinucleotide
mutations were calculated and plotted as a histogram. We measured statistical
significance using the 2-sided independent samples t-test assuming unequal
variances in SPSS Statistics 23 (IBM, Armonk, NY).
Transcript fusion products were detected using FusionCatcher v0.99.5a (Nicorici
et al., 2014), employing Bowtie v1.1.2 (Langmead et al., 2009) for alignment to mouse
genome build mm9 and STAR v2.5.1b (Dobin et al., 2013) for mapping reads to find
the fusion junction. Statistical significance was measured by Barnard’s exact test in
R Studio.
Western blot analysis
CGNPs isolated from P3 WT mice were cultured with 0.5 g/mL sonic hedgehog
(R&D Systems, Minneapolis, MN) and DMSO or VE-822 (MedKoo 406258, Chapel
Hill, NC) dissolved in DMSO at 0.1, 1, or 5 M. Cells were harvested after 2, 6, or 24
hr and lysates were probed for H2A.X Ser139 at 1:50 (CST 9718, Batch 10), cC3 at
1:100 (Biocare Medical CP229C, Batch 060115), and -actin at 1:5000 (CST 3700,
Batch 3) by Western blot.
pVE-822 formulation
The amphiphilic triblock copolymer poly(Methyl-Butyl-Methyl) oxazoline (POx),
P(MeOx37-b-BuOx21-b-MeOx36), was purchased from Rainer Jordan (Technische
Universität, Dresden, Germany). VE-822-loaded polyoxazoline micelles (pVE-822)
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were prepared as previously described (Luxenhofer et al., 2010), with slight
modifications. Briefly, VE-822 was dissolved in acetone and mixed with POx solution
in acetone (final drug:polymer of 4 mg:5 mg). Following complete removal of acetone,
the resulting thin film was rehydrated with saline at 60C. Samples were allowed to
cool to room temperature and then centrifuged at 10k RPM for 3 min to remove any
remaining residual solids. Only the transparent supernatant solution was used for
subsequent experiments. Micelle hydrodynamic diameter and polydisperity index
(PDI) were determined by dynamic light scattering (DLS) using a Malvern Nanosizer
(Malvern Instruments Ltd., Worcestershire, UK). VE-822 concentration was
determined by HPLC. Final VE-822 concentration was 26 mg/mL and non-loaded
POx micelles were used as Vehicle control.
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Antibodies for IHC/IF
Antigen Dilution Sourcea,b,c,d Batch
BrdU 1:200 CST 5292 3
cC3 1:50 BM CP229C 060115
Cyclin b1 1:100 CST 4138 2
Cyclin d1 1:500 CST 2978 8
Eif4ebp1 1:3000 CST 9644 10
NeuN 1:1000 EMD M MAB377 A60
p-Atm Ser1981 1:5000 EMD M 05740 2276333
p-MLKL Ser345 1:300 Abcam ab196436 GR238752-10
p-p53 Ser15 1:50 CST 9284 15
p21 1:500 CST 2947 5
PCNA 1:2000 CST 2586 10
pH3 Ser10 1:100 CST 9706 9
Trophinin 1:1000 Abcam ab78117 GR259420-1
H2A.X Ser139 1:2000 CST 9718 10
aCST = Cell Signaling Technology, Danvers, MA, USA.
Antibody validation information:
http://www.cellsignal.com/common/content/content.jsp?id=ourApproach-validation-principles
bAbcam, Cambridge, UK.
Antibody validation information: http://www.abcam.com/content/validating-our-products
cEMD M = EMD Millipore, Billerica, MA, USA.
Antibody validation information: http://www.emdmillipore.com/US/en/20140115_153621
dBM = Biocare Medical, Concord, CA, USA.
Antibody validated on brain sections from WT mice at P0, P3, P7, P12, and P20
(n = 10 for each) and WT mice exposed to 10 Gy XRT at P0, P3, P7, P12, and P20 (n =
10 for each).
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FIGURES
Figure 3.1: Atr deletion in CGNPs induces postnatal DNA damage, p53
activation, apoptosis and cerebellar hypoplasia. (A) H&E-stained sagittal
brain sections from mice of the indicated genotypes and ages.
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(B) Sagittal cerebellar sections from P3 mice of the indicated genotypes stained for
pH3, H2A.X and cC3. (C) Quantification of replicate cerebella of the indicated
genotypes, stained as in B and Fig. 3.S1. Average is shown with s.e.m. P-values by
two-sided independent samples t-test assuming unequal variances. All stainings
were repeated on at least three biological replicates (n). Scale bars: 800 m in A; 400
m (main) and 200 m (inset) for pH3, 50 m for cC3 (inset) in B.
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Figure 3.2: Co-deletion of Bax and Bak, but not p53, blocks cell death in
ATR-deficient CGNPs. (A) H&E-stained, sagittal brain sections from P12 mice of
the indicated genotypes, showing partial rescue of cerebellar development in
Atr;Bax;BakM-cre and Atr;p53M-cre mice. (B) Sagittal cerebellar sections from P3
mice of the indicated genotypes stained for p-p53, TUNEL, and p21.
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(C) Sagittal cerebellar sections from P3 mice of the indicated genotypes stained for
H2A.X, TUNEL, and p21. (D) Quantification of replicate cerebella of the indicated
genotypes, stained as in B,C, Fig. 3.S2 and Fig. 3.S3. Bax;BakM-cre and p53M-cre
controls were not significantly diﬀerent from theMath1-Cre controls presented in
Fig. 3.1. (E) pH3 quantification in the external granular layer (EGL) of mice of the
indicated genotypes at P3, P5, and P7. (F) NEUN staining on P20 sagittal cerebellar
sections from mice of the indicated genotypes. Average with s.e.m. P-values by two-
sided independent samples t-test assuming unequal variances. All stainings were
repeated on at least three biological replicates (n). Scale bars: 800 m in A; 400 m
(main) and 50 m (inset) for p-p53, 200 m for TUNEL (inset) in B; 400 m (main)
and 200 m (inset) in C; 200 m (main) and 50 m (inset) in F.
163
Figure 3.3: Increased DNA damage and inappropriate mitotic entry in
Atr-deleted CGNPs. (A) FACS analysis without subsetting for H2A.X on CGNPs
from P3 mice of the indicated genotypes. M-phase was determined by pH3 labeling.
P-values by chi-square test. (B) Quantification of H2A.X+/pH3+ CGNPs from P3
mice of the indicated genotypes. P-values by two-sided independent samples t-test
assuming unequal variances.
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(C) Double labeling for H2A.X/pH3 and p-53BP1/pH3 on sagittal cerebellar sections
from P3 mice of the indicated genotypes. Arrowheads indicate double positives.
Scale bars: 100 m (main) and 50 m (inset). (D) FACS analysis with subsetting for
H2A.X+ CGNPs from P3 mice of the indicated genotypes. P-values by chi-square
test. (E) Quantification of ’sub-G1’ DNA content detected by FACS in CGNPs from
mice of the indicated genotypes. P-values by two-sided independent samples t-test
assuming unequal variances. Average with s.e.m. All stainings were repeated on at
least three biological replicates (n).
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Figure 3.4: Atr deletion compromises the chromosome integrity of
proliferating CGNPs. (A) Metaphase chromosome spread and SKY analysis on
Atr;Bax;BakM-cre and Atr;p53M-cre CGNPs. (B) Severity of chromosome damage in
CGNPs with >10 chromosome breaks/cell, grouped into Mild, Moderate, and Severe.
(C) The distribution of CGNPs with chromosomal abnormalities by genotype.
Average with s.e.m. P-values by two-sided independent samples t-test assuming
unequal variances. n, number of biological replicates, with 35-50 metaphases
counted per replicate.
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Figure 3.5: The p53 pathway controls the CGNP transcriptomic response to
Atr deletion. (A) PCA on gene expression of CGNPs from P3 mice of the indicated
genotypes, as determined by RNA-Seq. (B) Diﬀerential gene expression analysis of
RNA-Seq data using the indicated criteria comparing mice of the indicated
genotypes. (C) Volcano plots of log2(FC) versus -log10(P-value) for Atr;Bax;BakM-cre
compared with Bax;BakM-cre and for Atr;p53M-cre compared with p53M-cre , with
color threshold (teal dots) set at log2(FC)>1.5 and FDR<0.01 (lines).
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(D) IF for TRO and EIF4EBP1 on sagittal cerebellar sections from P3 mice of the
indicated genotypes. Arrows indicate TRO+ cells. Scale bar: 100 m. IGL, internal
granular layer. All stains were repeated on at least three biological replicates (n).
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Figure 3.6: Atr deletion blocks medulloblastoma tumorigenesis, and acute,
in vivo ATR inhibition induces DNA damage and apoptosis in the postnatal
cerebellum. (A) Sagittal H&E- and PCNA-stained brain sections at P7 and P20
show the absence of tumor formation in SmoM2;AtrG-cre mice. Bar charts compare
total area and percentage PCNA+ cells in the P20 posterior fossa by genotype.
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(B-D) Sagittal sections of whole brains, cerebella and cortices from P5 WT mice
injected with pVE-822 or vehicle, stained for (B) H2A.X, (C) cC3 or (D) EIF4EBP1.
Arrows indicate EIF4EBP1+ cells. Average with s.e.m. P-values by two-sided
independent samples t-test assuming unequal variances. All stainings were repeated
on at least three biological replicates (n). Scale bars: 2 mm in A; 2 mm (brain), 500
m (cerebellum) and 100 m (EGL and cortex) in B-D.
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Figure 3.7: ATR is required to maintain G2/M checkpoint integrity and
prevent apoptosis induced by proliferation-associated DNA damage. (A)
CGNPs proliferate in the postnatal cerebellum, generating DNA damage (lightning
bolt) from endogenous processes, which stalls replication forks. ATR is recruited by
replication protein A (RPA), which binds single-stranded DNA at stalled replication
forks. Activated ATR initiates checkpoint arrest, promoting DNA repair with
minimal engagement of the p53 pathway.
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(B) ATR loss prolongs replication fork stalling across the CGNP genome, which
degenerates into widespread DSBs that are sensed by ATM. Resultant p53
activation triggers apoptosis through BAX/BAK and Caspase-3 (C-3) due to
overwhelming DNA damage, with some concurrent activation of p21 and cell cycle
arrest. G2/M checkpoint failure from ATR absence allows CGNPs with DNA damage
to enter mitosis, incurring chromosomal abnormalities; however, apoptosis removes
cells with aberrant chromosomes. (C) Co-deletion of Bax and Bak in ATR-deficient
CGNPs prevents apoptosis. Instead, cells with DNA damage and p53 activation are
driven to p21-mediated cell cycle exit, attenuating CGNP proliferation over time.
However, cells that escape arrest then inappropriately enter mitosis and experience
chromosome damage, which accumulates due to apoptotic failure. (D) In Atr;p53M-cre
CGNPs, DSBs from collapsed replication forks accumulate and propagate due to the
inability to undergo both ATR-mediated G2/M arrest and p53-mediated apoptosis
and cell cycle arrest. Excessive DNA damage triggers an as yet unidentified form of
non-apoptotic cell death.
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Supplemental Figure 3.1: Normal proliferation in Atr-deleted CGNPs
during early postnatal development despite later reduced cerebellar
cellularity and hypoplasia. (A) Conditional Atr deletion in CGNPs (AtrM-cre ) and
neural stem cells (AtrG-cre ) leads to cerebellar hypoplasia by P12, as measured by
IGL cellular density (cells/mm2). Average with s.e.m. P-values by two-sided
independent samples t-test assuming unequal variances. (B) Atr deletion in CGNPs
(AtrM-cre ) has no eﬀect on mouse survival, as seen on Kaplan-Meier curve, although
earlier and more broad neural deletion of Atr (AtrG-cre ) significantly reduces
survival. P-values by log-rank test. (C) P0 AtrG-cre cerebella show preserved mitotic
rate (pH3), increased DNA damage (H2A.X), increased phosphorylation of ATM
(p-ATM) and p53 (p-p53), and cleavage of Caspase-3 (cC3). Scale bars: 400 M and
200 M (inset) on pH3, and 50 M (inset) on p-ATM.
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(D) P3 AtrM-cre cerebella have increased activation of ATM and p53. Scale bars: 400
M and 200 M (inset). IGL = internal granular layer. All stains were repeated on at
least three biologic replicates (n).
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Supplemental Figure 3.2: Deletion of Bax or Bak alone fails to rescue the
ATR cerebellar phenotype. (A) Co-deletion of Bax and Bak (Atr;Bax;BakM-cre ),
but not Bax alone (Atr;BaxM-cre ), partially rescues the Atr-deleted cerebellar
phenotype at P0 and P3 when compared to Bax;BakM-cre control, as seen on
representative H&E-stained, sagittal sections. Scale bar = 800 M. (B) P3
Atr;BaxM-cre and Atr;BakM-cre cerebella have equivalently elevated levels of H2A.X,
p-p53, cC3, TUNEL, and p21, with no diﬀerence in pH3 compared to control (Fig.
2D). Scale bars = 400 M and 200 M (inset) on pH3, and 50 M (inset) on p-p53. (C)
Atr;Bax;BakM-cre cerebella have increased levels of H2A.X, but equivalent levels of
pH3 and cC3 compared to Bax;BakM-cre controls. Scale bars: 400 M and 200 M
(inset) on pH3, and 50 M (inset) on cC3. All stains were repeated on at least three
biologic replicates.
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Supplemental Figure 3.3: p53 deletion in ATR-deficient CGNPs is associated
with DNA damage accumulation but no change in proliferation. (A) Co-
deletion of Atr and p53 (Atr;p53M-cre ) partially rescues the ATR-deficient (AtrM-cre )
cerebellar phenotype at P3 when compared to p53M-cre control, as seen on
representative H&E-stained, sagittal sections. Scale bar: 800 M.
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(B) P3 Atr;p53M-cre cerebella have increased activation of DNA damage response as
seen by p-ATM, but no change in proliferation as assessed by pH3 and PCNA when
compared to p53M-cre control. Scale bars: 400 M and 200 M (inset). (C) IF for
PCNA in P3 Atr-deleted and ATR-intact cerebella shows no diﬀerence in
proliferation induced by Atr deletion in CGNPs, reflecting the results of pH3 staining
and quantification. Scale bars: 400 M and 200 M (inset). (D) Quantification of
replicate cerebella of the indicated genotypes, stained for PCNA as in B and C. (E)
Pyknotic nuclei (red arrow heads), characteristic of apoptotic cells, are found in the
EGL of P3 AtrM-cre mice (middle panel), as seen on representative H&E-stained,
sagittal sections. In contrast, the EGL of P3 Atr;p53M-cre mice (right panel) contain
multi-nucleated giant cells (yellow arrow) and cells with micronuclei (yellow arrow
head), typical of necrotic cells. Scale bar: 50 M. (F) Similar proportions of cells
positive for the necroptosis marker p-MLKL can be found in the EGL of P3
Math1-Cre, AtrM-cre , and Atr;p53M-cre mice. Scale bars: 200 M and 100 M (inset).
(G) Quantification of pH3 staining in control cerebella of the indicated genotypes
shows no diﬀerences in mitotic rate between controls at P3, P5, and P7. Average with
s.e.m. P-values by two-sided independent samples t-test assuming unequal
variances. All stains were repeated on at least 3 biologic replicates (n).
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Supplemental Figure 3.4: Atr deletion increases the fraction of CGNPs with
DNA damage, especially in M-phase. (A) Live CGNPs from P3 cerebella of the
indicated genotypes can be found in all phases of the cell cycle by staining for DNA
content with FxCycle Violet. H2A.X+ cells are found in Atr-deleted genotypes and
WT +XRT, but not in controls. P-values by two-sided independent samples t-test
assuming unequal variances.
178
(B) More H2A.X+ CGNPs in G2/M from Atr-deleted cerebella are pH3+ compared to
H2A.X+ CGNPs in G2/M from WT +XRT cerebella or all CGNPs in G2/M from
control cerebella. (C) No diﬀerence in cell cycle distribution is noted between the
indicated ATR-intact control genotypes. P-values by chi square test. Average with
s.e.m.. (D) IF labeling of P3 AtrM-cre cerebellar sections shows co-localization of
H2A.X with markers of G1- (Cyclin d1+), S- (BrdU+), and G2-phases (Cyclin
b1+/pH3-) of the cell cycle. Scale bars: 100 M and 50 M (inset). All stains were
repeated on at least three biologic replicates (n).
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Supplemental Figure 3.5: Atr deletion in CGNPs is not associated with a
specific mutational pattern. (A) Microarray validates 76% of the genes found by
RNA-Seq to be significantly diﬀerentially expressed between P3 Atr;Bax;BakM-cre
and Bax;BakM-cre . (B) Mismatch rate quantification shows no increase in mutation
in Atr;Bax;BakM-cre and Atr;p53M-cre samples versus Atr-intact controls. P-values by
two-sided independent samples t-test assuming unequal variances. (C) Transcript
fusion analysis on Atr;Bax;BakM-cre , Atr;p53M-cre , and Atr-intact controls shows
that Atr deletion is correlated with an increase in certain fusion products. However,
the sole fusion product that is significantly increased, Gm6976-Gm29096, is only
detected in Atr;Bax;BakM-cre samples and is only representative of a read-through
error fusing two predicted genes of unknown function on chromosome 10. P-value by
Barnards exact test. Average with s.e.m. RT = read-through. n = number of biologic
replicates.
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Supplemental Figure 3.6: In vitro characterization of pVE-822. (A) CGNPs
freshly dissociated from P3 WT mice were cultured in the presence of Sonic
Hedgehog and the ATR inhibitor VE-822 or DMSO at the indicated concentrations
and then collected for Western blot analysis after 2, 6, or 24 hr. H2A.X and cC3
levels increase in time- and dose-dependent manners. Experiment replicated twice.
(B) Micelle size and size distribution, as determined by DLS. (C) VE-822 and POx
concentrations and pVE-822 loading eﬃciency (LE) and loading capacity (LC).
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CHAPTER 4: ONGOING WORK3
ATR inhibition by pVE-822 for the treatment of medulloblastoma
Introduction
Medulloblastoma is a cerebellar tumor that is the most common brain cancer of
childhood (McNeil et al., 2002; Smoll and Drummond, 2012). Current standard of
care involves some combination of surgical resection of the primary tumor,
cranio-spinal radiation to destroy metastatic cells, and/or chemotherapy for any
residual cancer (Packer and Vezina, 2008; Packer et al., 1999, 2006, 1991). However,
these methods can produce substantial toxicity as they also damage normal,
untransformed, proliferating cells, which is of special concern in developing children.
Notable side eﬀects associated with medulloblastoma treatment include growth
impairment, mental disability, hearing loss, and early onset strokes (Packer and
Vezina, 2008; Bartlett et al., 2013). Moreover, not all patients respond to existing
therapies, and indeed, brain cancer is the second leading cause of death by disease in
children in the United States (CBTRUS, 2010). As a result, more eﬀective, targeted
therapies that can reduce side eﬀects and treat a greater fraction of patients are
required.
Medulloblastoma generally responds favorably to radiation and
chemotherapeutics like Cisplatin, which produce an anti-tumor eﬀect by inducing
DNA damage, highlighting the sensitivity of this cancer to genotoxicity (Bar and
Stearns, 2008; Bloom et al., 1969; Gentet et al., 1995; Klesse and Bowers, 2010). ATR
is a serine/threonine kinase that regulates the DNA damage response and its
canonical role is in mediating the resolution of stalled replication forks in S-phase
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that form as a result of genomic stress from either endogenous or exogenous sources
(Cimprich and Cortez, 2008; Shiloh, 2001). Seckel syndrome is a congenital
developmental disorder that can be caused by hypomorphic ATR mutations and is
characterized by intrauterine growth restriction, postnatal growth impairment,
microcephaly, mental disability, craniofacial deformities, and sometimes
hematological abnormalities (O’Driscoll et al., 2003; Seckel, 1960). Microcephaly
from ATR disruption has been shown in mice to arise due to failed expansion of
neural stem cells specifically, and surprisingly only, in the ganglionic eminence and
the nascent cerebellum (Lee et al., 2012), suggesting tissue-specific dependence on
ATR in the developing brain. Deleting Atr slightly later in embryonic development
mostly aﬀected the cerebellum during postnatal development, again highlighting the
special cerebellar requirement for ATR (Lang et al., 2016).
Indeed, our recent research provides evidence that ATR is required to maintain
genomic integrity in cerebellar granule neuron progenitors (CGNPs) of the neonatal
cerebellum and that ATR disruption results in widespread CGNP apoptosis that
produces cerebellar hypoplasia (Lang et al., 2016). CGNPs are one of the most highly
proliferative cells in the postnatal brain, with peak proliferation stimulated by the
potent mitogen Sonic hedgehog (SHH) in the external granular layer (EGL) of the
cerebellum between postnatal day (P) 3 and P7 in mice, generating the largest
population of neurons in the adult brain, the cerebellar granule neurons (CGNs)
(Hatten and Heintz, 1995; Wechsler-Reya and Scott, 1999, 2001). Molecular
characterization of human medulloblastoma has divided the cancer into four
subgroups, one of which is characterized by hyperactivation of the SHH pathway
(Gibson et al., 2010; Gilbertson and Ellison, 2008; Northcott et al., 2012; Taylor
et al., 2012). This SHH subgroup of medulloblastoma is thought to arise from
mutations in CGNPs, and mice with only activating mutations in the SHH pathway
in CGNPs develop medulloblastoma (Gilbertson and Ellison, 2008; Schuller et al.,
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2008; Yang et al., 2008). Importantly, tumor cells in SHH medulloblastoma retain
many molecular and genomic similarities to CGNPs, suggesting that programs
critical to CGNP survival may also be important in medulloblastoma tumorigenesis
(Gilbertson and Ellison, 2008; Wechsler-Reya and Scott, 2001). Thus, given the
critical dependence of CGNPs on ATR, targeting ATR may represent a viable and
novel therapeutic for medulloblastoma.
For preclinical testing of pharmacological ATR inhibition as a treatment for
medulloblastoma, we have previously developed a novel nanoparticle formulation of
the small molecule ATR inhibitor VE-822, called pVE-822, for eﬃcient in vivo
delivery (Lang et al., 2016). We have shown in neonatal wild-type (WT) mice that
intraperitoneal (IP)-injected pVE-822 is able to cross the blood-brain barrier in
bioactive concentrations and inhibit ATR to induce DNA damage and apoptosis
specifically in CGNPs without obvious eﬀect to the rest of the brain. In one model of
medulloblastoma-prone mice, Atr deletion completely abrogated tumor formation,
again while apparently sparing the rest of the brain. However, the possibility
remained that the anti-tumor eﬀect of Atr deletion could be attributed to early
depletion of the CGNP pool from which tumor cells arise. Nevertheless, the complete
absence of tumors in medulloblastoma-prone mice with Atr deletion and the specific
cytotoxic eﬀect of acute ATR inhibition by pVE-822 on CGNPs encourage further
investigation of ATR disruption to treat medulloblastoma.
Here, we show that pVE-822 administration after the point of tumor formation in
two mouse models of medulloblastoma induces tumor regression by specifically
increasing intra-tumoral DNA damage. Increased DNA damage, however, was not
associated with activation of the p53 pathway or caspase-mediated apoptosis. Tumor
regression caused by ATR inhibition could also not be explained by altered cell cycle
dynamics, as no diﬀerence was observed compared to Vehicle-treated mice with
medulloblastoma. Similarly, tumor cells from medulloblastoma mice treated with
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pVE-822 had high levels of >4N DNA content, but this type of aneuploidy was also
detected in cells from Vehicle-treated animals. Survival analysis showed no benefit
to treating medulloblastoma mice with pVE-822. Moreover, medulloblastoma mice
with Atr deletion did not survive any longer following a course of radiation therapy
than control medulloblastoma mice with intact Atr. Curiously, microarray analysis
of mice with Atr-deleted medulloblastoma showed no diﬀerentially expressed genes
compared to Atr-intact control mice with medulloblastoma. In vitro studies in
primary CGNPs failed to reveal any compounds that synergize with VE-822 to
increase DNA damage or cell death. While pVE-822 and ATR disruption in general
clearly have an anti-tumor eﬀect in medulloblastoma, further studies are required to
determine the therapeutic value of inhibiting ATR to treat medulloblastoma.
Results
ATR inhibition by pVE-822 induces DNA damage and tumor regression in
mice with medulloblastoma
To investigate the eﬀect of ATR inhibition in a preclinical model of
medulloblastoma, we treated mice with established, spontaneous SmoM2
medulloblastoma, which have a Cre-inducible, constitutively active form of the
Smoothened (SMO) receptor that drives SHH pathway activity (Schuller et al., 2008),
with a nano-formulation of the small molecule ATR inhibitor VE-822, pVE-822, by IP
injection, as previously described (Lang et al., 2016). Murine medulloblastoma is
slightly diﬀerent in the SmoM2 model of tumorigenesis depending on whether SHH
pathway hyperactivation, and consequently tumor formation, is driven by the hGFAP
(Human glial fibrillary acidic protein) promoter (G-SmoM2), expressed in neural
stem cells, or by theMath1 (Mammalian atonal homolog 1) promoter (M-SmoM2),
expressed in CGNPs. We have seen that tumor progression is more rapid and
aggressive in the G-SmoM2 model and these tumors are more resistant to the eﬀects
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of therapeutic radiation. With G-SmoM2 mice, tumor formation is apparent by P12
due to symptoms such as ataxia, lethargy, growth impairment, reduced grooming,
and posterior skull deformity (Schuller et al., 2008). These mice typically perish by
P20, with median survival until P18. WithM-SmoM2 mice, tumor formation is
apparent by P16 and mice can survive until P40, with median survival until P20
(Crowther et al., 2016). We analyzed the eﬀects of pVE-822 treatment in both of
these medulloblastoma models to discern any diﬀerences. In order to determine the
pharmacodynamics of pVE-822 treatment in mice with medulloblastoma, we injected
tumor-bearing mice once per day for five consecutive days starting either at P8 or
P12 and sacrificed animals 12 hr. following the fifth injection.
Treatment beginning at P12 had a stronger anti-tumor eﬀect in both models of
medulloblastoma, as seen on histology of brain sections (Fig. 4.1A). In order to
ascertain the anti-tumor eﬀect of pVE-822, we compared the density of the posterior
fossa between drug- and vehicle-treated mice, measured on mid-sagittal brain
sections as the number of nuclei per mm2 in the posterior fossa (Fig. 4.1B). Using
this method, we detected a significant anti-tumor eﬀect of pVE-822 treatment in
G-SmoM2 mice, but not inM-SmoM2 mice. Separation of the components of this
density measurement fails to detect an anti-tumor eﬀect in both models of
medulloblastoma (Fig. 4.S1A,B). That is, there was no significant diﬀerence in the
number of nuclei in the posterior possa or the size, in mm2, of the posterior fossa
between pVE-822- and Vehicle-treated mice.
In order to further understand the tumorigenic eﬀects of ATR inhibition by
pVE-822 treatment in mice with SmoM2 medulloblastoma, we looked at changes in
cell proliferation in the posterior fossa as measured by PCNA (Proliferating cell
nuclear antigen), mitosis as measured by pH3 (phosphorylated Histone H3), DNA
damage as measured by H2A.X (phosphorylated Histone H2A, member X), cell
cycle arrest and apoptosis as measured by p-p53 (phosphorylated p53), and cell
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death as measured by cC3 (cleaved Caspase-3) (Figs 4.1C,D, 4.S1C-E). On
quantification, we saw that cell proliferation in tumors was significantly reduced by
pVE-822 treatment in both models of medulloblastoma and that there was a
concurrent increase in DNA damage (Fig. 4.1E). Surprisingly, we did not detect
changes in mitosis, activation of cell cycle arrest, or apoptosis from pVE-822
treatment despite decreased proliferation, increased DNA damage, and smaller
tumors. As we have shown previously (Lang et al., 2016), pVE-822 treatment does
not illicit a strong response in the rest of the brain, measured as the percentage of
cortical cells staining positive for PCNA, pH3, H2A.X, p-p53, or cC3 (Fig. 4.S1F).
Nevertheless, there was no apparent survival benefit associated with pVE-822
treatment compared to Vehicle in G-SmoM2 andM-SmoM2 mice given 60 mg/kg of
drug or vehicle once per day for five days per week starting at P12 (Fig. 4.S1G,H).
Acute ATR inhibition by pVE-822 does not result in cell cycle changes in
medulloblastoma tumor cells
Despite lack of activation of the potent cell cycle inhibitor p53 (Agarwal et al.,
1995; Shaw, 1996), we hypothesized that altered cell cycle dynamics could account
for the reduced proliferation and tumor regression seen in medulloblastoma mice
treated with pVE-822. We interrogated acute changes induced by ATR inhibition to
the cell cycle of medulloblastoma cells by injecting P16 G-SmoM2 andM-SmoM2
mice with 60 mg/kg pVE-822 or Vehicle and then sacrificing animals 6 hr. later to
harvest tumor cells for fluorescence-activated cell sorting (FACS). By staining for
DNA content with FxCycle Violet, we could separate cells in G1-phase versus S-
phase versus G2/M-phase. Additional staining with pH3 allowed us to separate G2-
and M-phases (Fig. 4.S2A). In our initial studies with a small cohort of animals, we
did not detect any diﬀerences in cell cycle in medulloblastoma mice treated with
pVE-822 (Fig. 4.S2B). Similarly, analyzing the cell cycle after subsetting for tumor
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cells with DNA damage using H2A.X staining failed to reveal any significant
changes to cell cycle with pVE-822 treatment (Fig. 4.S2C). In ATR-disrupted
CGNPs, we had previously found increased inappropriate mitotic entry (Lang et al.,
2016). However, the proportion of tumor cells with DNA damage in M-phase
appeared to be unaﬀected by ATR inhibition with pVE-822 (Fig. 4.S2D). Finally, in
order to account for non-apoptotic or acute cell death that might have been missed by
quantification of immunostained brain sections from medulloblastoma mice treated
with pVE-822 for consecutive days, we analyzed the percentage of H2A.X+ tumor
cells with sub-G1 DNA content from mice treated with pVE-822 or Vehicle and
sacrificed after 6 hr. Although there were minimal levels of sub-G1 DNA content in
tumors from animals of both genotypes in both treatment groups (data not shown),
we did find that tumors, regardless of treatment status, generally had detectable
>4N DNA content, suggesting possible mitotic defects (Fig. 4.S2E).
No transcriptional changes are seen in Atr-deleted medulloblastoma mice
In a preliminary study to understand the genetic consequences of ATR disruption
in medulloblastoma, we generated medulloblastoma-proneM-SmoM2 mice with and
without conditional Atr deletion (M-SmoM2 andMath1-Cre;SmoM2;AtrloxP/loxP
(SmoM2;AtrM-cre)) and harvested tumors at P18 for microarray analysis. Our prior
work in Atr-deleted CGNPs demonstrated strong induction of the p53 pathway, and
almost exclusively the p53 pathway, as a consequence of proliferation-associated
DNA damage in CGNPs with ATR disruption (Lang et al., 2016). However, using the
same thresholds for diﬀerential expression – false discovery rate (FDR) < 0.01 and
fold-change (FC) of |log2(SmoM2;AtrM-cre/M-SmoM2)| > 1.5 – we failed to detect any
diﬀerentially expressed genes induced by Atr deletion in medulloblastoma (data not
shown). Analysis of principal components using four samples of each genotype
showed overlap between the two groups without strong separation (data not shown).
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Thus, we were unable to determine the transcriptional changes associated with ATR
disruption in medulloblastoma using our genetic mouse model.
VE-822 has a combined anti-proliferative eﬀect with Vismodegib or
Etoposide on CGNPs
To ascertain if ATR inhibition in medulloblastoma might provide a greater
therapeutic benefit in combination with other treatments, we performed an
exploratory study by culturing CGNPs freshly isolated from P5 WT mice in the
presence of VE-822 and various compounds. Synergy between VE-822 and the tested
compounds was determined by comparing the eﬀect of VE-822 alone on CGNPs, as
we have previously reported (Lang et al., 2016), to the eﬀect of the compound alone to
the eﬀect of VE-822 and the compound in combination. Vismodegib is an antagonist
of the SMO receptor that has shown good anti-tumor eﬀect against the SHH
medulloblastoma subgroup (Robinson et al., 2015; Gajjar et al., 2013). However, we
saw minimal eﬀect of Vismodegib on WT CGNPs, as measured by changes in
proliferation by Cyclin D2 (CD2), DNA damage by H2A.X, and apoptosis by cC3
(Fig. 4.S3A, left). Adding VE-822 decreased CD2 levels but did not increase levels of
H2A.X or cC3 (Fig. 4.S3A, right). Cisplatin is a DNA cross-linker commonly used
to treat medulloblastoma, including as a part of the eight-in-one regimen (Gentet
et al., 1995) and the POG regimen (Packer et al., 2006). VE-822 plus Cisplatin has
shown synergy in lung cancer cells in vitro (Hall et al., 2014) and the combination is
in clinical trials for various non-brain malignancies. Cisplatin alone reduced
proliferation and increased apoptosis in CGNPs, but adding VE-822 failed to provide
any further benefit (Fig. 4.S3B). Gemcitabine is a nucleoside analog that has shown
eﬃcacy against Group 3 medulloblastoma, which is associated withMYC
amplification (Taylor et al., 2012; Morfouace et al., 2014). ATR inhibition seems to
sensitize various cancer cells in vitro to the eﬀects of Gemcitabine (Hall et al., 2014;
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Prevo et al., 2012; Vendetti et al., 2015; Fokas et al., 2012), and VE-822 is currently
in clinical trials with Gemcitabine for urothelial and fallopian tube cancers.
Similarly, the topoisomerase inhibitor Irinotecan (bioactive as SN-38) has shown
synergy with VE-822 in lung cancer cells (Hall et al., 2014) and the combination is
being tested in clinical trials for metastatic solid tumors. In cultured CGNPs,
Gemcitabine had no marked eﬀect while SN-38 reduced proliferation and increased
cell death (Fig. 4.S3C). Addition of VE-822 did not heighten these eﬀects.
Like Irinotecan, Etoposide is a topoisomerase inhibitor and it is regularly used to
treat medulloblastoma as a part of the POG regimen (Packer et al., 2006). Etoposide
has also shown eﬃcacy in combination with VE-822 in lung cancer cells (Hall et al.,
2014), and topoisomerase inhibitors like Irinotecan and Topotecan are in clinical
trials with VE-822 for various non-brain cancers. Used alone, Etoposide
dramatically reduced proliferation while increasing DNA damage and apoptosis in
WT CGNPs (Fig. 4.S3D, left). We have previously shown that CGNPs exposed to
VE-822 alone exhibit a similar response (Lang et al., 2016). Interestingly, combining
the two agents was apparently cytoprotective despite possible synergy in reducing
proliferation (Fig. 4.S3D, right). SB-743921 is an investigational mitotic inhibitor
that targets EG5 and has a similar mechanism of action to Vincristine and
Paclitaxel, but with increased specificity for mitosis (Grisold et al., 2012; Marcus
et al., 2005). Mitotic inhibitors like Vincristine are standardly used in most
medulloblastoma treatment regimens, including eight-in-one (Gentet et al., 1995),
VCP (Mulhern et al., 1998), and POG (Packer et al., 2006). Moreover, the ATR
inhibitor AZD-6738 is in clinical trials with Paclitaxel for metastatic cancers,
suggesting therapeutic benefit in combining ATR inhibition with mitotic disruption.
In cultured CGNPs, SB-743921 reduced proliferation and increased DNA damage
and apoptosis in time- and dose-dependent manners (Fig. 4.S3E, left top and
bottom). However, as with Etoposide, adding VE-822 to SB-743921-treated cells
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appeared to have a cytoprotective eﬀect that was more pronounced with shorter drug
exposure (Fig. 4.S3E, right top and bottom). In a final test of synergy, VE-822 was
given alone or in combination with 2 Gy. X-ray radiation therapy (XRT) to cultured
CGNPs (Fig. 4.S3F). Here, again, VE-822 seemed to reduce the levels of H2A.X
and cC3 induced by radiation. To verify these eﬀects in vivo in mice with
medulloblastoma, we exposedM-SmoM2 and SmoM2;AtrM-cre mice to a single dose
of 10 Gy. XRT at P12 and followed animals for event-free survival. No diﬀerence in
survival was noted between XRT-treated medulloblastoma mice with and without
Atr deletion (Fig. 4.S3G).
Discussion
Here, we have shown that ATR is required by medulloblastoma tumor cells to
prevent toxic accumulation of DNA damage. Increased DNA damage from ATR
inhibition by pVE-822 was associated with tumor regression in two mouse models of
primary, spontaneous medulloblastoma. Actual tumor regression is suggested by
gross observation that the primary tumor in P16 pVE-822-treated medulloblastoma
mice is even smaller in cross-sectional area than the tumor in P12 Vehicle-treated
medulloblastoma mice. We noted decreased proliferation in tumors treated with
pVE-822 but did not observe diﬀerences in the mitotic rate, p53 activation, or
caspase-mediated apoptosis. Absence of cell cycle eﬀects was confirmed by FACS
analysis, which did, however, detect aneuploidy in tumor cells, but regardless of drug
treatment status. ATR disruption was not found to increase survival times in mice
with medulloblastoma. We postulated that combining ATR disruption with other
treatments might produce an enhanced anti-tumor eﬀect, but our preliminary
studies in cultured CGNPs did not reveal any remarkable combinations, and, if
anything, suggested that ATR inhibition may be cytoprotective against various
agents (Table 4.S1). Indeed, in vivo testing of ATR disruption combined with XRT in
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a mouse genetic model of Atr-deleted medulloblastoma showed no survival benefit to
radiation in mice with Atr deletion versus Atr intact.
Despite the significant anti-tumor eﬀect of pVE-822 treatment in mice with
medulloblastoma, the question remains as to how ATR inhibition promotes tumor
regression. We have previously shown in Atr-deleted CGNPs from neonatal mice
that accumulation of proliferation-associated DNA damage primarily induces
p53-mediated, caspase-dependent apoptosis, but can also promote p53- and
caspase-independent cell death as well as p21-induced cell cycle arrest (Lang et al.,
2016). With earlier developmental deletion of Atr in neural stem cells, including the
cells that give rise to CGNPs, endogenous DNA damage led to reduced proliferation
rather than frank cell death in the nascent cerebellum (Lee et al., 2012). In
medulloblastoma mice treated with pVE-822, we observed DNA damage that was
associated with reduced proliferation rather than increased cell death, as seen in
Atr-deleted neural stem cells. This could suggest that our tumor cells behave more
like neural stem cells than CGNPs, but the tumors are themselves derived from
CGNPs and other studies have demonstrated the similarity between CGNPs and
CGNP-derived tumor cells (Gibson et al., 2010; Schuller et al., 2008; Yang et al.,
2008). Another possibility is that the anti-tumor eﬀect from ATR inhibition was not
due to decreased proliferation as measured by PCNA since PCNA is also recognized
as a marker of DNA damage (Balajee and Geard, 2001; Strzalka and Ziemienowicz,
2011; Essers et al., 2005; Gamper et al., 2012). Indeed, we saw no diﬀerences in
mitotic rate or p53 activation in pVE-822-treated medulloblastomas compared to
Vehicle-treated and concordantly, there were no apparent cell cycle alterations
associated with ATR inhibition in medulloblastoma cells. This possibility, however,
would make interpretation of tumor regression even more diﬃcult. In any case,
reduced proliferation, as measured by PCNA, could explain failed tumor expansion
but not actual tumor regression, as we observed.
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Although our FACS findings were congruent with our immunohistochemical data
on the absence of cell cycle alterations associated with pVE-822 treatment in
medulloblastoma cells, FACS did not detect the high level of DNA damage in tumors
seen by immunohistochemistry. This inconsistency could be explained by the
diﬀering treatment regimens and pVE-822 pharmacokinetics. For the
immunohistochemistry studies, tumors were analyzed from mice that had been
treated with 60 mg/kg pVE-822 delivered by IP injection once per day for five
consecutive days. For FACS, we treated tumor-bearing mice with a single 60 mg/kg
dose of pVE-822 and sacrificed 6 hr. later. Therefore, it is likely that pVE-822 takes
longer than 6 hr. to produce an eﬀect in medulloblastoma mice in vivo. Even with
our prior experiments using pVE-822 in neonatal WT mice, we treated animals with
three doses of drug spaced 12 hr. apart, which allowed for detection of increased
DNA damage and apoptosis in CGNPs (Lang et al., 2016). The FACS experiment will
be repeated in the future under diﬀerent treatment conditions. It is also likely that
pVE-822 treatment induces tumor cell apoptosis in vivo between 6 hr. and 12 hr.
after administration since cC3 has a short half-life and apoptotic cells are cleared
rapidly by phagocytosis, which could have thus impaired our detection by
immunostaining at five days post-initial treatment (Elliott and Ravichandran, 2010;
Walsh et al., 2011). Therefore, apoptosis could account for actual tumor regression
while reduced proliferation would explain failed tumor expansion. Moreover, we have
previously shown that CGNPs with disrupted ATR can experience non-apoptotic cell
death, so this form of cell death could also be operational in ATR-inhibited
medulloblastoma cells (Lang et al., 2016). TUNEL analysis of brain sections from
medulloblastoma mice treated with pVE-822 should resolve this possibility.
While it is possible that tumor regression from ATR inhibition could be due to
tumor cell apoptosis early in the course of the pVE-822 regimen, the lack of p53
activation and Caspase-3 cleavage 12 hr. after drug administration on the fifth and
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final consecutive day of treatment suggests that at least some cells developed
resistance to apoptosis. That is, levels of DNA damage from ATR inhibition were still
elevated at this time point, and proliferation as measured by PCNA was reduced, but
there may have been clonal selection for tumor cells that can evade DNA
damage-induced apoptosis – a well-recognized phenomenon in cancer (Schimmer,
2004; Srinivasula and Ashwell, 2008; Fulda and Vucic, 2012; Deveraux et al., 1999).
Clonal selection could potentially also explain our microarray results. In this case,
Cre-mediated Atr deletion in early development could have been associated with
incomplete recombination, as we have previously described with Cre expression
under the control of theMath1 promoter (Lang et al., 2016), and subsequent
selection for CGNPs with functional ATR that then transform into medulloblastoma
cells. Selection for cells with intact ATR following Atr mutation has also been
previously described by others looking at the testes and lungs of mice (Murga et al.,
2009). Thus, to better understand the transcriptional changes induced by ATR
disruption in medulloblastoma, we will perform studies in the future where we inject
pVE-822 into mice with established medulloblastoma and isolate tumor RNA
between 6 and 12 hr. after administration.
pVE-822 treatment had a clear anti-tumor eﬀect in two mouse models of
spontaneous medulloblastoma. Yet, there was no survival benefit to ATR inhibition
in these animals. In fact, G-SmoM2 mice treated with pVE-822 had the same
median survival as untreated or Vehicle-treated G-SmoM2 mice, which is also the
same median survival for mice with Atr deletion driven by the hGFAP promoter
(Gershon et al., 2013; Lang et al., 2016). This observation suggests the possibility
that failure of ATR inhibition to extend tumor mouse survival despite tumor
regression could be due to the systemic toxicity of pVE-822, especially given that the
drug was administered by IP injection. Atr-null mice are embryonic lethal, perishing
by E8.5 due to DNA damage and chromosomal abnormalities that lead to cell death
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(Brown and Baltimore, 2000). Hypomorphic mutation of Atr in mice is also
unsustainable for life, as animals perish by 35 weeks postnatally (median survival 20
weeks) due to multiple organ failure (Murga et al., 2009). In postnatal life, mice with
global deficiency of ATR that was induced embryonically appear progeric, with
osteoporosis, greying hair, kyphosis, and pancytopenia. When Atr was deleted in
adult mice, animals again displayed these signs of progeria as well as thymic
involution, alopecia, and organ fibrosis (Ruzankina et al., 2007). In mature
Drosophila, ATR is required to maintain intestinal stem cells (Park et al., 2015). As
such, systemic ATR inhibition by IP pVE-822 delivery may be overly toxic to show a
survival benefit in medulloblastoma despite tumor regression. Even with a short
course of five consecutive days of pVE-822 administration, we observed treatment-
associated side eﬀects in mice such as growth impairment, lethargy, and diarrhea
that were more severe in pVE-822-treated compared to Vehicle-treated animals.
Direct delivery of pVE-822 through intracranial injection may bypass some of these
negative systemic eﬀects and is an attractive therapy strategy given the lack of
obvious neurotoxicity from pVE-822, and given the recent research suggesting that
ATR inhibition may actually protect quiescent cells like post-mitotic neurons from
genomic stress (Kemp and Sancar, 2016).
This suggested cytoprotective eﬀect of ATR inhibition was observed in our
experiments combining various therapeutics with VE-822 in cultured CGNPs. The
only tested compounds that may have had an additive or synergistic eﬀect with
VE-822 were Vismodegib and Etoposide, and only in reducing proliferation, not in
increasing DNA damage or apoptosis. Curiously, Etoposide, SB-743921, and XRT
may have a combined cytoprotective eﬀect with VE-822 in CGNPs. On their own,
increasing concentrations of Etoposide, SB-743921, and VE-822 led to dose-
dependent increases in DNA damage and apoptosis with concomitant decreases in
proliferation in CGNPs from P5 WT mice (Lang et al., 2016). However, in the
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presence of VE-822, increasing concentrations of Etoposide failed to increase DNA
damage and apoptosis and increasing concentrations of SB-743921 actually led to
dose-dependent decreases in DNA damage and apoptosis. With XRT, 2 Gy. caused
substantial DNA damage and apoptosis in cultured CGNPs after 2 hr., but pre-
treatment with VE-822 led to attenuation of these eﬀects in a dose-dependent
manner. These results were unexpected given prior research showing that ATR
inhibition, and even VE-822 treatment specifically, sensitizes various proliferating
cells in vitro to the eﬀects of the same therapeutics that we tested here in CGNPs for
the first time (Hall et al., 2014; Fokas et al., 2012). Further research is needed to
elucidate possible mechanisms leading to these cytoprotective eﬀects arising from
combinatorial therapy in a highly proliferative, primary neuronal progenitor cell
population like CGNPs.
A final consideration is in using pVE-822 to treat TP53-mutated
medulloblastoma. Mutations in TP53 are most common in the SHH subgroup of
medulloblastoma and TP53-mutated medulloblastoma is particularly aggressive and
unresponsive to current treatments (Zhukova et al., 2013). Similarly, in mice with
SHH subgroup medulloblastoma, loss of p53 accelerates tumorigenesis (Wetmore
et al., 2001). Combined deletion of p53 and various DNA repair pathway genes has
been shown to induce medulloblastoma in animal models (Frappart et al., 2007,
2009; Holcomb et al., 2006; Lee and McKinnon, 2002). Interestingly, when we
conditionally co-deleted Atr and p53 in CGNPs, no mice developed tumors (Lang
et al., 2016). Rather, this combination led to extremely high levels of DNA damage,
severe chromosomal abnormalities, and ultimately caspase-independent cell death.
Importantly, widespread chromosome damage is also found in tumor cells from
patients with TP53-mutated, SHH subgroup medulloblastoma (Rausch et al., 2012).
Thus, for a cancer that is resistant to most current therapies, TP53-mutated
medulloblastoma may respond well to ATR inhibition since an anti-tumor eﬀect
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could still potentially be achieved through an as yet uncharacterized form of
caspase-independent cell death.
Materials and Methods
Mice
We generated G-SmoM2 andM-SmoM2 SHH subgroup medulloblastoma mice by
crossing hGFAP-Cre (Jackson Labs, Bar Harbor, ME; Stock 012886) (Zhuo et al.,
2001) andMath1-Cre (Jackson Labs, Stock 011104) (Matei et al., 2005) animals with
SmoM2loxP/loxP mice, in which tumorigenesis is induced by deletion of a
loxP-flanked Stop cassette between the mutant, constitutively active, Rosa26-driven
SmoM2 promoter and coding region (Jackson Labs, Stock 005130) (Schuller et al.,
2008). Medulloblastoma-prone mice with Atr deletion, SmoM2;AtrM-cre, were born
from the cross betweenMath1-Cre;AtrloxP/+ and SmoM2loxP/loxP;AtrloxP/loxP, as
previously described (Lang et al., 2016). Animals were determined to have tumors
based both on PCR genotyping and phenotypic observation for symptoms such as
ataxia, lethargy, growth impairment, reduced grooming, and/or posterior skull
deformity. All mice were of speciesMus musculus and crossed into the C57BL/6
background through at least five generations. We used equal numbers of male and
female mice, as we did not observe any diﬀerences based on sex. Numbers (n)
indicated in each figure (biologic replicates) were determined so as to measure a 25%
diﬀerence in means with Power = 80% and  = 0.05. Animal use was in keeping with
the policies of the University of North Carolina at Chapel Hill Institutional Animal
Use and Care Committee.
Genotyping
PCR primers for Cre recombinase were: Forward = 5’ - GCG GTC TGG CAG TAA
AAA CTA TC - 3’ and Reverse = 5’ - GTG AAA CAG CAT TGC TGT CAC TT - 3’.
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Each reaction contained 0.2 M of each primer, 4% DNA from toe lysates, and 42%
nuclease-free water in Apex Red Taq DNA polymerase master mix (Genesee
Scientific, San Diego, CA; 42-137). Cycling conditions were 95C for 3 min. followed
by 40 cycles of 1.5C/s. to 95C, 95C for 30 s., 1.5C/s. to 51.7C, 51.7C for 30 s.,
1.5C/s. to 72C, and 72C for 30 s. Primers to detect mutant SmoM2 were: Forward
= 5’ - AAG TTC ATC TGC ACC ACC G - 3’ and Reverse = 5’ - TCC TTG AAG AAG
ATG GTG CG - 3’. Each reaction contained 0.5 M of each primer and 4% DNA from
toe lysates in Platinum blue PCR SuperMix (ThermoFisher Scientific (TFS),
Waltham, MA; 12580015). Cycling conditions were 94C for 2 min., 1.5C/s. to 94C,
94C for 30 s., 1.5C/s. to 64C, 64C for 30 s., 1.5C/s. to 68C, 68C for 1 min.,
1.5C/s. to 94C, 94C for 30 s., 1.5C/s. to 63.5C, 63.5C for 30 s., 1.5C/s. to 68C,
68C for 1 min., 1.5C/s. to 94C, 94C for 30 s., 1.5C/s. to 63C, 63C for 30 s.,
1.5C/s. to 68C, 68C for 1 min., 1.5C/s. to 94C, 94C for 30 s., 1.5C/s. to 62.5C,
62.5C for 30 s., 1.5C/s. to 68C, 68C for 1 min., 1.5C/s. to 94C, 94C for 30 s.,
1.5C/s. to 62C, 62C for 30 s., 1.5C/s. to 68C, 68C for 1 min., 1.5C/s. to 94C,
94C for 30 s., 1.5C/s. to 61.5C, 61.5C for 30 s., 1.5C/s. to 68C, 68C for 1 min.,
and 1.5C/s. to 94C followed by 24 cycles of 94C for 30 s., 1.5C/s. to 60C, 60C for
30 s., 1.5C/s. to 68C, and 68C for 1 min. To detect AtrloxP/loxP, we used the
following primers: Forward = 5’ - TAC ATT TTA GTC ATA GTT GCA TAA CAC - 3’
and Reverse = 5’ - CTT CTA ATC TTC CTC CAG AAT TGT AAA AGG - 3’. Each
reaction contained 0.5 M of each primer, 4% DNA from toe lysates, and 42%
nuclease-free water in Apex Red Taq DNA polymerase master mix. Cycling
conditions were 94C for 4 min. followed by 34 cycles of 1.5C/s. to 94C, 94C for 1
min., 1.5C/s. to 62C, 62C for 2.5 min., 1.5C/s. to 72C, and 72C for 2.5 min. All
primers were obtained from Invitrogen (TFS, Waltham, MA) and all PCR-amplified
products were resolved on a 1.4% agarose gel run at 170V for 50 min.
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pVE-822 formulation and in vivo administration
pVE-822 was formulated as previously described (Lang et al., 2016). For
immunohistochemical studies, medulloblastoma-bearing mice were injected IP with
60 mg/kg pVE-822 or an equal volume of Vehicle once per day for five consecutive
days starting either at P8 or P12 and animals were sacrificed 12 hr. following the
fifth and final administration.
Immunostaining brain sections
Mouse brains were processed and immunostained as previously described (Lang
et al., 2016). Primary antibodies used are listed in the Supplemental Materials
and Methods. Alexa 647 secondary antibody for PCNA staining was used at 1:2000
(TFS Z25108). DAPI and hematoxylin were used for nuclear counterstains.
Quantification of immunostaining
Stained slides were digitally imaged and positively stained cells were counted
using Aperio Software (Aperio Technologies, Vista, CA) for chromogen-stained slides
or Tissue Studio (Definiens, Munchen, Germany) for fluorescence, as previously
described (Lang et al., 2016). The entire posterior fossa region in each section was
manually annotated and used for staining quantifications, which were normalized to
the total number of nucleated cells in the designated region. Tumor density was
defined as the total number of nuclei in the manually annotated posterior fossa
region, in units of number/mm2. The entire posterior fossa was used for
quantifications so as to avoid bias in determining which regions contained tumor. We
measured statistical significance using the two-sided independent samples t-test
assuming unequal variances in SPSS Statistics 23 (IBM, Armonk, NY).
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Microarray analysis
For microarray comparison of SmoM2;AtrM-cre versusM-SmoM2, total RNA was
purified using the RNeasy Mini Kit (Qiagen, Hilden, Germany; 74104) from the
tumors of four P18 animals of each genotype. RNA quality and quantity were
assessed by spectrophotometry and capillary gel electrophoresis. 500 ng of RNA from
each sample was run on an Aﬀymetrix GeneChip Mouse Transcriptome Assay 1.0
(Aﬀymetric, Santa Clara, CA). Diﬀerential gene expression was analyzed in Partek
Genomics Suite (Partek Inc., Chesterfield, MO) using RMA normalization and
significance thresholds of FDR < 0.01 and |Log2(FC)| > 1.5.
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Supplemental Materials and Methods
Tumor size quantification
The number of nuclei in the posterior fossa was counted in a manually-annotated
region on H&E-stained, sagittal brain sections from P16 mice of the indicated
genotypes. Similarly, the size of the posterior fossa was determined in a manually-
annotated region on H&E-stained, mid-sagittal brain sections from P16 mice of the
indicated genotypes. Quantification of cortical staining was performed in
manually-annotated regions of the anterior cerebral cortex. We measured statistical
significance using the two-sided independent samples t-test assuming unequal
variances in SPSS Statistics 23 (IBM, Armonk, NY).
Survival analysis
pVE-822- and Vehicle-treated G-SmoM2 andM-SmoM2 mice and XRT-treated
M-SmoM2 and SmoM2;AtrM-cre mice were followed for event-free survival. XRT was
given as a single dose of 10 Gy. to the cranium and spine at P12. Tumor-bearing
mice were identified by PCR and phenotypic observation for symptoms such as
ataxia, lethargy, growth impairment, reduced grooming, and/or posterior skull
deformity. Animals were sacrificed either at the censure age of 300 days-old or at
observation of severe weight loss, marked diﬃculty ambulating, onset of seizures,
and/or significantly diminished physical activity. We measured statistical
significance using the log-rank test in SPSS Statistics 23 (IBM, Armonk, NY).
Tumor cell isolation
Tumor cells were isolated as previously described (Lang et al., 2016) from the
posterior fossa of P16 G-SmoM2 andM-SmoM2 mice treated with 60 mg/kg pVE-822
or Vehicle for 6 hr. Briefly, we separated the tumor from the rest of the brain,
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removed the meninges, and dissocated the tissue in 20 units/mL of papain
(Worthington Biochemical Corporation, Lakewood, NJ; PDS) at 37C for 15 min.
Tumor cells were then purified from the dissociated tissue by successive rounds of
centrifugation, discontinuous density gradient, and mesh filtering.
Flow cytometry
Flow cytometry on isolated tumor cells was performed by fixing and
permeabilizing (TFS GAS-004) the cells suspended in HBSS with 6 g/L glucose, as
previously described (Lang et al., 2016). Tumor cells were then stained successively
for DNA damage with e660-conjugated H2A.X Ser139 (eBioscience, San Diego, CA;
50-9865) at 1:10, for M-phase with 488-conjugated pH3 (Cell Signaling Technology
(CST), Danvers, MA; 9708) at 1:25, and for DNA content with FxCycle Violet (TFS
F-10347) at 1:50. Technical controls included no stain, single-stained, and
fluorescence-minus-one samples. FACS was performed on a LSR Fortessa (BD
Biosciences, Franklin Lakes, NJ). For all experiments, 10k-50k cells were counted.
Analysis of FACS data was done using FlowJo V10.0.8 (FlowJo LLC, Ashland, OR).
Western blot analysis
For Western blot analysis, CGNPs were isolated from the cerebella of P5 WT mice
in the same manner as tumor cells, described above. Purified CGNPs were cultured
in plates coated with poly-L-lysine (Sigma-Aldrich, St. Louis, MO; P4707) and in
media containing 0.5 mg/mL SHH (R&D Biosystems, Minneapolis, MN; 464SH025).
Cells were treated with the indicated drugs, harvested after the indicated times, and
lysates were probed for H2A.X Ser139 at 1:50 (CST 9708, Batch 10), cC3 at 1:100
(Biocare Medical, Concord, CA; CP229C), CD2 at 1:300 (CST 3741, Batch 14), and
-actin at 1:5000 (CST 3700, Batch 3). HRP-conjugated secondary antibodies were
used at 1:2000. VE-822 (MedKoo Biosciences, Chapel Hill, NC; 406258) was
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dissolved in DMSO, Vismodegib (SelleckChem, Houston, TX; GDC0449) was
dissolved in DMSO, Cisplatin (SelleckChem S1166) was dissolved in DI water,
Gemcitabine HCl (SelleckChem S1149) was dissolved in DI water, SN-38
(SelleckChem S4908) was dissolved in DMSO, Etoposide (SelleckChem S1225) was
dissolved in DMSO, and SB-743921 (SelleckChem S2182) was dissolved in NMP.
Synergistic eﬀect of combination therapies was approximated as greater than
additive eﬀect of single agents.
Primary antibodies
Antigen Dilution Sourcea,b Batch
cC3 1:50 BM CP229C 060115
p-p53 Ser15 1:50 CST 9284 15
PCNA 1:2000 CST 2586 10
pH3 Ser10 1:100 CST 9706 9
H2A.X Ser139 1:2000 CST 9718 10
CD2 1:300 CST 3741 14
-actin 1:5000 CST 3700 3
aBM = Biocare Medical, Concord, CA, USA.
Antibody validated on brain sections from WT mice at P0, P3, P7, P12, and P20
(n = 10 for each) and WT mice exposed to 10 Gy XRT at P0, P3, P7, P12, and P20 (n =
10 for each).
aCST = Cell Signaling Technology, Danvers, MA, USA.
Antibody validation information:
http://www.cellsignal.com/common/content/content.jsp?id=ourApproach-validation-principles
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Inhibition of KIF11/EG5 in CGNPs results in transient mitotic arrest
without DNA damage or apoptosis
Introduction
Microcephaly and brain cancer represent opposite neurodevelopmental
phenotypes that can arise from shared dysregulation of the same processes. As a
result, insight from microcephaly may provide novel therapeutic strategies for brain
cancer. Primary autosomal recessive microcephaly has been described as essentially
a mitotic disorder (Faheem et al., 2015). Mitotically important proteins whose genes
are mutated in primary microcephaly include the centrosome assembler SAS6
(Spindle assembly abnormal protein 6 homolog) (Khan et al., 2014;
Rodrigues-Martins et al., 2007) and the spindle organizers ASPM (Abnormal spindle
microtubule assembly) (Bond et al., 2002; Kouprina et al., 2005; Roberts et al., 2002;
Zhong et al., 2005), WDR62 (WD repeat domain 62) (Bastaki et al., 2016; Bhat et al.,
2011; Kousar et al., 2011; Nicholas et al., 2010), and CDK6 (Cylin-dependent kinase
6) (Hussain et al., 2013), which is canonically recognized for G1-S cell cycle
progression (Sherr et al., 2016; Tigan et al., 2016). Disruption of mitosis has also
been linked to other microcephalic disorders. Seckel syndrome is characterized by
intrauterine growth restriction, postnatal growth impairment, characteristic
cranio-facial deformities, and microcephaly (Goodship et al., 2000; O’Driscoll et al.,
2003). This disorder can be caused by mutation of ATR (Ataxia-telangiectasia and
Rad3-related), which codes for a DNA damage response protein that has also been
shown to regulate mitotic entry in proliferative cells (Lang et al., 2016; Brown and
Baltimore, 2003). CENPE (Centromere protein E) is a microtubule-associated motor
protein that aligns chromosomes in prometaphase (Cai et al., 2009; Kim et al., 2008),
and mutation of its coding gene has been identified in two siblings with microcephalic
primordial dwarfism (Mirzaa et al., 2014). On the other hand, mutations in NIPBL
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(Nipped-B-like protein) are the most common cause of Cornelia de Lange syndrome –
a complex congenital disorder that presents with hearing impairment, visual defects,
cardiac abnormalities, growth failure, seizures, and microcephaly (Ireland et al.,
1993; Jackson et al., 1993; Krantz et al., 2004; Tonkin et al., 2004). The NIPBL
protein is a cohesin that binds sister chromatids together after replication, and its
disruption results in mitotic arrest (Peters et al., 2008; Watrin et al., 2006). Finally,
KIF11 (Kinesin family member 11) mutation has been found in one family with
primary, autosomal dominant microcephaly (Ostergaard et al., 2012). This gene
codes for the protein EG5, which, like CENPE, is a microtubule-associated motor
protein (Sawin et al., 1992; Sawin and Mitchison, 1995). EG5 activity is limited to
mitosis and it acts in prophase and prometaphase to establish a bipolar mitotic
spindle that is required to pull apart sister chromatids (Kashina et al., 1997, 1996).
Importantly, while expression of these genes may be decreased in microcephalic
disorders, their expression is increased or otherwise vital in brain cancers.
Upregulation of ASPM and CDK6 has been reported in both glioblastoma (Bikeye
et al., 2010; Costello et al., 1997; Hagemann et al., 2008; Horvath et al., 2006; Lam
et al., 2000), the most common malignant brain tumor in adults, and
medulloblastoma (Mendrzyk et al., 2005; Vulcani-Freitas et al., 2011), the most
common malignant brain tumor in children. While ATR expression may not be
increased in medulloblastoma, we have recently shown that its protein product is
essential for medulloblastoma tumorigenesis (Lang et al., 2016). Overexpression of
KIF11 has been seen in glioblastoma, and inhibition of EG5 led to mitotic arrest and
reduced proliferation of glioblastoma cells in vitro and in a mouse xenograft model
(Venere et al., 2015). These observations suggest that mitotic disruption may be
particularly toxic to brain tumor cells in the same manner of toxicity experienced by
neural stem and progenitor cells in the genesis of microcephaly. Indeed,
medulloblastoma is highly sensitive to the eﬀects of mitotic disruption and
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Vincristine, which irreversibly binds microtubules to prevent mitotic spindle
formation, is used in three common medulloblastoma treatment regimens:
eight-in-one (Gentet et al., 1995), VCP/CCG (Mulhern et al., 1998), and POG (Packer
et al., 2006). However, Vincristine, and vinca alkaloids and taxanes in general, also
disrupt non-mitotic microtubules, which regulate diverse cellular processes such as
axonal transport, and therefore their use is associated with dose-limiting
neurotoxicity (Conde and Caceres, 2009; Grisold et al., 2012; Marcus et al., 2005). As
such, targeting a molecule like KIF11/EG5, whose downregulation produces
microcephaly through reduced neural stem/progenitor cell proliferation and whose
activity is limited to mitosis, may produce a strong anti-tumor eﬀect in
medulloblastoma with reduced side eﬀects.
Medulloblastoma is a tumor of the cerebellum that can arise from mutations in
cerebellar granule neuron progenitors (CGNPs) (Schuller et al., 2008; Yang et al.,
2008). Molecular and genomic analyses have shown that medulloblastoma tumor
cells with mutations in the Sonic hedgehog (SHH) signaling pathway are similar in
many aspects to CGNPs (Gibson et al., 2010; Gilbertson and Ellison, 2008; Taylor
et al., 2012; Wechsler-Reya and Scott, 2001). Indeed, mutation in CGNPs of a single
gene in the SHH pathway that increases pathway activity can produce
medulloblastoma in mice (Schuller et al., 2008; Yang et al., 2008). Here, we have
tested the eﬀect of EG5 inhibition on CGNPs using the specific small molecule
inhibitor SB-743921 in neonatal mice. CGNP proliferation in mice occurs in the
external granular layer (EGL) of the developing cerebellum and is maximal between
postnatal day (P) 3 and P7 (Wechsler-Reya and Scott, 1999, 2001; Hatten and Heintz,
1995). We found that in SB-743921-treated P5 mice, EG5 inhibition dramatically
increased the number of CGNPs in mitosis between 2 hr. and 12 hr. following
treatment. Mitotically arrested CGNPs were seen to be specifically in prometaphase
and prolonged delay in mitosis was associated with increased phosphorylation of the
213
translational repressor 4EBP1 (EIF4EBP1) (Gingras et al., 1999). To our surprise,
mitotic arrest was not associated with increased DNA damage or apoptosis, and
arrested CGNPs appeared to re-enter the cell cycle 24 hr. after SB-743921
administration. These results suggest that SB-743921 may not have a strong
anti-tumor eﬀect as single- agent therapy in CGNP-derived medulloblastoma, at
least at the concentrations that we tested.
Results
To investigate the eﬀect of KIF11/EG5 inhibition on CGNPs, we treated P5
wild-type (WT) mice with 7.5 mg/kg SB-743921 by IP injection and then sacrificed
animals 2 hr., 4 hr., 6 hr., 8 hr., 12 hr., or 24 hr. later. Immunohistochemical analysis
of brain sections stained for the mitotic marker phospho-Histone H3 (pH3)
demonstrated that SB-743921 induced mitotic arrest of CGNPs in a time-dependent
manner, with an apparent eﬀect by as early as 2 hr. post-treatment and a maximal
eﬀect 12 hr. post-treatment (Fig. 4.2A). By 24 hr. after treatment with SB-743921,
pH3 staining appeared almost back to baseline levels, and the EGL did not seem to
be diminished. The eﬀects of mitotic arrest were not limited to the cerebellum, as
increases pH3+ cells were also seen in the hippocampus and the subventricular zone
(SVZ). On quantification, we found that the proportion of CGNPs in the EGL
significantly increased with each successive length of time after treatment with
SB-743921, from 2 hr. to 12 hr. (Fig. 4.2B). Between 12 hr. and 24 hr. post-
treatment, the fraction of pH3+ CGNPs in the EGL decreased dramatically, but at 24
hr., the proportion of pH3+ was still significantly greater than with no treatment and
was equivalent to the proportion at 2 hr. Interestingly, mitotic arrest was not
accompanied by induction of DNA damage, as seen by phospho-Histone H2A.X
(H2A.X) (Fig. 4.S4A) or apoptosis, as seen by cleaved Caspase-3 (cC3) (Fig. 4.S4B).
Dual-staining for pH3 and Survivin allows for distinguishing between the
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diﬀerent stages of mitosis, as we have previously demonstrated in CGNPs (Williams
et al., 2015). Using this technique, we saw that CGNPs in the EGL of SB-743921-
treated mice arrested predominantly in prometaphase, beginning at 2 hr. post-
injection and maximally at 12 hr. (Fig. 4.2C). Arrest in prometaphase due to EG5
disruption, and specifically by SB-743921, has been previously described (Blangy
et al., 1995; Chen et al., 2014). One study has reported that transient arrest at
prometaphase increases inhibitory phosphorylation of the translational repressor
4EBP1 through metaphase (Velasquez et al., 2016). By double-labeling for pH3 and
phospho-4EBP1 (p4EBP1), we saw that prolonged mitotic arrest from EG5 inhibition
was associated with increased levels of p4EBP1 (Fig. 4.2D). Mitotic CGNPs had low
levels of p4EBP1 at 2 hr. following SB-743921 treatment that increased dramatically
through 12 hr. post-treatment and then declined again by 24 hr. p4EBP1 was
detected almost exclusively in pH3+ CGNPs.
Discussion
We report here that EG5 inhibition by SB-743921 in neonatal mice induces
widespread, transient mitotic arrest in CGNPs in the EGL of the cerebellum. A
single dose of SB-743921 at 7.5 mg/kg delayed cells for up to 12 hr. in prometaphase,
but by 24 hr., it appeared that arrested CGNPs had escaped the mitotic block
without consequence. That is, we did not detect any changes in CGNP DNA damage
or apoptosis over a 24 hr. time course of in vivo EG5 inhibition. However, we did see
increasing levels of p4EBP1 as CGNPs were delayed in M-phase, and these levels
declined again once cells began to progress through the cell cycle (Table 4.S2).
Cell cycle arrest is a physiological response to endogenous or exogenous sources of
stress that acts to prevent DNA damage that may result from attempted duplication
and redistribution of the genetic material, which could otherwise lead to neoplastic
transformation or cell death (Elledge, 1996; Levine, 1997; Pietenpol and Stewart,
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2002; Sancar et al., 2004). Even in a normal, unperturbed cell, delayed progression
through the cell cycle can occur due to natural phenomenon such as oxidation-
induced DNA damage (Willis et al., 2013), transcription - replication collision
(Deshpande and Newlon, 1996; Ivessa et al., 2003; Takeuchi et al., 2003), or absence
of growth factors (Braun-Dullaeus et al., 1998; Fingar and Blenis, 2004; Gross and
Rotwein, 2016; McCubrey et al., 2007). Once the source of stress has been resolved,
the cell cycle block can be lifted and cells are able to progress through the cycle
normally (Agarwal et al., 1995, 1998; Cortez et al., 2004; Murray, 1992; Yoo et al.,
2004). However, prolonged cell cycle arrest is often indicative of a serious underlying
problem and triggers permanent cell cycle exit or apoptosis (Borel et al., 2002; Orth
et al., 2012; Colin et al., 2015; Di Leonardo et al., 1994; Leontieva et al., 2010). How
a cell determines whether cell cycle arrest should lead to cell cycle re-entry, cell cycle
exit, or cell death is still being investigated. One possibility is that duration of arrest
may dictate outcome (Charp et al., 1983; Hoﬀman et al., 1991; Lalande, 1990; Kaur
et al., 1992; Linke et al., 1996; DiGregorio et al., 2001). Here, we have shown that the
dose of SB-743921 that we administered to neonatal mice induced mitotic arrest for
up to 24 hr. and that this length of mitotic arrest did not cause rapidly-proliferating
CGNPs to experience increased DNA damage or apoptosis.
CGNPs were specifically arrested in prometaphase by SB-743921. In this stage of
mitosis, the nuclear envelope breaks down and microtubules attach to chromosomes
in order to later arrange and separate them (Magidson et al., 2011). EG5 directs
microtubule activity in prophase and prometaphase to push apart duplicated
centrosomes and establish a bipolar mitotic spindle that can organize chromosomes
(Sawin et al., 1992; Kashina et al., 1997, 1996; Blangy et al., 1995). As such, EG5
inhibition by SB-743921 disrupts normal prophase and prometaphase mechanics,
which could lead to activation of the spindle assembly checkpoint that induces
mitotic arrest (Musacchio and Salmon, 2007; Peters, 2006; Cleveland et al., 2003).
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Indeed, other microtubule poisons like Vincristine (O’Connor et al., 2002; Steen
et al., 2008), Paclitaxel (Ikui et al., 2005; Snyder and Mullins, 1993; Uetake and
Sluder, 2010), Nocodazole (Uetake and Sluder, 2010; Velasquez et al., 2016; Han
et al., 2014), and Monastrol (Steen et al., 2008; Kapoor et al., 2000) have been
reported to increase the proportion of cells arrested in prometaphase. However, the
spindle assembly checkpoint is thought to prevent entry into anaphase, thus
blocking cells at metaphase, so how microtubule poisons promote prometaphase
arrest is a bit unclear, but could possibly relate to blurred distinctions between
prometaphase and metaphase.
At the concentration of SB-743921 that we tested (single dose of 7.5 mg/kg by IP
injection), mitotic arrest was transient. This observation is likely due to reversible
binding of SB-743921 to EG5, which has been shown with its related compound
SB-715992 (Ispinesib) (Lad et al., 2008). Thus, over time, SB-743921 dissociates
from EG5 and is cleared from cells, allowing EG5 to resume normal activity and
thereby clearing the block to mitotic progression. Nevertheless, during this period of
SB-743921-induced mitotic arrest in prometaphase, we observed an increase in
levels of p4EBP1 specifically in arrested CGNPs. 4EBP1 is a translational repressor
that sequesters the EIF4 translation initiation factors, which are required to bring
mRNA to the small ribosomal subunit (Gingras et al., 1998; Rousseau et al., 1996).
Phosphorylation of 4EBP1 is inhibitory and increases the rate of protein translation
(von Manteuﬀel et al., 1996; Beretta et al., 1996). Therefore, increased p4EBP1 in
M-phase-arrested CGNPs may be indicative of hyperactivation of translation. On the
one hand, increased translation could be a mechanism to enforce mitotic arrest. One
study found that Cyclin A levels peak in prometaphase and that Cyclin A
degradation was required for mitotic progression (den Elzen and Pines, 2001).
Increasing Cyclin A induced mitotic arrest that was independent of the spindle
assembly checkpoint, although the nature of this separate mitotic checkpoint has yet
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to be elucidated. Thus, EG5 inhibition may allow a cell to sense disrupted prophase/
prometaphase dynamics and increase 4EBP1 phosphorylation to promote translation
of Cyclin A for prometaphase arrest. On the other hand, prolonged arrest in mitosis
could exert a diﬀerential energy strain on cells. One report has demonstrated that
mitotically arrested cells lose mitochondria, activating AMPK (Adenosine
monophosphate-activated protein kinase) and increasing glycolysis over oxidative
respiration (Domenech et al., 2015). Increased AMPK production was attributed to
increased translation of the protein. Therefore, our observed increases in p4EBP1,
which were specific to cells in mitosis, could be due to greater cellular requirements
for glycolytic proteins such as AMPK. In either case, increasing translation is an
important mechanism for responding to changing cellular demands in mitosis since
transcription is suppressed during mitotic arrest (Taylor, 1960; Prescott and Bender,
1962; Prescott, 1964; Segil et al., 1996; Martinez-Balbas et al., 1995; Long et al.,
1998; Gottesfeld and Forbes, 1997).
Arrest of CGNPs in prometaphase for 12 hr. - 24 hr. by SB-743921 did not induce
DNA damage or apoptosis. The lack of cytotoxicity raises the question of the
therapeutic value of SB-743921 for CGNP-derived medulloblastoma. In cultured
leukemia cells, SB-743921, even at low concentrations, was found to cause mitotic
arrest that led to apoptosis (Yin et al., 2015). Recent research on the SB-743921-
related EG5 inhibitor Ispinesib has also been promising. Ispinesib reduced
proliferation and increased cell death in HeLa cells, although DNA damage was not
apparently increased and the cell death was described as p53-independent (Ohashi
et al., 2015). In human breast cancer cell lines and mouse xenograft models,
Ispinesib enhanced mitotic arrest that led to increased apoptosis (Purcell et al.,
2010). For the in vivo studies, Ispinesib given at 5, 7.5, 8, or 10 mg/kg every four days
for three total doses all reduced tumor growth, and with the 10 mg/kg treatment was
found to increase caspase-dependent apoptosis. Similarly, in glioblastoma cell lines
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and mouse xenograft models, Ispinesib, at 10 mg/kg for the in vivo studies, had a
significant anti-tumor eﬀect through mitotic arrest and induction of apoptosis
(Venere et al., 2015). Unfortunately, clinical trials with EG5 inhibitors like Ispinesib
have shown more attenuated eﬃcacy (Huszar et al., 2009; Khoury et al., 2012; Lee
et al., 2008). Although neurotoxicity has generally been absent with trials of EG5
inhibitors, in contrast to use of non-specific microtubule inhibitors like vinca
alkaloids and taxanes, the anti-tumor eﬀect of several inhibitors tried as
monotherapy in various cancers has been limited, which may be related to the short
half-life of these EG5 inhibitors. In addition, there have been no clinical trials for
EG5 inhibitors in primary brain tumors, few studies have explored the eﬃcacy of
EG5 inhibition for treating brain tumors in animal models, and thus the ability of
EG5 inhibitors like SB-743921 and Ispinesib to reach brain tumors in suﬃcient
concentrations and remain active long enough to induce cell death is uncertain. In
neonatal mice, a single IP injection of 7.5 mg/kg SB-743921 was insuﬃcient to cause
DNA damage or apoptosis in CGNPs of the proliferative cerebellum. Increased drug
concentration and/or more frequent drug dosing may lead to CGNP cytotoxicity, and
CGNP-derived medulloblastoma may be more sensitive to EG5 inhibition than
CGNPs. We will explore these possibilities in our future research.
Materials and Methods
Mice
WT C57BL/6J mice were used for all experiments (Jackson Labs, Bar Harbor,
ME; Stock 000664). All mice were of speciesMus musculus. We used equal numbers
of male and female mice, as we did not observe any diﬀerences based on sex.
Numbers (n) indicated in each figure (biologic replicates) were determined so as to
measure a 25% diﬀerence in means with Power = 80% and  = 0.05. Animal use was
in keeping with the policies of the University of North Carolina at Chapel Hill
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Institutional Animal Use and Care Committee.
SB-743921 formulation and in vivo administration
SB-743921 (SelleckChem, Houston, TX; S2182) was dissolved in NMP and diluted
in PEG-200. All animals were treated with a single dose of 7.5 mg/kg SB-743921 by
IP injection and then sacrificed after the indicated lengths of time.
Immunostaining of brain sections
Mouse brains were processed and immunostained as previously described (Lang
et al., 2016). Primary antibodies used are listed in the Primary antibodies table at
the end. Alexa 555 secondary antibody for pH3 staining was used at 1:2000
(ThermoFisher Scientific (TFS), Waltham, MA; Z25005), Cy5 secondary antibody for
Survivin staining was used at 1:2000 (TFS A10523), and Cy5 secondary antibody for
p4EBP1 staining was used at 1:2000 (TFS A10523). DAPI and hematoxylin were
used for nuclear counterstains.
Quantification of immunostaining
Stained slides were digitally imaged and positively stained cells were counted
using Aperio Software (Aperio Technologies, Vista, CA) for chromogen-stained slides
or Tissue Studio (Definiens, Munchen, Germany) for fluorescence, as previously
described (Lang et al., 2016). The entire EGL region in each section was manually
annotated and used for staining quantifications, which were normalized to the total
number of nucleated cells in the designated region. We measured statistical
significance using the two-sided independent samples t-test assuming unequal
variances in SPSS Statistics 23 (IBM, Armonk, NY).
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Primary antibodies
Antigen Dilution Sourcea,b Batch
cC3 1:50 BM CP229C 060115
pH3 Ser10 1:100 CST 9706 9
H2A.X Ser139 1:2000 CST 9718 10
Survivin 1:10000 CST 2808 2
p4EBP1 Thr37/46 1:500 CST 2855 3
aBM = Biocare Medical, Concord, CA, USA.
Antibody validated on brain sections from WT mice at P0, P3, P7, P12, and P20
(n = 10 for each) and WT mice exposed to 10 Gy XRT at P0, P3, P7, P12, and P20 (n =
10 for each).
aCST = Cell Signaling Technology, Danvers, MA, USA.
Antibody validation information:
http://www.cellsignal.com/common/content/content.jsp?id=ourApproach-validation-principles
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FIGURES
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Figure 4.1: ATR inhibition by pVE-822 induces medulloblastoma tumor
shrinkage. (A) Representative, H&E-stained, sagittal brain sections from mice of
the indicated genotypes and ages treated with 60 mg/kg pVE-822 or Vehicle QDx5.
(B) Quantification of posterior fossa density in P16 mice of the indicated genotypes
treated with 60 mg/kg pVE-822 or Vehicle QDx5. (C-D) P16 brains in sagittal section
from mice of the indicated genotypes, treated with 60mg/kg pVE-822 or Vehicle
QDx5, stained for PCNA and DAPI (C) or H2A.X (D). (E) Quantification of staining
as in C, D, and Fig. 4.S1. Average is shown with s.e.m. P-values by two-sided
independent samples t-test assuming unequal variances. All stainings were repeated
on at least three biological replicates (n). Scale bars: 2 mm in A; 2 mm in C; 2 mm in
D.
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Figure 4.2: SB-743921 induces transient cell cycle arrest in prometaphase in
CGNPs. (A) Sagittal brain (left) and cerebellar (right) sections, stained for pH3,
from P5 WT mice injected with SB-743921 and sacrificed after the indicated lengths
of time. Non-injected animals used as staining controls. (B) Quantification of pH3
staining as in A. Average shown with s.e.m. and trend line. P-values by two-sided
independent samples t-test assuming unequal variances. All pH3 stainings were
repeated on at least three biological replicates (n).
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(C) The EGL in cross-section from P5 WT mice treated with SB-743921 and
sacrificed after the indicated lengths of time, stained for pH3 (green), Survivin (red),
and DAPI (blue). White arrowheads indicate cells in prometaphase, red arrowheads
indicate cells in metaphase, and yellow arrowheads indicate cells in anaphase. (D)
The EGL in cross-section from P5 WT mice treated with SB-743921 and sacrificed
after the indicated lengths of time, stained for pH3 (green), p4EBP1 (red), and DAPI
(blue). White arrowheads indicate cells positive for all three stains and yellow
arrowheads indicate cells positive only for pH3 and DAPI. Scale bars: 2 mm in A
(left); 0.5 mm in A (right, inset); 50 m in C; 50 m in D.
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Supplemental Figure 4.1: ATR inhibition by pVE-822 produces no survival
benefit in mice with medulloblastoma. (A) Quantification of the number of
nuclei in the posterior fossa in P16 mice of the indicated genotypes treated with 60
mg/kg pVE-822 or Vehicle QDx5.
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(B) Quantification of the posterior fossa size in P16 mice of the indicated genotypes
treated with 60 mg/kg pVE-822 or Vehicle QDx5. (C-E) P16 brains in sagittal section
from mice of the indicated genotypes, treated with 60mg/kg pVE-822 or Vehicle
QDx5, stained for pH3 (C), p-p53 (D), or cC3 (E). (F) Quantification of the percentage
of cortical cells staining positive for PCNA, pH3, H2A.X, p-p53, or cC3 in P16 mice
of the indicated genotypes treated with 60 mg/kg pVE-822 or Vehicle QDx5. (G-H)
Kaplan-Meier survival curves of G-SmoM2 (F) orM-SmoM2 (G) mice treated once
daily, five times per week, with 60 mg/kg pVE-822 or Vehicle starting at P12.
Average is shown with s.e.m. P-values in A, B, and F by two-sided independent
samples t-test assuming unequal variances. P-values in G and H by log-rank test.
All stainings were repeated on at least three biological replicates (n). Scale bars: 2
mm in C; 2 mm in D; 2 mm in E.
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Supplemental Figure 4.2: pVE-822 treatment does not alter tumor cell cycle
dynamics in mice with medulloblastoma. (A) FACS analysis without subsetting
for H2A.X on tumor cells from P16 medulloblastoma mice of the indicated
genotypes treated with 60 mg/kg pVE-822 or Vehicle for 6 hr. M-phase was
determined by pH3 labeling.
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(B) FACS analysis with subsetting for H2A.X+ tumor cells from P16
medulloblastoma mice of the indicated genotypes treated with 60 mg/kg pVE-822 or
Vehicle for 6 hr. M-phase was determined by pH3 labeling. (C) Quantification of
H2A.X+/pH3+ tumor cells from P16 medulloblastoma mice of the indicated
genotypes treated with 60 mg/kg pVE-822 or Vehicle for 6 hr. (D) Live tumor cells
from the posterior fossa of P16 G-SmoM2 mice treated with 60 mg/kg pVE-822 or
Vehicle for 6 hr. can be found in all phases of the cell cycle by staining for DNA
content with FxCycle Violet. H2A.X+ cells are found in low abundance in both drug-
and vehicle-treated tumors. Equivalent proportions of H2A.X+ tumor cells in G2/M
from pVE-822-treated G-SmoM2 brains are pH3+ compared to H2A.X+ tumor cells
in G2/M from Vehicle-treated G-SmoM2 brains. (E) Quantification of >4N DNA
content detected by FACS in H2A.X+ tumor cells from P16 medulloblastoma mice of
the indicated genotypes treated with 60 mg/kg pVE-822 or Vehicle for 6 hr.
Individual data points are plotted. n = sample size.
230
231
Supplemental Figure 4.3: VE-822 combined with Vismodegib or Etoposide
enhances reduction of CGNP proliferation. (A) CGNPs isolated from P5 WT
mice treated in vitro with Vismodegib alone or in combination with VE-822 at the
indicated concentrations for 24 hr. and then collected for Western blot analysis of
CD2, cC3, and H2A.X, with -actin loading control. (B) CGNPs isolated from P5
WT mice treated in vitro with Cisplatin alone or in combination with VE-822 at the
indicated concentrations for 24 hr. and then collected for Western blot analysis of
CD2, cC3, and H2A.X, with -actin loading control. (C) CGNPs isolated from P5 WT
mice treated in vitro with VE-822, Gemcitabine, or SN-38 alone or in combination
with VE-822 at the indicated concentrations for 24 hr. and then collected for Western
blot analysis of CD2, cC3, and H2A.X, with -actin loading control. (D) CGNPs
isolated from P5 WT mice treated in vitro with Etoposide alone or in combination
with VE-822 at the indicated concentrations for 6 hr. and then collected for Western
blot analysis of CD2, cC3, and H2A.X, with -actin loading control. (E) CGNPs
isolated from P5 WT mice treated in vitro with SB-743921 alone or in combination
with VE-822 at the indicated concentrations for 6 hr. (top) or 12 hr. (bottom) and
then collected for Western blot analysis of CD2, cC3, and H2A.X, with -actin
loading control. (F) CGNPs isolated from P5 WT mice treated in vitro with VE-822
for 2 hr. at the indicated concentrations and then continued with VE-822 alone or
exposed to 2 Gy. XRT and then collected after another 2 hr. for Western blot analysis
of CD2, cC3, and H2A.X, with -actin loading control. (G) Kaplan-Meier survival
curve ofM-SmoM2 and SmoM2;AtrM-cre mice given one dose of 10 Gy. cranio-spinal
XRT at P12. P-values by log-rank test. Vis = Vismodegib, Cis = Cisplatin, VE =
VE-822, Gem = Gemcitabine, SN = SN-38, Eto = Etoposide, SB = SB-743921.
232
Supplemental Figure 4.4: SB-743921 does not induce DNA damage or
apoptosis in CGNPs. (A) Sagittal brain (left) and cerebellar (right) sections,
stained for H2A.X, from P5 WT mice injected with SB-743921 and sacrificed after
the indicated lengths of time. Non-injected animals used as staining controls. (B)
Sagittal brain (left) and cerebellar (right) sections, stained for cC3, from P5 WT mice
injected with SB-743921 and sacrificed after the indicated lengths of time.
Non-injected animals used as staining controls. All stainings were repeated on at
least three biological replicates. Scale bars: 2 mm in A (left); 0.5 mm in A (right,
inset); 2 mm in B (left); 0.5 mm in B (right, inset)
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CHAPTER 5: DISCUSSION
The role of ATR in the developing cerebellum
Chapter 1 of this dissertation provided an overview of the function of ATR
(Ataxia telangiectasia and Rad3-related) in normal physiology and in the pathology
of Seckel syndrome. On the other hand, Chapter 3 specifically investigated the role
of ATR in cerebellar granule neuron progenitors (CGNPs) and delineated the
consequences of ATR disruption in the developing cerebellum. Yet, the question
remains as to why ATR is disproportionately important in the cerebellum compared
to other brain structures. Two non-mutually exclusive possibilities will be briefly
explored here. One possibility is that the proliferative nature of the cerebellum, both
in terms of how long the cerebellum remains proliferative over developmental time
and how much proliferation actually occurs during that window, creates a unique
dependence on ATR, which mitigates replicative stress and prevents proliferation-
associated DNA damage. The other possibility is that ATR has a diﬀerent function or
set of functions in CGNPs compared to other brain cells, which is plausible given the
numerous posited and described functions of ATR, some of which diﬀer by cell type
and by situation. Indeed, a combination of these two possibilities may ultimately
explain cerebellar reliance on ATR.
The proliferative nature of CGNPs could explain cerebellar dependence on
ATR
In one study, early embryonic conditional deletion of Atr in the mouse central
nervous system (CNS) using the neural stem cell-expressed driver Nestin (AtrN-cre),
which is expressed starting around embryonic day (E) E9.5 and induces Cre-
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mediated deletion by E10.5, led to disruptions only in the ganglionic eminence and
rhombic lip/nascent cerebellum (Lee et al., 2012). ATR loss from the ganglionic
eminence resulted in high levels of DNA damage and apoptosis by E15.5, whereas
ATR loss from the rhombic lip/nascent cerebellum caused low levels of DNA damage
and apoptosis at E15.5 but significant reduction in proliferation by E17.5. These
defects combined to generate postnatal microcephaly and cerebellar hypoplasia and
the eﬀects were thought to be p53-independent. In AtrN-cre mice, neither DNA
damage nor apoptosis were detected at significant levels in other parts of the brain
through E17.5, including highly proliferative regions such as the cerebellar
ventricular zone (CVZ), the hippocampus, and the cortical subventricular zone (SVZ).
Even earlier conditional deletion of Atr from cortical progenitors using Emx1 (Empty
spiracles homeobox 1) (AtrE-cre), which is expressed around E8.5 and leads to
Cre-mediated deletion by E9.5 (Gorski et al., 2002; Chou et al., 2009), induced
decreased proliferation and increased DNA damage and apoptosis in the neocortex
that produced a diminished hippocampus and cortex later in development (Lee et al.,
2012).
The authors of the studies using AtrN-cre and AtrE-cre mice suggested that the
selective eﬀect of Atr deletion on specific cell populations in the developing brain
could be attributed to a critical role for ATR in proliferation. Part of this assertion
stems from the observation that significant cortical defects are absent from AtrN-cre
mice but exacerbated in AtrE-cre mice in which Atr is deleted slightly earlier in
development (E9.5 versus E10.5), at what the authors propose might be a period of
more rapid cortical proliferation. However, the peak period of proliferation for most
neural stem and progenitor populations occurs after E10.5 in mice (Mody et al.,
2001; Finlay and Darlington, 1995; Dehay and Kennedy, 2007; Huang et al., 2010).
Moreover, the authors remarked upon the surprising finding that not all rapidly-
proliferating areas of the embryonic brain were aﬀected by Atr deletion. Indeed, our
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own research has supported the observation that Atr deletion does not aﬀect all
areas of the brain. Conditional deletion of Atr in mice using the hGFAP (human
Glial fibrillary acidic protein) promoter (AtrG-cre ), which is expressed by neural stem
cells around E11.5 (Andrae et al., 2001), caused widespread DNA damage and
apoptosis almost exclusively in CGNPs at postnatal day (P) P0, with relative sparing
of other proliferative regions such as the SVZ and the hippocampus (Lang et al.,
2016). Similar results were seen upon administration of the ATR inhibitor pVE-822
(nano-formulated VE-822) to P5 WT mice. Thus, ATR is clearly critically important
in some proliferative structures but less vital in others.
In a separate study released concurrently with the AtrN-cre and AtrE-cre
experiments (Lee et al., 2012), the authors found that E17.5 AtrN-cre mice had
reduced proliferation and increased cell death in the SVZ, the cortical ventricular
zone (VZ), and the rhombic lip/nascent cerebellum (Zhou et al., 2012). Specifically, in
the E17.5 cerebellum, cell death was limited to TUJ1+ (Neuron-specific class III
-tubulin) non-progenitor cells. In addition, cultured primary mouse neurons
experienced cell death without external stimulus following induced Atr deletion.
These post-mitotic neurons were H2A.X- but enriched for RPA (Replication protein
A), which the authors interpreted as evidence of DNA single-strand breaks (SSBs)
but not DNA double-strand breaks (DSBs). Without external stimulus, neuronal cell
death from ATR loss did not involve p53 activation, although upon irradiation, p53
was activated in ATR-depleted neurons. It is unclear why disparate results were
obtained by diﬀerent authors both investigating the eﬀect of Atr deletion on E17.5
mouse brains using AtrN-cre mice. That is, why was cell death in the SVZ seen to be
elevated in one study but not the other? On the other hand, the findings in the
cerebellum may be parallel, since both studies found decreased proliferation in the
stem/progenitor region of the nascent cerebellum and minimal cell death in that
area. Both results are in contrast to our own findings, however, of increased
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cerebellar progenitor cell death and relatively unaﬀected proliferation with deletion
of Atr later in development (Lang et al., 2016). The observation of increased cell
death in post-mitotic neurons following Atr deletion was also interesting and again
in contrast to our own findings with Atr deletion and inhibition. Indeed, a recent
study using non-cycling keratinocyte-derived HaCaT cells has suggested that ATR
inhibition has a cytoprotective eﬀect in post-mitotic cells (Kemp and Sancar, 2016).
The authors who described neuronal cell death from Atr deletion speculated that the
loss of viability in diﬀerentiated neurons could have been due to accumulation of
DNA damage associated with ATR loss in progenitor cells prior to neuronal
diﬀerentiation, which has previously been suggested (Ruzankina et al., 2007).
One possible explanation for why ATR is necessary for the development of some
brain structures but not others could be diﬀerences in proliferation rate and/or
duration. With regards to the cerebellum in particular, CGNPs proliferate over a
long period spanning from mid-embryonic development through the third week of
postnatal life in mice, and peaking between P5 and P7 (Carletti and Rossi, 2008;
Chizhikov and Millen, 2003; Goldowitz and Hamre, 1998; Hatten and Heintz, 1995).
This extended period of rapid proliferation ultimately gives rise to the largest
population of neurons in the entire brain. Interestingly, in three mouse models of
conditional Atr deletion from the brain (AtrN-cre, AtrG-cre , and with theMath1
promoter in AtrM-cre ), the cellular consequence of ATR loss on the cerebellum,
whether in the form of reduced proliferation or increased apoptosis, occurred prior to
the period of peak CGNP proliferation (Lee et al., 2012; Lang et al., 2016). Moreover,
maximal DNA damage and cell death from Atr deletion in the neocortex and
ganglionic eminence were also detected before the periods of maximal proliferation
for those structures (Lee et al., 2012; Finlay and Darlington, 1995; Dehay and
Kennedy, 2007). Therefore, it seems unlikely that the special cerebellar role of ATR
is exclusively a consequence of the proliferation rate of CGNPs. Likewise, the length
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of the CGNP proliferative period in development may not by itself fully explain the
particular importance of ATR in the cerebellum since other neurons, such as found in
the olfactory bulbs, the SVZ, and the hippocampus, are known to proliferate over
long periods of time through development (Finlay and Darlington, 1995; Ming and
Song, 2011; Gage, 2000; Lledo et al., 2006; Lim et al., 2000). If still the proliferative
nature of CGNPs is to be thought of as responsible for the cerebellar dependence on
ATR, then perhaps this importance could be due to a combination of the proliferative
index and proliferation duration of CGNPs.
ATR may function in a unique manner in CGNPs
ATR is thought to have many possible functions. In a large-scale proteomic
analysis, ATR was found to respond to DNA damage by putatively regulating
hundreds of targets encompassing numerous biological processes such as cell cycle
control, signal transduction, cell proliferation and diﬀerentiation, immune function,
protein metabolism and modification, mRNA transcription, and DNA replication,
recombination, and repair (Matsuoka et al., 2007). Moreover, the functions of ATR
are not limited to responding to DNA damage, suggesting that ATR may potentially
regulate thousands of molecules spanning dozens of categories of biological
functions. Therefore, it is conceivable that ATR does not display its full range of
possible activity in all cells at all times but rather functions diﬀerently in specific cell
types under specific conditions. In addition, beyond ATR, there can exist remarkable
heterogeneity in the transcriptional profile of disparate cells, such that certain
molecules like ATR may be more important in some cells than others. For example,
in the cerebellum, DNA damage from deficiency of the DNA repair protein XRCC1
(X-ray repair cross complementing 1) leads to cell cycle arrest in cerebellar
interneuron progenitors but apoptosis in CGNPs, suggesting that XRCC1 may
function diﬀerently in these cell types or that the transcriptional profile diﬀers
253
between these cells to cause variable dependence on XRCC1 or some other DNA
damage response molecule that operates in the absence of XRCC1 (Lee et al., 2009).
Our group has reported that CGNPs maintain the key apoptotic regulator BAX
(BCL2 (B-cell lymphoma 2)-associated X) in an active state at mitochondria in order
to be able to induce rapid cell death, which may be another unique feature of CGNPs
and supports the idea that ATR too could function in a special manner in CGNPs
(Crowther et al., 2013).
Most of the research into the function of ATR has been performed in
immortalized human cell lines and mouse embryonic fibroblasts (MEFs). As such, it
is unclear whether these functions are retained in other cell types and especially in
primary cells. Indeed, there have sometimes been conflicting reports of ATR
behavior and function and some of these diﬀerences could be attributed to variable
roles for ATR in specific cell types or on exposure of the same cell type to distinct
stimuli that then induce altered ATR responses. A selection of prior findings will be
reviewed here in brief to illustrate both the multitude of processes that can be
regulated by ATR and to suggest that ATR may perform a unique function in CGNPs
compared to other brain cells.
The most widely studied function of ATR has been in its response to DNA damage
and Chapter 1 presents a summary of what may be considered the canonical DNA
damage response of ATR. Additional roles for ATR in various other aspects of DNA
damage and repair have also been described, but it is unclear whether all of these
functions are always all active in every cell type. In cultures of human fibroblasts,
ATR has been found to directly phosphorylate and activate the DNA repair protein
BRCA1 (Breast cancer 1), which has previously been proposed to rely predominantly
on ATM (Ataxia-telangiectasia-mutated) for activation (Cortez et al., 1999; Gatei
et al., 2000; Tibbetts et al., 2000). Also in studies using human fibroblasts, the DNA
damage response protein Nibrin facilitated ATR phosphorylation of targets like
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CHK1 (Checkpoint kinase 1) and p53 (Stiﬀ et al., 2005). Interestingly, in a separate
study using a human lymphoblast cell line, Nirbin did not interact with ATR, but
rather with ATM (Marcelain et al., 2005).
In primary human melanocytes, PKA (Protein kinase A) was found to directly
activate ATR, inducing recruitment of the nucleotide excision repair molecule XPA
(Xeroderma pigmentosum group A) to repair ultraviolet (UV) light damage (Jarrett
et al., 2014). In turn, XPA has been found to directly activate ATR in MEFs and
cervical cancer-derived HeLa and osteosarcoma-derived U2OS cell lines (Bomgarden
et al., 2006; Shell et al., 2009). Other studies using MEFs have found that
phosphorylation of the DNA damage marker H2A.X (Histone H2A, member X) is
ATR-dependent and ATM-independent following exposure to UV light and
hydroxyurea (Ward and Chen, 2001), which is in contrast to prior suggestions that
H2A.X phosphorylation is primarily ATM-dependent (Burma et al., 2001). In MEFs,
the multifunctional tyrosine kinase c-ABL (Abelson murine leukemia viral oncogene
homolog 1) has also been found to directly activate ATR (Wang et al., 2011).
Apart from nucleotide excision repair, ATR has also been implicated in mediating
mismatch and DSB repair. In HeLa and the human embryonic kidney HEK293 cell
lines, ATR has been found to activate the mismatch repair program (Stojic et al.,
2004; Yamane et al., 2004). Similarly, mismatch repair molecules like MutS (Mutator
S) and MutL (Mutator L) have been shown to activate ATR in HeLa cells (Yoshioka
et al., 2006; Liu et al., 2010). This type of mismatch repair positive feedback loop
may also involve the mismatch repair protein HEXO1 (-hexosaminidase 1), which
has been shown to both activate ATR and be activated by ATR in HEK293, HeLa,
U2OS, and MEF cell lines (El-Shemerly et al., 2008; Sertic et al., 2011). With
regards to DSB repair, FANCM (Fanconi anemia complementation group M) was
seen to respond to the presence of DSBs by mediating ATR pathway signaling, which
in turn activated FANCM in HEK293, HeLa, and U2OS cells (Collis et al., 2008;
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Singh et al., 2013). Using these same cell types, other authors have further shown
ATR involvement in the Fanconi anemia repair pathway through ATR activation of
FANCD2 and FANCJ (Andreassen et al., 2004; Sakasai et al., 2012). Additional
ATR-mediated regulation of DSB repair may be through the helicase WRN (Werner
syndrome RecQ-like helicase), which has exonuclease activity and has been shown to
form a complex with ATR and require ATR activation for DNA repair in HeLa cells
(Pichierri et al., 2003; Otterlei et al., 2006).
HeLa cells have also demonstrated an interesting self-regulatory mechanism for
ATR inactivation in which the ATR-activated kinase CHK1 phosphorylates the
phosphatase PP2A (Protein phosphatase 2A), which then opposes ATR activation of
CHK1 (Leung-Pineda et al., 2006). Another protein phosphatase, PP5, may regulate
ATR activity in a similar way, as has been shown in HeLa, HEK293, and U2OS cell
lines (Kang et al., 2011; Zhang et al., 2005). The SRC (Rous sarcoma) family of
protein kinases can provide additional negative control over ATR signaling in HeLa
cells to limit the DNA damage response (Fukumoto et al., 2014). In terms of positive
regulation, studies in HeLa and breast cancer-derived MCF7 cell lines found ATR
recruitment to sites of DNA damage by the protein MDC1/NFBD1 (Mediator of DNA
damage checkpoint 1/Nuclear factor with BRCT (BRCA1 C-terminus) domains 1)
(Peng and Chen, 2005). In response to replication fork stalling, a primary ATR
activating event, ATR was shown to phosphorylate and inactivate SMARCAL1 (SWI
(Switch)/SNF (Sucrose-non-fermentable)-related, matrix-associated, actin-dependent
regulator of chromatin, subfamily A-like 1) in U2OS cells, thereby preventing
SMARCAL1-mediated regression of stalled forks, which would otherwise generate
DSBs (Couch et al., 2013). To promote the recovery of stalled replication forks, ATR
may activate the DNA repair protein XRCC3, as has been seen in HEK293, HeLa,
U2OS, and MCF7 cell lines (Somyajit et al., 2013).
Following the initial response to DNA damage, one possible outcome is cell cycle
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arrest to potentially allow for additional time to repair DNA. As highlighted in
Chapter 1, ATR predominantly mediates cell cycle arrest in S-phase or at the G2/M
checkpoint. Indeed, in primary human fibroblasts and HeLa cells, ATR has been
shown to inactivate the serine/threonine kinase PLK1 (Polo-like kinase 1) so as to
inhibit entry into M-phase by preventing activation of the Cyclin B - CDK1/CDC2
(Cyclin-dependent kinase 1/cell division cycle 2) complex (van Vugt et al., 2001;
Deming et al., 2002). ATR has similarly been seen to regulate mitotic entry in MEFs,
with inappropriate entry in the absence of ATR leading to chromosome breaks
(Brown and Baltimore, 2003). Curiously, in a separate study employing MEFs, forced
hyperactivation of ATR in the absence of DNA damage induced p53-mediated cell
cycle arrest in G1-phase rather than at G2/M (Toledo et al., 2008). In support of the
hypothesis that ATR can have varied function in diﬀerent cell types, forced
overexpression of Atr in the C2C12 mouse myoblast cell line resulted in inhibition of
the muscle diﬀerentiation factor MYOD1 (Myogenic diﬀerentiation 1), duplication of
centrosomes, and failed cell cycle arrest at G1-phase, all in the absence of induced
DNA damage (Smith et al., 1998). As mentioned, though ATR can induce S-phase
arrest, inhibition of ATR was recently found to similarly promote S-phase arrest in
human breast cancer cells that subsequently experienced apoptosis (Kim et al.,
2017).
Should DNA damage be extensive, cell death may result following or independent
of cell cycle arrest and ATR can mediate this process through activation of p53. In
U2OS and the H1299 non-small cell lung cancer (NSCLC) cell lines, ATR
phosphorylates MDM2 (Mouse double minute 2) following DNA damage to allow for
p53 activation and apoptosis (Shinozaki et al., 2003). Although ATR can either
directly activate p53 or indirectly through its downstream kinase CHK1, a study in
HEK293 and U2OS cells exposed to DNA damaging agents also found that ATR
phosphorylated DBC1 (Deleted in breast cancer 1), which inhibited the p53 negative
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regulator SIRT1 (Silent mating type information regulation 2 homolog 1), inducing
apoptosis (Zannini et al., 2012). As another indirect mechanism for activating
p53-mediated apoptosis, ATR can prevent degradation of the p53-activator HIPK2
(Homeodomain-interacting protein kinase 2) by inhibiting SIAH2 (Seven in absentia
homolog 1) in HEK293, U2OS, and MCF7 cell lines (Winter et al., 2008). Apart from
promoting cell death through p53, ATR has been suggested to promote autophagy,
through an as yet uncharacterized mechanism, when hyperactivated in HeLa and
U2OS cells (Mori et al., 2013). While the above studies have all implicated a pro-cell
death role for ATR, one recent report has actually revealed that outside of the
nucleus in MEFs and HEK293 cells, ATR antagonizes the apoptotic function of tBID
(truncated BH3-interacting domain death agonist) at the mitochondrion in order to
suppress Cytochrome C release following DNA damage (Hilton et al., 2015). This
anti-apoptotic function of ATR is apparently normally suppressed by the isomerase
PIN1 (Peptidylpropyl cis/trans isomerase, NIMA (never-in-mitosis gene A)-
interacting 1), which alters the conformation of ATR, but ATR was found to be freed
from PIN1 in the presence of DNA damage. In a separate study, nuclear BID
promoted the necessary, activating ATR-ATRIP (ATR-interacting protein)
interaction with RPA following DNA damage in U2OS cells (Liu et al., 2011). Taken
together with the previous study, these results suggest a complex relationship
between ATR and BID that may diﬀer by cell type. Another component of the classic
apoptotic pathway, MCL1 (Myeloid cell leukemia 1), which normally suppresses
apoptosis, has been seen to promote ATR activation of CHK1 in HeLa cells (Jamil
et al., 2008). In contrast, the p53 negative regulator PPM1D/WIP1 (Protein
phosphatase 1D/Wild-type p53-induced phosphatase 1), which, like MCL1,
suppresses apoptosis, reduced the activity of ATR and its substrates in PC3 prostate
cancer cell lines but not in CHO Chinese hamster ovary cell lines, again suggesting
that ATR can behave in non-identical ways in diﬀerent cell types (Song et al., 2013;
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Oliva-Trastoy et al., 2007).
Since ATR has a demonstrated role in responding to DNA damage in almost all
cell types investigated, the absence of ATR should have significant consequences. As
we have revealed with our experiments in CGNPs, loss of ATR can lead to the
accumulation of severe chromosome aberrations (Lang et al., 2016). Earlier
experiments with Atr deletion in mice found that ATR loss was similarly associated
with widespread chromosome breaks in blastocysts that led to embryonic lethality
(Brown and Baltimore, 2000). In a study using human lymphocytes, ATR disruption
was seen to induce chromosome damage through allowing the expression of common
fragile sites (Casper et al., 2002). Hypomorphic Atr mutation had a similar eﬀect in
primary mouse fibroblasts, which displayed increased chromosome damage and
fragile site expression (Ragland et al., 2009). However, a separate study described
the ATR pathway as actually being inactive in human lymphocytes, putting into
question why the absence of ATR would promote chromosome damage in these cells
(Jones et al., 2004). Through yet another set of experiments in human lymphocytes,
Atr amplification paradoxically increased chromosomal instability (Mossafa et al.,
2004). Other relationships between ATR and chromosomes have also been reported
in various types of cells. In HeLa cells, ATR cooperates with UPF1 (Up-frameshift
suppressor 1 homolog), which regulates nonsense-mediated decay, to degrade histone
mRNAs upon cessation of DNA synthesis (Kaygun and Marzluﬀ, 2005).
Furthermore, chromatin remodeling in HeLa cells could involve ATR association
with HDAC2 (Histone deacetylase 2) (Schmidt and Schreiber, 1999). ATR’s binding
to chromatin, however, was seen in another study to occur only in S-phase and not in
M-phase in HeLa cells (Dart et al., 2004). Association of ATR with chromatin, as
suggested by one group using MEFs, HeLa, U2OS, and the NIH3T3 MEF cell lines,
regulates chromatin condensation and this regulation requires that ATR be tethered
to the nuclear envelope, which occurs in S- and M-phases, where ATR also modulates
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envelope plasticity in response to mechanical stress and mediates envelope
breakdown in mitosis (Kumar et al., 2014). Chromatin condensation prohibits
transcription, and ATR may employ chromatin condensation as a mechanism to
inactivate the extra X-chromosome in female cells, as seen in MEFs (Ouyang et al.,
2005). ATR-mediated chromosome silencing has also been described by several
groups as operative in human and murine meiotic cells of the seminiferous tubules,
where ATR phosphorylated H2A.X on unpaired and un-synapsed chromosomes to
mark them for degradation (Keegan et al., 1996; Perera et al., 2004; Royo et al.,
2013). Clearly then, ATR may either directly or indirectly control chromosome
stability, with variable function by cell type.
The association of ATR with chromosomes has been further elaborated in terms
of its interaction with telomeres and telomeric molecules. In HEK293 and HeLa
cells, ATR recruited telomerase, the ribonucleoprotein that adds DNA repeat
sequences to the end of telomeres (Tong et al., 2015). Atr-knockout studies using
MEFs and primary human fibroblasts have also demonstrated a role for ATR in
protecting telomeres (McNees et al., 2010; Pennarun et al., 2010). At the same time,
however, MEFs were found to paradoxically utilize the telomere-protecting protein
POT1 (Protection of telomeres 1) to prevent ATR association with telomeres (Gong
and de Lange, 2010). Indeed, other components of the Shelterin telomere-protecting
complex, which includes POT1, have shown activity in preventing ATR-mediated
DNA resection at telomeres in MEFs (Kibe et al., 2016). Even the non-coding RNA
component of telomerase has been implicated in directly inhibiting ATR activity in
HEK293, U2OS, and MCF7 cell lines (Kedde et al., 2006). As such, it is unclear
whether ATR actively protects telomeres or is excluded from telomeres for its
detrimental eﬀect since reports have been conflicting, and even in one cell type used
by two groups under similar conditions, both roles have been reported for ATR.
In the immune system, ATR can facilitate immunoglobulin class switching and
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somatic hyper-mutation, as seen in human B-cells (Pan-Hammarstrom et al., 2006).
Studies performed in HeLa and HCT116 human colon cancer cell lines have found
that ATR activates the V(D)J recombination complex Artemis (Zhang et al., 2004).
An additional role for ATR may be in responding to tissue oxygenation since ATR has
been found to activate p53 following both hypoxia and hyperoxia in HEK293 and
HCT116 cell lines (Das and Dashnamoorthy, 2004; Hammond et al., 2002, 2003). To
further add to the complexity of ATR activity, various unrelated transcription factors
have been shown to regulate ATR. In mouse kidneys, the purine hydrolase and
transcriptional regulator FHIT (Fragile histidine triad) modulated ATR activity and
promoted p53 signaling following DNA damage (Hu et al., 2005b,a). The
transcriptional activator SNIP1 (SMAD (Mothers against decapentaplegic) nuclear-
interacting protein 1) has also demonstrated the ability to enhance ATR-mediated
activation of p53 and CHK1 in U2OS cell lines in response to DNA damage (Roche
et al., 2007). Finally, MEFs lacking the transcription factor CUX1 (Cut-like
homeobox 1) have reduced ATR pathway signaling upon induction of DNA damage
(Vadnais et al., 2012). These studies combine to further demonstrate how ATR can
have a unique role in a specific cell type, such as generating immune diversity in
lymphocytes and sensing oxygen levels in kidney cells.
Another putative cell-specific function of ATR has been described in primary
mouse retinal photoreceptors, where ATR disruption led to shorter cilia and
photoreceptor degeneration (Valdes-Sanchez et al., 2013). ATR’s role in maintaining
ciliary length has also been seen in human fibroblasts, and in these cells, ATR
additionally controlled secretion of factors like Sonic hedgehog (SHH) – a potent
mitogen that coincidentally is critical for CGNP proliferation (Stiﬀ et al., 2016). In
the gastrointestinal (GI) system, ATR has been described, using in vivo fruit fly and
mouse studies, as necessary for maintaining the proliferation of intestinal stem cells
by preventing proliferation-associated DNA damage – a well-recognized function of
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ATR (Ruzankina et al., 2007; Park et al., 2015). Recently, work using HEK293 cells
has suggested another possible role of ATR in the GI system: negative regulation of
the appetite-stimulating molecule Leptin, which can be secreted by adipose tissue
and cells in the stomach (Ericson et al., 2015). In a diﬀerent part of the GI system,
primary mouse hepatocytes apparently down-regulate ATR upon becoming
senescent, suggesting that ATR is not even active in all cell types (Panda et al.,
2008). Likewise, other tissues may also experience low levels of ATR activity as the
hormone Estrogen has been found to inhibit ATR pathway signaling in studies
employing human breast cancer cell lines (Pedram et al., 2009).
Several miscellaneous ATR functions and associations have been described in
specific cells and these descriptions help complete the picture of the known
complexity of ATR regulation and activity. For instance, experiments in MCF7 and
NIH3T3 cell lines have suggested that the MEK/ERK (Mitogen-activated protein
kinase kinase/Extracellular signal-related kinase) pathway can regulate ATR
activation in response to DNA damage (Wei et al., 2011; Wu et al., 2006). ATR
activation following DNA damage could also require the putative oxidoreductase
WWOX (WW domain-containing oxidoreductase), as seen in MEF, HEK293, HeLa,
and MCF7 cell lines (Abu-Odeh et al., 2016). Moreover, the SUMO (Small ubiquitin-
like modifier) ligase PIAS3 (Protein inhibitor of activated STAT3 (signal transducer
and activator of transcription 3)) activated ATR in response to DNA damage in
HEK293, HeLa, and U2OS cell lines (Wu and Zou, 2016). Research using HeLa cells
further demonstrated that the acetyltransferases P300 and CBP (CREB (cAMP
(Cyclic adenosine monophosphate) response element binding)-binding protein)
interact with ATR to activate CHK1 (Stauﬀer et al., 2007). Another interesting
method utilized by HEK293 and HeLa cells to promote ATR activity is to increase
ATRIP binding to RPA through association with the mRNA splicing factors PRPF19
(Pre-mRNA processing factor 19) and BCAS2 (Breast carcinoma-amplified sequence
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2) (Wan and Huang, 2014). Most recently, the newly identified ETAA1 (Ewing’s
tumor-associated antigen 1) protein was shown to directly activate ATR independent
of the key ATR regulator TOPBP1 (Topoisomerase DNA II-binding protein 1) in
HeLa, U2OS, and HCT116 cell lines (Haahr et al., 2016). Finally, ATR pathway
activity has even been suggested to follow a circadian rhythm in primary MEFs and
mouse livers due to CRY1 (Cryptochrome circadian clock 1) regulation of the
circadian factor TIM (Timeless circadian clock), which can mediate ATR
phosphorylation of CHK1 (Kang and Leem, 2014; Yoshizawa-Sugata and Masai,
2007; Chou and Elledge, 2006).
Given this vast sum of work on ATR, again only presented in brief here, that
demonstrates a multitude of possible roles for this protein and that suggests yet
many more potential roles, with significant variability by cell type and even within
the same cell type under similar or diﬀerent conditions, it becomes easy to imagine
that ATR could have a unique and special function in CGNPs. However, it must be
noted that, as summarized in Chapter 1, specific disturbances to the cerebellum of
greater severity than in other brain regions are not commonly associated with the
ATR-mutated human condition Seckel syndrome. Moreover, in mice, pan-CNS Atr
deletion from neural stem cells using Nestin-Cre disrupted both the ganglionic
eminence and nascent cerebellum according to one report (Lee et al., 2012), and
targeted additional proliferative regions beyond the cerebellum like the SVZ and the
VZ according to another study (Zhou et al., 2012). In our own research, we have
observed that Atr deletion from neural stem cells using hGFAP-Cre almost
exclusively perturbed the neonatal cerebellum (Lang et al., 2016). Despite the
disparity between these three reports on CNS Atr deletion in mice, the one common
tissue that is clearly severely aﬀected is the proliferative cerebellum. This
discrepancy in specific cerebellar pathology associated with ATR disruption between
man and mouse could be attributed to the fact that Seckel syndrome is caused by
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hypomorphic mutations in ATR whereas the described murine experiments utilized
complete Atr deletion. As has been highlighted in this section, comparison of several
studies can lend support to the idea of interspecies variations in ATR function and
regulation, and indeed, the hypomorphic ATR mutation that has been identified in
several cases of Seckel syndrome fails to produce a phenotype in mice (Ragland et al.,
2009). Therefore, whether ATR has a unique and special function in CGNPs remains
an open question, and although it is an interesting consideration, it might be more
important to focus on the fact that ATR clearly has a vital pro-survival function in
CGNP-derived medulloblastoma and that ATR disruption seems to be relatively-well
tolerated by other normal cells in the postnatal brain. Future research can reveal
whether, beyond surveillance of DNA damage, any of the spectrum of ATR activities
described in other cells make ATR indispensable to the cerebellum.
ATR inhibition as treatment for medulloblastoma
Regulation of proliferation controls both normal development and oncogenesis. In
the cerebellum, CGNPs proliferate maximally in early postnatal life to generate the
largest neuronal population in the brain. Failed CGNP expansion, such as with
disruption of the DNA damage response protein ATR, produces cerebellar hypoplasia,
as demonstrated in mouse models in Chapter 3. Excessive CGNP expansion
promotes formation of medulloblastoma, the most common malignant brain tumor of
childhood. Chapter 2 explored a possible role for ATR in tumorigenesis and outlined
therapeutics for inhibiting ATR that are being explored in cancer treatment.
Meanwhile, Chapter 4 specifically addressed the possibility of targeting ATR to
treat medulloblastoma. This section will briefly explore the benefits and pitfalls of
pursuing ATR inhibition for the treatment of medulloblastoma and present possible
future directions for improving medulloblastoma treatment using ATR inhibition.
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ATR inhibitors with good in vivo activity and their uses in cancer treatment
Given the pivotal role of ATR in maintaining the viability of various cell types,
there has been longstanding interest in probing the therapeutic potential of ATR
inhibition. Caﬀeine was among the first described non-specific ATR inhibitors, with
additional activity against ATR-related molecules like ATM (Sarkaria et al., 1999;
Blasina et al., 1999). Although caﬀeine sensitizes cultured cells to DNA damage, the
concentrations required for eﬀective ATR/ATM inhibition in vivo are toxic. Cell-
based studies and compound screens have since identified several other more
selective ATR inhibitors such as Torin2, NU6027, ETP-46464, and NVP-BEZ235, but
these chemicals still exhibited non-trivial disruption of related kinases like ATM,
mTOR (mammalian Target of rapamycin), and PI3K (Phosphoinositide 3-kinase)
(Nishida et al., 2009; Peasland et al., 2011; Mukherjee et al., 2012; Liu et al., 2013;
Toledo et al., 2011). VE-821 was the first discovered ATR inhibitor with very high
selectivity over ATM, mTOR, PI3K, and DNA-PK (DNA protein kinase) (Charrier
et al., 2011). Addition of VE-821 to various cancer cell lines in vitro increased
sensitivity to radiation and diﬀerent chemotherapeutics (Prevo et al., 2012; Pires
et al., 2012; Huntoon et al., 2013; Vavrova et al., 2013). Unfortunately, as we have
found through our own experience, VE-821 is poorly soluble, preventing its use in
vivo, and indeed, shortly after reporting VE-821, Vertex Pharmaceuticals developed
the related compound VE-822/VX-970, which has better pharmacodynamic
properties and even greater ATR selectivity (Fokas et al., 2014, 2012).
In the initial study using VE-822, addition of VE-822 shortly before X-ray
radiation therapy (XRT) significantly reduced the viability TP53-mutant/KRAS-
mutant PSN-1 and MiaPaCa-2 pancreatic ductal adenocarcinoma cell lines (Fokas
et al., 2012). Similar reductions in the viability of these cell lines was observed when
VE-822 was added after pre-treatment with Gemcitabine. Interestingly, VE-822
demonstrated no cytotoxic eﬀect against normal HFL-1 fibroblasts or human dermal
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microvascular endothelial cells, suggesting a tumor-specific eﬀect. For the in vivo
experiments, mice with PSN-1 xenografts had reduced tumor growth when treated
with 60 mg/kg VE-822 by oral gavage once per day over five days and either
concurrently with 2 Gy XRT once per day over five days or with a single dose of 6 Gy
XRT on the first day of VE-822 treatment. Mice bearing MiaPaCa-2 xenografts
responded with great variability to the five days of VE-822 plus five days of XRT
regimen, with some mice failing to grow tumors at all and others showing minimal
response. In both experiments, VE-822 mono-therapy had no significant eﬀect. The
addition of 100 mg/kg Gemcitabine, given once by intraperitoneal (IP) injection on
the day before VE-822 and XRT treatment, to the regimen of a single dose of 6 Gy
XRT further restricted tumor xenograft growth. Importantly, there was no observed
intestinal pathology from use of VE-822 alone or in combination with XRT, which is
salient given the proliferative nature of the intestinal tract and its sensitivity to
various chemotherapeutics.
In H2009 lung cancer cells, VX-970 alone only mildly increased DNA damage, but
this eﬀect was markedly increased in concurrent combination with Cisplatin (Hall
et al., 2014). Moreover, in a panel of thirty-five lung cancer cell lines, VX-970
significantly reduced cell viability in over 40% of these cell lines when combined with
Cisplatin, Oxaliplatin, Gemcitabine, Etoposide, or SN-38. VX-970 combination with
Cisplatin or Gemcitabine actually reduced the viability of more than 75% of the cell
lines. Here, again, VX-970 produced no cytotoxic eﬀect against normal cultured
HFL-1 human fibroblasts, but cell viability was decreased upon the addition of
Gemcitabine. Interestingly, knockdown of TP53 in A549 human lung cancer cells
greatly enhanced the combined anti-tumor eﬀect of VX-970 paired with Cisplatin or
Gemcitabine. Just as in H2009 cells, VX-970 and Cisplatin combined to produce a
cytotoxic eﬀect in cultured, primary human NSCLC samples. In vivo, VX-970 alone,
given by oral gavage at either 30 or 60 mg/kg once per day for four times per week,
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failed to reduce the growth of mice with human NSCLC xenografts, but addition of
Cisplatin, given by IP injection at 3 mg/kg once per week, led to diminished tumor
burden. Similarly, in mice bearing OD26749 NSCLC xenografts, the combination of
VX-970 at 60 mg/kg and Cisplatin, given as above, produced nearly complete tumor
regression. VX-970 has also been found to have a synergistic cytotoxic eﬀect when
combined with SN-38 in cultured COLO205 colorectal cancer cells (Josse et al.,
2014). This anti-tumor eﬀect was also seen in mice with COLO205 xenografts, where
VX-970 was given by oral gavage at 60 mg/kg on the first three days of a four-day
cycle and Irinotecan, which is metabolized into SN-38, was given at 20 mg/kg by IP
injection on the first day of the cycle. Active clinical trials for VX-970, all of in which
VX-970 is delivered by intravenous (IV) injection, in the United States are
summarized in Chapter 2.
In 2013, one year after the first publication on VE-822/VX-970 and two years
after the discovery of VE-821, AstraZeneca described the compound AZ-20 as
another highly selective ATR inhibitor, with similar activity to VE-821 (Foote et al.,
2013). As with VE-821, AZ20 had poor solubility, limiting its translational
applications, so AZD-6738, as with VE-822/VX-970, was developed, demonstrating
better solubility and pharmacodynamics. In one study, cultured LoVo human colon
adenocarcinoma cells treated with AZD-6738 experienced dose-dependent apoptosis
(Checkley et al., 2015). Mice bearing LoVo xenografts were treated with variable
doses of AZD-6738 by oral gavage once per day for up to twenty-one consecutive days,
and 80 mg/kg was found to be the optimal dose in producing an anti-tumor eﬀect as
monotherapy. Addition of two rounds of five consecutive days of 2 Gy. XRT enhanced
these anti-tumor eﬀects from ATR inhibition.
Unlike VX-970, AZD-6738 alone significantly reduced the viability of four
diﬀerent NSCLC cell lines in vitro through increased p21-mediated cell cycle arrest
and apoptosis (Vendetti et al., 2015). Specifically, AZD-6738-treated cells were found
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to arrest at G1/S, with depletion from G2- and M-phases. Here again, addition of
Gemcitabine, and especially Cisplatin, enhanced with cytotoxic eﬀect of AZD-6738,
particularly in the ATM-deficient H23 cell line. Cell death from AZD-6738 and
Cisplatin treatment could similarly be elevated in non-ATM-deficient NSCLC cell
lines that had ATM knocked down. For in vivo studies, mice bearing ATM-competent
H460 NSCLC xenografts were treated with 50 mg/kg AZD-6738 by oral gavage once
daily for fourteen consecutive days and/or with 3 mg/kg Cisplatin by IP injection once
on days 1 and 8. Single-agent therapy failed to reduce tumor growth whereas
combination therapy had a significant anti-tumor eﬀect. Moreover, using the same
dosing schedule but with an even lower amount of 25 mg/kg AZD-6738, mice bearing
ATM-deficient H23 xenografts experienced near-complete tumor regression.
ATR inhibition through AZD-6738 has also shown eﬃcacy in chronic myeloid
leukemia (CLL), which can present with mutations in ATM and TP53 (Kwok et al.,
2016). AZD-6738 treatment greatly reduced the viability of ATM-deficient or p53-
deficient human-derived CLL cell lines compared to CLL cells with intact ATM or
p53 and compared to non-CLL cells. Administration of AZD-6738 for two weeks in
mice with ATM- or TP53-mutated CLL xenografts led to significant reductions in
tumor load compared to Vehicle. Molecular studies revealed that AZD-6738 induced
cell cycle arrest at G1/S in ATM/p53-proficient CLL cells, with minimal activation of
apoptosis, but that in cells with mutated ATM or TP53, cell cycle checkpoints failed
and cells proceeded into mitosis, ultimately undergoing what the authors described
as mitotic catastrophe. Combining AZD-6738 with chemotherapeutic agents like
Chlorambucil, Fludarabine, and 4-hydroperoxycyclophosphamide reduced the
viability of normally chemo-resistant ATM- or p53-deficient CLL cell lines. In vivo,
the combination of AZD-6738 plus Chlorambucil produced a significant anti-tumor
eﬀect in mice xenografted with primary, human, ATM-deficient CLL cells.
AZD-6738 has also been tested in human breast cancer cell lines, where it was
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shown to attenuate the proliferation of six diﬀerent cell lines (Kim et al., 2017). On
further analysis, administration of AZD-6738 alone in the SK-BR-3 breast cancer
cell line increased both S-phase arrest and apoptosis. Moreover, in SK-BR-3 cells,
but not in the related BT-474 cell line, AZD-6738 increased DNA damage while
reducing the levels of DNA repair mediators like RAD51, MRE11 (Meiotic
recombination 11), and ERCC1 (Excision repair cross-complementation group 1).
Proliferative signaling was thought to be reduced by AZD-6738 due to dose-
dependent decreases in the phosphorylation of AKT (Protein kinase B) and ERK.
Addition of Cisplatin, as in other studies with AZD-6738 and with VE-822/VX-970,
produced a synergistic cytotoxic eﬀect in all six breast cancer cell lines through
inhibiting proliferation, promoting apoptosis, and suppressing other DNA repair
mechanisms. Clinical trials for AZD-6738 are currently underway and a summary of
these is provided in Chapter 2.
Synthesis of the available data on VE-822/VX-970 and AZD-6738 can inform our
own research on nano-formulated pVE-822 in medulloblastoma preclinical studies,
as presented in Chapter 4. For instance, the in vivo studies using VX-970 reported
to date all seem to find that 60 mg/kg given once daily on consecutive days provides
the maximum therapeutic index, which informed our choice for using 60 mg/kg of
pVE-822 given once daily for five consecutive days in treating mice with
medulloblastoma. Notably, however, in vivo VX-970 experiments all utilized oral
gavage for drug delivery while clinical trials for VX-970 use IV injection. Our
strategy of IP pVE-822 administration was based on the contingency that
medulloblastoma develops at a very early age in our mouse models, making IV
injection diﬃcult due to the diminutive size of the animals. But, perhaps, oral
gavage could be attempted in our medulloblastoma-bearing animals, especially given
that the reports to date have described no systemic toxicity from oral administration
of VX-970 whereas we have noted considerable extra-CNS adverse side eﬀects with
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IP delivery of pVE-822. Other routes of pVE-822 administration should also be
explored so as to minimize undesired reactions, including intracranial (IC) injection
and intranasal (IN) delivery, both of which we are actively investigating. Inclusion of
inhibitors against the blood-brain barrier eﬄux regulator PGP (P-glycoprotein) into
VE-822-bearing polymeric micelles could potentially further increase drug
bioavailability in the brain and tumor, again reducing systemic toxicity. Use of PGP
inhibitors to increase the potency of cancer therapeutics in the brain has been well-
studied (Abdallah et al., 2015; Kemper et al., 2004, 2003; Amin, 2013; Agarwal et al.,
2011), and encapsulation of PGP inhibitors into nanoparticles is an active area of
research (Singh and Lamprecht, 2016, 2015; Singh et al., 2015). In order to better
understand systemic toxicity from pVE-822 administration, whether by IP, IV, IC,
IN, or oral delivery, various tissues, such as intestine, liver, heart, kidneys, spleen,
and bone marrow, as well as blood can be harvested from mice at diﬀerent time
points (i.e.: 2, 4, 6, 8, 12, and 24 hours) following a single treatment with pVE-822 at
60 mg/kg. High performance liquid chromatography and mass spectrometry can
ascertain the presence of VE-822 in these tissues and immunohistochemical staining
can reveal whether specific cells are adversely aﬀected. Not only will such
experiments provide valuable information for future clinical trials in human
patients, but they will also inform on how to better formulate and deliver pVE-822 so
as to minimize specific toxicities.
Another important observation taken from these published studies is that VX-970
failed to provide an anti-tumor eﬀect as monotherapy in preclinical mouse xenograft
experiments, and, indeed, most clinical trials with VX-970 employ at least one
adjunct form of therapy. AZD-6738 demonstrated eﬃcacy as single agent therapy in
the context of ATM- or p53-deficient tumors and is thus being investigated as
monotherapy in clinical trials with relapsed/refractory CLL, prolymphocytic
leukemia (PLL), or B-cell lymphoma, all of which frequently demonstrate ATM or
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TP53 mutations. It is thus informative that pVE-822 alone achieved a significant
anti-tumor eﬀect in ATM- and p53-proficient medulloblastoma, suggesting that this
tumor is critically dependent on ATR. Nevertheless, other therapeutics could be tried
in combination with pVE-822 in preclinical models of medulloblastoma. Cisplatin,
Gemcitabine, and XRT were the most commonly used adjunct therapies in
preclinical experiments using either VX-970 or AZD-6738, showing eﬀective synergy
with ATR inhibition. Moreover, clinical trials with VX-970 and AZD-6738 are also
utilizing addition of Cisplatin, Gemcitabine, or XRT. As discussed in Chapter 4,
however, Cisplatin and Gemcitabine failed to show a combinatorial eﬀect with
VE-822 in cultured CGNPs, and VE-822 actually possibly provided a cytoprotective
eﬀect against XRT in these cells, putting into question the likely eﬃcacy of these
combinations in treating CGNP-derived medulloblastoma. Nevertheless,
medulloblastoma cells in vivo may ultimately demonstrate a disparate response to
pVE-822 plus Cisplatin, Gemcitabine, and/or XRT than CGNPs in vitro. But again,
we found treating Atr-deleted medulloblastoma-prone mice with XRT failed to
improve survival. Importantly, we did note possible synergy between VE-822 and
Etoposide as well as the SHH pathway antagonist Vismodegib in reducing CGNP
proliferation, albeit not in increasing DNA damage or apoptosis. Thus, future
experiments should try combining pVE-822 with either of these compounds in
medulloblastoma-bearing mice.
Further considerations for future experiments are that besides optimizing the
route of pVE-822 delivery, the dose and schedule of pVE-822 should also be
optimized for treating young mice with medulloblastoma. Again, we chose 60 mg/kg
once per day for five consecutive days for most of our experiments, but this dosage
and schedule were based on reports of eﬃcacy in much older mice with non-primary,
non-brain tumors. As such, it is conceivable that a diﬀerent dose could provide a
better therapeutic index. For example, we have tried dosing 30 mg/kg once per day
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for five consecutive days, and this dose seems to provide some, albeit diminished,
anti-tumor eﬀect with reduced peripheral toxicity. Perhaps, as with AZD6738 in
CLL, 50 mg/kg of pVE-822 given once daily is ideal. Then again, the route of drug
delivery will conceivably impact the optimal dose of pVE-822 and therefore several
concentrations should be tried with each mode of delivery. To add further complexity
to the consideration of optimizing the pVE-822 therapeutic index in treating
medulloblastoma, drug delivery once per day for consecutive days may not be ideal.
Toxicity might be reduced if pVE-822 were given once per day every other day for a
certain period of time, or maybe given in two smaller doses in a day either every day
or every other day. This then begs the question of how long pVE-822 should be
administered. Five total days? Ten? Until evidence of complete tumor regression?
Or, upon observation of discontinued tumor response to drug? It is currently unclear
which, if any, of these possibilities might improve the therapeutic index of pVE-822
for medulloblastoma treatment, but these prospects should certainly be explored.
Moreover, as a part of determining the optimal pVE-822 dosing schedule for treating
mice with medulloblastoma, the age at which mice begin receiving treatment must
be decided. In our studies, we chose to initiate therapy either at P8 or at P12 since
SmoM2G-cre mice typically perish before P20, but commencing treatment at a
diﬀerent age, such as P6, P10, or P14, might lead to improved outcomes.
Once the optimal route of delivery, dose, and dosing schedule for pVE-822 have
been established, the same must be done for any adjunct therapies that will be tried.
There is evidence that the proper sequence of agent administration is imperative:
that is, whether ATR inhibitor should be given before, concurrent with, or after
another therapeutic like Gemcitabine or XRT (Karnitz and Zou, 2015). In the wrong
sequence, pVE-822 combined with another therapy may either fail to demonstrate an
anti-tumor eﬀect or may in fact provide a cytoprotective eﬀect, both of which we have
encountered in our own experiments, as highlighted in Chapter 4. Indeed, in the
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initial study reporting VE-822 eﬃcacy in pancreatic cancer, VE-822 produced
cytotoxicity only when given after Gemcitabine and before XRT both in vitro and in
vivo (Fokas et al., 2012). In that same study, fractionated radiation – 2 Gy. once per
day over five consecutive days – induced less of an eﬀect in combination with VE-822
– also given once daily over five consecutive days – than a single dose of 6 Gy. given
after the first of five doses of VE-822. In clinical trials, VX-970 is given one day after
Cisplatin in treatment cycles for patients with refractory/metastatic solid
malignancies or locally-advanced head and neck squamous cell carcinoma. Similarly,
VX-970 is given one day after Gemcitabine in a treatment regimen for patients with
recurrent ovarian, primary peritoneal, or fallopian tube cancers. Even with
combined administration of Gemcitabine and either Cisplatin or Carboplatin in
patients with recurrent ovarian, primary peritoneal, fallopian tube, or metastatic
urothelial cancers, VX-970 is given one day after the concurrent administration of
the other two drugs. Interestingly, Irinotecan, Topotecan, or Veliparib are
administered concurrent with VX-970 in patients with refractory/metastatic solid
tumors, small cell lung cancer, or refractory/advanced solid tumors, respectively.
Similarly, XRT is administered before, on the same day, and after VX-970 dosing in
patients with locally-advanced head and neck squamous cell carcinoma or brain
metastases from NSCLC, unlike the most eﬀective regimen in mice with pancreatic
tumor xenografts (Fokas et al., 2012). Surprisingly, unlike the variability in and
consideration for dosing sequence seen with VX-970 plus adjunct therapies, AZD-
6738 is given concurrently with Paclitaxel, XRT, or Carboplatin in patients with
metastatic/refractory/advanced cancers. Combinatorial studies using pVE-822 in
medulloblastoma mice must therefore carefully consider in what sequence each
additional therapy is given with relation to pVE-822, besides also determining the
optimal synergistic dose and route of delivery.
Taken together, our own findings and the published data on ATR inhibition in
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tumor-bearing mice suggest continued investigation of pVE-822 for the treatment of
medulloblastoma. As detailed here, many more experiments must be performed in
order to ascertain the optimal delivery strategy for pVE-822 and any combinatorial
therapies in order to maximize the therapeutic index. Furthermore, molecular
analyses should then be performed so as to describe in detail the mechanism by
which pVE-822-mediated ATR inhibition, alone or in combination with another
therapy, eﬀects medulloblastoma cytotoxicity and/or attenuated proliferation. Our
experiments with disrupting ATR in CGNPs have already hinted at some of the
likely operative mechanisms, but these should be confirmed with in vivo
medulloblastoma models (Lang et al., 2016).
ATR inhibition for the treatment of TP53-mutated medulloblastoma
In our initial studies, we had hypothesized that given the importance of ATR in
preventing DNA damage in the cerebellum (Lee et al., 2012; Zhou et al., 2012),
conditional Atr deletion in CGNPs might actually promote tumor formation through
accumulation of mutations. Instead, we found that loss of ATR led to widespread
p53-mediated, BAX/BAK-dependent apoptosis in CGNPs in the postnatal period,
which has not been previously reported (Lang et al., 2016). Tp53 mutation has been
shown to induce medulloblastoma in combination with deletion of various DNA
repair pathway genes in mice (Frappart et al., 2009, 2007; Holcomb et al., 2006; Lee
and McKinnon, 2002), so we predicted that co-deletion of Atr and p53 would result in
mice with medulloblastoma, especially given that pathology in ATR-deficient CGNPs
was almost exclusively p53-driven. That is, since ATR prevents proliferation-
associated DNA damage that activates p53-mediated apoptosis, or, to a lesser extent,
cell cycle arrest, deletion of Atr should lead to increased DNA damage and co-
deletion of p53 should allow for the accumulation of that DNA damage, leading to
mutation and tumorigenesis. As presented in Chapter 3, we instead found that loss
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of both ATR and p53 resulted in persistent cerebellar pathology through caspase-
independent CGNP cell death, emphasizing the critical importance of ATR to CGNP
survival.
We were surprised that tumors did not develop in Atr/p53-co-deleted mice.
Although Atr-knockout is embryonic lethal, Atr+/- mice variably develop tumors such
as mixed follicular center cell lymphoma, hepatocellular adenoma, fibrous
histiocytoma, ovarian cystadenoma, and ovarian fibroma (Brown and Baltimore,
2000). Interestingly, increased tumor incidence is not associated with Seckel
syndrome, as summarized in Chapter 1. Indeed, there have been very few reports
on ATR mutations in human cancers. In one study, a subset of stomach tumors with
microsatellite instability demonstrated ATR mutations (Menoyo et al., 2001).
Another study found that a very small subset of endometrioid endometrial cancers
harbored ATR mutations and that these mutations were associated with tumor
aggressiveness as measured by worse disease-free and overall survival times
(Zighelboim et al., 2009). Finally, the most convincing evidence for the association of
ATR with cancer formation has come from a report where twenty-four related
individuals across a five-generation pedigree were found to have an autosomal
dominant disorder caused by a missense mutation spanning the region containing
ATR, which presented with oropharyngeal cancer (Tanaka et al., 2012). Thus, while
ATR hypomorphism may sporadically induce various tumors in mice, neither
decreased, increased, nor altered ATR expression appears to have a strong
correlation with the development of cancer in humans. As such, and based on our
own findings, inhibition of ATR should not have a pro-tumor eﬀect, but rather, as we
have demonstrated in mice with medulloblastoma, produce an anti-tumor eﬀect.
Chapter 4 and the preceding subsection provided data and speculation on the
use of pVE-822 for the treatment of medulloblastoma. However, our observation of
persistent cerebellar pathology in the context of combined Atr and p53 deletion due
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to caspase-independent cell death suggests the additional therapeutic potential for
ATR inhibition in treating intractable TP53-mutated medulloblastoma, as discussed
in Chapter 4. VE-822 reduced tumor growth in mice bearing TP53- and KRAS-
mutated PSN-1 pancreatic adenocarcinoma xenografts, but only with adjunct XRT
(Fokas et al., 2012). Similarly, AZD-6738 produced a significantly stronger
anti-tumor eﬀect as monotherapy in mice bearing TP53-mutated CLL xenografts
compared to TP53-intact xenografts (Kwok et al., 2016). These results have led to
suggestions for the use of ATR inhibition in cancers with TP53 mutation (Murga
et al., 2009; O’Driscoll, 2009). Indeed, it is well-known that TP53 pathway mutation
is a hallmark of many cancers and that these mutations can confer therapeutic
resistance, at least partially through attenuated cell death programs (Muller and
Vousden, 2013, 2014; Shetzer et al., 2014; Hanahan and Weinberg, 2011, 2000;
Weinberg, 2013). We have provided evidence that, at least in CGNPs, ATR
disruption can still induce cell death even in the absence of p53 (Lang et al., 2016).
Whether this observation can be reproduced in other cell types, including TP53-
mutant cancers, remains to be tested, but at least recommends experiments in ATR
inhibition in p53-mutated medulloblastoma.
For these experiments, p53-mutated, medulloblastoma-prone mice can be
generated by crossing SmoM2loxP/loxP;p53loxP/loxP withMath1-Cre;p53loxP/loxP or
hGFAP-Cre;p53loxP/loxP to generateMath1-Cre;SmoM2;p53loxP/loxP or hGFAP-Cre;
SmoM2;p53loxP/loxP mice in which p53-deficient CGNPs initiate formation of
p53-deficient medulloblastoma. Tumor-bearing mice can then be treated with
pVE-822 or Vehicle and followed for tumor burden by magnetic resonance imaging
(MRI) and for survival. As outlined in the previous subsection, pVE-822
administration must be optimized in these animals to determine the route of
delivery, dose, and dosing schedule that provides the maximum therapeutic index.
To start, 60 mg/kg of pVE-822 given by IP injection once a day for five consecutive
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days per week over two weeks starting at P12 could be attempted. Additionally,
should several combinations of delivery, dose, and scheduling of pVE-822
monotherapy fail to provide a therapeutic benefit in mice with p53-mutated
medulloblastoma, supplementation with adjunct therapies like XRT, Vismodegib, or
Etoposide may lead to an anti-tumor eﬀect. Apart from measuring therapeutic
response by following tumor burden and survival, some animals should be sacrificed
after a shorter course of pVE-822 for molecular analyses. Immunostaining will
reveal whether pVE-822 compared to Vehicle treatment increases DNA damage
(H2A.X) and cell death (TUNEL) in p53-deleted medulloblastomas, as the case in
CGNPs. Flow cytometry can provide information on disturbed cell cycle mechanics,
which could potentially inform the selection of adjuvant therapies. Transcriptional
profiling of tumors from p53-deleted medulloblastoma mice treated with pVE-822
would also reveal the genetic response of these tumor cells to acute ATR inhibition,
oﬀering further information for selecting potential combinatorial therapeutics.
A remaining consideration in treating p53-mutated medulloblastoma mice with
pVE-822 is the precise nature of cell death that occurs from ATR disruption in the
absence of p53. In CGNPs, we found that co-deletion of Atr and p53 led to the
abrogation of cleaved Caspase-3 (cC3) positivity in the EGL, which was present with
just Atr deletion (Lang et al., 2016). Yet, CGNPs in mice of both genotypes were
TUNEL-reactive, suggesting persistent caspase-independent cell death. We
confirmed that TUNEL positivity was a valid marker for frank cell death rather than
simply DNA damage by showing that CGNPs with deletion of Atr and the key
apoptotic mediators Bax and Bak were TUNEL- despite very high levels of DNA
damage. Further examination of Atr/p53-deleted CGNPs in the EGL revealed the
presence of cells with micronuclei and giant multinucleated cells, suggestive of
necrosis (Vakifahmetoglu et al., 2008). Curiously, the EGL in these mice failed to
show positive staining for the marker of regulated necrosis, or necroptosis, p-MLKL
277
(phosphorylated Mixed lineage kinase domain-like) (Cai et al., 2014). Therefore, it
remains an open question as to how CGNPs undergo cell death in the absence of ATR
and p53 if not through apoptosis or necrosis, and better understanding of this
mechanism will also be important in understanding the anti-tumor mechanism of
ATR inhibition in p53-mutated medulloblastoma.
Chapter 1 provided a detailed outline of the apoptotic pathway. In brief,
Caspase-3 is considered the primary executioner caspase both because it is able to
activate the other executioner Caspases, 6 and 7, and because Caspases-6 and -7
perform many roles redundant to those of Caspase-3. Thus, absence of cC3 positivity
in the TUNEL+ EGL of Atr/p53-deleted mice argues against engagement of the
apoptotic program. However, the possibility must be explored that Atr/p53-deleted
CGNPs are simply cC3+ earlier in development, such as at P0, P1, or P2, and that
TUNEL positivity, as a marker for apoptosis, is retained longer than cC3 positivity.
Immunohistochemical analyses of cerebellar sections from these double-deletion
mice at earlier ages will resolve this possibility. Immunostaining for cC6 and cC7
should also be done with sections from the double-knockout mice at all of these ages,
including P3, in order to determine if CGNPs can utilize intrinsic pathway apoptosis
independent of Caspase-3. While it is conceivable that Caspase-6/7-dependent,
Caspase-3-indpendent apoptosis could occur in cells with deletion of Atr and p53
since cC6 can promote nuclear degradation and cC7 can further inhibit DNA repair,
this possibility remains unlikely due to limited reports on such a mechanism (Hirata
et al., 1998; Kaufmann et al., 1993; Boulares et al., 1999). It is further possible that
apoptosis in ATR/p53-deficient CGNPs proceeds through the extrinsic pathway
mediated by either TNFR1 (Tumor necrosis factor receptor 1) or CD95 (Cluster of
diﬀerentiation 95) (McIlwain et al., 2013). Caspase-8 is activated through these two
receptors, so immunostaining could be performed for cC8 on Atr/p53-deleted
cerebellar sections. However, signaling downstream of cC8 ultimately involves the
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same executioner caspases as the intrinsic apoptotic pathway, so cC3-negativity
suggests absence of apoptosis in general.
Necroptosis is most commonly associated with an inflammatory response
(Kanduc et al., 2002). In this pathway, TNF- (Tumor necrosis factor ) acts as the
apical signal (Vandenabeele et al., 2010). This pro-inflammatory molecule is
primarily secreted by immune cells such as macrophages, but in the brain, TNF- is
released predominantly by microglia in response to infection (Welser-Alves and
Milner, 2013; Hanisch, 2002), although it can also be made by astrocytes and
neurons (Chung and Benveniste, 1990; Gahring et al., 1996; Breder et al., 1993).
TNF- binds to TNFR1, which recruits the adaptor TRADD (TNFR1-associated
Death domain protein) complex that allows the docking and activation of RIPK1
(Receptor-interacting serine/threonine kinase 1) (Declercq et al., 2009; Zhao et al.,
2015; Hitomi et al., 2008). Activated RIPK1 recruits and activates RIPK3, which in
turn phosphorylates/activates MLKL (Newton et al., 2014; Wang et al., 2014; Li
et al., 2012). RIPK3 has been shown to mediate the release of reactive oxygen species
from the mitochondria, which contributes to organelle and DNA damage (Moriwaki
and Chan, 2013; Cai and Liu, 2014; Dondelinger et al., 2013). Activated MLKL, on
the other hand, relocates to the plasma membrane to promote calcium influx, which
leads to plasma membrane rupture (Cai et al., 2014). As a result, a response to
inflammation ultimately promotes further inflammation (Davidovich et al., 2014;
Pasparakis and Vandenabeele, 2015). In our initial analyses, we did not observe
either an increase pMLKL or in signs of gross inflammation in the cerebella of
Atr/p53-deleted mice. In future experiments, immunostaining for other markers of
necroptosis like phosphorylated RIPK1 or RIPK3 could confirm whether necroptosis
occurs in these double-knockout CGNPs. A more careful investigation as to the
presence of an inflammatory response and frank necrosis in the EGL of ATR/
p53-deficient mice should also be performed.
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A final recognized form of cell death is by autophagy (Diaz et al., 2005). Cells
experiencing autophagic cell death display cytosolic double membrane vacuoles and
fused autophagosomes with lysosomes (Tasdemir et al., 2008). Increased expression
of genes like ATG5 (Autophagy-related 5), ATG12, andMAP1LC3A (Microtubule-
associated protein 1 light chain 3 ) are also considered hallmarks of autophagy
(Shintani and Klionsky, 2004). We did not specifically look for or observe signs of
autophagy in Atr/p53-deleted CGNPs. High-power microscopy on H&E-stained
cerebellar sections from double-knockout animals, which are presently already
available, may reveal the presence of morphological signs of autophagy. However, in
our RNA-Seq experiments, described in Chapter 3, we did not find increased
expression of Atg5, Atg12, orMap1lc3a in CGNPs from ATR/p53-deficient mice. In
the end, more experiments should be performed in order to parse out the true
mechanism – whether by intrinsic or extrinsic apoptosis, necroptosis, autophagy, or
necrosis – of cell death, as seen by TUNEL reactivity, that is operant in CGNPs with
co-deletion of Atr and p53. These same experiments must then also be performed
with Atr-deleted medulloblastoma mice treated with pVE-822, should ATR
inhibition lead to cell death in the tumors.
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